

BreastScreen Aotearoa

Monitoring Report for women screened between 1 July 2018 and 30 June 2020

Bridget Robson, Te Rōpū Rangahau Hauora a Eru Pōmare, University of
Otago Wellington

Lis Ellison-Loschmann, Mona Jeffreys, Fiona McKenzie, Flax Analytics

6 December 2022

Contents

Contents	2
List of Tables	4
List of Figures	4
Executive Summary	8
Introduction	8
Overall Programme Performance	9
Lead Provider Variation	13
Equity Issues	16
Impact of COVID-19	17
Is BSA making a difference?	18
Introduction	20
National Indicator Overviews for Māori, Pacific, Total women	21
Lead Provider Indicator Overviews for Māori, Pacific and Total women aged 50–69 years	25
Introduction	25
BreastScreen Waitemata Northland (BSWN) Overview	26
BreastScreen Counties Manukau (BSCM) Overview	31
BreastScreen Auckland Limited (BSAL) Overview	36
BreastScreen Midlands (BSM) Overview	41
BreastScreen Coast to Coast (BSCC) Overview	47
BreastScreen Central (BSC) Overview	52
BreastScreen South Limited (BSSL) Overview	57
BreastScreen Otago Southland (BSOS) Overview	62
Coverage	67
1.a.1, Overall coverage of eligible women	67
1.a.2, Percentage of screens that are initial or subsequent	70
1.a.3, Screening unit type	74
1.a.4, Age specific coverage	78
1.b.3, Routine rescreening	80
Screening and Assessment	84
2.a, Screening image usage	84
2.b, Technical recall rate	88
2.c, Technical reject rate	92
2.d, Assessment rate	96
2.e, False positive rate	100
2.f, Positive predictive value	104
2.g, Benign open biopsy weight	108
2.h, Preoperative diagnosis rate	111
2.i, Specificity	114

2.m, Benign open biopsy rate	118
Breast Cancer Detection	122
3.a.1, DCIS and invasive cancer detection	122
3.a.2, Invasive breast cancer detection	126
3.a.3, Summary of assessment outcomes	130
3.c.p, Detection of invasive breast cancer less than or equal to 15mm (percentage)	131
3.c.r, Detection of invasive breast cancer less than or equal to 15mm (rate)	135
3.d, Nodal involvement.....	139
3.e, Ductal carcinoma in situ diagnosis.....	143
Treatment: Early detection of DCIS or invasive breast cancer	146
3.a.2.t, Detection of invasive breast cancer, women screened during the 4 years to December 2019	146
3.c.p.t, Detection of invasive breast cancer less than or equal to 15mm (percentage), women screened during the 4 years to December 2019.....	148
3.d.t, Nodal involvement, women screened during the 4 years to December 2019	150
3.e.t, Ductal carcinoma in situ diagnosis, women screened during the 4 years to December 2019	151
4.a.1.t, Women with invasive breast cancers ≤ 30 mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to December 2019	152
4.b.t, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2019	155
4.e.t, DCIS having breast conserving surgery, women screened during the 4 years to December 2019.....	158
4.f.t, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2019	161
4.g.t, Invasive cancer having radiotherapy, women screened during the 4 years to December 2019	164
4.h.t, DCIS having radiotherapy, women screened during the 4 years to December 2019	167
4.i.t, Invasive cancer having chemotherapy, women screened during the 4 years to December 2019	170
4.j.t, Invasive cancer having endocrine therapy, women screened during the 4 years to December 2019	174
Timeliness	177
5.a, Time taken for provision of screening results	177
5.b, Time taken from screening visit to first offer of an assessment	180
5.c.1, Women receiving a needle biopsy within 5 working days of assessment	183
5.c.2, Women having an open biopsy procedure within 20 working days.....	186
5.d, Time taken from final diagnostic biopsy to reporting assessment results.....	189
5.e.t, First surgical treatment, women screened during the 4 years to December 2019	192
Appendices	195
Technical notes	195
Indicator targets	195
Data source and extraction date	195
Ethnicity	195
Confidence intervals	195
Population projections.....	196

List of Tables

Table 1: 1.a.1.1, Coverage of eligible women.....	69
Table 2: 1.a.2.1, Initial and subsequent screen proportions	73
Table 3: 1.a.3.1, Percentages screened at fixed and mobile units	77
Table 4: 1.a.4.1, Age specific coverage	79
Table 5: 1.b.3.1, Routine rescreening within 27 months of an initial and subsequent screen	83
Table 6: 2.a.1, Screening image usage.....	87
Table 7: 2.b.1, Technical recall rate	91
Table 8: 2.c.1, Technical reject rate	95
Table 9: 2.d.1, Assessment rate	99
Table 10: 2.e.1, False positive rate	103
Table 11: 2.f.1, Positive predictive value	107
Table 12: 2.g.1, Benign open biopsy weight	110
Table 13: 2.h.1, Preoperative diagnosis rate	113
Table 14: 2.i.1, Specificity	117
Table 15: 2.m.1, Benign open biopsy rate	121
Table 16: 3.a.1.1, Breast cancer detection rates (DCIS and invasive combined)	125
Table 17: 3.a.2.1, Invasive breast cancer detection	129
Table 18: 3.a.3.1, Summary of assessment outcomes	130
Table 19: 3.c.p.1, Detection of invasive breast cancer less than or equal to 15mm (percentage)	134
Table 20: 3.c.r.1, Detection of invasive breast cancer less than or equal to 15mm (rate).....	138
Table 21: 3.d.1, Nodal involvement.....	142
Table 22: 3.e.1, Ductal carcinoma in situ diagnosis.....	145
Table 23: 3.a.2.t, Detection of invasive cancer, women screened during the 4 years to December 2019.....	146
Table 24: 3.a.3.t.1, Treatment Data Completeness, women screened during the 4 years to December 2019	147
Table 25: 3.c.p.t Detection of invasive breast cancer less than or equal to 15mm (percentage), women screened during the 4 years to December 2019	148
Table 26: 3.c.r.t Detection of invasive breast cancer less than or equal to 15mm (rate per 10,000 screens), women screened during the 4 years to December 2019	149
Table 27: 3.d.t, Nodal involvement, women screened during the 4 years to December 2019.....	150
Table 28: 3.e.t.1, Ductal carcinoma in situ diagnosis, women screened during the 4 years to December 2019.....	151
Table 29: 4.a.1.t.1, Women with invasive breast cancers ≤30mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2019.....	154
Table 30: 4.b.t.1, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2019.....	157
Table 31: 4.e.t.1, DCIS having breast conserving surgery, women screened during the 4 years to December 2019.....	160
Table 32: 4.f.t.1, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2019	163
Table 33: 4.g.t.1, Invasive cancer having radiotherapy, women screened during the 4 years to December 2019	166
Table 34: 4.h.t.1, DCIS having radiotherapy, women screened during the 4 years to December 2019	169
Table 35: 4.i.t.1, Invasive cancer having chemotherapy, women screened during the 4 years to December 2019.....	171
Table 36: 4.j.t.1, Invasive cancer having endocrine therapy, women screened during the 4 years to December 2019 ...	175
Table 37: 5.a.1, Time taken for provision of screening results.....	179
Table 38: 5.b.1, Time taken from screening visit to first offer of an assessment	182
Table 39: 5.c.1.1, Women receiving a needle biopsy within 5 working days of assessment	185
Table 40: 5.c.2.1, Women having an open biopsy procedure within 20 working days	188
Table 41: 5.d.1, Time taken from final diagnostic biopsy to reporting assessment results	191
Table 42: 5.e.t.1, First surgical treatment, women screened during the 4 years to December 2019.....	194
Table 43: Mid-year population projections for 2019 by ethnicity, Lead Provider, and 5-year age group	196

List of Figures

Figure 1: BreastScreen Aotearoa Lead Provider map.....	13
--	----

Figure 2: National Overview, Māori women, 50 to 69 years.....	22
Figure 3: National Overview, Pacific women aged 50 to 69 years	23
Figure 4: National Overview, Total women aged 50 to 69 years.....	24
Figure 5: BSWN Overview, Māori women aged 50 to 69 years.....	26
Figure 6: BSWN Overview, Pacific women aged 50 to 69 years.....	27
Figure 7: BSWN Overview, Total women aged 50 to 69 years	28
Figure 8: BSCM Overview, Māori women aged 50 to 69 years	31
Figure 9: BSCM Overview, Pacific women aged 50 to 69 years.....	32
Figure 10: BSCM Overview, Total women aged 50 to 69 years.....	33
Figure 11: BSAL Overview, Māori women aged 50 to 69 years.....	36
Figure 12: BSAL Overview, Pacific women aged 50 to 69 years	37
Figure 13: BSAL Overview, Total women aged 50 to 69 years	38
Figure 14: BSM Overview, Māori women aged 50 to 69 years	41
Figure 15: BSM Overview, Pacific women aged 50 to 69 years.....	42
Figure 16: BSM Overview, Total women aged 50 to 69 years.....	43
Figure 17: BSCC Overview, Māori women aged 50 to 69 years.....	47
Figure 18: BSCC Overview, Pacific women aged 50 to 69 years.....	48
Figure 19: BSCC Overview, Total women aged 50 to 69 years	49
Figure 20: BSC Overview, Māori women aged 50 to 69 years.....	52
Figure 21: BSC Overview, Pacific women aged 50 to 69 years.....	53
Figure 22: BSC Overview, Total women aged 50 to 69 years	54
Figure 23: BSSL Overview, Māori women aged 50 to 69 years	57
Figure 24: BSSL Overview, Pacific women aged 50 to 69 years.....	58
Figure 25: BSSL Overview, Total women aged 50 to 69 years.....	59
Figure 26:BSOS Overview, Māori women aged 50 to 69 years	62
Figure 27: BSOS Overview, Pacific women aged 50 to 69 years.....	63
Figure 28: BSOS Overview, Total women aged 50 to 69 years.....	64
Figure 29: 1.a.1.1, Coverage of eligible women, 45 to 49 and 50 to 69 years, total BSA.....	67
Figure 30: 1.a.1.3, Coverage of eligible women, 50 to 69, by LP.....	68
Figure 31: 1.a.2.1, Initial and subsequent screen proportions, 50 to 69.....	70
Figure 32:1.a.2.3, Initial screen proportions, 50 to 69, by LP	71
Figure 33: 1.a.2.5, Subsequent screen proportions, 50 to 69, by LP	72
Figure 34: 1.a.3.1, Percentage screened at fixed and mobile units, 50 to 69, total BSA.....	74
Figure 35: 1.a.3.3, Percentage screened at fixed units, 50 to 69, by LP	75
Figure 36: 1.a.3.5, Percentage screened at mobile units, 50 to 69, by LP.....	76
Figure 37: 1.b.3.1, Percentage rescreened within 27 months of an initial and subsequent screen, 50 to 67, all BSA	80
Figure 38: 1.b.3.3, Routine rescreening within 27 months of an initial screen, 50 to 67, by LP	81
Figure 39: 1.b.3.5, Routine rescreening within 27 months of a subsequent screen, 50 to 67, by LP	82
Figure 40: 2.a.1, Screening image usage, 50 to 69, fixed and mobile units	84
Figure 41: 2.a.3, Fixed, 50 to 69, Screening image usage, by LP	85
Figure 42: 2.a.5, Mobile, 50 to 69, Screening image usage, by LP	86
Figure 43: 2.b.1, Technical recall rate, 50 to 69, fixed and mobile units.....	88
Figure 44 2.b.3, Fixed site, 50 to 69, Technical recall rate, by LP	89
Figure 45: 2.b.5, Mobile units, 50 to 69, Technical recall rate, by LP	90
Figure 46: 2.c.1, Technical reject rate, 50 to 69, fixed and mobile units.....	92
Figure 47: 2.c.3, Fixed sites 50 to 69, Technical reject rate, by LP	93
Figure 48: 2.c.5, Mobile units, 50 to 69, Technical reject rate, by LP.....	94
Figure 49: 2.d.1, 50 to 69, Assessment rate, initial and subsequent screens.....	96
Figure 50: 2.d.3, Initial, 50 to 69, Assessment rate, by LP	97
Figure 51: 2.d.5, Subsequent, 50 to 69, Assessment rate, by LP	98
Figure 52: 2.e.1, 50 to 69, False positive rate.....	100
Figure 53: 2.e.3, Initial, 50 to 69, False positive rate, by LP	101
Figure 54: 2.e.5, Subsequent, 50 to 69, False positive rate, by LP	102
Figure 55: 2.f.1, 50 to 69, Positive predictive value, initial and subsequent screens.....	104

Figure 56: 2.f.3, Initial, 50 to 69, Positive predictive value, by LP	105
Figure 57: 2.f.5, Subsequent, 50 to 69, Positive predictive value, by LP	106
Figure 58: 2.g.1, 50 to 69, Benign open biopsy weight	108
Figure 59: 2.g.3, 50 to 69, Benign open biopsy weight, by LP	109
Figure 60: 2.h.1, 50 to 69, Preoperative diagnosis rate.....	111
Figure 61: 2.h.3, 50 to 69, Preoperative diagnosis rate, by LP	112
Figure 62: 2.i.1, 50 to 69, Specificity.....	114
Figure 63: 2.i.3, Initial, 50 to 69, Specificity, by LP	115
Figure 64: 2.i.5, Subsequent, 50 to 69, Specificity, by LP	116
Figure 65: 2.m.1, 50 to 69, Benign open biopsy rate, total BSA.....	118
Figure 66: 2.m.3, Initial, 50 to 69, Benign open biopsy rate, by LP	119
Figure 67: 2.m.5, Subsequent, 50 to 69, Benign open biopsy rate, by LP	120
Figure 68: 3.a.1.1, 50 to 69, breast cancer detection rates (DCIS and invasive combined), initial and subsequent screens	122
Figure 69: 3.a.1.3, Initial, 50 to 69 breast cancer detection rates (DCIS and invasive combined), by LP.....	123
Figure 70: 3.a.1.5, Subsequent, 50 to 69, breast cancer detection rates (DCIS and invasive combined), by LP.....	124
Figure 71: 3.a.2.1, 50 to 69, Invasive breast cancer detection, initial and subsequent screens	126
Figure 72: 3.a.2.3, Initial, 50 to 69, Invasive breast cancer detection, by LP	127
Figure 73: 3.a.2.5, Subsequent, 50 to 69, Invasive breast cancer detection, by LP	128
Figure 74: 3.c.p.1, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), initial and subsequent screens	131
Figure 75: 3.c.p.3, Initial, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), by LP	132
Figure 76: 3.c.p.5, Subsequent, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), by LP.....	133
Figure 77: 3.c.r.1, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate per 10,000), initial and subsequent screens	135
Figure 78: 3.c.r.3, Initial, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate), by LP.....	136
Figure 79: 3.c.r.5, Subsequent, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate), by LP.....	137
Figure 80: 3.d.1, 50 to 69, Nodal involvement	139
Figure 81: 3.d.3, Initial, 50 to 69, Nodal involvement, by LP.....	140
Figure 82: 3.d.3, Subsequent, 50 to 69, Nodal involvement, by LP.....	141
Figure 83: 3.e.1, 45 to 49 and 50 to 69, Ductal carcinoma in situ diagnosis	143
Figure 84: 3.e.3, 50 to 69, Ductal carcinoma in situ diagnosis, by LP	144
Figure 85: 4.a.1.t.1, 50 to 69, Women with invasive breast cancers ≤ 30 mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2019	152
Figure 86: 4.a.1.t.2, 50 to 69, Women with invasive breast cancers ≤ 30 mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2019, by LP.....	153
Figure 87: 4.b.t.1, 50 to 69, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2019.....	155
Figure 88: 4.b.t.3, 50 to 69, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2019, by LP	156
Figure 89: 4.e.t.3, 50 to 69, DCIS having breast conserving surgery, women screened during the 4 years to December 2019	158
Figure 90: 4.e.t.3, 50 to 69, DCIS having breast conserving surgery, women screened during the 4 years to December 2019, by LP.....	159
Figure 91: 4.f.t.3, 50 to 69, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2019.....	161
Figure 92: 4.f.t.3, 50 to 69, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2019, by LP	162
Figure 93: 4.g.t.3, 50 to 69, Invasive cancer having radiotherapy, women screened during the 4 years to December 2019	164
Figure 94: 4.g.t.3, 50 to 69, Invasive cancer having radiotherapy, women screened during the 4 years to December 2019, by LP.....	165

Figure 95: 4.h.t.3, 50 to 69, DCIS having radiotherapy, women screened during the 4 years to December 2019	167
Figure 96: 4.h.t.3, 50 to 69, DCIS having radiotherapy, women screened during the 4 years to December 2019, by LP ..	168
Figure 97: 5.a.1, Time taken for provision of screening results, 50 to 69 years, total BSA	177
Figure 98:5.a.1 Time taken for provision of screening results, by LP	178
Figure 99: 5.b.1, 50 to 69, Time taken from screening visit to first offer of an assessment	180
Figure 100: 5.b.3, 50 to 69, Time taken from screening visit to first offer of an assessment, by LP	181
Figure 101: 5.c.1.1, 50 to 69, Women receiving a needle biopsy within 5 working days of assessment, total BSA	183
Figure 102: 5.c.1.3, 50 to 69, Women receiving a needle biopsy within 5 working days of assessment, by LP	184
Figure 103: 5.c.2.1, 50 to 69, Women having an open biopsy procedure within 20 working days	186
Figure 104: 5.c.2.3, 50 to 69, Women having an open biopsy procedure within 20 working days, by LP	187
Figure 105: 5.d.1, 50 to 69, Time taken from final diagnostic biopsy to reporting assessment results.....	189
Figure 106: 5.d.3, 50 to 69, Time taken from final diagnostic biopsy to reporting assessment results, by LP	190
Figure 107: 5.e.t.3, 50 to 69, First surgical treatment, women screened during the 4 years to December 2019	192
Figure 108: 5.e.t.3, 50 to 69, First surgical treatment, women screened during the 4 years to December 2019, by LP...	193

Executive Summary

Introduction

This report summarises the performance of BreastScreen Aotearoa (BSA) based on quality indicators for women screened during the two- year period to 30 June 2020. Treatment indicators are presented for women diagnosed through screening during the four year period to 31 December 2019.

Breast cancer is the most commonly diagnosed cancer among women in Aotearoa New Zealand. Screening aims to detect cancers at an early stage when tumours are more amenable to treatment. A properly organised breast screening programme can significantly reduce illness and death from breast cancer.

BSA offers free two-yearly mammographic screening to women aged 45 to 69 years. It plays a vital role, firstly by finding breast cancer tumours at a very early and treatable stage; and secondly by systematically following up women whose cancer is found by the screening programme to ensure timely pathways through the cancer care continuum. Women screened by BSA have a third lower risk of dying from breast cancer than women who are not screened¹. Māori and Pacific mortality rates from breast cancer are disproportionately higher than those of other women² and more equitable outcomes could be achieved if more Māori and Pacific women were diagnosed at an earlier stage. For this reason, BSA prioritises screening these women.

BSA has eight Lead Provider (LP) regions. Each LP is responsible for providing or subcontracting mammography screening and assessment services in their region. Support to Screening Providers are contracted by the National Screening Unit (NSU) to support women from priority groups to screening and assessment. District Health Boards (DHBs) provide breast cancer treatment after diagnosis. Surgery is performed by DHB services and private providers; oncology and radiation therapy are provided by six Cancer Centres (or by private providers in some areas). Data on the treatment provided to women whose breast cancer was detected by BSA is collected by each LP and reported to the NSU.

Previous monitoring reports and details of the indicator measures are available on the [NSU's website](#).

The period covered by this report includes five months when screening was affected by the COVID-19 Pandemic. Breast screening paused from 25 March to 27 April 2020 in COVID Alert Level 4, with gradual recommencement of screening once in COVID Alert Level 3 from 28 April 2020. This resulted in lower coverage for the last 6 months of the biennial period reported here. The impact of the COVID-19 pandemic on screening coverage will also be evident in future annual reports. The potential impact on screen-detected tumour size has yet to be determined.

¹ Ministry of Health. 2016. Summary of the BreastScreen Aotearoa Mortality evaluation 1999–2011. Wellington: Ministry of Health. Available on www.health.govt.nz

² Ministry of Health. 2016. Cancer: New registrations and deaths 2013. Wellington: Ministry of Health.

Overall Programme Performance

This section examines the performance of the BSA programme at the national level. Quality indicators by Lead Provider may differ from those of the overall programme. The online data tool includes tables and graphs of trends over time for all indicators for women aged 45–49 and 50–69 years by ethnicity and Lead Provider. Apart from detection related and assessment related indicators, this section generally refers to indicators for women aged 45–69 years, unless otherwise indicated. Because underlying breast cancer incidence varies by age, detection and assessment related indicators are reported separately for the two age groups.

Coverage – decreased for all women, to 60% for Māori women, 69% for Pacific, and 68% for other women aged 45–69 years

- Biennial screening coverage reduced for all groups and the 70% biennial target was not achieved. Māori women's coverage was 6.2% lower than the previous biennium, Pacific coverage 3.8% lower, and other women 5.1% lower.
- To achieve the same coverage as non-Māori, BSA needed to screen 7,519 more Māori women, 1,518 more than in the previous biennium, showing the gap widened.

During the two years to 30 June 2020 BSA screened 510,215 women, 33,039 fewer than the previous biennium to 30 June 2019, while the total eligible population aged 45 to 69 years increased by 9,905 women.

BSA aims to screen 70% of eligible women aged 45 to 69 years. The COVID-19 Pandemic resulted in a 5% decrease in overall biennial coverage, from 72% in June 2019 to 67% in June 2020. Screening coverage of Māori women was most affected, decreasing from 66% to 60%. Pacific coverage was least impacted, reducing from 73% to 69%.

If Māori were screened at the same rate as non-Māori (68%), there would have been 7,519 more Māori women screened over the two years. In the previous biennium the additional number of screens needed to achieve equity was 6,001. Māori women remain the highest priority group for screening during the COVID-19 recovery era.

Timely rescreening – decreased overall, lower after initial than subsequent screens, small shifts toward equitable rates for Māori and Pacific women

- Among women aged 45–67 years, 68% of Māori, 67% of Pacific, 76% of other women were rescreened between 20 and 27 months of an initial screen (target 75% or more). After a subsequent screen, 82% of Māori, 81% of Pacific and 86% of other women had a timely rescreen (target 85% or more).
- Timely rescreening after an initial screen varied by age – higher for women having their first screen at ages 45–49 years than those who started at age 50 or above.

Women who screen regularly have a lower risk of dying from breast cancer than those who screen less regularly³. If there is too long an interval between screens, new cancers have a longer time to develop beyond the early stages and screening is less effective at preventing illness and death. BSA aims to have 75% of women rescreened between 20 and 27 months of their initial screen and 85% rescreened within 20 and 27 months of any subsequent screen.

The COVID lockdowns had some impact on the rates of timely rescreens.

Among women aged 50–67 years at their first screen with BSA, 56% of Māori (0.1% decrease) and Pacific women were rescreened within 27 months (no change), and 67% of other women had a timely rescreen (1.8% decrease).

Timely rescreens after a subsequent screen were higher. Among women aged 50 to 67, 82% of Māori women (0.5% increase), 81% of Pacific women (0.3% increase), and 86% of non-Māori non-Pacific women (1.9% decrease) were rescreened within 20 to 27 months.

Among women aged 45–49 years at their first screen, 71% of Māori (0.7% increase), 70% of Pacific (1.4% increase) and 79% of other women (1.9% decrease) had a timely rescreen. Rescreen rates after a subsequent screen in this age group were 81% for Māori (1% increase), 81% for Pacific (2.4% increase) and 85% for other women (1.5% decrease).

³ Ministry of Health. 2015. Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 to 2011. Wellington: Ministry of Health.

The additional numbers of women aged 45–67 who needed to be rescreened within 27 months to achieve the targets were 2,106 for Māori and 1,096 for Pacific women (initial and subsequent combined). The number of non-Māori non-Pacific women rescreened beyond the target values was 2,962, around a third of the number in the previous biennium (10,329). To achieve equitable rates with non-Māori non-Pacific women, the additional numbers required were 2,509 Māori and 1,271 Pacific women, about a third lower than in the previous biennium, mainly due to the slightly lower rescreen rates for non-Māori non-Pacific women.

Screening quality – technical recall rates and image quality on track. Proportions of women having no more than four images increased

- Technical recall rates in mobile (0.2%) and fixed units (0.2%) remained in the target range ($\leq 0.5\%$).
- The proportions of women having no more than 4 images per screening episode were on target ($>80\%$).
- The rate of rejected images (0.8%) remained well within the target range ($<3\%$).

With all screening units using digital technology the low rate of women recalled for technical reasons has been maintained at 0.2% in both fixed and mobile units (target $< 0.5\%$). This indicator is monitored to ensure the number of women having to return to a screening unit for further images to complete their screening episode is minimal.

The $>80\%$ target for the proportions of women having no more than four images was met for Māori (82%) and non-Māori non-Pacific women (88%), and the total proportion of Pacific women (80%). For Pacific women the proportion was lower for those screened in mobile units (78%) than fixed units (80%).

Less than 1% of images were rejected (target $<3\%$).

Timely reporting of screening results – on target

- The proportion of women who received their screening results within 10 working days remained within the target range of 90% or more but decreased by 1% to 93%.

Assessment – quality on track, timeliness outside target range

- Targets for assessment quality indicators continued to be met for all groups of women aged 50–69 years having an initial or subsequent screen.
- For women aged 45–49 years, all indicators were as expected. Positive predictive values were around half those of women aged 50–69 years.
- The proportion of women offered their first assessment appointment within 15 working days was 85% (target 90%).

For women aged 50–69 years having an **initial screen** the rates of referral to assessment, false positives, and positive predictive value were in the target ranges. The rate of referral for further assessment was 12.0% for Māori, higher than the target of $<10\%$, but the positive predictive value (the proportion of women referred for assessment who were found to have breast cancer) was also high at 17.5% (target $>9\%$). False positive rates met the target of $<9\%$ for each population (7.4% overall) and positive predictive values were well within the target range for all groups. Around one in six Māori, one in seven Pacific, and one in eight other women referred for an assessment from an initial screen had a cancer detected. Specificity was just below the target of $>93\%$ at 91%.

All assessment quality indicators for women aged 50–69 years having a **subsequent screen** were within the target ranges. Among women aged 50–69 years who had a subsequent screen, the rate of referral for assessment was 3.6% for Māori and Pacific women and 3.3% for other women (target $<5\%$). False positive rates were 2.5% (target $<4\%$). Positive predictive values were around twice the target of $>9\%$ at 18% overall. Specificity was 96%, well within the target range of $>93\%$.

Assessment quality indicators for women aged 45–49 years having initial screens were within the expected values of $<10\%$ assessment rate, $<8\%$ false positives, $>6\%$ PPV for initial screens and 92% for specificity. For women having subsequent screens, they were also within the expected ranges of $<5\%$ referred to assessment, $<4\%$ false positives, $>8\%$ positive predictive value, and $>95\%$ specificity.

To expedite diagnosis and minimise anxiety, BSA aims to have 90% of women offered their first assessment appointment within 15 working days of their screening mammogram. Among women aged 45–69 years, this indicator

declined slightly to 81% for Māori, increased by 4% for Pacific women to 85% and increased slightly by 1% for other women to 86%.

Biopsies – most diagnosed without open surgery and on time, open biopsies less timely and benign biopsy weight remained below target

- Most women (95%) had a definitive diagnosis of breast cancer without open surgery and within 5 working days of their assessment (97%).
- Some women required open surgery to obtain a definitive diagnosis. Fewer than one per 1,000 women screened had an open biopsy that turned out to be benign. Of those women, most (85%) had a benign biopsy that weighed under 30g (target >90%).
- Just over half (56%) had their open biopsy within 20 working days (target ≥90%).
- The proportion of women who received their final diagnostic biopsy results within 5 working days was 85% overall (target ≥90%).

Around 95% of women whose breast cancer was detected by BSA had a definitive diagnosis from a needle biopsy, meeting the target value of >90% for all groups of women. Most percutaneous biopsies (97%) were received within 5 working days of assessment.

The benign open biopsy rates were within the target ranges for initial (≤ 3.5 per 1,000) and subsequent screens (≤ 1.6 per 1,000). Two women per 1,000 having an initial screen and less than one per 1,000 women having a subsequent screen underwent an open biopsy for a benign condition. Among the women who had an open biopsy that turned out to be benign, just over four out of five had a biopsy weighing less than 30 grams (target >90%). This indicator relates to minimising harms from surgery that might not have occurred without screening.

The proportion of women who received their open biopsy within 20 working days of being notified that they needed it was 56% (target ≥90%) overall, 46% for Māori, 58% for Pacific and for non-Māori non-Pacific women.

The proportion of women who received their final diagnostic biopsy results within five working days was 85% overall (target ≥90%). This indicator was lower for Māori women (80%) than for Pacific (87%) and other women (86%). This indicator aims to minimise anxiety and delays in treatment planning.

Early detection – on target for all indicators for Māori, Pacific and other women aged 45–49 and 50–69 years

- Invasive breast cancer detection targets were met for all populations.
- Māori women were more likely to have an invasive breast cancer detected from an initial and from a subsequent screen than non-Māori women in both age groups.
- Over half of the invasive cancers detected from initial (54%) and subsequent screens (63%) were ≤ 15 mm diameter.
- The targets for the proportions of invasive cancers without nodal involvement were met or were within the confidence interval for all population groups.
- The proportion of cancers that were DCIS (23%) was in the target range for women aged 50–69 years and higher for women aged 45–49 years (31%).

Among women aged 45–49 years having an initial screen the rate of invasive breast cancer detection was 4.0 per 1,000 overall, 5.7 per 1,000 for Māori women and 6.1 per 1,000 for Pacific women (target ≥ 3.8 per 1,000 women screened). Small cancer detection rates (≤ 15 mm) were also in the target range at 19.3 per 10,000 initial screens (target ≥ 19.0), 30.9 per 10,000 for Māori and 24.0 per 10,000 for Pacific women. The 70% target for invasive cancers without nodal involvement was within the confidence interval (67.5%).

Among women aged 45–49 years having a subsequent screen 2.4 per 1,000 had an invasive cancer detected (target ≥ 2.4). The rate of small cancers detected was 14.6 per 10,000 women screened (target ≥ 12.0), with 17.9 per 10,000 for Māori, 9.0 per 10,000 for Pacific women. Three quarters had no nodal involvement, meeting the 75% target.

Among women aged 50–69 years, invasive cancer detection rates were within the target ranges for all groups of women having an initial or a subsequent screen. Over half were 15mm or less in diameter, as were two-thirds of those detected

from subsequent screens. The rate of detection of small breast cancers per 10,000 screens was twice as high for Māori as for non-Māori having an initial screen and 55% higher for those having a subsequent screen. There were no significant differences between small cancer detection rates for Pacific and non-Māori non-Pacific women. Among women aged 45–69 years, the total proportions of invasive cancers detected that had no nodal involvement were 69% for initial screens (target >70%) and 80% for subsequent screens (target >75%).

The proportion of breast cancers that were DCIS was 23%, within the target range of 10% to 25% for women aged 50–69 years, lower for Māori women (13%) and similar for Pacific women (26%). Among women aged 45–49 years, the overall proportion of screen-detected cancers that were DCIS was 31%, similar for Māori, and 21% for Pacific women.

Treatment – most indicators met targets with no ethnic differences, time to surgery under target and not equitable

- Among all women whose invasive cancer was detected by BSA during the four years to 31 December 2019, 54% had their first surgical treatment within 20 working days of receiving their final diagnosis (target 90%), 47% of Māori and 48% of Pacific women aged 45–69 years.
- Most women had breast conserving surgery.
- Among women whose invasive cancer was $\leq 30\text{mm}$, 82% had sentinel node biopsy as their first axillary procedure.
- The proportion of women who had radiation therapy with breast conserving surgery for invasive cancer was 89% (target 95% or more) with a gradual declining trend continuing.
- The targets were met for other treatment indicators, for all populations.

The proportion of women who had their first surgical treatment within 20 working days of diagnosis during the four years to December 2019 was below the 90% target for all ethnic groups.

Among women aged 45–69 years with invasive breast cancer 30mm or less, 82% had sentinel node biopsy as their first axillary procedure. There is no target for this indicator. Sentinel lymph node biopsy is useful for staging of cancers and may help avoid more extensive lymph node surgery.


Most women (86%) had only a single excisional breast treatment procedure.

The majority of women diagnosed with DCIS or invasive cancer $\leq 20\text{mm}$ had breast conserving surgery (88% and 84% respectively).

The proportion of women who had radiation therapy with breast conserving surgery for invasive cancer was 89% (target 95% or more).

Lead Provider Variation

Figure 1: BreastScreen Aotearoa Lead Provider map



The eight BSA Lead Provider regions are shown in the figure above. Note that BreastScreen Auckland Limited was operating during the period of this report, but has since been replaced by BreastScreen Auckland Central.

The following acronyms are used in this section:

- BSWN BreastScreen Waitemata Northland
- BSAL BreastScreen Auckland Limited
- BSCM BreastScreen Counties Manukau
- BSM BreastScreen Midland
- BSCC BreastScreen Coast to Coast
- BSSL BreastScreen South Limited
- BSOS BreastScreen Otago Southland

Coverage – LPs varied in coverage and equity

- For Māori women aged 45–69 years, biennial coverage was over 60% in six LPs. BSM and BSCC screened 55% and 57% respectively. No LP met the 70% target. BSWN achieved equal coverage for Māori and non-Māori.
- For Pacific women aged 45–69 years, BSCM achieved coverage of 77%, BSAL (69%) and BSWN (68%). Each was higher or similar to non-Māori non-Pacific coverage. Other LPs ranged from 55% to 62% coverage.
- For total women aged 45–69 years, BSSL achieved the target (72%), with others ranging from 63% to 69%.

Timely rescreening – variation between LPs, equal rates for Māori and Pacific women in some LPs

- For total women aged 45–69 years, routine rescreens within 27 months of an initial screen ranged from 65% to 83%. After a subsequent screen, rates ranged from 80% to 91%.
- For Māori women aged 45–69 years, timely rescreening after an initial screen ranged from 58% (BSM) to 84% (BSC). After a subsequent screen, rates ranged from 76% to 87%. Māori and non-Māori rates were similar in BSWN, BSC, BSSL, and BSOS for rescreens after initial and subsequent screens.
- For Pacific women aged 45–69 years, timely rescreens ranged from 60% to 75% after an initial screen, and from 75% to 87% after a subsequent screen. Pacific women had higher rescreen rates than non-Māori non-Pacific women in BSWN for both initial and subsequent screens, and in BSOS for subsequent screens.
- Rescreen rates after initial screens were higher in younger women (45–49 years) than older women (50–69 years) with the differences ranging from 7% to 15% higher. Timely rescreening rates after a subsequent screen were very similar in both age groups in each LP.

Screening quality – few differences between LPs

- Technical recall rates and technical reject rates were within the target ranges for mobile and fixed units for most LPs. Technical recall rates were outside the target range for BSC but showing a possible improving trend in mobile units.
- The target of >80% of women having four images or fewer per screening episode was met for total women by all LPs, but not for Pacific women in some LPs.

Assessment – some variation in initial screens but not in subsequent screens

- The target values for referrals to assessment, false positives, specificity, and positive predictive value for subsequent screens were met or within the confidence interval for all LPs.
- For initial screens the target was met or was within the confidence interval for assessment rate, false positive rate and positive predictive value for most LPs. Specificity was slightly below for most LPs apart from BSCC and BSC. For BSOS the assessment rate, false positive rate, and specificity were outside the target ranges while the target was within the confidence interval for positive predictive value.

Biopsies – no significant variation between LPs

- Over 90% of women had a preoperative diagnosis of breast cancer in each LP.
- The targets for the benign open biopsy rate were met or were within the confidence interval for all LPs for initial and subsequent screens.
- The target of >90% of benign open biopsies weight <30g was met or within the confidence interval for most LPs, with BSM at 81% and BSCC 53% where the number of open biopsies was low (9 of 17 benign open biopsies).

Early detection – no significant variation between LPs

- The targets for detection of small invasive breast cancers and node-negative invasive cancers were met or within the confidence interval for initial and subsequent screens for women aged 45–49 and 50–69 in all LPs.
- There was no significant difference between LPs in the proportion of screen-detected cancers that were DCIS, ranging from 19% to 32% with the target range within the confidence interval for each LP.

Timeliness – some variation in most indicators

- Most LPs met the target 90% for receipt of screening results within 10 days, with one LP just under target and BSM dropping to 78%.
- Four LPs achieved or were within 2% of the 90% target for the proportion of women receiving their offer of a first assessment appointment within 15 working days. BSAL increased significantly to 82%, BSM and BSCC decreased to 80% and 66% respectively, BSOS remained just under 80%.
- All LPs were well within the target range for the receipt of needle biopsies within 5 working days of assessment.

- The target for receipt of open biopsies within 20 working days was within the confidence interval for three LPs (BSAL, BSSL, BSOS). The lowest proportions were in BSCC (19% of 27 biopsies) and BSCM (25% of 67 biopsies).
- The 90% target for the percentage of women receiving their final diagnostic biopsy results within five working days was met by or was within the confidence interval for three LPS. BSOS was lowest at 72%.

Treatment – some variation in time to surgery and in radiotherapy

- The proportion of women receiving their first treatment surgery within 20 working days (over four years) ranged from 45% to 61% for women aged 45–69 years. Most showed a decrease in the last 6 months of the reporting period, indicating an impact from COVID restrictions.
- There were no significant variations between LPs in the proportions of women who had sentinel node biopsy as their first axillary procedure; single excisional procedures for invasive cancer; breast conserving surgery for DCIS or invasive cancer.
- The proportion of women with invasive cancer who had breast conserving surgery and went on to have radiotherapy was outside the target range of 95% or more in some LPs, including BSCM (83%), BSAL (82%), BSM (84%). Over 90% of women in other LPs had radiotherapy.
- There was some variation in the proportions receiving adjuvant hormone therapy within diagnostic groups.

Equity Issues

BSA has a priority goal of providing equitable screening and achieving equitable outcomes for Māori, Pacific, and other populations in Aotearoa New Zealand. Equity is a fundamental component of a high-quality service. Systematic monitoring by ethnicity is a critical part of quality assurance and quality improvement.

A range of tools are available to support health systems and providers to monitor for equity and implement strategies to achieve equitable outcomes (see previous monitoring report). Strategies that improve equity generally benefit all populations. Equity needs to be prioritised at the system level (policy, contracting, standard setting, monitoring and responses to identified inequities), organisation level (are systems in place to identify and respond promptly to equity issues?), workforce level (e.g., composition, professional development and expectations), and at the community level.

The current monitoring report includes six months (December 2019-June 2020) in which there was overlap with the initial period of the COVID-19 response in Aotearoa New Zealand. During that time screening services changed consistent with the requirements of working within an Alert Level (1-4) system. Under Alert Level 4 all screening appointments were paused, while under Alert Levels 3 and 2, BSA operated with restricted capacity to ensure adequate safeguards for women and staff (further detail below).

While BSA has done all it could to minimise the impact of COVID-19 on screening services and the associated provision of diagnostic and treatment services, there is no doubt that these will have been affected. It is important to emphasise that any potential effects on particular indicators as a result of the COVID-19 response, will be greater than those noted in the current report since the COVID period is only a small proportion of the overall period included in the report. The full implications for BSA services with regard to COVID-19 will become clearer in the subsequent monitoring reports.

Māori women

Māori women have higher underlying breast cancer incidence and mortality rates than other women. If more Māori women have their breast cancer detected early the disparity in breast cancer mortality can be reduced. From data in the current report, to achieve equal rates of breast screening coverage between Māori and non-Māori non-Pacific women, an additional 2,540 Māori women needed to be screened each year (or an additional 213 women per month). However, to achieve the 70% target would have required an additional 4,900 per year. The higher incidence means that more cancers will be detected per 1,000 Māori women screened than among 1,000 other women (i.e. screening is more cost effective).

The proportions of cancers that were small or that had not spread to the lymph nodes were similar for Māori and non-Māori, and the rate of small cancers detected per 10,000 screens was higher for Māori than for non-Māori in this reporting period. Thus, BSA is certainly making a difference to breast cancer outcomes for Māori. The lower coverage and lower rate of timely rescreens among Māori are two key factors preventing BSA from achieving greater reductions in breast cancer mortality and morbidity among the Māori population.

A strong, ongoing commitment to prioritising Māori women is required to firstly achieve and maintain the target levels of coverage and timely rescreens, and then to achieve equitable rates.. However, due to the higher underlying rates of breast cancer, the non-Māori non-Pacific coverage rate would not achieve equitable outcomes for Māori women.

Māori women are also waiting longer for their first surgical treatment than non-Māori non-Pacific women. Regional differences in wait times may contribute to longer waiting times for Māori and may have been further challenged by the restrictions imposed during the COVID-19 response.

For other treatment indicators, the differences between Māori and non-Māori, non-Pacific women were small in magnitude and/or not statistically significant.

Pacific women

Pacific women have a higher incidence and mortality rate than non-Māori non-Pacific women. The BSA Mortality Evaluation found that participating in the screening programme had a significant beneficial impact on Pacific women's risk of dying from breast cancer⁴. Thus, BSA is a critical component in breast cancer control for Pacific women in Aotearoa.

Close to three-quarters of Pacific women in the screening age group reside in three LP regions: BreastScreen Waitemata Northland, BreastScreen Auckland Ltd, and BreastScreen Counties Manukau. The national rates are therefore strongly influenced by the performance of these LPs. Coverage is higher for Pacific women than for Māori, and higher than or similar to the coverage for all women, in each of these LPs, as well as for the overall national coverage rate.

However, this masks the fact that Pacific coverage in other LPs is lower than target and lower than non-Māori non-Pacific coverage, despite the smaller numbers of women to be screened. Equitable coverage for Pacific women will be achieved when participation is high in all regions. Relatively small additional numbers of Pacific women per month were required to achieve the target of 70% in the regions which have not yet reached this level.

Although coverage was higher overall for Pacific women, timely rescreening rates were lower than for non-Māori non-Pacific women after both initial and subsequent screens.

Pacific women were less likely to receive their first treatment surgery within 20 working days than non-Māori non-Pacific women (48% vs 56%), and less likely to receive radiotherapy after breast conserving surgery for invasive cancer (83% vs 91%). For other treatment indicators, the differences between Pacific and non-Māori non-Pacific women were small in magnitude and/or not statistically significant.

Impact of COVID-19

The data presented in this report were extracted from the national BSA database during January 2021. The data for BSA screening and assessment indicators related to the two-year period up to June 2020, and as such include some data that include the first national Alert Level 3 and 4 lockdown periods. As the treatment data in this report cover the four-year period to December 2019, these are not affected by COVID-19.

During Alert Level 4 (25th March to 27th April 2020) routine breast screening was paused. During Alert Level 3 (28th April to 13th May 2020) and Alert Level 2 (14th May to 8th June), routine breast screening slowly recommenced, with appropriate safeguards in place. However, these safeguards included restricting the number of women who could attend, and staffing issues as well as hesitancy among women to attend screening due to COVID restrictions, and/or other impacts of the COVID situation will have affected screening rates.

Given the relatively short time frame of COVID-19 Alert Level restrictions included in the report (i.e. three months of the 24-month period), it is not possible to make definitive conclusions regarding the impact of these restrictions on BSA screening and assessment indicators.

However, in periods subsequent to this report, there will likely be a substantial impact due to the COVID response on coverage of screening, re-screening, assessment and treatment of breast cancer. This is likely to be most evident in the northern areas of the country, i.e. those covered by BSWN, BSAL and BSCM, as well as some areas covered by BSM, due to regional lockdowns in August 2020, February 2021 and August to November 2021.

Despite the current limited availability of evidence, it is essential that BSA undertake to rectify inequities which are very likely to have widened as a result of the COVID-19 restrictions. Pro-equity invitation strategies which prioritise Māori and Pacific women having initial or subsequent screens are one strategy towards achieving equitable outcomes in key areas of BSA regarding coverage and timely rescreening which in turn will have positive impacts on breast cancer mortality and morbidity among Māori and Pacific populations. Support to screening services may need further resourcing in pandemic recovery periods.

⁴ Ministry of Health. 2015. Summary of the BreastScreen Aotearoa Mortality Evaluation 1999–2011. Wellington: Ministry of Health.

Is BSA making a difference?

- BSA met its goals for early detection and treatment of breast cancers among screened women, but not its goals for equitable screening coverage and timely rescreening.
- Over half the invasive breast cancers detected by BSA were still small and most had no nodal involvement. These cancers have a better prognosis and reduced morbidity from treatment.
- Māori women were more likely than non-Māori to have a small cancer detected by BSA. Māori coverage decreased at the same rate as non-Māori during the first six months of the pandemic. Prioritising Māori in scheduling and recruitment efforts during and after the COVID-19 pandemic thus remains critical to achieving equitable outcomes from breast cancer.
- Pacific women had similar overall coverage to non-Māori non-Pacific women and similar rates of small cancers detected. However, coverage of Pacific women also decreased during the early months of the pandemic.
- Women aged 45–49 years had lower detection rates, reflecting the lower underlying incidence, but the proportions of screen-detected cancers that were small were similar to those of older women.
- Four out of five women had breast conserving surgery, with most going on to have radiotherapy (89%). Chemotherapy and hormone therapy rates were similar for Māori, Pacific and other women.
- BSA aims to minimise harms by keeping false positive rates and open biopsy rates as low as possible. These indicators were within the target ranges.
- These indicators show that BSA is making a positive difference to breast cancer outcomes in Aotearoa.

BSA provides a high-quality breast cancer diagnostic service and monitors the quality of treatments received by women whose cancer is detected by BSA. This enables women in Aotearoa to receive a best practice, evidence-based pathway through the breast cancer care continuum.

The COVID-19 pandemic continues to present challenges to BSA as new outbreaks affect service provision and the ability of communities to access screening. Significant further resources – financial, technical, workforce, and community based – will be needed to manage the impacts of the pandemic on the screening programme, including its providers of screening, assessment, treatment, and support. Given Māori and Pacific communities were most affected in the 2021 outbreak of the Delta variant of COVID-19, mostly in the greater Tamaki Makaurau (Auckland) region, this region may require specific support to recover from the Delta outbreak and work towards equitable coverage. Delayed elective surgical operations, including for breast cancer, may also affect BSA's mortality outcomes. A systematic review by Johnson et al (2021) suggests a delay in surgery of 12 weeks impacts overall survival for Stage I and II breast cancers⁵ (the majority of those diagnosed by BSA). The Omicron outbreak will no doubt bring new challenges.

Maximising benefits

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability. The risk of dying from breast cancer is also reduced.

Over half of the invasive cancers detected from initial screens were small (15mm or less in diameter) as were nearly two-thirds of invasive cancers detected from subsequent screens. Over 70% of cancers had no nodal involvement. Most women were treated with breast conserving surgery, over 80% had a sentinel node biopsy as their first axillary procedure, and 86% only underwent a single excisional treatment procedure.

The move to an opt-off breast screening register in the coming years should also support BSA's equity goals as it should reduce barriers to enrolment in the programme.

⁵ Johnson BA, Waddimba AC, Ogola GO, Fleshman JW Jr, Preskitt JT. A systematic review and meta-analysis of surgery delays and survival in breast, lung and colon cancers: Implication for surgical triage during the COVID-19 pandemic. *Am J Surg.* 2021;222(2):311-318. doi:10.1016/j.amjsurg.2020.12.015

Minimising harms

High quality screening programmes aim to minimise any harms from screening, since well women are invited to participate in an intervention. Possible harms include unnecessary procedures and surgery from false positive screens, or increased anxiety while waiting for assessment or biopsy results.

BSA achieved most targets relevant to harm minimisation, including low numbers of women recalled for technical reasons; false positive rates were on target; nearly all women had a definitive diagnosis without undergoing open surgery; the benign open biopsy rates were on target as were the timely receipt of needle biopsies.

Just over half of women received their open biopsy or their first surgical treatment within 20 working days of their final diagnosis. Waiting for biopsies or treatment can heighten anxiety levels for some women and potentially affect outcomes. These indicators may be further impacted by hospital restrictions during the next reporting periods as the pandemic continues.

The effectiveness of mammography screening depends on regular rescreening within recommended screening intervals. BSA aims to have most women rescreened within 27 months of a previous screen. During this reporting period, BSA reduced the gap between Māori, Pacific and other women aged 45–49 years in the proportions rescreened after an initial screen or subsequent screen. Among women aged 50–67 years at their previous screen, the rescreening gaps reduced for subsequent screens but not for initial screens. This indicates the prioritisation of Māori and Pacific women in screening scheduling may be having an effect on the programme overall, although these trends varied between LPs. “Of all the harms associated with breast screening, the greatest harm comes from non-attendance.”⁶ Increasing the proportion of Māori and Pacific women whose cancer is diagnosed early through breast screening is one of the most critical pathways for achieving equitable breast cancer mortality rates.

In summary, BSA is providing a high-quality screening service to women in Aotearoa and contributing to reduced illness and deaths from breast cancer. Most potential harms are being minimised. Catching up on backlogs of missed screens due to the pandemic and achieving equitable screening coverage and timely rescreening are key challenges facing the programme.

⁶ British Institute of Radiology. 2019 Breast screening: insights and controversies — an interview with Dr Laszlo Tabar 19 February 2019. <https://www.birpublications.org/page/podcasts/2019/breast-screening-tabar>

Introduction

This report summarises the performance of BreastScreen Aotearoa (BSA) based on quality indicators for women screened during the two-year period to 30 June 2020. Treatment indicators are presented for women diagnosed through screening during the four-year period to December 2019.

Breast cancer is the most commonly diagnosed cancer among women in Aotearoa New Zealand. Screening aims to detect cancers at an early stage when tumours are more amenable to treatment. A properly organised breast screening programme can significantly reduce illness and death from breast cancer.

BSA offers free two-yearly mammographic screening to women aged 45 to 69 years. It plays a vital role, firstly by finding breast cancer tumours at a very early and treatable stage; and secondly by systematically following up women whose cancer is found by the screening programme to ensure timely pathways through the cancer care continuum. Women screened by BSA have a third lower risk of dying from breast cancer than women who are not screened⁷.

Māori and Pacific mortality rates from breast cancer are disproportionately higher than those of other women⁸ and more equitable outcomes could be achieved if more Māori and Pacific women were diagnosed at an earlier stage. For this reason, BSA prioritises screening these women and those who are unscreened or under-screened.

This report includes tables and graphs for each quality indicator. This report, and the tables and graphs, are also available in an online data tool on the [NSU's website](#). Previous monitoring reports and details of the indicator measures are also available online.

This report summarises the results of BSA quality indicators related to coverage, screening quality and assessment, early detection, and timeliness for women screened between 1 July 2018 and 30 June 2020. Breast cancer treatment indicators are summarised for women whose breast cancer was detected by BSA during the four-year period to 31 December 2019.

The period covered by this report includes 5 months in which Aotearoa was affected by the COVID-19 pandemic, from February to June 2020. Routine breast screening was paused during Alert Level 4 from 25 March to 27 April 2020. Screening recommenced during Alert Level 3 (28 April to 13 May 2020 and Alert Level 2 (14 May to 8 June) but with reduced numbers due to the need for appropriate safeguards and other impacts of COVID. The full impact of the pandemic on breast screening is not reflected in these data since three-quarters of the period was prior to the pandemic (July 2018-January 2020).

BSA has eight Lead Provider (LP) regions (see Figure 1). Each LP is responsible for providing or subcontracting mammography screening and assessment services in their region. Note BreastScreen Auckland Limited was operating during this reporting period but has since been replaced by another Lead Provider. Support to Screening Providers are contracted by the National Screening Unit (NSU) to support women from priority groups to screening and assessment. District Health Boards (DHBs) provide breast cancer treatment after diagnosis. Surgery is performed by DHB services and private providers; oncology and radiation therapy are provided by six Cancer Centres (or by private providers in some areas). Data on the treatment provided to women whose breast cancer was detected by BSA is collected by each LP and reported to the NSU.

⁷ Ministry of Health. 2016. Summary of the BreastScreen Aotearoa Mortality evaluation 1999–2011. Wellington: Ministry of Health. Available on www.health.govt.nz

⁸ Ministry of Health. 2016. Cancer: New registrations and deaths 2013. Wellington: Ministry of Health.

National Indicator Overviews for Māori, Pacific, Total women


This section provides national overview charts of how well BSA is achieving the targets and which indicators require continued focus. Charts are provided for Māori, Pacific and total women aged 50–69 years.

Data for most indicators are for the two-year time period 1 July 2018 to 30 June 2020, however some detection indicators and all treatment indicators cover the 4-year period 1 January 2016 to 30 December 2019 in order to maximise numbers and increase statistical precision.

The charts show the percentage difference of each indicator from the target value. The central line of the graph represents the target and all indicators with bars above this line achieved or exceeded the target, those below the line were outside the target value, if the confidence interval did not include the target value (central line).


Indicators that do not have targets developed are not included in these charts.

Figure 2: National Overview, Māori women, 50 to 69 years




For Māori women aged 50–69 years, BSA met or exceeded the target values for: screening quality; assessment quality; invasive cancer detection (including small and node-negative cancers); preoperative diagnosis, benign open biopsy rate; timeliness of screening results and needle biopsies; and breast conserving surgery rates. Indicators outside the target range included: timeliness of first offer of assessment, first treatment surgery and open biopsies; radiotherapy for invasive cancer; coverage; and rescreening within 27 months (especially after an initial screen). 9,805 additional Māori women needed to be screened to achieve the 70% coverage target. Māori women comprised 12% of the eligible population but 39% of the additional numbers needed to achieve the target for all women.

Figure 3: National Overview, Pacific women aged 50 to 69 years



For Pacific women aged 50–69 years, BSA met or exceeded the targets values for: overall coverage; screening quality; assessment quality; benign biopsy rates and preoperative diagnosis; invasive cancer detection; breast conserving surgery; timeliness of screening results and needle biopsies. Indicators not meeting target values included: timeliness of first surgical treatment and open biopsies; timely routine rescreening; timeliness of first offer of assessment and biopsy results.

Figure 4: National Overview, Total women aged 50 to 69 years



For total women aged 50–69 years, BSA met or exceeded the target values for: rescreening after a subsequent screen; screening quality; assessment quality, open biopsy rate (but not weight) and preoperative diagnosis; invasive cancer detection; breast conserving surgery. Indicators not meeting the target values included: overall coverage; timely rescreens after an initial screen; timely first offer of assessment; timely open biopsies; benign open biopsy weight; timely reporting of biopsy results; timely first surgical treatment; and radiotherapy for invasive cancer. An additional 25,432 women needed to be screened to reach the 70% coverage target.

Lead Provider Indicator Overviews for Māori, Pacific and Total women aged 50–69 years

Introduction

This section provides an overview chart for each Lead Provider (LP) of how well they are achieving the targets and which indicators require continued focus. Charts are provided for Māori, Pacific and total women aged 50–69 years. For some LPs the relatively small number of Pacific women means there are too little data to interpret the results for some indicators.

Data for most indicators are for the two-year time period 1 July 2018 to 30 June 2020, however some detection indicators and all treatment indicators cover the 4-year period 1 January 2016 to 30 December 2019 in order to maximise numbers and increase statistical precision.

The data presented in the graphs show the percentage difference of each indicator from the target value. The central line of the graph represents the target and all indicators with bars above this line achieved or exceeded the target, those below the line were outside the target value, if the confidence interval did not include the target value (central line).

Indicators that do not have targets developed are not included in the overview charts.

BreastScreen Waitemata Northland (BSWN) Overview

Figure 5: BSWN Overview, Māori women aged 50 to 69 years




Figure 6: BSWN Overview, Pacific women aged 50 to 69 years





Figure 7: BSWN Overview, Total women aged 50 to 69 years



BreastScreen Waitemata Northland (BSWN)

During the two years to 30 June 2020 BSWN screened 80,099 women aged 45–69 years (63% of the eligible population), including 10,071 Māori (64%) and 3,705 Pacific women (68%). Overall, 82 breast cancers were detected from initial screens (65 invasive) and 408 from subsequent screens (309 invasive), with 96% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met, with 55% of initial and 69% of subsequent screen-detected cancers ≤ 15 mm. A majority had no nodal involvement (69% initial and 82% subsequent).

Among BSWN women diagnosed with invasive cancer ≤ 20 mm over the 4 years to June 2020, 84% had breast conserving surgery, of whom 92% also had radiotherapy. Sentinel node biopsy was the first axillary procedure for 80%. Most women who had DCIS ≤ 20 mm detected by BSWN had breast conserving surgery (87%). 61% had their first treatment surgery within 20 working days of receiving their final diagnostic results.

Māori women were more likely than non-Māori to have breast cancer detected and the proportions of small and node-negative cancers were similar in both groups. 17 cancers (14 invasive) were detected from initial screens and 85 from subsequent screens (69 invasive) among Māori women aged 45–69 years. Treatment indicators were similar for Māori and non-Māori women, apart from the proportion having their first treatment surgery within 20 working days which was lower for Māori (40% compared to 65%).

BSWN detected 1 invasive cancer from initial screens among Pacific women aged 45–69 and 23 breast cancers from subsequent screens (15 invasive). A third of invasive cancers detected were ≤ 15 mm, and three-quarters were node negative. Treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability, and reduce risk of dying from breast cancer. Over half of the invasive cancers detected by BSWN were small and two-thirds had no nodal involvement. Most women were treated with breast conserving surgery and only underwent a single surgical procedure. These indicators show BSWN is making a positive difference to breast cancer mortality and morbidity in their region.

BSWN achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were on target; nearly all women had a definitive diagnosis without undergoing open surgery; the benign biopsy rate was on target; as was the timely receipt of needle biopsy. The percentage of benign open biopsies weighing < 30 g was within the target range for women aged 45–49 but appears to be declining for women aged 50–69 years (although the trend is not significant).

The next section relates to the BSWN overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSWN area were within the target range. BSWN is doing particularly well for Māori women in the areas of screening and assessment quality, breast cancer detection, treatment, and most timeliness indicators.

In a few instances, indicators fell outside the target range:

- Coverage
 - o Overall coverage for Māori women was 64% (target 70%). This indicator decreased between December 2019 and June 2020 and may have been affected by COVID restrictions. BSWN needed to have screened a further 761 Māori women in this age group to reach the target.
 - o The proportion of women rescreened within 27 months of an initial screen (56%) was outside the target range of $\geq 75\%$. Only 38 additional Māori women were needed to reach the target. Timely rescreening was higher after a subsequent screen (80%) though outside the target range of $\geq 85\%$, with 333 more women needed to reach the target range.
- Timeliness
 - o The targets of $\geq 90\%$ were met or were within the confidence interval for most timeliness indicators, including screening results, first assessment offer, needle biopsies, biopsy results.
 - o The targets were not met for the receipt of open biopsies within 20 working days (35%) nor for first treatment surgery within 20 working days (36%).

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSWN area were within the target range. BSWN is doing particularly well for Pacific women in the areas of overall coverage, screening and assessment quality, breast cancer detection, treatment, and most timeliness indicators.

Indicators that fell outside the target range included:

- Coverage
 - o Routine rescreens within 27 months of an initial screen (59%), with a target of $\geq 75\%$. However, this indicator has shown steady improvement over the last four years, and only 11 additional women were needed to reach the target.
- Timeliness
 - o First surgical treatment within 20 working days, women screened during the 4 years to December 2019 (57%, target 90%).

All women aged 50–69 years

The majority of indicators for women of all ethnicities aged 50–69 years in the BSWN area were within the target range. BSWN is doing particularly well in the areas of screening and assessment, breast cancer detection, and treatment.

Indicators fell outside the recommended range in the areas of:

- Coverage
 - o Overall coverage was 64% (target $\geq 70\%$) declining between December 2019 and June 2020, indicating impact from COVID restrictions.
 - o Routine rescreening within 27 months after an initial screen was 58% (target $\geq 75\%$). This indicator decreased slightly from the previous years.
- Timeliness
 - o The targets of $\geq 90\%$ were met or were within the confidence interval for most timeliness indicators, including screening results, first assessment offer, needle biopsies, biopsy results.
 - o The targets were not met for the receipt of open biopsies within 20 working days (54%) nor for first treatment surgery within 20 working days (61% over a four-year period, although this was the highest of all LPs).

Other indicators which may require attention for all women include:

- o Routine rescreens within 27 months of a subsequent screen (81% with a target of $\geq 85\%$). This indicator, while close to the recommended range, dropped slightly in the last year, indicating an effect of COVID restrictions. Over the two years, 2,163 additional women were needed to achieve the target.

Focus on Equity

BSWN successfully achieved equitable coverage and routine rescreening rates for Māori, Pacific, and non-Māori non-Pacific women. Screening and assessment quality, the proportions of small and node-negative breast cancer detected, treatment indicators, and most timeliness indicators were similar for each group.

One indicator showing possible inequity was time to first surgery. Waiting longer for surgery can heighten anxiety levels and potentially affect outcomes. The proportions of women having their first surgical treatment within 20 working days of receiving their final diagnostic results were 36% for Māori women, 57% for Pacific women, and 67% for non-Māori non-Pacific women. Wait times for surgery may be affected by the COVID pandemic as DHBs develop strategies to manage staffing and theatre or ICU availability during lockdown periods or outbreaks.

BreastScreen Counties Manukau (BSCM) Overview

Figure 8: BSCM Overview, Māori women aged 50 to 69 years




Figure 9: BSCM Overview, Pacific women aged 50 to 69 years





Figure 10: BSCM Overview, Total women aged 50 to 69 years



BreastScreen Counties Manukau (BSCM)

During the two years to 30 June 2020 BSCM screened 53,707 women aged 45–69 years (69% of the eligible population), including 6,162 Māori (61%) and 10,284 Pacific women (77%). Overall, 59 breast cancers were detected from initial screens (44 invasive) and 245 from subsequent screens (185 invasive), with 97% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met. A third of initial and 56% of subsequent screen-detected cancers were ≤15mm in diameter. A majority had no nodal involvement (68% initial and 80% subsequent).

Among BSCM women diagnosed with invasive cancer ≤20mm over the 4 years to June 2020, 78% had breast conserving surgery (BCS), of whom 83% also had radiotherapy. Sentinel node biopsy was the first axillary procedure for 82%. Over two-thirds of women with DCIS ≤20mm had BCS (71%). 52% had their first treatment surgery within 20 working days of receiving their final diagnostic results.

Māori women were more likely than non-Māori to have breast cancer detected and the proportions of small and node-negative cancers were similar in both groups. 11 breast cancers (9 invasive) were detected from initial screens and 38 (29 invasive) from subsequent screens among Māori women aged 45–69 years. Treatment indicators were generally similar for Māori and non-Māori women.

Pacific women were more likely than non-Māori non-Pacific women to have a cancer detected from an initial screen, with the difference not significant for subsequent screens. BSCM detected 18 breast cancers (11 invasive) from initial screens among Pacific women aged 45–69 years and 51 cancers (42 invasive) from subsequent screens. A third of initial screen-detected and just under half of subsequent screen-detected invasive cancers were ≤15mm in diameter, with three-quarters of node negative. Treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability, and reduce risk of dying from breast cancer. Half of invasive cancers detected by BSCM were small and over three-quarters had no nodal involvement. Most women (three-quarters) were treated with BCS and 90% underwent a single excisional procedure. These indicators show BSCM is making a positive difference to breast cancer mortality and morbidity in their region.

BSCM achieved targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were in the target ranges; nearly all women had a definitive diagnosis without undergoing open surgery; the benign biopsy rate and the percent of benign open biopsies <30gm were on target; as was the timely receipt of needle biopsy.

The next sections relate to the BSCM overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSCM area were within the target range. BSCM is doing particularly well for Māori women in the areas of screening and assessment quality, breast cancer detection, and treatment.

In a few instances, indicators fell outside the target range:

- Coverage
 - Overall coverage was 61% (target >70%). This appears to be trending down since December 2018, with a sharper decline from December 2019 to June 2020, indicating possible impacts of COVID restrictions. An additional 358 Māori women per year needed to be screened over two years to achieve the target coverage.
 - The proportion having a routine rescreen within 27 months of an initial screen was 48% (target ≥75%). Only 24 more per year needed to reach the target. Timely rescreening after a subsequent screen was 75% (target ≥85% with 128 more per year needed to be rescreened within 27 months to reach the target).
- Timeliness
 - The targets of ≥90% were met for most timeliness indicators, including receipt of screening results, needle biopsies, biopsy results.
 - Other indicators included: offer of assessment within 15 working days (85%); open biopsy within 20 working days (33% of 6 women); and first surgical treatment within 20 working days (59% over a four-year period).

Another indicator which may require consideration by BSCM for Māori women include:

- Treatment
 - Among Māori women diagnosed with invasive cancer during the 4 years to December 2019 who had breast conserving surgery, 79% also had radiotherapy (target $\geq 95\%$).

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSCM area were within the target range. BSCM is doing particularly well for Pacific women in the areas of overall coverage (77%), screening and assessment quality, breast cancer detection, and treatment.

Indicators that fell outside the target range were in areas of:

- Rescreening within 27 months
 - The proportion of Pacific women rescreened within 27 months of an initial screen was 53% (target $\geq 75\%$) with only 41 more per year needed to reach the target. The proportion rescreened within 27 months of a subsequent screen was 79% (target $\geq 85\%$) with a further 183 more per year needed to reach the target.
- Timeliness
 - The targets of $\geq 90\%$ were met for timely receipt of screening results, needle biopsies, biopsy results.
 - Targets were not met for offer of assessment within 15 working days (84%); open biopsy within 20 working days (30% of 10 women); and first surgical treatment within 20 working days (51% over a four-year period).

Total women aged 50–69 years

The majority of indicators for total women aged 50–69 years in the BSCM area were within the target range. BSCM is doing particularly well in the areas of screening and assessment, breast cancer detection, and treatment.

Where indicator targets fell outside the recommended range were in areas of:

- Coverage
 - Overall coverage and routine rescreens after initial screens both decreased in the last 12 months of the reporting period, indicating impacts of COVID restrictions
 - Coverage declined between December 2019 and June 2020 from 74% to below target at 68%. A further 488 women per year needed to be screened to achieve 70%.
 - The proportion who were routinely rescreened within 27 months of an initial screen was 64% (target $\geq 75\%$), with an additional 117 per year needed to achieve the target. The target of $\geq 85\%$ rescreened after a subsequent screen was met by BSCM.
- Timeliness
 - The targets of $\geq 90\%$ were met for most timeliness indicators, including receipt of screening results, needle biopsies, biopsy results.
 - Indicators outside the target ranges were: offer of assessment within 15 working days (87%); open biopsy within 20 working days (29% of 48 women); and first surgical treatment within 20 working days (53% over a four-year period).

Another indicator which may require consideration include:

- Treatment
 - 82% of women screened during the 4 years to December 2019 who had breast conserving surgery for invasive cancer also had radiotherapy (target $\geq 95\%$).

Focus on Equity

Coverage is a key equity focus. In this period, which included the first 6 months of the pandemic, coverage for all women aged 50 to 69 years was 68%, 60% for Māori and the high rate of 77% for Pacific women. To achieve an equal level of coverage as non-Māori women, BSCM needed to have screened an additional 273 Māori women per year.

Timely routine rescreening after an initial screen was outside the target range for all women aged 50–69 years (64%), but lower for Māori (48%) and Pacific women (53%). To achieve equal levels of timely rescreening, an additional 15 Māori women and 28 Pacific women per year were needed. However equal coverage or rescreening rates may not achieve equitable outcomes, since underlying rates of breast cancer are higher in Māori women.

BreastScreen Auckland Limited (BSAL) Overview

Figure 11: BSAL Overview, Māori women aged 50 to 69 years




Figure 12: BSAL Overview, Pacific women aged 50 to 69 years





Figure 13: BSAL Overview, Total women aged 50 to 69 years



BreastScreen Auckland Limited (BSAL)

During the two years to 30 June 2020 BSAL screened 46,250 women aged 45–69 years (68% of the eligible population), including 3,008 Māori (62%) and 4,580 Pacific women (69%). Overall, 47 breast cancers were detected from initial screens (30 invasive) and 203 from subsequent screens (135 invasive), with 91% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met in both age groups, with 55% of initial and 67% of subsequent screen-detected cancers ≤ 15 mm in diameter. A majority had no nodal involvement (57% initial and 76% subsequent).

Among BSAL women diagnosed with invasive cancer ≤ 20 mm over the 4 years to June 2020, 86% had breast conserving surgery (BCS). Of those who had BCS for invasive cancer, 82% had radiotherapy (target 95%). Sentinel node biopsy was the first axillary procedure for 88%. Over four-fifths of women with DCIS ≤ 20 mm had BCS. 50% had their first treatment surgery within 20 working days of receiving their final diagnostic results.

Māori women were more likely than non-Māori to have breast cancer detected and the proportions of small and node-negative cancers were similar in both groups. Five breast cancers (4 invasive) were detected from initial screens and 17 (14 invasive) from subsequent screens among Māori women aged 45–69 years. Treatment indicators were generally similar for Māori and non-Māori women.

BSAL detected 6 breast cancers (4 invasive) from initial screens among Pacific women aged 45–69 years and 23 cancers (18 invasive) from subsequent screens. A quarter of initial screen- and three-quarters of subsequent screen-detected invasive cancers were ≤ 15 mm in diameter, with 90% of all invasive cancers node negative. Treatment indicators were similar to those of non-Māori non-Pacific women, apart from the proportion of women receiving their first treatment surgery within 20 working days, which was lower for Pacific women (36% compared to 54%).

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability, and reduce risk of dying from breast cancer. Two-thirds of the invasive cancers detected by BSAL were small and nearly three-quarters had no nodal involvement. Most women were treated with breast conserving surgery and only underwent a single surgical procedure. These indicators show BSAL is making a positive difference to breast cancer mortality and morbidity.

BSAL achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were on target; nearly all women had a definitive cancer diagnosis without undergoing open surgery; the targets for the benign biopsy rate and biopsies < 30 g were met or within the confidence interval; as was the timely receipt of needle biopsy. The proportion of women receiving their first offer of assessment within 15 working days improved significantly and is close to the target range.

The next section relates to the BSAL overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSAL area were within the target range. BSAL is doing particularly well for Māori women in the areas of screening and assessment, breast cancer detection from subsequent screens and most timeliness indicators. No invasive cancers were detected from initial screens.

In a few instances, target indicators fell outside the recommended range, including:

- Coverage
 - o Overall coverage of Māori women aged 50–69 was 60% (target $> 70\%$), with little change over time. There was some increase in coverage in the 45–49 age group to 69% which may flow through to the older age group in future years (although COVID restrictions will likely affect coverage in the next reporting period).
 - o Routine rescreening within 27 months of an initial screen was 55% (target $\geq 75\%$), with only 15 more women were needed to reach the target. Routine rescreening after a subsequent screen was close to the 85% target at 82%, with only 57 additional women needed to reach the target.
- Timeliness
 - o Among women screened during the 4 years to December 2019, 38% received their first treatment surgery within 20 working days (target $\geq 90\%$).

Another indicator which may require attention for Māori women was:

- Treatment
 - 73% of women who had breast conserving surgery for invasive cancer went on to have radiotherapy (target $\geq 95\%$) among women screened during the 4 years to December 2019. This indicator may be trending down.

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSAL area were within the target range, although for many indicators there is a large degree of uncertainty due to the small numbers of women included in the calculation.

Indicators which may require attention for Pacific women include:

- Coverage
 - Overall coverage was on target at 69%. However, routine rescreening within 27 months was 54% after an initial screen (target $\geq 75\%$) showing little change over time, and 79% after a subsequent screen (target $\geq 85\%$) showing some increase in the last 2 years.
- Timeliness
 - Most timeliness targets of 90% were met for Pacific women, including screening results, assessments, needle biopsies, open biopsies, and biopsy results. However, among women screened over four years to December 2019, only 32% received their first surgical treatment within 20 working days.

All women aged 50–69 years

The majority of indicators for total women aged 50–69 years in the BSAL area were within the target range. BSAL is doing particularly well in the areas of screening and assessment quality, breast cancer detection, treatment and timeliness.

Indicators that fell outside the recommended range were in areas of:

- Coverage
 - Routine rescreening within 27 months of an initial screen was 67% (target $\geq 75\%$), showing an improving trend, with only 60 additional women per year required to reach the target value.
- Treatment
 - Invasive cancer having radiotherapy after breast conserving surgery, women screened during the 4 years to December 2019 was 81% (target $\geq 95\%$).
- Timeliness
 - First surgical treatment within 20 working days for women screened during the 4 years to December 2019 was 50% with a target of 90%.

Focus on Equity

The main focus for BSAL to achieve equity for Māori women and for Pacific women is in the area of **coverage**. Coverage for Māori women was 60%, whereas for non-Māori and Pacific women it was 69%. To achieve an equal level of coverage as non-Māori non-Pacific women, BSAL needed to have screened an additional 178 Māori women and 14 Pacific women per year. It is important to note that equal coverage rates are unlikely to achieve equity in outcomes, since the underlying rate of breast cancer in Māori and in Pacific women is higher than in non-Māori non-Pacific women.

Timely routine rescreening after an initial screen was outside the target range for non-Māori non-Pacific women (67%), but was lower for Māori (55%) and Pacific women (54%). The target for non-Māori non-Pacific women was not met, so achieving this level of equal rescreening rates is not the final goal, but a step on the way to providing an excellent service. For rescreening after subsequent screens there was some movement towards equity for both Māori and Pacific women.

Around half of non-Māori non-Pacific women received their first treatment surgery within 20 working days, compared to around a third of Māori and Pacific women. It is acknowledged that some of this delay is outside the remit of the lead provider, and lies with the ability of the DHB to equitably meet the needs of women with breast cancer.

BreastScreen Midlands (BSM) Overview

Figure 14: BSM Overview, Māori women aged 50 to 69 years




Figure 15: BSM Overview, Pacific women aged 50 to 69 years





Figure 16: BSM Overview, Total women aged 50 to 69 years



BreastScreen Midlands (BSM)

During the two years to 30 June 2020 BSM screened 80,054 women aged 45–69 years (63% of the eligible population), including 13,687 Māori (55%) and 1,216 Pacific women (59%). Overall, 70 breast cancers were detected from initial screens (48 invasive) and 424 from subsequent screens (327 invasive), with 94% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met in both age groups, with 61% of initial and 64% of subsequent screen-detected cancers ≤ 15 mm in diameter. A majority had no nodal involvement (63% initial and 75% subsequent).

Among BSM women diagnosed with invasive cancer ≤ 20 mm over the 4 years to June 2020, 89% had breast conserving surgery (BCS). Of women who had invasive cancer ≤ 20 mm and BCS, 84% had radiotherapy (target 95%). Sentinel node biopsy was the first axillary procedure for 84%. Most women with DCIS ≤ 20 mm had breast conserving surgery (92%). 57% had their first treatment surgery within 20 working days of receiving their final diagnostic results.

BSM detected 27 breast cancers (17 invasive) from initial screens and 107 (87 invasive) from subsequent screens among Māori women aged 45–69 years. Māori women were more likely than non-Māori to have breast cancer detected and the proportions of small and node-negative cancers were generally similar in both groups. Treatment indicators were generally similar for Māori and non-Māori women, although Māori women were slightly less likely to have a sentinel node biopsy as their first axillary procedure (78% compared to 86%).

BSM detected 2 breast cancers (1 invasive) from initial screens among Pacific women aged 45–69 years and 7 cancers (4 invasive) from subsequent screens. Four-year treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability, and reduce risk of dying from breast cancer. Over half the cancers detected by BSM were small and around three-quarters had no nodal involvement. Most women were treated with breast conserving surgery and only underwent a single surgical procedure. These indicators show BSM is making a positive difference to breast cancer mortality and morbidity in their region.

BSM achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were on target; nearly all women had a definitive cancer diagnosis without undergoing open surgery; the benign biopsy rate was on target; as was the timely receipt of needle biopsy. The percentage of benign open biopsies weighing < 30 g (81%) was outside the target range (> 90 %).

The next section relates to the BSM overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSM area were within the target range. BSM is doing particularly well for Māori women in the areas of screening and assessment and breast cancer detection.

Target indicators were outside the recommended range for specific areas for:

- Coverage
 - Overall coverage of eligible women. This indicator has remained outside of the target (> 70 %) reaching its lowest value (55%) for the June 2020 period, possibly as a result of COVID-19 restrictions.
 - Routine rescreening - both targets for initial (≥ 75 %) and subsequent (≥ 85 %) screens appear to have been consistently challenging to meet. These remained outside of the target range (46% for initial screens, 77% for subsequent screens).
- Timeliness (all targets ≥ 90 %)
 - Time taken for provision of screening results. This indicator has previously been well within the target but declined to 79% over the June 2019 to June 2020 period.
 - Time taken from screening visit to first offer of assessment had shown steady improvement from June 2015, reaching and maintaining target from Dec 2017–Dec 2018. Since that time, there has been a decline to 75%.
 - Women having an open biopsy procedure within 20 working days. This indicator has been consistently outside the recommended target range but with some suggestion of improvement to 58%.
 - Time taken from final diagnostic biopsy to reporting assessment results. This indicator has remained outside of the target range over the last 5 years trending downward to 73%.

- First surgical treatment within 20 working days among women screened during the 4 years to December 2019. This indicator has been consistently outside the target at 53%.
- Treatment
 - Invasive cancer treated with breast conserving surgery who had radiotherapy, women screened during the 4 years to December 2019. This indicator has been consistently outside the target range ($\geq 95\%$), decreasing to 70% in 2018, with a small increase to 75% in this reporting period. The proportion of non-Māori women having radiotherapy was higher at 86%.

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSM area were within the target range, although for a number of indicators there is a large degree of uncertainty (as seen in the wide confidence intervals), due to small numbers. BSM is doing particularly well for Pacific women in the areas of screening and assessment, breast cancer detection and treatment.

There were some indicators outside the recommended target range for Pacific women, specifically in the areas of:

- Coverage
 - Overall coverage of eligible women. This target ($>70\%$) has consistently been a challenge to meet, and there appears to be a gradual decline in the last reporting period in June 2020, to 60% of Pacific women compared to 64% in the previous period.
 - Routine rescreening (initial target $\geq 75\%$ and subsequent target $\geq 85\%$). These indicators remained outside the target ranges with 56% rescreened within 27 months of an initial screen and 79% receiving a timely rescreen after a subsequent screen.
- Timeliness (all targets $\geq 90\%$)
 - Time taken for provision of screening results. This indicator has previously been within the target range but has declined since June 2019 to 72%.
 - Time taken from screening visit to first offer of an assessment. After a steady movement towards this target, there has been a consistent decline for Pacific women in BSM since December 2017, with 74% offered an assessment appointment within 15 working days.
 - First surgical treatment, women screened during the 4 years to December 2019. 11 out of 17 Pacific women aged 50–69 years (65%) received their first treatment surgery within 20 working days.

Other indicators which may require attention for Pacific women include:

- Timeliness
 - Women receiving a needle biopsy within 5 working days of assessment. This indicator has previously been at 100% and remains within range but declined to 92% between December 2019-June 2020 and may have been adversely affected by COVID-19 restrictions on the operation of health services.

All women aged 50–69 years

The majority of indicators for women of all ethnicities aged 50–69 years in the BSM area were within the target range. BSM is doing particularly well in the areas of screening and assessment and breast cancer detection.

Some indicators were outside the recommended target range for all women, specifically in the areas of:

- Coverage
 - After a number of years of being very close to reaching this target ($>70\%$), this indicator declined to its lowest value of 63% in the most recent reporting period, indicating an impact of COVID restrictions. A further 6,618 women needed to be screened over two years to reach 70%.
 - Routine rescreening within 27 months – the target of $\geq 75\%$ for initial screens appears challenging to meet at 53% (a further 294 was needed per year to reach 75%) while for subsequent rescreens BSM remained close to the $\geq 85\%$ target at 83%.
- Screening and assessment
 - Benign open biopsy weight (target $>90\%$). This indicator was 80% (65 of 80 biopsies).
- Treatment

- Invasive cancer having radiotherapy, women screened during the 4 years to December 2019 (target $\geq 95\%$). This indicator was 84%.
- Timeliness (all targets $\geq 90\%$)
 - Provision of screening results within 10 working days. This indicator was previously within the target range but fell to 79% in this reporting period.
 - First offer of an assessment within 15 working days. Previously in the target range, this indicator fell to 79%.
 - Open biopsy procedure within 20 working days. This indicator remained at 44%.
 - Final diagnostic biopsy reported within 5 working days. This indicator showed a small improvement to 80%.
 - First surgical treatment within 20 working days, women screened during the 4 years to December 2019. This indicator remained just under 60%.

Focus on Equity

The main focus for BSM to achieve equity in for Māori and for Pacific women is in the area of **coverage**.

Coverage

Coverage for non-Māori non-Pacific women aged 50 to 69 years was 65%, while it was 55% for Māori women and 60% for Pacific women. There was a drop in coverage across all ethnic groups during this last reporting period. To achieve an equal level of coverage with non-Māori non-Pacific women, BSM would have to screen an additional 950 Māori women and 35 Pacific women per year. It is important to note that equal coverage rates are unlikely to achieve equity in outcomes, since the underlying rate of breast cancer in Māori and in Pacific women is higher than in non-Māori non-Pacific women.

Routine rescreening after an initial screen was not within the target range for non-Māori non-Pacific women (55%), similar for Pacific women (56%), but lower for Māori (46%). To achieve the target, BSM needed to rescreen an additional 83 Māori women per year within 27 months of their initial screen, but to achieve the same level as non-Māori, an additional 26 Māori women per year were required. However, as noted above, Māori and Pacific women have higher underlying breast cancer incidence which means higher rates of timely rescreening are likely required to achieve equitable outcomes.

BSM serves more than a quarter (26%) of the national eligible Māori population aged 45–69 years and 24% of all Māori screened by BSA were screened by BSM. This makes BSM a key screening provider for Māori women nationally. It has the largest number of eligible Māori women out of all LPs (25,100 aged 45–69 years) and screened the largest number of Māori women (13,687 in this reporting period). If BSM achieved 70% screening of Māori women aged 45–69, the number of Māori women needed to be screened to achieve the national target would decrease by 40%. This indicates that it is unlikely the national Māori coverage target could be achieved without significant increases in Māori coverage by BSM. BSM needed to screen a further 3,883 Māori women aged 45–69 over 2 years (or 1941 more per year) to reach 70%.

Timeliness

The indicator for time taken from final diagnostic biopsy to reporting assessment results (5d) was lower for Māori women (73% within five working days) compared to non-Māori (82%). This inequity has been evident for 2 years and possible reasons may need exploration.

BreastScreen Coast to Coast (BSCC) Overview

Figure 17: BSCC Overview, Māori women aged 50 to 69 years




Figure 18: BSCC Overview, Pacific women aged 50 to 69 years





Figure 19: BSCC Overview, Total women aged 50 to 69 years



BreastScreen Coast to Coast (BSCC)

During the two years to 30 June 2020 BSCC screened 65,491 women aged 45–69 years (67% of the eligible population), including 10,531 Māori (57%) and 971 Pacific women (61%). Overall, 50 breast cancers were detected from initial screens (39 invasive) and 293 from subsequent screens (216 invasive), with 97% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met in both age groups, with 54% of initial and 58% of subsequent screen-detected cancers ≤ 15 mm in diameter. A majority had no nodal involvement (67% initial and 79% subsequent).

Among BSCC women diagnosed with invasive cancer ≤ 20 mm over the 4 years to June 2020, 75% had breast conserving surgery (BCS). Among women who had invasive cancer and BCS, 91% had radiotherapy (target $\geq 95\%$). Sentinel node biopsy was the first axillary procedure for 79% (of those with breast cancers ≤ 30 mm). Most women with DCIS ≤ 20 mm had breast conserving surgery (83%). 45% had their first treatment surgery within 20 working days of receiving their final diagnostic results.

BSCC detected 17 breast cancers (15 invasive) from initial screens and 64 (46 invasive) from subsequent screens among Māori women aged 45–69 years. Māori women were more likely than non-Māori to have breast cancer detected from initial and subsequent screens and the proportions of small and node-negative cancers were comparable in both groups. Treatment indicators were generally similar for Māori and non-Māori women, although Māori women were slightly less likely to have a sentinel node biopsy as their first axillary procedure (69% compared to 82%) and less likely to have their first treatment surgery within 20 working days (35% compared to 48%).

BSCC detected no breast cancers from initial screens among Pacific women aged 45–69 years and 5 cancers (all invasive) from subsequent screens. Four-year treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability, and reduce risk of dying from breast cancer. Over half of invasive cancers detected by BSCC were small and three-quarters had no nodal involvement. Most women were treated with breast conserving surgery and underwent a single excisional procedure. These indicators show BSCC is making a positive difference to breast cancer mortality and morbidity in their region.

BSCC achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were low; nearly all women had a definitive diagnosis without undergoing open surgery; the benign open biopsy rate was low; and almost all needle biopsies were received within 5 days of assessment.

The next section relates to the BSCC overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSCC area were within the target range. BSCC is doing particularly well for Māori women in the areas of screening and assessment quality and breast cancer detection.

For a few indicators, results were outside the recommended target range for Māori women, specifically:

- Coverage
 - Overall coverage of eligible women. After a number of years of being around 65% (target $>70\%$), this indicator has declined since June 2019 to 58%, possibly affected by COVID restrictions.
 - Routine rescreening (initial). This target ($\geq 75\%$) has been consistently challenging to meet but declined to 63% in this most recent reporting period, while the non-Māori rate was within the target range at 79%.
- Timeliness
 - Time taken from screening visit to first offer of an assessment. This indicator has shown a slow decline away from target (90%) over the last 5 years to 67% for the current reporting period (similar to that of non-Māori).
 - Time taken from final diagnostic biopsy to reporting assessment results. The 90% target for this indicator was reached in June 2018 but has steadily declined since that time to 79%.
 - First surgical treatment within 20 working days among women screened during the 4 years to December 2019. This indicator remains well outside the target range (90%) at 38%.

Other indicators which may require attention by BSCC for Māori women include:

- Radiation therapy after breast conserving surgery for invasive cancer. This indicator was outside the target range of $\geq 95\%$, at 83%.

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSCC region were within the target range, although for many indicators there is a large degree of uncertainty due to small numbers. BSCC is doing particularly well for Pacific women in the areas of screening and assessment, breast cancer detection, treatment and timeliness.

For a few indicators, results were outside the recommended target range for Pacific women, specifically:

- Coverage
 - Overall coverage of eligible women. This indicator has been around 65% for the past 5 years but declined to its lowest value of 61% in the current reporting period, possibly affected by COVID restrictions. Just over 100 further Pacific women needed to be screened over the 2 years to reach the 70% target.

All women aged 50–69 years

The majority of indicators for women of all ethnicities aged 50–69 years in the BSCC area were within the target range. BSCC is doing particularly well in the areas of screening and assessment quality, breast cancer detection, and treatment.

- Coverage
 - Overall coverage of eligible women. This target (>70%) has consistently been met for the past five years, but declined for the first time in this reporting period to 67%, indicating an effect of COVID restrictions.
- Treatment
 - Invasive cancer having radiotherapy after breast conserving surgery, women screened during the 4 years to December 2019. This indicator was close to target ($\geq 95\%$) at 91%.
- Timeliness
 - Time taken from screening visit to first offer of an assessment. This indicator has shown a decline over recent reporting periods being at its lowest value of 67% for the two years ending June 2020.
 - Time taken from final diagnostic biopsy to reporting assessment results. This indicator has been close to the recommended target range of 90% in the past but showed a slow decline since 2018 to 83%.
 - Women having an open biopsy procedure within 20 working days. Only 14 women had an open biopsy during this biennium with 3 women having their biopsy within 20 working days.
 - First treatment surgery within 20 working days, women screened during the 4 years to December 2019. This indicator remained outside the 90% target range at 45%.

Focus on Equity

The main focus for BSCC to achieve equity in for Māori and for Pacific women is in the areas of **coverage**.

Coverage for non-Māori women aged 50 to 69 years was 69%, whereas it was 58% for Māori and 61% for Pacific women. To achieve equal coverage with non-Māori non-Pacific women, BSCC needed to have screened an additional 800 Māori women and 50 Pacific women per year. Equal coverage rates are unlikely to achieve equity in outcomes, since the underlying rate of breast cancer in Māori and in Pacific women is higher than in non-Māori non-Pacific women.

Routine rescreening after an initial screen met the target for all women (75%), but was substantially lower for Māori (63%) and for Pacific women (65%). To achieve equity in rescreening after initial screens compared to non-Māori women, it was necessary for BSCC to rescreen within 27 months an additional 37 Māori women each year. Routine rescreening after a subsequent screen was within the target range for all groups, but to achieve the same rate as non-Māori women BSCC needed to rescreen a further 268 Māori women per year and an additional 21 Pacific women per year.

BreastScreen Central (BSC) Overview

Figure 20: BSC Overview, Māori women aged 50 to 69 years




Figure 21: BSC Overview, Pacific women aged 50 to 69 years





Figure 22: BSC Overview, Total women aged 50 to 69 years



BreastScreen Central (BSC)

During the two years to 30 June 2020 BSC screened 52,649 women aged 45–69 years (66% of the eligible population), including 5,230 Māori (63%) and 2,725 Pacific women (62%). Overall, 47 breast cancers were detected from initial screens (37 invasive) and 280 from subsequent screens (220 invasive), with 95% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met in both age groups, with 51% of initial and 58% of subsequent screen-detected cancers ≤ 15 mm in diameter. The majority had no nodal involvement (87% initial and 80% subsequent).

Among BSC women diagnosed with invasive cancer ≤ 20 mm over the 4 years to June 2020, 90% had breast conserving surgery. Among women who had invasive cancer and breast conserving surgery, 95% had radiotherapy (on target). Sentinel node biopsy was the first axillary procedure for 85% (of those with breast cancers ≤ 30 mm). Nearly all women with DCIS ≤ 20 mm had breast conserving surgery (97%). 59% had their first treatment surgery within 20 working days of receiving their final diagnostic results.

Among Māori women aged 45–69 years, BSC detected 10 breast cancers (all invasive) from initial screens and 20 (19 invasive) from subsequent screens. Māori women were more likely than non-Māori to have breast cancer detected from initial screens but not from subsequent screens. The proportions of small and node-negative cancers were similar in both groups. Treatment indicators were similar for Māori and non-Māori women.

BSC detected 6 breast cancers (4 invasive) from initial screens among Pacific women aged 45–69 years and 21 cancers (15 invasive) from subsequent screens. Four-year treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability, and reduce risk of dying from breast cancer. Over half of invasive cancers detected by BSC were small and four-fifths had no nodal involvement. Most women were treated with breast conserving surgery and only underwent a single excisional procedure. These indicators show BSC is making a positive difference to breast cancer mortality and morbidity in their region.

BSC achieved most targets relevant to harm minimisation. False positive rates were on target; almost all women had a definitive diagnosis without undergoing open surgery; most had a timely needle biopsy; the benign biopsy rate was low and most benign biopsies weighed < 30 gm (86%). The technical recall rates were outside the $< 0.5\%$ target range for fixed and mobile sites.

The next section relates to the BSC overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSC area were within the target range. BSC is doing particularly well for Māori women in the areas of coverage and rescreening, including after initial screens, breast cancer detection and treatment.

For a few indicators, results were outside the recommended target range for Māori women, specifically:

- Timeliness
 - First surgical treatment within 20 working days, women screened during the 4 years to December 2019. This indicator was outside the target range of $> 90\%$ but, at 60%, was highest of all LPs.

Other indicators which could be considered by BSC for Māori women include:

- Screening and assessment
 - Technical recall rate for fixed sites. This indicator was met up to June 2018 but was outside the target range in this reporting period, with 20 women recalled over 2 years. The target for mobile sites was within the confidence interval, with 13 women recalled over 2 years.
 - Initial screens – 22 of 139 Māori women having their first screen during this biennium were referred for assessment, giving an assessment rate of 16% with a false positive rate of 13%. However, the PPV (14%) and the invasive cancer detection rate (22 per 1,000) were high. All assessment indicators were in the target range for subsequent screens.
- Timeliness

- The proportion of women having an open biopsy procedure within 20 working days was 33% but is based on only three open biopsies in Māori women in this time period. Apart from first surgical treatment, all timeliness targets were met for Māori women.

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSC area were within the target range, although for many indicators there is a large degree of uncertainty due to the small numbers of women. BSC is doing particularly well for Pacific women in the areas of screening and assessment, breast cancer detection and treatment.

In a few instances, BSC did not meet the recommended targets for Pacific women in the specific areas of:

- Coverage
 - Overall coverage of eligible Pacific women aged 50–69 years was 66% and remained stable during this period despite COVID restrictions.

Other indicators which could be considered by BSC for Pacific women include:

- Coverage
 - Routine rescreening within 27 months (initial). This indicator has improved since 2014/15, but has plateaued at 67% (although the 75% target is within the confidence interval). It remained stable despite COVID restrictions.
- Timeliness
 - Time taken from screening visit to first offer of an assessment. This indicator has shown a steady improvement to 89% in this reporting period, with the 90% target within the confidence interval.
 - Time taken to first surgical treatment. This indicator was under target for Pacific women at 38% and remained lower than for Māori and non-Māori, non-Pacific women.

All women aged 50–69 years

The majority of indicators for women of all ethnicities aged 50–69 years in the BSC area were within the target ranges. BSC is doing well in the majority of areas of coverage, screening and assessment, breast cancer detection, and treatment and timeliness.

In a few instances, BSC did not meet the recommended targets, notably in the specific areas of:

- Screening and assessment:
 - Technical recall rates. The <0.5% target was met prior to June 2018, but outside the target range in this reporting period at 0.7% for fixed sites and 0.6% for mobile sites.
- Timeliness
 - Women having an open biopsy procedure within 20 working days. A steep decline in timeliness is evident in BSC since June 2018. The number of women having an open biopsy during the two years was relatively small (29) but only 38% had their biopsy in a timely manner, possibly affected by COVID restrictions.
 - First surgical treatment within 20 working days, women screened during the 4 years to December 2019. This indicator was 60%, one of the highest among all LPs. In the most recent time period, there is a suggestion of a reduction from previous years, indicating a possible effect of COVID restrictions.

Focus on Equity

BSC has achieved equitable coverage for Māori, Pacific and non-Māori non-Pacific in the most recent period. Detection rates of small and node negative cancers were similar for Māori, Pacific and other women. This indicates BSC is contributing to equitable breast cancer outcomes.

BreastScreen South Limited (BSSL) Overview

Figure 23: BSSL Overview, Māori women aged 50 to 69 years




Figure 24: BSSL Overview, Pacific women aged 50 to 69 years





Figure 25: BSSL Overview, Total women aged 50 to 69 years



BreastScreen South Limited (BSSL)

During the two years to 30 June 2020 BSSL screened 96,582 women aged 45–69 years (72% of the eligible population), including 5,809 Māori (67%) and 1,074 Pacific women (61%). Overall, 68 breast cancers were detected from initial screens (42 invasive) and 482 from subsequent screens (357 invasive), with 95% having a pre-operative diagnosis. Targets for invasive cancer detection rates were met or within the confidence interval in both age groups, with 62% of initial and 66% of subsequent screen-detected cancers ≤ 15 mm in diameter. The majority had no nodal involvement (69% initial and 83% subsequent).

Among BSSL women diagnosed with invasive cancer ≤ 20 mm over the 4 years to June 2020, 81% had breast conserving surgery. Of those who had breast conserving surgery for invasive cancer, 94% had radiotherapy (target 95%). Sentinel node biopsy was the first axillary procedure for 83% (with breast cancers ≤ 30 mm). Most women with DCIS ≤ 20 mm had breast conserving surgery (93%). 54% had their first treatment surgery within 20 working days of receiving their final diagnostic results (target 90%).

Among Māori women aged 45–69 years, BSSL detected 3 breast cancers (non-invasive) from initial screens and 41 (37 invasive) from subsequent screens. Māori women were more likely than non-Māori to have invasive breast cancer detected from subsequent but not from initial screens. The proportions of small and node-negative cancers were similar in both groups. Treatment indicators were similar for Māori and non-Māori women.

BSSL detected 2 breast cancers (both invasive) from initial screens among Pacific women aged 45–69 years and 6 cancers (4 invasive) from subsequent screens. Four-year treatment indicators were similar to those of non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability, and reduce risk of dying from breast cancer. Nearly two-thirds of invasive breast cancers detected by BSSL were small and four-fifths had no nodal involvement. Most women were treated with breast conserving surgery (over 90%) and most only underwent a single excisional procedure. These indicators show BSSL is making a positive difference to breast cancer mortality and morbidity in their region.

BSSL achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; false positive rates were on target; nearly all women had a definitive diagnosis without undergoing open surgery; benign biopsy rate was within the target range, as was the proportion of benign open biopsies weighing < 30 g. The proportion of women receiving their final diagnostic biopsy results within 5 working days was just under target at 86%.

The next section relates to the BSSL overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSSL area were within the target range. BSSL is doing particularly well for Māori women in the areas of coverage, screening and assessment, breast cancer detection, treatment and timeliness, other than in some specific indicators:

- Coverage:
 - Routine rescreening (initial). Although BSSL met the target of $\geq 75\%$ rescreened within 27 months of an initial screen for women aged 45–49 years (78%), the target was not met for Māori women aged 50–69 years at 55%. The target was met for rescreens after a subsequent screen (86%) for both age groups.
- Timeliness
 - Final biopsy results. There appears to be a slow decline in the proportion of women receiving their final biopsy results in five working days to 82%.
 - First surgical treatment, women screened during the 4 years to December 2019. This target has consistently been a challenge to meet with 50% receiving their first surgical treatment within 20 working days.

Pacific women aged 50–69 years

The majority of indicators for Pacific women aged 50–69 years in the BSSL area were within the target range, although for many indicators there is a large degree of uncertainty due to small numbers. BSSL is doing particularly well for Pacific

women in the areas of breast cancer detection and treatment, and less well in areas of coverage. Indicators of timeliness show important improvements for Pacific women in the last period.

- Coverage
 - Overall coverage of eligible women.. In June 2020, 61% of Pacific women were screened (target $\geq 70\%$).
 - Routine rescreening (initial). This indicator increased to 55% of women rescreened within 27 months of their first screen (target $\geq 75\%$). Routine rescreening after a subsequent screen was close to target at 82%.
- Timeliness
 - First assessment appointment. There has been a sustained improvement in the last 18 months for Pacific women in BSSL, with 88% offered an assessment appointment within 15 days of their screen.
 - First surgical treatment within 20 working days, women screened during the 4 years to December 2019: Although the target for Pacific women was not met, this indicator was at the highest it has been for the last five years at 62%.

Other indicators which may require consideration for Pacific women include:

- Screening and assessment
 - Screening image usage (mobile). This indicator was 70% (target $>80\%$).

All women aged 50–69 years

The majority of indicators for women of all ethnicities aged 50–69 years in the BSSL area were within the target range. BSSL is doing well in each of the areas of coverage, screening and assessment, breast cancer detection, treatment and timeliness. A few indicators were not in the target range, including:

- Coverage
 - Routine rescreening (initial). The latest period showed a marked decline in this indicator to 66% rescreened within 27 months of an initial screen. A similar decline was seen for rescreening after subsequent screens, indicating possible impact of COVID restrictions (although this indicator remained in the target range at 86%).
- Timeliness
 - Most timeliness targets were met, including 90% receiving their open biopsies within 20 working days.
 - Final biopsy results reported within 5 working days. This indicator dropped to just below the 90% target, at 86%.
 - First surgical treatment, women screened during the 4 years to December 2019. This indicator remained steady at 56%.

Focus on Equity

BSSL showed movement towards equity in coverage for Māori and for Pacific women, with a steeper decline in non-Māori non-Pacific coverage during the last 12-month period. Coverage for all women aged 50 to 69 years was 71%, 68% for Māori and 61% for Pacific women. To achieve an equal level of coverage as non-Māori non-Pacific women, BSSL would have had to screen an additional 110 Māori women and 65 Pacific women per year. It is important to note that equal coverage rates may not achieve equity in outcomes, since the underlying rate of breast cancer in Māori and in Pacific women is higher than in non-Māori non-Pacific women.

BreastScreen Otago Southland (BSOS) Overview

Figure 26: BSOS Overview, Māori women aged 50 to 69 years




Figure 27: BSOS Overview, Pacific women aged 50 to 69 years





Figure 28: BSOS Overview, Total women aged 50 to 69 years



BreastScreen Otago Southland (BSOS)

During the two years to 30 June 2020 BSOS screened 35,383 women aged 45–69 years (66% of the eligible population), including 2,386 Māori (63%) and 331 Pacific women (55%). Overall, 25 breast cancers were detected from initial screens (17 invasive) and 211 from subsequent screens (164 invasive), with 95% having a pre-operative diagnosis. Invasive cancer detection rate targets were met, or within the confidence interval, in both age groups, with 60% of initial and 65% of subsequent screen-detected cancers $\leq 15\text{mm}$ in diameter. The majority had no nodal involvement (82% initial and 83% subsequent).

Among BSOS women diagnosed with invasive cancer $\leq 20\text{mm}$ over the 4 years to June 2020, 88% had breast conserving surgery (BCS). Of women who had BCS for invasive cancer, 95% had radiotherapy. Sentinel node biopsy was the first axillary procedure for 79% (of those with breast cancers $\leq 30\text{mm}$). Most women with DCIS $\leq 20\text{mm}$ had BCS (86%). 51% had their first treatment surgery within 20 working days of receiving their final diagnostic results.

Among Māori women aged 45–69 years, BSOS detected 1 breast cancer (not invasive) from initial screens and 10 (9 invasive) from subsequent screens. The proportions of small and node-negative cancers were similar in Māori and non-Māori. Treatment indicators were similar for Māori and non-Māori women.

Among Pacific women aged 45–69 years BSOS detected 1 invasive breast cancer from initial screens and 3 invasive cancers from subsequent screens. Four-year treatment indicators were similar to those for non-Māori non-Pacific women.

Detecting breast cancers while they are small and before they have spread to the axillary lymph nodes (armpit) means that the treatment can be breast conserving and cause less long-term illness and disability, and reduce risk of dying from breast cancer. Over half of invasive cancers detected by BSOS were small and four-fifths had no nodal involvement. Most women were treated with breast conserving surgery and only underwent a single excisional procedure. These indicators show BSOS is making a positive difference to breast cancer mortality and morbidity in their region.

BSOS achieved most targets relevant to harm minimisation. Low numbers of women were recalled for technical reasons; nearly all women had a definitive diagnosis without undergoing open surgery, and almost all had their needle biopsy within 5 days of assessment; the target was met or within the confidence interval for benign open biopsy rates and open biopsy weight $< 30\text{gm}$.

The next section relates to the BSOS overview figures shown above for women aged 50–69 years.

Māori women aged 50–69 years

The majority of indicators for Māori women aged 50–69 years in the BSOS area were within the target range. BSOS is doing particularly well for Māori women in the areas of rescreening rates, screening and assessment, breast cancer detection and treatment. Targets were not met for overall coverage and some timeliness indicators.

- Coverage
 - Overall coverage of eligible women. Although the 70% target was not met, Māori coverage remained relatively stable despite COVID restrictions during the last 6 months at 66%, while non-Māori coverage declined to be the same as Māori. Timely rescreening rates improved for Māori women to meet the targets for both initial and subsequent screens. This would have contributed to the more equitable overall coverage.
- Timeliness
 - Time taken from screening visit to first offer of an assessment. After substantial improvements in this indicator from 2016 to 2018, the recent reporting periods have shown a plateauing of this marker of timeliness at 76%.
 - Time taken from final diagnostic biopsy to reporting assessment results. The 90% target was not met (65%) but there is a suggestion of an improving trend.
 - First surgical treatment, women screened during the 4 years to December 2019. Around half of Māori women (47%) received their first treatment surgery within 20 working days of receiving their final diagnosis. This indicator was similar for non-Māori women.

Pacific women aged 50–69 years

Many of the indicators for Pacific women aged 50–69 years in the BSOS area were within the target range, although there is a large degree of uncertainty (as seen in the wide confidence intervals), due to the small numbers of women included in the calculation of some indicators. BSOS is doing particularly well for Pacific women in the areas of breast cancer detection and treatment, but less well in terms of coverage and timeliness.

- Coverage
 - Coverage. The 70% target has consistently been a challenge to meet, with 56% screened in this biennial period.
 - Routine rescreening. The target of 85% rescreened within 27 months of a subsequent screen was met (87%), but the 75% target for rescreening after an initial screen was not met (52%).
- Timeliness
 - Time taken from screening visit to first offer of an assessment. After substantial improvements in this indicator from 2016 to 2018, recent reporting periods have shown a decline in this indicator of timeliness to 38% offered an assessment within 15 working days.
 - Time taken from final diagnostic biopsy to reporting assessment results. This indicator has improved for Pacific women aged 50–69 years to 83%.
 - First surgical treatment, women screened during the 4 years to December 2019. Only 6 Pacific women aged 50–69 years had treatment surgery, with 2 receiving their surgery within 20 working days of their final diagnosis.

All women aged 50–69 years

The majority of indicators for women of all ethnicities aged 50–69 years in the BSOS area were within the target range. BSOS is doing particularly well in screening quality, breast cancer detection and treatment. Some indicators in the areas of coverage, screening and assessment, and timeliness were outside the target ranges.

- Coverage
 - Coverage. After a number of years comfortably in the target range of 70% or more, this indicator has now fallen out of this range, reaching 66%, possibly affected by COVID restrictions.
 - Routine rescreening within 27 months. This indicator fell for rescreens after initial (to 67%) and subsequent screens (to 80%), likely affected by COVID restrictions.
- Screening and assessment
 - Initial assessment rate. Assessment rates from initial screens have increased since 2018 to 17% (target <10%), with false positives at 15% (target <9%), PPV at 8% with the target of >9% within the confidence interval, and specificity 83% (target >93%). These indicators were all within the target ranges for subsequent screens.
- Timeliness
 - The 90% targets were met for screening results within 10 working days, needle biopsies within 5 working days, and open biopsies within 20 working days.
 - Time taken from screening visit to first offer of an assessment. After substantial improvements in this indicator from 2016 to 2018, this indicator plateaued with 78% offered an assessment in 15 working days.
 - Time taken from final diagnostic biopsy to reporting assessment results. 73% received their final biopsy results within 5 working days.
 - First surgical treatment, women screened during the 4 years to December 2019. Half of BSOS women had their first treatment surgery within 20 working days of their final diagnosis.

Focus on Equity

Coverage

There was a reduction in the biennial coverage gap between Māori (64%), Pacific (56%) and non-Māori women (66%). To achieve equal level of coverage with non-Māori non-Pacific women, BSOS needed to screen an additional 30 Māori and 20 Pacific women per year, noting that equal coverage rates may not achieve equity in outcomes, since the underlying rates of breast cancer are higher. Equitable rescreening rates were also achieved for Māori and Pacific women.

Timeliness

The gap between the proportions of Māori and non-Māori receiving their first surgical treatment within 20 working days reduced (47% vs 51%). There appears to be a gap between the proportion of Pacific and non-Pacific women offered an assessment within 15 days which may need consideration, although based on small numbers of Pacific women (6/16).


Coverage

1.a.1, Overall coverage of eligible women


Description: The number of women screened as a percentage of women eligible.

Target: ≥70% of eligible women aged 45–69 years receive a screen within the most recent 24-month period

Figure 29: 1.a.1.1, Coverage of eligible women, 45 to 49 and 50 to 69 years, total BSA



Women aged 45 to 49 years



Women aged 50 to 69 years

BSA screened 67% of eligible women aged 45–69 years during the two years to 30 June 2020. This period included COVID pandemic Alert Level 4 (25 March to 27 April 2020) when breast screening paused nationally and Alert Level 3 (28 April to 13 May 2020) and Alert Level 2 (14 May to 8 June), when screening recommenced but was slowed down due to COVID safety requirements. Coverage of Māori women aged 45–69 (60%) was lower than that of non-Māori (68%), while Pacific coverage was similar (69%) to that of non-Māori non-Pacific women (68%). Total coverage was higher in BSSL (72%). Māori coverage was highest in BSSL (67%) and lowest in BSM (55%) and BSCC (57%). Pacific coverage was highest in BSCM (77%) and lowest in BSOS (55%). Coverage of Māori women aged 45–69 was similar to that of non-Māori women in BSWN, BSC, and BSOS, and lower in other LPs.

Figure 30: 1.a.1.3, Coverage of eligible women, 50 to 69, by LP




Table 1: 1.a.1.1, Coverage of eligible women

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Screened	Eligible Women	% Screened (95% CI)	Māori / Non-Māori Ratio	Women Screened	Eligible Women	% Screened (95% CI)	Pacific / Non-Pacific Ratio	Women Screened	Eligible Women	% Screened (95% CI)	Women Screened	Eligible Women	% Screened (95% CI)	Women Screened	Eligible Women	% Screened (95% CI)
45 to 49	BSWN	2,509	3,900	64.3 (62.82, 65.82)	1.04 (1.01, 1.06)	850	1,400	60.7 (58.1, 63.2)	0.98 (0.94, 1.02)	15,245	24,570	62.0 (61.4, 62.7)	14,385	23,170	62.1 (61.5, 62.7)	17,744	28,470	62.3 (61.76, 62.89)	
	BSCM	1,734	2,820	61.5 (59.68, 63.27)	0.86 (0.84, 0.89)	2,741	3,600	76.1 (74.7, 77.5)	1.09 (1.07, 1.11)	11,410	15,980	71.4 (70.7, 72.1)	8,669	12,380	70.0 (69.2, 70.8)	13,144	18,800	69.9 (69.26, 70.57)	
	BSAL	865	1,250	69.2 (66.59, 71.7)	1.02 (0.98, 1.06)	1,116	1,570	71.1 (68.8, 73.3)	1.06 (1.03, 1.09)	10,385	15,350	67.7 (66.9, 68.4)	9,254	13,780	67.2 (66.4, 67.9)	11,235	16,600	67.7 (66.97, 68.39)	
	BSM	3,207	6,160	52.1 (50.81, 53.31)	0.79 (0.77, 0.81)	311	570	54.6 (50.5, 58.6)	0.82 (0.76, 0.89)	13,444	20,380	66.0 (65.3, 66.6)	13,133	19,810	66.3 (65.6, 66.9)	16,651	26,540	62.7 (62.16, 63.32)	
	BSCC	2,481	4,580	54.2 (52.72, 55.61)	0.79 (0.77, 0.81)	249	405	61.5 (56.7, 66.1)	0.89 (0.83, 0.97)	10,681	15,570	68.6 (67.9, 69.3)	10,427	15,165	68.8 (68, 69.5)	13,157	20,150	65.3 (64.64, 65.95)	
	BSC	1,214	2,260	53.7 (51.66, 55.76)	0.91 (0.87, 0.95)	563	1,155	48.7 (45.9, 51.6)	0.82 (0.77, 0.87)	9,823	16,625	59.1 (58.3, 59.8)	9,244	15,470	59.8 (59, 60.5)	11,021	18,885	58.4 (57.65, 59.06)	
	BSSL	1,496	2,370	63.1 (61.16, 65.04)	0.82 (0.79, 0.84)	310	495	62.6 (58.3, 66.8)	0.81 (0.76, 0.87)	20,462	26,465	77.3 (76.8, 77.8)	20,090	25,970	77.4 (76.8, 77.9)	21,896	28,835	75.9 (75.44, 76.43)	
	BSOS	621	1,020	60.9 (57.85, 63.83)	0.90 (0.86, 0.95)	102	190	53.7 (46.6, 60.6)	0.79 (0.69, 0.9)	6,807	10,060	67.7 (66.7, 68.6)	6,693	9,870	67.8 (66.9, 68.7)	7,416	11,080	66.9 (66.05, 67.8)	
	Total	14,127	24,360	58.0 (57.37, 58.61)	0.86 (0.85, 0.87)	6,242	9,385	66.5 (65.5, 67.5)	0.98 (0.97, 1)	98,257	145,000	67.8 (67.5, 68)	91,895	135,615	67.8 (67.5, 68)	112,264	169,360	66.3 (66.06, 66.51)	
	50 to 69	BSWN	7,562	11,890	63.6 (62.73, 64.46)	1.00 (0.99, 1.02)	2,855	4,070	70.1 (68.7, 71.5)	1.11 (1.09, 1.13)	54,815	86,250	63.6 (63.2, 63.9)	51,938	82,180	63.2 (62.9, 63.5)	62,355	98,140	63.5 (63.24, 63.84)
BSCM		4,428	7,350	60.2 (59.12, 61.36)	0.87 (0.85, 0.88)	7,543	9,770	77.2 (76.4, 78)	1.14 (1.13, 1.16)	36,136	52,020	69.5 (69.1, 69.9)	28,592	42,250	67.7 (67.2, 68.1)	40,563	59,370	68.3 (67.95, 68.7)	
BSAL		2,143	3,600	59.5 (57.92, 61.12)	0.86 (0.83, 0.88)	3,464	5,030	68.9 (67.6, 70.1)	0.99 (0.97, 1.01)	32,914	47,400	69.4 (69, 69.9)	29,408	42,370	69.4 (69, 69.8)	35,015	51,000	68.7 (68.25, 69.06)	
BSM		10,480	18,940	55.3 (54.62, 56.04)	0.85 (0.84, 0.86)	905	1,500	60.3 (57.8, 62.8)	0.92 (0.89, 0.96)	52,924	81,090	65.3 (64.9, 65.6)	52,018	79,590	65.4 (65, 65.7)	63,403	100,030	63.4 (63.08, 63.68)	
BSCC		8,050	13,950	57.7 (56.88, 58.52)	0.84 (0.82, 0.85)	722	1,180	61.2 (58.4, 63.9)	0.88 (0.85, 0.93)	44,316	64,180	69.0 (68.7, 69.4)	43,562	63,000	69.1 (68.8, 69.5)	52,334	78,130	67.0 (66.65, 67.31)	
BSC		4,016	6,040	66.5 (65.29, 67.67)	0.97 (0.96, 0.99)	2,162	3,270	66.1 (64.5, 67.7)	0.97 (0.94, 0.99)	37,667	55,165	68.3 (67.9, 68.7)	35,450	51,895	68.3 (67.9, 68.7)	41,628	61,205	68.0 (67.64, 68.38)	
BSSL		4,313	6,370	67.7 (66.55, 68.85)	0.95 (0.94, 0.97)	764	1,255	60.9 (58.1, 63.5)	0.86 (0.82, 0.89)	70,465	99,035	71.2 (70.9, 71.4)	69,609	97,780	71.2 (70.9, 71.5)	74,686	105,405	70.9 (70.58, 71.13)	
BSOS		1,765	2,770	63.7 (61.91, 65.49)	0.97 (0.94, 1)	229	410	55.9 (51, 60.6)	0.85 (0.78, 0.92)	26,226	39,800	65.9 (65.4, 66.4)	25,973	39,390	65.9 (65.5, 66.4)	27,967	42,570	65.7 (65.24, 66.15)	
Total		42,757	70,910	60.3 (59.94, 60.66)	0.89 (0.88, 0.9)	18,644	26,485	70.4 (69.8, 70.9)	1.04 (1.03, 1.05)	355,463	524,940	67.7 (67.6, 67.8)	336,550	498,455	67.5 (67.4, 67.6)	397,951	595,850	66.8 (66.67, 66.91)	
45-69		BSWN	10,071	15,790	63.8 (63.03, 64.53)	1.01 (1, 1.02)	3,705	5,470	67.7 (66.5, 69)	1.08 (1.06, 1.1)	70,060	110,820	63.2 (62.9, 63.5)	66,323	105,350	63.0 (62.7, 63.2)	80,099	126,610	63.3 (63, 63.53)
	BSCM	6,162	10,170	60.6 (59.64, 61.54)	0.87 (0.85, 0.88)	10,284	13,370	76.9 (76.2, 77.6)	1.13 (1.12, 1.14)	47,546	68,000	69.9 (69.6, 70.3)	37,261	54,630	68.2 (67.8, 68.6)	53,707	78,170	68.7 (68.38, 69.03)	
	BSAL	3,008	4,850	62.0 (60.65, 63.38)	0.90 (0.88, 0.92)	4,580	6,600	69.4 (68.3, 70.5)	1.01 (0.99, 1.03)	43,299	62,750	69.0 (68.6, 69.4)	38,662	56,150	68.9 (68.5, 69.2)	46,250	67,600	68.4 (68.07, 68.77)	
	BSM	13,687	25,100	54.5 (53.91, 55.15)	0.83 (0.82, 0.84)	1,216	2,070	58.7 (56.6, 60.8)	0.90 (0.86, 0.93)	66,368	101,470	65.4 (65.1, 65.7)	65,151	99,400	65.5 (65.2, 65.8)	80,054	126,570	63.2 (62.98, 63.51)	
	BSCC	10,531	18,530	56.8 (56.12, 57.54)	0.82 (0.81, 0.84)	971	1,585	61.3 (58.8, 63.6)	0.89 (0.85, 0.92)	54,997	79,750	69.0 (68.6, 69.3)	53,989	78,165	69.1 (68.7, 69.4)	65,491	98,280	66.6 (66.34, 66.93)	
	BSC	5,230	8,300	63.0 (61.97, 64.04)	0.95 (0.94, 0.97)	2,725	4,425	61.6 (60.1, 63)	0.93 (0.91, 0.95)	47,490	71,790	66.2 (65.8, 66.5)	44,694	67,365	66.3 (66, 66.7)	52,649	80,090	65.7 (65.41, 66.07)	
	BSSL	5,809	8,740	66.5 (65.47, 67.45)	0.92 (0.9, 0.93)	1,074	1,750	61.4 (59.1, 63.6)	0.85 (0.82, 0.88)	90,927	125,500	72.5 (72.2, 72.7)	89,699	123,750	72.5 (72.2, 72.7)	96,582	134,240	71.9 (71.71, 72.19)	
	BSOS	2,386	3,790	63.0 (61.41, 64.48)	0.95 (0.93, 0.97)	331	600	55.2 (51.2, 59.1)	0.83 (0.77, 0.89)	33,033	49,860	66.3 (65.8, 66.7)	32,666	49,260	66.3 (65.9, 66.7)	35,383	53,650	66.0 (65.55, 66.35)	
	Total	56,884	95,270	59.7 (59.4, 60.02)	0.88 (0.88, 0.89)	24,886	35,870	69.4 (68.9, 69.9)	1.03 (1.02, 1.03)	453,720	669,940	67.7 (67.6, 67.8)	428,445	634,070	67.6 (67.5, 67.7)	510,215	765,210	66.7 (66.57, 66.78)	



1.a.2, Percentage of screens that are initial or subsequent

Description: The number of women who had an initial/subsequent as a percentage of the number of women screened.



Target: No target

Figure 31: 1.a.2.1, Initial and subsequent screen proportions, 50 to 69

45–49 years



50–69 years



Among women aged 45–49 years, 42% of screens were initial, compared to only 3% of those aged 50–69 years. Overall, 12% of BSA screens were initial.

Figure 32:1.a.2.3, Initial screen proportions, 50 to 69, by LP




Figure 33: 1.a.2.5, Subsequent screen proportions, 50 to 69, by LP




Table 2: 1.a.2.1, Initial and subsequent screen proportions


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
			Women Screened by Type	Women Screened	% Screened (95% CI)	Māori / Non-Māori Ratio	Women Screened by Type	Women Screened	% Screened (95% CI)	Pacific / Non-Māori Ratio	Women Screened by Type	Women Screened	% Screened (95% CI)	Women Screened by Type	Women Screened	% Screened (95% CI)	Women Screened by Type	Women Screened	% Screened (95% CI)	
45 to 49	Initial	BSWN	1,204	2,513	47.9 (46, 49.9)	1.06 (1.02, 1.11)	389	849	45.8 (42.5, 49.2)	1.02 (0.97, 1.25)	6,880	15,239	45.1 (44.4, 45.9)	6,485	14,382	45.1 (45.1, 45.1)	8,078	17,744	45.5 (44.8, 46.3)	
		BSCM	796	1,739	45.8 (43.4, 48.1)	1.10 (1.04, 1.16)	1,312	2,741	47.9 (46, 49.7)	1.21 (0.83, 1.46)	4,747	11,405	41.6 (40.7, 42.5)	3,435	8,664	39.6 (39.6, 39.6)	5,543	13,144	42.2 (41.3, 43)	
		BSAL	436	865	50.4 (47.1, 53.7)	1.15 (1.07, 1.23)	506	1,114	45.4 (42.5, 48.4)	1.04 (0.72, 1.27)	4,563	10,385	43.9 (43, 44.9)	4,049	9,254	43.8 (43.8, 43.8)	4,991	11,233	44.4 (43.5, 45.4)	
		BSM	1,559	3,227	48.3 (46.6, 50)	1.12 (1.08, 1.17)	155	307	50.5 (44.9, 56)	1.18 (0.82, 1.42)	5,784	13,425	43.1 (42.2, 43.9)	5,629	13,117	42.9 (42.9, 42.9)	7,343	16,651	44.1 (43.3, 44.9)	
		BSCC	1,164	2,489	46.8 (44.8, 48.7)	1.13 (1.07, 1.18)	128	249	51.4 (45.2, 57.5)	1.25 (0.87, 1.49)	4,430	10,674	41.5 (40.6, 42.4)	4,300	10,420	41.3 (41.3, 41.3)	5,592	13,158	42.5 (41.7, 43.3)	
		BSC	492	1,217	40.4 (37.7, 43.2)	1.04 (0.97, 1.12)	235	565	41.6 (37.6, 45.7)	1.08 (0.72, 1.32)	3,814	9,820	38.8 (37.9, 39.8)	3,573	9,243	38.7 (38.7, 38.7)	4,300	11,025	39.0 (38.1, 39.9)	
		BSSL	565	1,497	37.7 (35.3, 40.2)	0.95 (0.89, 1.02)	149	310	48.1 (42.6, 53.6)	1.22 (0.84, 1.47)	8,133	20,461	39.7 (39.1, 40.4)	7,935	20,092	39.5 (39.5, 39.5)	8,649	21,899	39.5 (38.8, 40.1)	
		BSOS	239	619	38.6 (34.9, 42.5)	0.94 (0.84, 1.04)	37	101	36.6 (27.9, 46.4)	0.89 (0.59, 1.12)	2,807	6,809	41.2 (40.1, 42.4)	2,765	6,696	41.3 (41.3, 41.3)	3,041	7,416	41.0 (39.9, 42.1)	
		Total	6,455	14,166	45.6 (44.7, 46.4)	1.09 (1.07, 1.11)	2,911	6,236	46.7 (45.4, 47.9)	1.12 (0.77, 1.37)	41,158	98,218	41.9 (41.6, 42.2)	38,171	91,868	41.5 (41.5, 41.5)	47,537	112,270	42.3 (42.1, 42.6)	
		Subsequent	BSWN	1,309	2,513	52.1 (50.1, 54)	0.95 (0.91, 0.99)	460	849	54.2 (50.8, 57.5)	0.99 (0.71, 1.2)	8,359	15,239	54.9 (54.1, 55.6)	7,897	14,382	54.9 (54.9, 54.9)	9,666	17,744	54.5 (53.7, 55.2)
	BSCM		943	1,739	54.2 (51.9, 56.6)	0.93 (0.89, 0.97)	1,429	2,741	52.1 (50.3, 54)	0.86 (0.62, 1.06)	6,658	11,405	58.4 (57.5, 59.3)	5,230	8,664	60.4 (60.4, 60.4)	7,602	13,144	57.8 (57, 58.7)	
	BSAL		429	865	49.6 (46.3, 52.9)	0.88 (0.83, 0.95)	608	1,114	54.6 (51.6, 57.5)	0.97 (0.7, 1.18)	5,822	10,385	56.1 (55.1, 57)	5,205	9,254	56.2 (56.2, 56.2)	6,242	11,233	55.6 (54.6, 56.5)	
	BSM		1,668	3,227	51.7 (50, 53.4)	0.91 (0.88, 0.94)	152	307	49.5 (44, 55.1)	0.87 (0.62, 1.07)	7,641	13,425	56.9 (56.1, 57.8)	7,488	13,117	57.1 (57.1, 57.1)	9,308	16,651	55.9 (55.1, 56.7)	
	BSCC		1,325	2,489	53.2 (51.3, 55.2)	0.91 (0.87, 0.95)	121	249	48.6 (42.5, 54.8)	0.83 (0.59, 1.03)	6,244	10,674	58.5 (57.6, 59.4)	6,121	10,420	58.7 (58.7, 58.7)	7,567	13,158	57.5 (56.7, 58.4)	
	BSC		725	1,217	59.6 (56.8, 62.3)	0.97 (0.93, 1.02)	330	565	58.4 (54.3, 62.4)	0.95 (0.69, 1.16)	6,006	9,820	61.2 (60.2, 62.1)	5,670	9,243	61.3 (61.3, 61.3)	6,725	11,025	61.0 (60.1, 61.9)	
	BSSL		932	1,497	62.3 (59.8, 64.7)	1.03 (0.99, 1.08)	161	310	51.9 (46.4, 57.4)	0.86 (0.62, 1.06)	12,328	20,461	60.3 (59.6, 60.9)	12,156	20,092	60.5 (60.5, 60.5)	13,249	21,899	60.5 (59.9, 61.1)	
	BSOS		380	619	61.4 (57.5, 65.1)	1.04 (0.98, 1.12)	64	101	63.4 (53.6, 72.1)	1.08 (0.79, 1.29)	4,002	6,809	58.8 (57.6, 59.9)	3,931	6,696	58.7 (58.7, 58.7)	4,375	7,416	59.0 (57.9, 60.1)	
	Total		7,711	14,166	54.4 (53.6, 55.3)	0.94 (0.92, 0.95)	3,325	6,236	53.3 (52.1, 54.6)	0.91 (0.66, 1.12)	57,060	98,218	58.1 (57.8, 58.4)	53,698	91,868	58.5 (58.5, 58.5)	64,734	112,270	57.7 (57.4, 57.9)	
	50 to 69		Initial	BSWN	276	7,591	3.6 (3.2, 4.1)	0.76 (0.67, 0.86)	121	2,855	4.2 (3.6, 5)	0.99 (0.21, 1.31)	2,618	54,787	4.8 (4.6, 5)	2,217	51,913	4.3 (4.3, 4.3)	2,614	62,359
		BSCM		184	4,437	4.1 (3.6, 4.8)	0.93 (0.8, 1.08)	307	7,559	4.1 (3.6, 4.5)	1.03 (0.21, 1.33)	1,617	36,126	4.5 (4.3, 4.7)	1,127	28,567	3.9 (3.9, 3.9)	1,618	40,563	4.0 (3.8, 4.2)
		BSAL		109	2,146	5.1 (4.2, 6.1)	1.03 (0.85, 1.25)	157	3,467	4.5 (3.9, 5.3)	0.99 (0.22, 1.31)	1,620	32,910	4.9 (4.7, 5.2)	1,348	29,391	4.6 (4.6, 4.6)	1,614	35,004	4.6 (4.4, 4.8)
BSM		524		10,496	5.0 (4.6, 5.4)	1.17 (1.07, 1.28)	48	904	5.3 (4, 7)	1.64 (0.33, 1.71)	2,256	52,912	4.3 (4.1, 4.4)	1,683	52,007	3.2 (3.2, 3.2)	2,255	63,407	3.6 (3.4, 3.7)	
BSCC		355		8,071	4.4 (4, 4.9)	1.22 (1.09, 1.36)	43	723	5.9 (4.4, 7.9)	2.16 (0.42, 1.97)	1,603	44,295	3.6 (3.4, 3.8)	1,197	43,541	2.7 (2.7, 2.7)	1,595	52,335	3.0 (2.9, 3.2)	
BSC		131		4,028	3.3 (2.7, 3.8)	0.96 (0.81, 1.15)	74	2,158	3.4 (2.7, 4.3)	1.14 (0.18, 1.38)	1,270	37,655	3.4 (3.2, 3.6)	1,063	35,447	3.0 (3, 3)	1,268	41,633	3.0 (2.9, 3.2)	
BSSL		104		4,313	2.4 (2, 2.9)	1.16 (0.95, 1.41)	44	764	5.8 (4.3, 7.6)	3.08 (0.47, 2.22)	1,465	70,466	2.1 (2, 2.2)	1,303	69,611	1.9 (1.9, 1.9)	1,451	74,688	1.9 (1.8, 2)	
BSOS		53		1,768	3.0 (2.3, 3.9)	1.21 (0.92, 1.59)	18	229	7.9 (5, 12.1)	3.53 (0.67, 2.56)	652	26,224	2.5 (2.3, 2.7)	578	25,971	2.2 (2.2, 2.2)	649	27,968	2.3 (2.2, 2.5)	
Total		1,736		42,850	4.1 (3.9, 4.2)	1.10 (1.05, 1.15)	812	18,659	4.4 (4.1, 4.7)	1.39 (0.26, 1.54)	13,101	355,375	3.7 (3.6, 3.7)	10,516	336,448	3.1 (3.1, 3.1)	13,064	397,957	3.3 (3.2, 3.3)	
Subsequent		BSWN		7,315	7,591	96.4 (95.9, 96.8)	1.01 (1, 1.01)	2,734	2,855	95.8 (95, 96.4)	1.00 (0.79, 1.17)	52,445	54,787	95.7 (95.6, 95.9)	49,696	51,913	95.7 (95.7, 95.7)	59,745	62,359	95.8 (95.7, 96)
		BSCM	4,253	4,437	95.9 (95.2, 96.4)	1.00 (0.99, 1)	7,252	7,559	95.9 (95.5, 96.4)	1.00 (0.79, 1.17)	34,693	36,126	96.0 (95.8, 96.2)	27,440	28,567	96.1 (96.1, 96.1)	38,945	40,563	96.0 (95.8, 96.2)	
		BSAL	2,037	2,146	94.9 (93.9, 95.8)	0.99 (0.98, 1)	3,310	3,467	95.5 (94.7, 96.1)	1.00 (0.79, 1.17)	31,399	32,910	95.4 (95.2, 95.6)	28,043	29,391	95.4 (95.4, 95.4)	33,390	35,004	95.5 (95.3, 95.7)	
		BSM	9,972	10,496	95.0 (94.6, 95.4)	0.98 (0.98, 0.99)	856	904	94.7 (93, 96)	0.98 (0.77, 1.15)	51,180	52,912	96.7 (96.6, 96.9)	50,324	52,007	96.8 (96.8, 96.8)	61,152	63,407	96.4 (96.3, 96.6)	
		BSCC	7,716	8,071	95.6 (95.1, 96)	0.98 (0.98, 0.99)	680	723	94.1 (92.1, 95.6)	0.97 (0.76, 1.14)	43,047	44,295	97.2 (97, 97.3)	42,344	43,541	97.3 (97.3, 97.3)	50,740	52,335	97.0 (96.8, 97.1)	
		BSC	3,897	4,028	96.7 (96.2, 97.3)	1.00 (0.99, 1)	2,084	2,158	96.6 (95.7, 97.3)	1.00 (0.79, 1.17)	36,516	37,655	97.0 (96.8, 97.1)	34,384	35,447	97.0 (97, 97)	40,365	41,633	97.1 (96.9, 97.2)	
		BSSL	4,209	4,313	97.6 (97.1, 98)	1.00 (0.99, 1)	720	764	94.2 (92.4, 95.7)	0.96 (0.76, 1.13)	69,105	70,466	98.1 (98, 98.2)	68,308	69,611	98.1 (98.1, 98.1)	73,237	74,688	98.2 (98.1, 98.3)	
		BSOS	1,715	1,768	97.0 (96.1, 97.7)	0.99 (0.98, 1)	211	229	92.1 (87.9, 95)	0.94 (0.74, 1.11)	25,625	26,224	97.7 (97.5, 97.9)	25,393	25,971	97.8 (97.8, 97.8)	27,319	27,968	97.8 (97.6, 97.9)	
		Total	41,114	42,850	95.9 (95.8, 96.1)	0.99 (0.99, 0.99)	17,847	18,659	95.6 (95.3, 95.9)	0.99 (0.78, 1.16)	344,010	355,375	96.8 (96.7, 96.9)	325,932	336,448	96.9 (96.9, 96.9)	384,893	397,957	96.8 (96.7, 96.8)	
		45 to 69	Initial	BSWN	1,480	10,104	14.6 (14, 15.4)	1.08 (1.03, 1.14)	510	3,704	13.8 (12.7, 14.9)	1.05 (0.48, 1.37)	9,498	70,026	13.6 (13.3, 13.8)	8,702	66,295	13.1 (13.1, 13.1)	10,692	80,103
BSCM				980	6,176	15.9 (15, 16.8)	1.19 (1.11, 1.26)	1,619	10,300	15.7 (15, 16.4)	1.28 (0.6, 1.59)	6,364	47,531	13.4 (13.1, 13.7)	4,562	37,231	12.3 (12.3, 12.3)	7,161	53,707	13.3 (13, 13.6)
BSAL				545	3,011	18.1 (16.8, 19.5)	1.27 (1.17, 1.37)	663	4,581	14.5 (13.5, 15.5)	1.04 (0.49, 1.35)	6,183	43,295	14.3 (14, 14.6)	5,397	38,645	14.0 (14, 14)	6,605	46,237	14.3 (14, 14.6)
BSM	2,083			13,723	15.2 (14.6, 15.8)	1.25 (1.2, 1.31)	203	1,211	16.8 (14.8, 19)	1.49 (0.7, 1.78)	8,040	66,337	12.1 (11.9, 12.4)	7,312	65,124	11.2 (11.2, 11.2)	9,598	80,058	12.0 (11.8, 12.2)	
BSCC	1,519			10,560	14.4 (13.7, 15.1)	1.31 (1.24, 1.38)	171	972	17.6 (15.3, 20.1)	1.73 (0.79, 1.99)	6,033	54,969	11.0 (10.7, 11.2)	5,497	53,961	10.2 (10.2, 10.2)	7,187	65,493	11.0 (10.7, 11.2)	
BSC	623			5,245	11.9 (11, 12.8)	1.11 (1.03, 1.2)	309	2,723	11.3 (10.2, 12.6)	1.09 (0.45, 1.41)	5,084	47,475	10.7 (10.4, 11)	4,636	44,690	10.4 (10.4, 10.4)	5,568	52,658	10.6 (10.3, 10.8)	
BSSL	669			5,810	11.5 (10.7, 12.4)	1.09 (1.01, 1.17)	193	1,074	18.0 (15.8, 20.4)	1.74 (0.81, 2)	5,958	90,927	10.6 (10.4, 10.8)	9,238	89,703	10.3 (10.3, 10.3)	10,100	96,587	10.5 (10.3, 10.7)	
BSOS	292			2,387	12.2 (11, 13.6)	1.17 (1.04, 1.31)	55	330	16.7 (13, 21.1)	1.63 (0.74, 1.9)	3,459	33,033	10.5 (10.1, 10.8)	3,343	32,667	10.2 (10.2, 10.2)	3,690	35,384	10.4 (10.1, 10.8)	
Total	8,191			57,016	14.4 (14.1, 14.7)	1.20 (1.18, 1.23)	3,723	24,895	15.0 (14.5, 15.4)	1.32 (0.6, 1.62)	54,259	453,593	12.0 (11.9, 12.1)	48,687						

1.a.3, Screening unit type

Description: The number of women who had a screen at a fixed/mobile site as a percentage of the number of women screened.

Target: No target

Figure 34: 1.a.3.1, Percentage screened at fixed and mobile units, 50 to 69, total BSA



Just over three-quarters of women screened by BSA were screened at a fixed unit, and just under one-quarter were screened at a mobile unit.

Māori women (29%) were 30% more likely than non-Māori women (22%) to be screened at a mobile unit, and Pacific women (26%) were 19% more likely than non-Māori non-Pacific women (22%).

Figure 35: 1.a.3.3, Percentage screened at fixed units, 50 to 69, by LP




Figure 36: 1.a.3.5, Percentage screened at mobile units, 50 to 69, by LP







Table 3: 1.a.3.1, Percentages screened at fixed and mobile units

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Women Screened at Unit	Women Screened	% Screened (95% CI)	Māori / Non-Māori Ratio	Women Screened at Unit	Women Screened	% Screened (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Women Screened at Unit	Women Screened	% Screened (95% CI)	Women Screened at Unit	Women Screened	% Screened (95% CI)	Women Screened at Unit	Women Screened	% Screened (95% CI)	
45 to 49	Fixed	BSWN	1,639	2,513	65.2 (63.3, 67.1)	0.83 (0.8, 0.85)	749	849	88.2 (85.9, 90.2)	1.13 (1.1, 1.16)	11,991	15,239	78.7 (78, 79.3)	11,237	14,382	78.1 (77.4, 78.8)	13,625	17,744	76.8 (76.2, 77.4)
		BSCM	1,386	1,739	79.7 (77.7, 81.5)	1.03 (1.01, 1.06)	2,238	2,740	81.7 (80.2, 83.1)	1.08 (1.06, 1.1)	8,808	11,405	77.2 (76.5, 78)	6,570	8,665	75.8 (74.9, 76.7)	10,194	13,144	77.6 (76.8, 78.3)
		BSAL	607	865	70.2 (67, 73.1)	0.90 (0.86, 0.94)	620	1,114	55.7 (52.7, 58.5)	0.69 (0.66, 0.73)	8,081	10,385	77.8 (77, 78.6)	7,444	9,254	80.4 (79.6, 81.2)	8,671	11,233	77.2 (76.4, 78)
		BSM	2,374	3,227	73.6 (72, 75.1)	0.93 (0.91, 0.95)	229	307	74.6 (69.4, 79.1)	0.94 (0.88, 1)	10,666	13,425	79.4 (78.8, 80.1)	10,436	13,117	79.6 (78.9, 80.2)	13,039	16,651	78.3 (77.7, 78.9)
		BSCC	1,940	2,489	77.9 (76.3, 79.5)	0.90 (0.88, 0.92)	204	249	81.9 (76.7, 86.2)	0.95 (0.89, 1)	9,224	10,674	86.4 (85.8, 87.1)	9,015	10,420	86.5 (85.8, 87.2)	11,159	13,158	84.8 (84.2, 85.4)
		BSC	693	1,217	56.9 (54.1, 59.7)	0.97 (0.92, 1.02)	266	565	47.1 (43, 51.2)	0.79 (0.73, 0.87)	5,753	9,820	58.6 (57.6, 59.6)	5,481	9,243	59.3 (58.3, 60.3)	6,440	11,025	58.4 (57.5, 59.3)
		BSSL	1,338	1,497	89.4 (87.7, 90.8)	0.97 (0.95, 0.98)	269	310	86.8 (82.5, 90.1)	0.94 (0.9, 0.98)	18,913	20,461	92.4 (92.1, 92.8)	18,591	20,092	92.5 (92.2, 92.9)	20,198	21,899	92.2 (91.9, 92.6)
		BSOS	534	619	86.3 (83.3, 88.8)	1.03 (1, 1.07)	94	101	93.1 (86.4, 96.6)	1.12 (1.06, 1.18)	5,681	6,809	83.4 (82.5, 84.3)	5,577	6,696	83.3 (82.4, 84.2)	6,205	7,416	83.7 (82.8, 84.5)
		Total	10,511	14,166	74.2 (73.5, 74.9)	0.92 (0.91, 0.93)	4,669	6,235	74.9 (73.8, 75.9)	0.93 (0.91, 0.94)	79,117	98,218	80.6 (80.3, 80.8)	74,351	91,869	80.9 (80.7, 81.2)	89,531	112,270	79.7 (79.5, 80)
		Mobile	BSWN	874	2,513	34.8 (32.9, 36.7)	1.63 (1.53, 1.74)	100	849	11.8 (9.8, 14.1)	0.54 (0.45, 0.65)	3,248	15,239	21.3 (20.7, 22)	3,145	14,382	21.9 (21.2, 22.6)	4,119	17,744
	BSCM		353	1,739	29.3 (28.5, 30.1)	0.89 (0.81, 0.98)	502	2,740	18.3 (16.9, 19.8)	0.76 (0.7, 0.83)	2,597	11,405	22.8 (22, 23.5)	2,095	8,665	24.2 (23.3, 25.1)	2,950	13,144	22.4 (21.7, 23.2)
	BSAL		258	865	20.8 (20.9, 20.8)	1.34 (1.21, 1.5)	494	1,114	44.3 (41.5, 47.3)	2.27 (2.12, 2.45)	2,304	10,385	22.2 (21.4, 23)	1,810	9,254	19.6 (18.8, 20.4)	2,562	11,233	22.8 (22, 23.6)
	BSM		853	3,227	26.4 (24.9, 28)	1.29 (1.2, 1.37)	78	307	25.4 (20.9, 30.6)	1.24 (1.03, 1.51)	2,759	13,425	20.6 (19.9, 21.2)	2,681	13,117	20.4 (19.8, 21.1)	3,612	16,651	21.7 (21.1, 22.3)
	BSCC	549	2,489	22.1 (20.5, 23.7)	1.62 (1.49, 1.77)	45	249	18.1 (13.8, 23.3)	1.34 (1.03, 1.75)	1,450	10,674	13.6 (12.9, 14.2)	1,405	10,420	13.5 (12.8, 14.2)	1,999	13,158	15.2 (14.6, 15.8)	
BSC	524	1,217	43.1 (40.3, 45.9)	1.04 (0.97, 1.11)	299	565	52.9 (48.8, 57)	1.30 (1.2, 1.41)	4,067	9,820	41.4 (40.4, 42.4)	3,762	9,243	40.7 (39.7, 41.7)	4,585	11,025	41.6 (40.7, 42.5)		
BSSL	159	1,497	10.6 (9.2, 12.3)	1.40 (1.2, 1.64)	41	310	13.2 (9.9, 17.5)	1.77 (1.33, 2.36)	1,548	20,461	7.6 (7.2, 7.9)	1,501	20,922	7.5 (7.1, 7.8)	1,701	21,899	7.8 (7.4, 8.1)		
BSOS	85	619	13.7 (11.2, 16.7)	0.83 (0.68, 1.02)	7	101	6.9 (3.4, 13.6)	0.41 (0.2, 0.85)	1,128	6,809	16.6 (15.7, 17.5)	1,119	6,696	16.7 (15.8, 17.6)	1,211	7,416	16.3 (15.5, 17.2)		
Total	3,655	14,166	25.8 (25.1, 26.5)	1.33 (1.29, 1.37)	1,566	6,235	25.1 (24.1, 26.2)	1.32 (1.26, 1.38)	19,101	98,218	19.4 (19.2, 19.7)	17,518	91,869	19.1 (18.8, 19.3)	22,739	112,270	20.3 (20, 20.5)		
50 to 69	Fixed	BSWN	4,571	7,591	60.2 (59.1, 61.3)	0.80 (0.79, 0.82)	2,571	2,855	90.1 (88.9, 91.1)	1.21 (1.2, 1.23)	41,133	54,787	75.1 (74.7, 75.4)	38,549	51,913	74.3 (73.9, 74.6)	45,691	62,359	73.3 (72.9, 73.6)
		BSCM	3,379	4,438	76.1 (74.9, 77.4)	1.01 (0.99, 1.03)	6,146	7,559	81.3 (80.4, 82.1)	1.11 (1.09, 1.12)	27,165	36,125	75.2 (74.7, 75.6)	21,018	28,566	73.6 (73.1, 74.1)	30,543	40,563	75.3 (74.9, 75.7)
		BSAL	1,388	2,146	64.7 (62.6, 66.7)	0.83 (0.81, 0.86)	1,910	3,467	55.1 (53.4, 56.7)	0.69 (0.67, 0.71)	25,584	32,910	77.7 (77.3, 78.2)	23,624	29,391	80.4 (79.9, 80.8)	26,922	35,004	76.9 (76.5, 77.3)
		BSM	7,449	10,496	71.0 (70.1, 71.8)	0.95 (0.94, 0.96)	652	904	72.1 (69.1, 74.9)	0.97 (0.93, 1.01)	39,452	52,912	74.6 (74.2, 74.9)	38,799	52,007	74.6 (74.2, 75)	46,900	63,407	74.0 (73.6, 74.3)
		BSCC	5,858	8,071	72.6 (71.6, 73.5)	0.88 (0.87, 0.89)	575	723	79.5 (76.4, 82.3)	0.96 (0.93, 1)	36,629	44,295	82.7 (82.3, 83)	36,025	43,541	82.7 (82.4, 83.1)	42,458	52,335	81.1 (80.8, 81.5)
		BSC	2,201	4,028	54.6 (53.1, 56.2)	1.03 (1, 1.06)	996	2,158	46.2 (44.1, 48.3)	0.86 (0.82, 0.9)	20,058	37,655	53.3 (52.8, 53.8)	19,037	35,447	53.7 (53.2, 54.2)	22,234	41,633	53.4 (52.9, 53.9)
		BSSL	3,796	4,313	88.0 (87, 88.9)	0.97 (0.96, 0.98)	656	764	85.9 (83.2, 88.2)	0.95 (0.92, 0.97)	63,904	70,466	90.7 (90.5, 90.9)	63,166	69,611	90.7 (90.5, 91)	67,618	74,688	90.5 (90.3, 90.7)
		BSOS	1,405	1,768	79.5 (77.5, 81.3)	1.06 (1.04, 1.09)	200	229	87.3 (82.4, 91)	1.17 (1.11, 1.23)	19,628	26,224	74.8 (74.3, 75.4)	19,412	25,971	74.7 (74.2, 75.3)	21,017	27,968	75.1 (74.6, 75.6)
		Total	30,407	42,851	70.1 (69.7, 70.6)	0.91 (0.91, 0.92)	13,706	18,659	73.5 (72.8, 74.1)	0.95 (0.94, 0.96)	273,553	355,374	77.0 (76.8, 77.1)	259,630	336,447	77.2 (77, 77.3)	303,383	397,957	76.2 (76.1, 76.4)
		Mobile	BSWN	3,020	7,591	39.8 (38.7, 40.9)	1.60 (1.55, 1.65)	284	2,855	9.9 (8.9, 11.1)	0.39 (0.35, 0.43)	13,654	54,787	24.9 (24.6, 25.3)	13,364	51,913	25.7 (25.4, 26.1)	16,668	62,359
	BSCM		1,059	4,438	23.9 (22.6, 25.1)	0.96 (0.91, 1.02)	1,413	7,559	18.7 (17.8, 19.6)	0.71 (0.67, 0.74)	8,960	36,125	24.8 (24.4, 25.3)	7,548	28,566	26.4 (25.9, 26.9)	10,020	40,563	24.7 (24.3, 25.1)
	BSAL		758	2,146	35.3 (33.3, 37.4)	1.59 (1.49, 1.69)	1,557	3,467	44.9 (43.3, 46.6)	2.29 (2.21, 2.39)	7,326	32,910	22.3 (21.8, 22.7)	5,767	29,391	19.6 (19.2, 20.1)	8,082	35,004	23.1 (22.7, 23.5)
	BSM		3,047	10,496	29.0 (28.2, 29.9)	1.14 (1.1, 1.18)	2,552	904	27.9 (25.1, 30.9)	1.10 (0.99, 1.22)	13,460	52,912	25.4 (25.1, 25.8)	13,208	52,007	25.4 (25, 25.8)	16,507	63,407	26.0 (25.7, 26.4)
	BSCC	2,213	8,071	27.4 (26.5, 28.4)	1.58 (1.52, 1.65)	148	723	20.5 (17.7, 23.6)	1.19 (1.03, 1.37)	7,666	44,295	17.3 (17, 17.7)	7,516	43,541	17.3 (16.9, 17.6)	9,877	52,335	18.9 (18.5, 19.2)	
BSC	1,827	4,028	45.4 (43.8, 46.9)	0.97 (0.94, 1.01)	1,162	2,158	53.8 (51.7, 55.9)	1.16 (1.12, 1.21)	17,597	37,655	46.7 (46.2, 47.2)	16,410	35,447	46.3 (45.8, 46.8)	19,399	41,633	46.6 (46.1, 47.1)		
BSSL	517	4,313	12.0 (11.1, 13)	1.29 (1.18, 1.4)	108	764	14.1 (11.8, 16.8)	1.53 (1.28, 1.82)	6,562	70,466	9.3 (9.1, 9.5)	6,445	69,611	9.3 (9, 9.5)	7,070	74,688	9.5 (9.3, 9.7)		
BSOS	363	1,768	20.5 (18.7, 22.5)	0.82 (0.74, 0.9)	29	229	12.7 (9, 17.6)	0.50 (0.36, 0.71)	6,596	26,224	25.2 (24.6, 25.7)	6,559	25,971	25.3 (24.7, 25.8)	6,951	27,968	24.9 (24.4, 25.4)		
Total	12,804	42,851	29.9 (29.4, 30.3)	1.30 (1.28, 1.32)	4,953	18,659	26.5 (25.9, 27.2)	1.16 (1.14, 1.19)	81,821	355,374	23.0 (22.9, 23.2)	76,817	336,447	22.8 (22.7, 23)	94,574	397,957	23.8 (23.6, 23.9)		
45 to 69	Fixed	BSWN	6,210	10,104	61.5 (60.5, 62.4)	0.81 (0.8, 0.82)	3,320	3,704	89.6 (88.6, 90.6)	1.19 (1.18, 1.21)	53,124	70,026	75.9 (75.5, 76.2)	49,786	66,295	75.1 (74.8, 75.4)	59,316	80,103	74.0 (73.7, 74.4)
		BSCM	4,765	6,177	77.1 (76.1, 78.2)	1.02 (1, 1.03)	8,384	10,299	81.4 (80.6, 82.1)	1.10 (1.09, 1.11)	35,973	47,530	75.7 (75.3, 76.1)	27,588	37,231	74.1 (73.7, 74.5)	40,737	53,707	75.9 (75.5, 76.2)
		BSAL	1,995	3,011	66.3 (64.5, 67.9)	0.85 (0.83, 0.87)	2,530	4,581	55.2 (53.8, 56.7)	0.69 (0.67, 0.71)	33,665	43,295	77.8 (77.4, 78.1)	31,068	38,645	80.4 (80, 80.8)	35,593	46,237	77.0 (76.6, 77.4)
		BSM	9,823	13,723	71.6 (70.8, 72.3)	0.95 (0.94, 0.96)	881	1,211	72.7 (70.2, 75.2)	0.96 (0.93, 1)	50,118	66,337	75.6 (75.2, 75.9)	49,235	65,124	75.6 (75.3, 75.9)	59,939	80,058	74.9 (74.6, 75.2)
		BSCC	7,798	10,560	73.8 (73, 74.7)	0.89 (0.87, 0.9)	779	972	80.1 (77.5, 82.5)	0.96 (0.93, 0.99)	45,853	54,969	83.4 (83.1, 83.7)	45,040	53,961	83.5 (83.2, 83.8)	53,617	65,493	81.9 (81.6, 82.2)
		BSC	2,894	5,245	55.2 (53.8, 56.5)	1.01 (0.99, 1.04)	1,262	2,723	46.3 (44.5, 48.2)	0.84 (0.81, 0.88)	25,811	47,475	54.4 (53.9, 54.8)	24,518	44,690	54.9 (54.4, 55.3)	28,674	52,658	54.5 (54, 54.9)
		BSSL	5,134	5,810	88.4 (87.5, 89.2)	0.97 (0.96, 0.98)	925	1,074	86.1 (83.9, 88.1)	0.94 (0.92, 0.97)	82,817	90,927	91.1 (90.9, 91.3)	81,757	89,703	91.1 (91, 91.3)	87,816	96,587	90.9

1.a.4, Age specific coverage

Description: The number of women screened as a percentage of women eligible by 5-year age group.

Target: No target



Māori coverage was lower than that of non-Māori in each age group, with the gap wider in the two youngest age groups. Pacific coverage generally increased with age.

Table 4: 1.a.4.1, Age specific coverage

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Screened	Eligible Women	% Screened (95% CI)	Māori / Non-Māori Ratio	Women Screened	Eligible Women	% Screened (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Women Screened	Eligible Women	% Screened (95% CI)	Women Screened	Eligible Women	% Screened (95% CI)	Women Screened	Eligible Women	% Screened (95% CI)
45 to 49	none	BSWN	2,514	3,900	64.5 (62.9, 65.9)	1.04 (1.01, 1.07)	850	1,400	60.7 (85.2, 89.6)	0.98 (0.94, 1.02)	15,237	24,570	62.0 (61.4, 62.6)	14,387	23,170	62.1 (61.5, 62.7)	17,751	28,470	62.3 (61.8, 62.9)
		BSCM	1,742	2,820	61.8 (60, 63.5)	0.87 (0.84, 0.89)	2,743	3,600	76.2 (82.0, 84.7)	1.09 (1.07, 1.11)	11,411	15,980	71.4 (70.7, 72.1)	8,668	12,380	70.0 (69.2, 70.8)	13,153	18,800	70.0 (69.3, 70.6)
		BSAL	865	1,250	69.2 (66.6, 71.7)	1.02 (0.99, 1.06)	1,114	1,570	71.0 (49.2, 55.0)	1.06 (1.02, 1.09)	10,372	15,350	67.6 (66.8, 68.3)	9,258	13,780	67.2 (66.4, 68)	11,237	16,600	67.7 (67, 68.4)
		BSM	3,227	6,160	52.4 (51.1, 53.6)	0.80 (0.78, 0.82)	307	570	53.9 (64.8, 74.8)	0.81 (0.75, 0.88)	13,425	20,380	65.9 (65.2, 66.5)	13,118	19,810	66.2 (65.6, 66.9)	16,652	26,540	62.7 (62.2, 63.3)
		BSCC	2,489	4,580	54.3 (52.9, 55.8)	0.79 (0.77, 0.82)	249	405	61.5 (75.9, 85.9)	0.89 (0.83, 0.97)	10,669	15,570	68.5 (67.8, 69.2)	10,420	15,165	68.7 (68, 69.4)	13,158	20,150	65.3 (64.6, 66)
		BSC	1,217	2,260	53.8 (51.8, 55.9)	0.91 (0.88, 0.95)	565	1,155	48.9 (46.5, 54.4)	0.82 (0.77, 0.87)	9,808	16,625	59.0 (58.2, 59.7)	9,243	15,470	59.7 (59, 60.5)	11,025	18,885	58.4 (57.7, 59.1)
		BSSL	1,497	2,370	63.2 (61.2, 65.1)	0.82 (0.79, 0.85)	310	495	62.6 (85.4, 92.7)	0.81 (0.76, 0.87)	20,402	26,465	77.1 (76.6, 77.6)	20,092	25,970	77.4 (76.9, 77.9)	21,899	28,835	75.9 (75.4, 76.4)
		BSOS	619	1,020	60.7 (57.7, 63.6)	0.90 (0.85, 0.94)	101	190	53.2 (87.3, 97.7)	0.78 (0.69, 0.9)	6,802	10,060	67.6 (66.7, 68.5)	6,701	9,870	67.9 (67, 68.8)	7,421	11,080	67.0 (66.1, 67.8)
		Total	14,170	24,360	58.2 (57.5, 58.8)	0.86 (0.85, 0.87)	6,239	9,385	66.5 (74.0, 76.0)	0.98 (0.97, 1)	98,126	145,000	67.7 (67.4, 67.9)	91,887	135,615	67.8 (67.5, 68)	112,296	169,360	66.3 (66.1, 66.5)
		50 to 54	none	BSWN	2,219	3,600	61.6 (60, 63.2)	0.96 (0.93, 0.99)	929	1,390	66.8 (10.4, 14.8)	1.04 (1.01, 1.08)	15,244	23,730	64.2 (63.6, 64.8)	14,315	22,340	64.1 (63.4, 64.7)	17,463
BSCM	1,429			2,520	56.7 (54.8, 58.6)	0.84 (0.81, 0.87)	2,469	3,490	70.7 (15.3, 18.0)	1.06 (1.03, 1.08)	10,443	15,390	67.9 (67.1, 68.6)	7,974	11,900	67.0 (66.2, 67.8)	11,872	17,910	66.3 (65.6, 67)
BSAL	684			1,130	60.5 (57.7, 63.3)	0.91 (0.86, 0.95)	1,148	1,680	68.3 (45.0, 50.8)	1.03 (0.99, 1.06)	9,345	14,000	66.8 (66, 67.5)	8,197	12,320	66.5 (65.7, 67.4)	10,029	15,130	66.3 (65.5, 67)
BSM	2,997			5,660	53.0 (51.6, 54.2)	0.75 (0.73, 0.77)	286	500	57.2 (25.2, 35.2)	0.81 (0.75, 0.87)	14,203	20,110	70.6 (70, 71.3)	13,917	19,610	71.0 (70.3, 71.6)	17,200	25,770	66.7 (66.2, 67.3)
BSCC	2,321			4,170	55.7 (54.1, 57.2)	0.72 (0.7, 0.74)	219	370	59.2 (14.1, 24.1)	0.76 (0.7, 0.83)	12,071	15,615	77.3 (76.6, 78)	11,852	15,245	77.7 (77.1, 78.4)	14,392	19,785	72.7 (72.1, 73.4)
BSC	1,322			1,990	66.4 (64.3, 68.5)	0.96 (0.93, 0.99)	692	1,045	66.2 (45.6, 53.5)	0.96 (0.92, 1)	10,739	15,545	69.1 (68.4, 69.8)	10,047	14,500	69.3 (68.5, 70)	12,061	17,535	68.8 (68.1, 69.5)
BSSL	1,436			2,130	67.4 (65.4, 69.4)	0.93 (0.9, 0.95)	254	445	57.1 (7.3, 14.6)	0.78 (0.72, 0.85)	18,936	26,005	72.8 (72.3, 73.4)	18,682	25,560	73.1 (72.5, 73.6)	20,372	28,135	72.4 (71.9, 72.9)
BSOS	580			950	61.1 (57.9, 64.1)	0.82 (0.78, 0.86)	81	150	54.0 (2.3, 12.7)	0.72 (0.62, 0.84)	7,571	10,150	74.6 (73.7, 75.4)	7,490	10,000	74.9 (74, 75.7)	8,151	11,100	73.4 (72.6, 74.2)
Total	12,988			22,150	58.6 (58, 59.3)	0.84 (0.83, 0.85)	6,078	9,070	67.0 (24.0, 26.0)	0.95 (0.94, 0.97)	98,552	140,545	70.1 (69.9, 70.4)	92,474	131,475	70.3 (70.1, 70.6)	111,540	162,695	68.6 (68.3, 68.8)
55 to 59	none			BSWN	2,301	3,550	64.8 (63.2, 66.4)	1.00 (0.98, 1.03)	816	1,150	71.0 (88.5, 90.8)	1.10 (1.06, 1.15)	15,131	23,400	64.7 (64, 65.3)	14,315	22,250	64.3 (63.7, 65)	17,432
		BSCM	1,306	2,120	61.6 (59.5, 63.7)	0.88 (0.85, 0.91)	2,101	2,800	75.0 (81.5, 83.1)	1.09 (1.07, 1.12)	10,075	14,390	70.0 (69.3, 70.8)	7,974	11,590	68.8 (68, 69.6)	11,381	16,510	68.9 (68.2, 69.6)
		BSAL	685	1,090	62.8 (59.9, 65.7)	0.90 (0.86, 0.94)	981	1,400	70.2 (51.4, 54.7)	1.00 (0.97, 1.04)	9,178	13,090	70.1 (69.3, 70.9)	8,197	11,690	70.1 (69.3, 70.9)	9,863	14,180	69.6 (68.8, 70.3)
		BSM	3,027	5,560	54.4 (53.1, 55.7)	0.83 (0.81, 0.85)	236	380	62.1 (67.0, 73.1)	0.94 (0.87, 1.02)	14,153	21,510	65.8 (65.2, 66.4)	13,917	21,130	65.9 (65.2, 66.5)	17,180	27,070	63.5 (62.9, 64)
		BSCC	2,431	4,020	60.5 (59, 62)	0.87 (0.85, 0.89)	213	325	65.5 (77.5, 83.3)	0.94 (0.87, 1.02)	12,065	17,380	69.4 (68.7, 70.1)	11,852	17,055	69.5 (68.8, 70.2)	14,496	21,400	67.7 (67.1, 68.4)
		BSC	1,202	1,780	67.5 (65.3, 69.7)	0.98 (0.94, 1.01)	599	890	67.3 (48.9, 53.2)	0.97 (0.93, 1.02)	10,646	15,405	69.1 (68.4, 69.8)	10,047	14,515	69.2 (68.5, 70)	11,848	17,185	68.9 (68.2, 69.6)
		BSSL	1,248	1,920	65.0 (62.8, 67.1)	0.93 (0.9, 0.96)	214	380	56.3 (83.1, 88.2)	0.80 (0.73, 0.88)	18,896	26,985	70.0 (69.5, 70.6)	18,682	26,605	70.2 (69.7, 70.8)	20,144	28,905	69.7 (69.2, 70.2)
		BSOS	572	830	68.9 (65.7, 72)	1.01 (0.96, 1.06)	65	130	50.0 (81.9, 91.4)	0.73 (0.61, 0.87)	7,555	11,040	68.4 (67.6, 69.3)	7,490	10,910	68.7 (67.8, 69.5)	8,127	11,870	68.5 (67.6, 69.3)
		Total	12,772	20,870	61.2 (60.5, 61.9)	0.90 (0.89, 0.91)	5,225	7,455	70.1 (73.5, 74.8)	1.03 (1.01, 1.04)	97,699	143,200	68.2 (68, 68.5)	92,474	135,745	68.1 (67.9, 68.4)	110,471	164,070	67.3 (67.1, 67.6)
		60 to 64	none	BSWN	1,776	2,750	64.6 (62.8, 66.3)	1.03 (1, 1.06)	604	840	71.9 (9.2, 11.5)	1.15 (1.1, 1.2)	13,205	20,980	62.9 (62.3, 63.6)	12,601	20,140	62.6 (61.9, 63.2)	14,981
BSCM	955			1,580	60.4 (58, 62.8)	0.86 (0.82, 0.89)	1,698	1,960	86.6 (16.9, 18.5)	1.28 (1.26, 1.31)	8,579	12,150	70.6 (69.8, 71.4)	6,881	10,190	67.5 (66.6, 68.4)	9,534	13,730	69.4 (68.7, 70.2)
BSAL	441			790	55.8 (52.3, 59.2)	0.83 (0.78, 0.88)	768	1,120	68.6 (45.3, 48.6)	1.02 (0.98, 1.06)	7,572	11,250	67.3 (66.4, 68.2)	6,804	10,130	67.2 (66.2, 68.1)	8,013	12,040	66.6 (65.7, 67.4)
BSM	2,542			4,480	56.7 (55.3, 58.2)	0.88 (0.85, 0.9)	226	340	66.5 (26.9, 33.0)	1.03 (0.95, 1.11)	13,205	20,400	64.7 (64.1, 65.4)	12,979	20,060	64.7 (64, 65.4)	15,747	24,880	63.3 (62.7, 63.9)
BSCC	1,866			3,290	56.7 (55, 58.4)	0.82 (0.8, 0.85)	162	280	57.9 (16.7, 22.5)	0.84 (0.76, 0.93)	11,126	16,145	68.9 (68.2, 69.6)	10,964	15,865	69.1 (68.4, 69.8)	12,992	19,435	66.8 (66.2, 67.5)
BSC	911			1,350	67.5 (64.9, 69.9)	0.98 (0.95, 1.02)	480	720	66.7 (46.8, 51.1)	0.97 (0.92, 1.02)	8,911	13,005	68.5 (67.7, 69.3)	8,431	12,285	68.6 (67.8, 69.4)	9,822	14,355	68.4 (67.7, 69.2)
BSSL	905			1,330	68.0 (65.5, 70.5)	0.95 (0.92, 0.99)	171	235	72.8 (11.8, 16.9)	1.02 (0.94, 1.1)	17,418	24,385	71.4 (70.9, 72)	17,247	24,150	71.4 (70.8, 72)	18,323	25,715	71.3 (70.7, 71.8)
BSOS	341			600	56.8 (52.8, 60.7)	0.86 (0.8, 0.92)	51	60	85.0 (8.6, 18.1)	1.29 (1.16, 1.44)	6,558	9,930	66.0 (65.1, 67)	6,507	9,870	65.9 (65, 66.9)	6,899	10,530	65.5 (64.6, 66.4)
Total	9,737			16,170	60.2 (59.5, 61)	0.89 (0.88, 0.9)	4,160	5,555	74.9 (25.2, 26.5)	1.11 (1.1, 1.13)	86,574	128,245	67.5 (67.2, 67.8)	82,414	122,690	67.2 (66.9, 67.4)	96,311	144,415	66.7 (66.4, 66.9)
65 to 69	none			BSWN	1,296	1,990	65.1 (63, 67.2)	0.99 (0.96, 1.03)	511	690	74.1 (88.5, 90.8)	1.13 (1.09, 1.19)	11,901	18,140	65.6 (64.9, 66.3)	11,390	17,450	65.3 (64.6, 66)	13,197
		BSCM	748	1,130	66.2 (63.4, 68.9)	0.92 (0.88, 0.96)	1,295	1,520	85.2 (81.5, 83.1)	1.23 (1.2, 1.26)	7,229	10,090	71.6 (70.8, 72.5)	5,934	8,570	69.2 (68.3, 70.2)	7,977	11,220	71.1 (70.3, 71.9)
		BSAL	339	590	57.5 (53.4, 61.4)	0.82 (0.77, 0.88)	572	830	68.9 (51.4, 54.7)	0.99 (0.94, 1.03)	6,324	9,060	69.8 (68.8, 70.7)	5,752	8,230	69.9 (68.9, 70.9)	6,663	9,650	69.0 (68.1, 70)
		BSM	1,930	3,240	59.6 (57.9, 61.2)	0.89 (0.86, 0.92)	157	280	56.1 (67.0, 73.1)	0.84 (0.75, 0.93)	12,753	19,070	66.9 (66.2, 67.5)	12,596	18,790	67.0 (66.4, 67.7)	14,683	22,310	65.8 (65.2, 66.4)
		BSCC	1,453	2,470	58.8 (56.9, 60.8)	0.85 (0.82, 0.88)	129	205	62.9 (77.5, 83.3)	0.91 (0.82, 1.01)	10,382	15,040	69.0 (68.3, 69.8)	10,253	14,835	69.1 (68.4, 69.9)	11,835	17,510	67.6 (66.9, 68.3)
		BSC	593	920	64.5 (61.3, 67.5)	0.91 (0.87, 0.96)	387	615	62.9 (48.9, 53.2)	0.88 (0.83, 0.94)	7,934	11,210	70.8 (69.9, 71.6)	7,547	10,595	71.2 (70.4, 72.1)	8,527	12,130	70.3 (69.5, 71.1)
		BSSL	724	990	73.1 (70.3, 75.8)	0.98 (0.94, 1.02)	125	195	64.1 (83.1, 88.2)	0.86 (0.77, 0.95)	16,151	21,660	74.6 (74, 75.1)	16,026	21,465	74.7			


1.b.3, Routine rescreening

Description: The number of women rescreened within 27 months of their previous screen as a percentage of the number of women eligible for a rescreen.

Targets: Initial: ≥75% of women aged 45–67 years who attend for their first screen within the programme are rescreened within 20 to 27 months.

Subsequent: ≥85% of women aged 45–67 years participating in their subsequent rescreens within the programme, are rescreened within 20 to 27 months of their previous screening episode..

Figure 37: 1.b.3.1, Percentage rescreened within 27 months of an initial and subsequent screen, 50 to 67, all BSA



Timely rescreening rates were affected by COVID related lockdowns in the last 6 months of this reporting period. Among women aged 45–67 years, 75% were rescreened within 27 months of their initial screen and 85% within 27 months of a subsequent screen. Women aged 45–49 years at their first screen were more likely to be rescreened within 27 months (77%) than those aged 50 and above at their initial screen (65%). Timely rescreening after subsequent screens did not differ by age group.

Māori women were less likely than non-Māori women to have a timely rescreen after an initial screen overall (68% compared to 76%) and in both age groups. The gap between Māori and non-Māori rescreening rates was smaller after a subsequent screen – 82% compared to 85% for non-Māori aged 45–69 years. These patterns were similar for Pacific women.

For women aged 45–67 years, the highest proportions of timely rescreens after an initial screen were in BSCC and BSC (83% each). Timely rescreens after a subsequent screen were 91% in BSCC and 89% in BSC. BSWN, BSC, BSSL and BSOS achieved equitable rescreening rates for Māori and non-Māori after both initial and subsequent screens.

Figure 38: 1.b.3.3, Routine rescreening within 27 months of an initial screen, 50 to 67, by LP




Figure 39: 1.b.3.5, Routine rescreening within 27 months of a subsequent screen, 50 to 67, by LP




Table 5: 1.b.3.1, Routine rescreening within 27 months of an initial and subsequent screen

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
			Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)	Māori / Non-Māori Ratio	Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)	Pacific / Non-Pacific Ratio	Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)	Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)	Women Rescreened Within 27 Months	Women Eligible for Rescreen	% of Eligible Women Rescreened Within 27 Months (95% CI)	
45 to 49	Initial	BSWN	761	1,098	69.3 (66.5, 72)	0.97 (0.93, 1.01)	253	345	73.3 (68.4, 77.7)	1.03 (0.97, 1.1)	4,897	6,875	71.2 (70.1, 72.3)	4,644	6,530	71.1 (70, 72.2)	5,658	7,973	71.0 (70, 72)	
		BSCM	620	956	64.9 (61.8, 67.8)	0.84 (0.8, 0.88)	949	1,401	67.7 (65.2, 70.1)	0.85 (0.82, 0.88)	4,370	5,671	77.1 (75.9, 78.1)	3,421	4,270	80.1 (78.9, 81.3)	4,990	6,627	75.3 (74.2, 76.3)	
		BSAL	262	361	72.6 (67.8, 76.9)	0.91 (0.85, 0.97)	375	541	69.3 (65.3, 73.1)	0.85 (0.8, 0.9)	3,555	4,443	80.0 (78.8, 81.2)	3,180	3,902	81.5 (80.2, 82.7)	3,817	4,804	79.5 (78.3, 80.6)	
		BSM	1,053	1,693	62.2 (59.9, 64.5)	0.89 (0.85, 0.93)	1,053	1,70	61.8 (54.3, 68.7)	0.88 (0.78, 0.99)	4,646	6,647	69.9 (68.8, 71)	4,541	6,477	70.1 (69.7, 71.2)	5,699	8,340	68.3 (67.3, 69.3)	
		BSCC	931	1,241	75.0 (72.5, 77.3)	0.86 (0.83, 0.89)	77	101	76.2 (67.1, 83.5)	0.87 (0.78, 0.97)	4,282	4,888	87.6 (86.6, 88.5)	4,205	4,787	87.8 (86.9, 88.7)	5,213	6,129	85.1 (84.1, 85.9)	
		BSC	516	601	85.9 (82.8, 88.4)	1.02 (0.98, 1.05)	209	270	77.4 (72.1, 82)	0.91 (0.86, 0.97)	4,441	5,260	84.4 (83.4, 85.4)	4,232	4,990	84.8 (83.8, 85.8)	4,957	5,861	84.6 (83.6, 85.5)	
		BSSL	532	678	78.5 (75.2, 81.4)	0.96 (0.92, 1)	99	137	72.3 (64.2, 79.1)	0.88 (0.8, 0.98)	7,285	8,933	81.6 (80.7, 82.3)	7,186	8,796	81.7 (80.9, 82.5)	7,817	9,611	81.3 (80.5, 82.1)	
		BSOS	234	292	80.1 (75.2, 84.3)	1.06 (1, 1.13)	40	55	72.7 (59.8, 82.7)	0.96 (0.82, 1.13)	2,419	3,208	75.4 (73.9, 76.9)	2,379	3,153	75.5 (73.9, 76.9)	2,653	3,500	75.8 (74.4, 77.2)	
		Total	4,909	6,920	70.9 (69.9, 72)	0.91 (0.89, 0.92)	2,107	3,020	69.8 (68.1, 71.4)	0.89 (0.87, 0.91)	35,895	45,925	78.2 (77.8, 78.5)	33,788	42,905	78.8 (78.4, 79.1)	40,804	52,845	77.2 (76.9, 77.6)	
		Subsequent	BSWN	1,075	1,332	80.7 (78.5, 82.7)	1.00 (0.98, 1.03)	401	484	82.9 (79.2, 85.9)	1.03 (0.99, 1.08)	7,450	9,263	80.4 (79.6, 81.2)	7,049	8,779	80.3 (79.4, 81.1)	8,525	10,595	80.5 (79.7, 81.2)
	BSCM		715	912	78.4 (75.6, 80.9)	0.92 (0.89, 0.95)	1,125	1,415	79.5 (77.3, 81.5)	0.92 (0.89, 0.94)	5,668	6,653	85.2 (84.3, 86)	4,543	5,238	86.7 (85.8, 87.6)	6,383	7,565	84.4 (83.5, 85.2)	
	BSAL		371	441	84.1 (80.4, 87.2)	0.97 (0.93, 1.01)	537	677	79.3 (76.1, 82.2)	0.90 (0.87, 0.94)	5,274	6,071	86.9 (86, 87.7)	4,737	5,394	87.8 (86.9, 88.7)	5,645	6,512	86.7 (85.8, 87.5)	
	BSM		1,161	1,566	74.1 (71.9, 76.2)	0.91 (0.88, 0.94)	117	158	74.1 (66.7, 80.3)	0.91 (0.83, 1)	6,129	7,524	81.5 (80.6, 82.3)	6,012	7,366	81.6 (80.7, 82.5)	7,290	9,090	80.2 (79.4, 81)	
	BSCC		1,155	1,391	83.0 (81, 84.9)	0.91 (0.89, 0.93)	113	135	83.7 (76.6, 89)	0.91 (0.85, 0.98)	5,887	6,437	91.5 (90.7, 92.1)	5,774	6,302	91.6 (90.9, 92.3)	7,042	7,828	90.0 (89.3, 90.6)	
	BSC		642	723	88.8 (86.3, 90.9)	1.00 (0.97, 1.03)	337	409	82.4 (78.4, 85.8)	0.92 (0.88, 0.97)	5,509	6,210	88.7 (87.9, 89.5)	5,172	5,801	89.2 (88.3, 89.9)	6,151	6,933	88.7 (88, 89.4)	
	BSSL		820	947	86.6 (84.3, 88.6)	1.02 (0.99, 1.05)	121	143	84.6 (77.8, 89.6)	1.00 (0.93, 1.07)	11,095	13,065	84.9 (84.3, 85.5)	10,974	12,922	84.9 (84.3, 85.5)	11,915	14,012	85.0 (84.4, 85.6)	
	BSOS		306	369	82.9 (78.8, 86.4)	1.07 (1.02, 1.12)	49	55	89.1 (78.2, 94.9)	1.15 (1.05, 1.26)	3,448	4,448	77.5 (76.3, 78.7)	3,399	4,393	77.4 (76.1, 78.6)	3,754	4,817	77.9 (76.7, 79.1)	
	Total		6,245	7,681	81.3 (80.4, 82.2)	0.96 (0.95, 0.97)	2,800	3,476	80.6 (79.2, 81.8)	0.95 (0.93, 0.97)	50,460	59,671	84.6 (84.3, 84.9)	47,660	56,195	84.8 (84.5, 85.1)	56,705	67,352	84.2 (83.9, 84.5)	
	50 to 67		Initial	BSWN	115	204	56.4 (49.5, 63)	0.97 (0.86, 1.1)	41	70	58.6 (46.9, 69.4)	1.01 (0.83, 1.24)	1,285	2,219	57.9 (55.8, 59.9)	1,244	2,149	57.9 (55.8, 60)	1,400	2,423
		BSCM		85	177	48.0 (40.8, 55.3)	0.74 (0.63, 0.86)	193	366	52.7 (47.6, 57.8)	0.77 (0.7, 0.86)	1,238	1,900	65.2 (63, 67.3)	1,045	1,534	68.1 (65.7, 70.4)	1,323	2,077	63.7 (61.6, 65.7)
		BSAL		42	76	55.3 (44.1, 65.9)	0.82 (0.67, 1)	67	124	54.0 (45.3, 62.6)	0.78 (0.67, 0.93)	951	1,407	67.6 (65.1, 70)	884	1,283	68.9 (66.3, 71.4)	993	1,483	67.0 (64.5, 69.3)
BSM		263		573	45.9 (41.9, 50)	0.84 (0.76, 0.92)	37	66	56.1 (44.1, 67.4)	1.02 (0.82, 1.27)	1,157	2,105	55.0 (52.8, 57.1)	1,120	2,039	54.9 (52.8, 57.1)	1,420	2,678	53.0 (51.1, 54.9)	
BSCC		286		454	63.0 (58.5, 67.3)	0.79 (0.74, 0.86)	24	37	64.9 (48.8, 78.2)	0.81 (0.64, 1.03)	1,126	1,419	79.4 (77.2, 81.4)	1,102	1,382	79.7 (77.5, 81.8)	1,412	1,873	75.4 (73.4, 77.3)	
BSC		132		175	75.4 (68.5, 81.2)	0.97 (0.89, 1.07)	62	93	66.7 (56.6, 75.4)	0.85 (0.74, 0.99)	1,251	1,617	77.4 (75.3, 79.3)	1,189	1,524	78.0 (75.9, 80)	1,383	1,792	77.2 (75.2, 79.1)	
BSSL		52		94	55.3 (45.3, 65)	0.83 (0.69, 1)	24	44	54.5 (40.1, 68.3)	0.81 (0.62, 1.07)	984	1,474	66.8 (64.3, 69.1)	960	1,430	67.1 (64.7, 69.5)	1,036	1,568	66.1 (63.7, 68.4)	
BSOS		39		53	73.6 (60.4, 83.6)	1.11 (0.94, 1.32)	12	23	52.2 (33, 70.8)	0.78 (0.53, 1.16)	445	674	66.0 (62.4, 69.5)	433	651	66.5 (62.8, 70)	484	727	66.6 (63.1, 69.9)	
Total		1,014		1,806	56.1 (53.8, 58.4)	0.85 (0.82, 0.89)	460	823	55.9 (52.5, 59.3)	0.84 (0.79, 0.89)	8,437	12,815	65.8 (65, 66.7)	7,977	11,992	66.5 (65.7, 67.4)	9,451	14,621	64.6 (63.9, 65.4)	
Subsequent		BSWN		5,201	6,511	79.9 (78.9, 80.8)	0.98 (0.97, 1)	1,986	2,345	84.7 (83.2, 86.1)	1.04 (1.03, 1.06)	39,943	49,144	81.3 (80.9, 81.6)	37,957	46,799	81.1 (80.7, 81.5)	45,144	55,655	81.1 (80.8, 81.4)
		BSCM	3,074	3,918	78.5 (77.1, 79.7)	0.92 (0.9, 0.93)	5,159	6,500	79.4 (78.4, 80.3)	0.91 (0.9, 0.92)	26,858	31,382	85.6 (85.2, 86)	21,699	24,882	87.2 (86.8, 87.6)	29,932	35,300	84.8 (84.4, 85.2)	
		BSAL	1,480	1,808	81.9 (80, 83.6)	0.94 (0.92, 0.96)	2,263	2,868	78.9 (77.4, 80.4)	0.89 (0.88, 0.91)	24,760	28,320	87.4 (87, 87.8)	22,497	25,452	88.4 (88, 88.8)	26,240	30,128	87.1 (86.7, 87.5)	
		BSM	6,514	8,510	76.5 (75.6, 77.4)	0.92 (0.9, 0.93)	529	700	75.6 (72.3, 78.6)	0.90 (0.87, 0.94)	38,658	46,227	83.6 (83.3, 84)	38,129	45,527	83.8 (83.4, 84.1)	45,172	54,737	82.5 (82, 82.8)	
		BSCC	5,959	7,042	84.6 (83.8, 85.4)	0.92 (0.91, 0.93)	526	616	85.4 (82.4, 88)	0.92 (0.89, 0.96)	37,155	40,282	92.2 (92, 92.5)	36,629	39,666	92.3 (92.1, 92.6)	43,114	47,324	91.1 (90.8, 91.4)	
		BSC	2,970	3,366	88.2 (87.1, 89.3)	0.99 (0.98, 1.01)	1,509	1,772	85.2 (83.4, 86.7)	0.96 (0.94, 0.98)	30,651	34,491	88.9 (88.5, 89.2)	29,142	32,719	89.1 (88.7, 89.4)	33,621	37,857	88.8 (88.5, 89.1)	
		BSSL	3,019	3,499	86.3 (85.1, 87.4)	1.01 (0.99, 1.02)	492	603	81.6 (78.3, 84.5)	0.95 (0.92, 0.99)	56,155	65,478	85.8 (85.5, 86)	55,663	64,875	85.8 (85.5, 86.1)	59,174	68,977	85.8 (85.5, 86)	
		BSOS	1,287	1,469	87.6 (85.8, 89.2)	1.10 (1.08, 1.12)	146	168	86.9 (81, 91.2)	1.09 (1.03, 1.16)	19,979	25,040	79.8 (79.3, 80.3)	19,833	24,872	79.7 (79.2, 80.2)	21,266	26,509	80.2 (79.7, 80.7)	
		Total	29,504	36,123	81.7 (81.3, 82.1)	0.95 (0.95, 0.96)	12,610	15,572	81.0 (80.4, 81.6)	0.94 (0.94, 0.95)	274,159	320,364	85.6 (85.5, 85.7)	261,549	304,792	85.8 (85.7, 85.9)	303,663	356,487	85.2 (85.1, 85.3)	
		45 to 67	Initial	BSWN	876	1,302	67.3 (64.7, 69.8)	0.99 (0.95, 1.03)	294	415	70.8 (66.3, 75)	1.04 (0.98, 1.11)	6,182	9,094	68.0 (67, 68.9)	5,888	8,679	67.8 (66.9, 68.8)	7,058	10,396
BSCM				705	1,133	62.2 (59.4, 65)	0.84 (0.8, 0.88)	1,142	1,767	64.6 (62.4, 66.8)	0.84 (0.81, 0.87)	5,608	7,571	74.1 (73.1, 75)	4,466	5,804	76.9 (75.8, 78)	6,313	8,704	72.5 (71.6, 73.5)
BSAL				304	437	69.6 (65.1, 73.7)	0.90 (0.85, 0.96)	442	665	66.5 (62.8, 70)	0.85 (0.8, 0.9)	4,506	5,850	77.0 (75.9, 78.1)	4,064	5,185	78.4 (77.2, 79.5)	4,810	6,287	76.5 (75.4, 77.5)
BSM	1,316			2,266	58.1 (56, 60.1)	0.88 (0.84, 0.91)	142	236	60.2 (53.8, 66.2)	0.91 (0.82, 1.01)	5,803	8,752	66.3 (65.3, 67.3)	5,661	8,516	66.5 (65.5, 67.5)	7,119	11,018	64.6 (63.7, 65.5)	
BSCC	1,217			1,695	71.8 (69.6, 73.9)	0.84 (0.81, 0.86)	101	138	73.2 (65.2, 79.9)	0.85 (0.77, 0.94)	5,408	6,307	85.7 (84.9, 86.6)	5,307	6,169	86.0 (85.1, 86.9)	6,625	8,002	82.8 (81.9, 83.6)	
BSC	648			776	83.5 (80.7, 86)	1.01 (0.98, 1.04)	271	363	74.7 (69.9, 78.9)	0.90 (0.84, 0.95)	5,692	6,877	82.8 (81.9, 83.6)	5,421	6,514	83.2 (82.3, 84.1)	6,340	7,653	82.8 (82, 83.7)	
BSSL	584			772	75.6 (72.5, 78.5)	0.95 (0.91, 0.99)	123	181	68.0 (60.8, 74.3)	0.85 (0.77, 0.94)	8,269	10,407	79.5 (78.7, 80.2)	8,146	10,226	79.7 (78.9, 80.4)	8,853	11,179	79.2 (78.4, 79.9)	
BSOS	273			345	79.1 (74.5, 83.1)	1.07 (1.01, 1.14)	52	78	66.7 (55.6, 76.1)	0.90 (0.77, 1.06)										


Screening and Assessment

2.a, Screening image usage

Description: The percentage of women screened who have had four or fewer images taken.

Target: >80% of women screened have four or fewer images taken.

Figure 40: 2.a.1, Screening image usage, 50 to 69, fixed and mobile units



For BSA overall, the proportions of Māori women aged 45–69 years having no more than 4 images taken has increased to meet the >80% for fixed and mobile units. For Pacific women the target was met in fixed units but was just below target in mobile units (78% for women aged 45–69 years). The target was met for other women at 88% in both fixed and mobile units.

Figure 41: 2.a.3, Fixed, 50 to 69, Screening image usage, by LP




Figure 42: 2.a.5, Mobile, 50 to 69, Screening image usage, by LP




Table 6: 2.a.1, Screening image usage


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
		Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)	Māori / Non-Māori Ratio	Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)	Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)	Women Having ≤ 4 Images	Women Screened	% of Women Screened who had ≤ 4 Images (95% CI)		
45 to 49	Fixed	BSWN	1,373	1,660	82.7 (80.8, 84.5)	0.94 (0.92, 0.96)	585	758	77.2 (74.1, 80)	0.87 (0.84, 0.91)	10,588	12,065	87.8 (87.2, 88.3)	10,003	11,307	88.5 (87.9, 89)	11,961	13,725	87.1 (86.6, 87.7)	
		BSCM	1,077	1,391	77.4 (75.2, 79.5)	0.92 (0.89, 0.94)	1,844	2,250	82.0 (80.3, 83.5)	0.96 (0.94, 0.98)	7,495	8,863	84.6 (83.8, 85.3)	5,651	6,613	85.5 (84.6, 86.3)	8,572	10,254	83.6 (82.9, 84.3)	
		BSAL	500	608	82.2 (79, 85.1)	0.95 (0.91, 0.99)	461	620	74.4 (70.8, 77.6)	0.85 (0.81, 0.89)	6,991	8,070	86.6 (85.9, 87.4)	6,530	7,450	87.7 (86.9, 88.4)	7,491	8,678	86.3 (85.6, 87)	
		BSM	2,099	2,448	85.7 (84.3, 87.1)	0.96 (0.94, 0.97)	188	228	82.5 (77, 86.8)	0.92 (0.86, 0.98)	9,622	10,732	89.7 (89.1, 90.2)	9,434	10,504	89.8 (89.2, 90.4)	11,721	13,180	88.9 (88.4, 89.5)	
		BSCC	1,616	1,943	83.2 (81.4, 84.8)	0.93 (0.91, 0.95)	167	204	81.9 (76, 86.5)	0.92 (0.86, 0.98)	8,232	9,220	89.3 (88.6, 89.9)	8,065	9,016	89.5 (88.8, 90.1)	9,848	11,163	88.2 (87.6, 88.8)	
		BSC	560	725	77.2 (74.1, 80.1)	0.91 (0.87, 0.95)	203	285	71.2 (65.7, 76.2)	0.83 (0.77, 0.9)	4,900	5,764	85.0 (84.1, 85.9)	4,697	5,479	85.7 (84.8, 86.6)	5,460	6,489	84.1 (83.2, 85)	
		BSSL	1,140	1,378	82.7 (80.6, 84.6)	0.96 (0.94, 0.98)	213	274	77.7 (72.4, 82.3)	0.90 (0.85, 0.96)	16,280	18,891	86.2 (85.7, 86.7)	16,067	18,617	86.3 (85.8, 86.8)	17,420	20,269	85.9 (85.5, 86.4)	
		BSOS	468	542	86.3 (83.2, 89)	1.00 (0.97, 1.04)	75	93	80.6 (71.5, 87.4)	0.94 (0.85, 1.03)	4,899	5,689	86.1 (85.2, 87)	4,824	5,596	86.2 (85.3, 87.1)	5,367	6,231	86.1 (85.3, 87)	
		Total	8,833	10,695	82.6 (81.9, 83.3)	0.95 (0.94, 0.96)	3,736	4,712	79.3 (78.1, 80.4)	0.91 (0.89, 0.92)	69,007	79,294	87.0 (86.8, 87.3)	65,271	74,582	87.5 (87.3, 87.8)	77,840	89,989	86.5 (86.3, 86.7)	
		Mobile	BSWN	772	878	87.9 (85.6, 89.9)	0.99 (0.96, 1.02)	89	99	89.9 (89.9, 89.9)	1.01 (0.95, 1.08)	2,890	3,251	88.0 (87.8, 89.9)	2,799	3,151	88.8 (87.7, 89.9)	3,660	4,128	88.7 (87.7, 89.6)
	BSCM		272	354	76.8 (72.2, 80.9)	0.90 (0.85, 0.95)	396	513	77.2 (77.2, 77.2)	0.88 (0.84, 0.93)	2,231	2,609	85.5 (84.1, 86.8)	1,842	2,105	87.5 (86, 88.9)	2,510	2,972	84.5 (83.1, 85.7)	
	BSAL		212	261	81.2 (76, 85.5)	0.95 (0.9, 1.01)	370	496	74.6 (74.6, 74.6)	0.85 (0.81, 0.89)	1,962	2,305	85.1 (83.6, 86.5)	1,594	1,811	88.0 (86.4, 89.4)	2,176	2,568	84.7 (83.3, 86.1)	
	BSM		704	860	81.9 (79.1, 84.3)	0.92 (0.89, 0.95)	60	77	77.9 (77.9, 77.9)	0.87 (0.78, 0.99)	2,447	2,757	88.8 (87.5, 89.9)	2,386	2,679	89.1 (87.8, 90.2)	3,150	3,616	87.1 (86, 88.2)	
	BSCC		440	558	78.9 (75.3, 82)	0.91 (0.86, 0.95)	32	45	71.1 (71.1, 71.1)	0.81 (0.67, 0.98)	1,266	1,454	87.1 (85.2, 88.7)	1,234	1,408	87.6 (85.8, 89.3)	1,706	2,011	84.8 (83.2, 86.3)	
	BSC		435	538	80.9 (77.3, 84)	0.93 (0.89, 0.97)	233	314	74.2 (74.2, 74.2)	0.84 (0.79, 0.9)	3,551	4,085	86.9 (85.9, 87.9)	3,318	3,771	88.0 (86.9, 89)	3,986	4,623	86.2 (85.2, 87.2)	
	BSSL		124	158	78.5 (71.4, 84.2)	0.91 (0.84, 0.99)	24	42	57.1 (57.1, 57.1)	0.66 (0.51, 0.85)	1,332	1,545	86.2 (84.4, 87.8)	1,308	1,503	87.0 (85.2, 88.6)	1,456	1,703	85.5 (83.3, 87.1)	
	BSOS		74	86	86.0 (77.2, 91.8)	1.00 (0.92, 1.1)	5	7	71.4 (71.4, 71.4)	0.83 (0.52, 1.33)	963	1,124	85.7 (83.5, 87.6)	958	1,117	85.8 (83.6, 87.7)	1,037	1,210	85.7 (83.6, 87.6)	
	Total		3,033	3,693	82.1 (80.9, 83.3)	0.94 (0.93, 0.96)	1,209	1,593	75.9 (75.9, 75.9)	0.86 (0.84, 0.89)	16,642	19,130	87.0 (86.5, 87.5)	15,439	17,545	88.0 (87.5, 88.5)	19,681	22,810	86.2 (85.8, 86.6)	
	50 to 69		Fixed	BSWN	3,890	4,617	84.3 (83.2, 85.3)	0.95 (0.94, 0.97)	2,074	2,601	79.7 (78.2, 81.2)	0.90 (0.88, 0.92)	36,531	41,378	88.3 (88, 88.6)	34,457	38,777	88.9 (88.5, 89.2)	40,421	45,995
		BSCM		2,713	3,396	79.9 (78.5, 81.2)	0.94 (0.92, 0.95)	5,057	6,172	81.9 (81, 82.9)	0.95 (0.94, 0.96)	23,297	27,322	85.3 (84.8, 85.7)	18,240	21,150	86.2 (85.8, 86.7)	26,010	30,718	84.7 (84.3, 85.1)
BSAL		1,166		1,395	83.6 (81.5, 85.4)	0.94 (0.92, 0.96)	1,573	1,910	82.4 (80.6, 84)	0.92 (0.9, 0.94)	22,668	25,548	88.7 (88.3, 89.1)	21,095	23,638	89.2 (88.8, 89.6)	23,834	26,943	88.5 (88.1, 88.8)	
BSM		6,541		7,697	85.0 (84.2, 85.8)	0.94 (0.93, 0.95)	558	657	84.9 (82, 87.5)	0.94 (0.91, 0.97)	35,764	39,727	90.0 (89.7, 90.3)	35,206	39,070	90.1 (89.8, 90.4)	42,305	47,424	89.2 (88.9, 89.5)	
BSCC		4,897		5,867	83.5 (82.5, 84.4)	0.94 (0.93, 0.95)	479	575	83.3 (80, 86.1)	0.94 (0.9, 0.97)	32,503	36,623	88.8 (88.4, 89.1)	32,024	36,048	88.8 (88.5, 89.2)	37,400	42,490	88.0 (87.7, 88.3)	
BSC		1,785		2,318	77.0 (75.2, 78.7)	0.91 (0.89, 0.93)	773	1,037	74.5 (71.8, 77.1)	0.88 (0.85, 0.91)	17,037	20,142	84.6 (84.1, 85.1)	16,264	19,105	85.1 (84.6, 85.6)	18,822	22,460	83.8 (83.3, 84.3)	
BSSL		3,196		3,885	82.3 (81, 83.4)	0.95 (0.94, 0.96)	496	674	73.6 (70.1, 76.8)	0.85 (0.81, 0.89)	55,359	63,929	86.6 (86.3, 86.9)	54,863	63,255	86.7 (86.5, 87)	58,555	67,814	86.3 (86.1, 86.6)	
BSOS		1,213		1,424	85.2 (83.2, 86.9)	0.99 (0.97, 1.02)	158	205	77.1 (70.9, 82.3)	0.90 (0.83, 0.97)	16,838	19,659	85.7 (85.2, 86.1)	16,680	19,454	85.7 (85.2, 86.2)	18,051	21,083	85.6 (85.1, 86.1)	
Total		25,401		30,599	83.0 (82.6, 83.4)	0.95 (0.94, 0.95)	11,168	13,831	80.7 (80.1, 81.4)	0.92 (0.91, 0.93)	239,997	274,328	87.5 (87.4, 87.6)	228,829	260,497	87.8 (87.7, 88)	265,398	304,927	87.0 (86.9, 87.2)	
Mobile		BSWN		2,542	3,024	84.1 (82.7, 85.3)	0.95 (0.93, 0.96)	240	287	83.6 (78.9, 87.5)	0.94 (0.89, 0.99)	11,991	13,501	88.8 (88.3, 89.3)	11,900	13,401	88.8 (88.3, 89.3)	14,682	16,712	87.9 (87.4, 88.4)
		BSCM	840	1,067	78.7 (76.2, 81.1)	0.91 (0.88, 0.94)	1,126	1,429	78.8 (76.6, 80.8)	0.90 (0.88, 0.93)	6,994	8,090	86.5 (85.7, 87.2)	6,605	7,586	87.1 (86.3, 87.8)	8,571	10,082	85.6 (84.8, 86.3)	
		BSAL	613	761	80.6 (77.6, 83.2)	0.89 (0.86, 0.93)	1,272	1,560	81.5 (79.5, 83.4)	0.89 (0.87, 0.91)	5,653	6,268	90.2 (89.4, 90.9)	5,285	5,774	91.5 (90.8, 92.2)	7,170	8,095	89.1 (88.4, 89.9)	
		BSM	2,459	3,070	80.1 (78.6, 81.5)	0.91 (0.89, 0.92)	203	258	78.7 (73.3, 83.2)	0.89 (0.84, 0.95)	11,763	13,313	88.4 (87.8, 88.9)	11,702	13,235	88.4 (87.9, 89)	14,364	16,563	86.8 (86.3, 87.3)	
		BSCC	1,757	2,227	78.9 (77.2, 80.5)	0.92 (0.9, 0.94)	109	149	73.2 (65.5, 79.6)	0.85 (0.77, 0.94)	6,562	7,632	86.0 (85.2, 86.7)	6,530	7,586	86.1 (85.3, 86.8)	8,396	9,962	84.4 (83.5, 85.1)	
		BSC	1,489	1,863	79.9 (78, 81.7)	0.92 (0.9, 0.94)	885	1,202	73.6 (71.1, 76)	0.84 (0.82, 0.87)	14,573	16,769	86.9 (86.4, 87.4)	14,340	16,455	87.1 (86.6, 87.6)	16,714	19,520	86.2 (85.7, 86.7)	
		BSSL	424	517	82.0 (78.5, 85.1)	0.95 (0.91, 0.99)	76	109	69.7 (60.5, 77.6)	0.81 (0.71, 0.91)	5,613	6,498	86.4 (85.5, 87.2)	5,589	6,456	86.6 (85.7, 87.4)	6,089	7,082	86.1 (85.2, 86.8)	
		BSOS	309	364	84.9 (80.8, 88.2)	1.00 (0.96, 1.05)	20	29	69.0 (50.8, 82.7)	0.81 (0.64, 1.04)	5,581	6,572	84.9 (84, 85.8)	5,576	6,565	84.9 (84, 85.8)	5,905	6,958	84.9 (84.1, 85.7)	
		Total	10,433	12,893	80.9 (80.2, 81.6)	0.93 (0.92, 0.93)	3,931	5,023	78.3 (77.1, 79.4)	0.89 (0.88, 0.91)	68,730	78,643	87.4 (87.2, 87.6)	67,527	77,058	87.6 (87.4, 87.9)	81,891	94,974	86.5 (86.3, 86.7)	
		45 to 69	Fixed	BSWN	5,263	6,277	83.8 (82.9, 84.7)	0.95 (0.94, 0.96)	2,659	3,359	79.2 (77.8, 80.5)	0.89 (0.88, 0.91)	47,119	53,443	88.2 (87.9, 88.4)	44,460	50,084	88.8 (88.5, 89)	52,382	59,720
BSCM				3,790	4,787	79.2 (78, 80.3)	0.93 (0.92, 0.94)	6,901	8,422	81.9 (81.1, 82.7)	0.95 (0.94, 0.96)	30,792	36,185	85.1 (84.7, 85.5)	23,891	27,763	86.1 (85.6, 86.5)	34,582	40,972	84.4 (84.4, 84.4)
BSAL	1,666			2,003	83.2 (81.5, 84.7)	0.94 (0.92, 0.96)	2,034	2,530	80.4 (78.8, 81.9)	0.90 (0.89, 0.92)	29,659	33,618	88.2 (87.9, 88.6)	27,625	31,088	88.9 (88.5, 89.2)	31,325	35,621	87.9 (87.94, 87.94)	
BSM	8,640			10,145	85.2 (84.5, 85.8)	0.95 (0.94, 0.96)	746	885	84.3 (81.7, 86.5)	0.94 (0.91, 0.96)	45,386	50,459	89.9 (89.7, 90.2)	44,640	49,574	90.0 (89.8, 90.3)	54,026	60,604	89.1 (89.15, 89.15)	
BSCC	6,513			7,810	83.4 (82.6, 84.2)	0.94 (0.93, 0.95)	646	779	82.9 (80.1, 85.4)	0.93 (0.9, 0.96)	40,735	45,843	88.9 (88.6, 89.1)	40,089	45,064	89.0 (88.7, 89.2)	47,248	53,653	88.1 (88.06, 88.06)	
BSC	2,345			3,043	77.1 (75.5, 78.5)	0.91 (0.89, 0.93)	976	1,322	73.8 (71.4, 76.1)	0.87 (0.84, 0.89)	21,937	25,906	84.7 (84.2, 85.1)	20,961	24,584	85.3 (84.8, 85.7)	24,282	28,949	83.9 (83.88, 83.88)	
BSSL	4,336			5,263	82.4 (81.3, 83.4)	0.95 (0.94, 0.96)	709	948	74.8 (71.9, 77.4)	0.86 (0.83, 0.9)	71,639	82,820	86.5 (86.3, 86.7)	70,930	81,872	86.6 (86.4, 86.9)	75,975	88,083	86.3 (86.25,	

2.b, Technical recall rate

Description: The number of women recommended for technical recall as a percentage of number of women screened.

Target: ≤0.5% of women screened

Figure 43: 2.b.1, Technical recall rate, 50 to 69, fixed and mobile units



For BSA overall, technical recall rates were 0.2% for both fixed sites and mobile units, well within the target range of 0.5% or less. BSC had rates of 0.9% in fixed sites and 0.7% in mobile units for women aged 45–69 years.

Figure 44 2.b.3, Fixed site, 50 to 69, Technical recall rate, by LP




Figure 45: 2.b.5, Mobile units, 50 to 69, Technical recall rate, by LP




Table 7: 2.b.1, Technical recall rate


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)	Māori / Non-Māori Ratio	Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)	Pacific / Non-Pacific Ratio	Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)	Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)	Women Having Technical Recall	Women Screened	% of Women Screened who had Technical Recall (95% CI)
45 to 49	Fixed	BSWN	0	1,655	0.0 (0, 0.2)	0.00 -	2	755	0.3 (0.1, 1)	5.99 (1.5, 30.81)	7	12,055	0.1 (0, 0.1)	5	11,300	0.0 (0, 0.1)	7	13,710	0.1 (0, 0.1)
		BSCM	4	1,390	0.3 (0.1, 0.7)	1.27 (0.44, 3.72)	3	2,248	0.1 (0, 0.4)	0.52 (0.17, 1.77)	20	8,856	0.2 (0.1, 0.3)	17	6,608	0.3 (0.2, 0.4)	24	10,246	0.2 (0.2, 0.3)
		BSAL	2	608	0.3 (0.1, 1.2)	1.56 (0.36, 6.74)	4	620	0.6 (0.3, 1.6)	3.70 (1.39, 11.31)	17	8,070	0.2 (0.1, 0.3)	13	7,450	0.2 (0.1, 0.3)	19	8,678	0.2 (0.1, 0.3)
		BSM	7	2,436	0.3 (0.1, 0.6)	1.71 (0.72, 4.09)	0	228	0.0 (0, 1.7)	0.00 -	18	10,724	0.2 (0.1, 0.3)	18	10,496	0.2 (0.1, 0.3)	25	13,160	0.2 (0.1, 0.3)
		BSCC	4	1,942	0.2 (0.1, 0.5)	2.37 (0.72, 7.88)	0	204	0.0 (0, 1.8)	0.00 -	8	9,220	0.1 (0, 0.2)	8	9,016	0.1 (0, 0.2)	12	11,162	0.1 (0.1, 0.2)
		BSC	12	714	1.7 (1, 2.9)	1.18 (0.65, 2.15)	6	282	2.1 (1, 4.6)	1.53 (0.7, 3.49)	82	5,761	1.4 (1.1, 1.8)	76	5,479	1.4 (1.1, 1.7)	94	6,475	1.5 (1.2, 1.8)
		BSSL	6	1,370	0.4 (0.2, 1)	1.76 (0.75, 4.11)	0	273	0.0 (0, 1.4)	0.00 -	47	18,885	0.2 (0.2, 0.3)	47	18,612	0.3 (0.2, 0.3)	53	20,255	0.3 (0.2, 0.3)
		BSOS	4	540	0.7 (0.3, 1.9)	1.08 (0.39, 3.01)	1	92	1.1 (0.2, 5.9)	1.60 (0.23, 11.53)	39	5,684	0.7 (0.5, 0.9)	38	5,592	0.7 (0.5, 0.9)	43	6,224	0.7 (0.5, 0.9)
		Total	39	10,655	0.4 (0.3, 0.5)	1.22 (0.87, 1.71)	16	4,702	0.3 (0.2, 0.6)	1.14 (0.7, 1.9)	238	79,255	0.3 (0.3, 0.3)	222	74,553	0.3 (0.3, 0.3)	277	89,910	0.3 (0.3, 0.3)
		Mobile	BSWN	1	878	0.1 (0, 0.6)	1.23 (0.13, 11.85)	0	100	0.0 (0, 3.7)	0.00 -	3	3,251	0.1 (0, 0.3)	3	3,151	0.1 (0, 0.3)	4	4,129
	BSCM		0	354	0.0 (0, 1.1)	0.00 -	2	504	0.4 (0.1, 1.4)	1.19 (0.3, 5.73)	9	2,609	0.3 (0.2, 0.7)	7	2,105	0.3 (0.2, 0.7)	9	2,963	0.3 (0.2, 0.6)
	BSAL		0	261	0.0 (0, 1.5)	0.00 -	2	494	0.4 (0.1, 1.5)	1.83 (0.46, 9.98)	6	2,305	0.3 (0.1, 0.6)	4	1,811	0.2 (0.1, 0.6)	6	2,566	0.2 (0.1, 0.5)
	BSM		2	860	0.2 (0.1, 0.8)	0.92 (0.19, 4.4)	1	78	1.3 (0.2, 6.9)	5.72 (0.82, 46.98)	7	2,757	0.3 (0.1, 0.5)	6	2,679	0.2 (0.1, 0.5)	9	3,617	0.2 (0.1, 0.5)
	BSCC		1	556	0.2 (0, 1)	- -	0	45	0.0 (0, 7.9)	- -	0	1,453	0.0 (0, 0.3)	0	1,408	0.0 (0, 0.3)	1	2,009	0.0 (0, 0.3)
	BSC		5	534	0.9 (0.4, 2.2)	0.98 (0.39, 2.47)	2	307	0.7 (0.2, 2.3)	0.66 (0.17, 2.74)	39	4,078	1.0 (0.7, 1.3)	37	3,771	1.0 (0.7, 1.3)	44	4,612	1.0 (0.7, 1.3)
	BSSL		0	158	0.0 (0, 2.4)	0.00 -	0	42	0.0 (0, 8.4)	0.00 -	3	1,545	0.2 (0.1, 0.6)	3	1,503	0.2 (0.1, 0.6)	3	1,703	0.2 (0.1, 0.5)
	BSOS		3	86	3.5 (1.2, 9.8)	4.36 (1.2, 15.8)	0	7	0.0 (0, 35.4)	0.00 -	9	1,124	0.8 (0.4, 1.5)	9	1,117	0.8 (0.4, 1.5)	12	1,210	1.0 (0.6, 1.7)
	Total		12	3,687	0.3 (0.2, 0.6)	0.82 (0.45, 1.5)	7	1,577	0.4 (0.2, 0.9)	1.13 (0.54, 2.45)	76	19,122	0.4 (0.3, 0.5)	69	17,545	0.4 (0.3, 0.5)	88	22,809	0.4 (0.3, 0.5)
	50 to 69		Fixed	BSWN	2	4,609	0.0 (0, 0.2)	2.24 (0.48, 10.55)	0	2,592	0.0 (0, 0.1)	0.00 -	8	41,326	0.0 (0, 0)	8	38,734	0.0 (0, 0)	10
BSCM		4		3,394	0.1 (0, 0.3)	1.40 (0.48, 4.04)	4	6,163	0.1 (0, 0.2)	0.72 (0.27, 2.12)	23	27,286	0.1 (0.1, 0.1)	19	21,123	0.1 (0.1, 0.1)	27	30,680	0.1 (0.1, 0.1)
BSAL		1		1,393	0.1 (0, 0.4)	0.48 (0.07, 3.51)	1	1,910	0.1 (0, 0.3)	0.33 (0.05, 2.44)	38	25,548	0.1 (0.1, 0.2)	37	23,638	0.2 (0.1, 0.2)	39	26,941	0.1 (0.1, 0.2)
BSM		10		7,634	0.1 (0.1, 0.2)	3.06 (1.4, 6.67)	0	656	0.0 (0, 0.6)	0.00 -	17	39,674	0.0 (0, 0.1)	17	39,018	0.0 (0, 0.1)	27	47,308	0.1 (0, 0.1)
BSCC		8		5,867	0.1 (0.1, 0.3)	2.00 (0.9, 4.43)	0	575	0.0 (0, 0.7)	0.00 -	25	36,622	0.1 (0, 0.1)	25	36,047	0.1 (0, 0.1)	33	42,489	0.1 (0.1, 0.1)
BSC		20		2,280	0.9 (0.6, 1.4)	1.25 (0.78, 1.99)	7	1,024	0.7 (0.3, 1.4)	0.97 (0.47, 2.07)	141	20,096	0.7 (0.6, 0.8)	134	19,072	0.7 (0.6, 0.8)	161	22,376	0.7 (0.6, 0.8)
BSSL		7		3,865	0.2 (0.1, 0.4)	0.96 (0.45, 2.06)	0	662	0.0 (0, 0.6)	0.00 -	120	63,892	0.2 (0.2, 0.2)	120	63,230	0.2 (0.2, 0.2)	127	67,757	0.2 (0.2, 0.2)
BSOS		3		1,419	0.2 (0.1, 0.6)	0.40 (0.13, 1.27)	1	204	0.5 (0.1, 2.7)	0.93 (0.13, 6.67)	103	19,651	0.5 (0.4, 0.6)	102	19,447	0.5 (0.4, 0.6)	106	21,070	0.5 (0.4, 0.6)
Total		55		30,461	0.2 (0.1, 0.2)	1.04 (0.79, 1.38)	13	13,786	0.1 (0.1, 0.2)	0.53 (0.31, 0.92)	475	274,095	0.2 (0.2, 0.2)	462	260,309	0.2 (0.2, 0.2)	530	304,556	0.2 (0.2, 0.2)
Mobile		BSWN		0	3,022	0.0 (0, 0.1)	0.00 #NUM!	0	285	0.0 (0, 1.3)	0.00 -	3	13,682	0.0 (0, 0.1)	3	13,397	0.0 (0, 0.1)	3	16,704
		BSCM	3	1,067	0.3 (0.1, 0.8)	2.11 (0.6, 7.46)	2	1,416	0.1 (0, 0.5)	1.07 (0.27, 4.89)	12	9,002	0.1 (0.1, 0.2)	10	7,586	0.1 (0.1, 0.2)	15	10,069	0.1 (0.1, 0.2)
		BSAL	1	761	0.1 (0, 0.7)	1.93 (0.23, 16.47)	3	1,558	0.2 (0.1, 0.6)	5.56 (1.79, 33.24)	5	7,332	0.1 (0, 0.2)	2	5,774	0.0 (0, 0.1)	6	8,093	0.1 (0, 0.2)
		BSM	1	3,070	0.0 (0, 0.2)	0.34 (0.04, 2.58)	0	253	0.0 (0, 1.5)	0.00 -	13	13,488	0.1 (0.1, 0.2)	13	13,235	0.1 (0.1, 0.2)	14	16,558	0.1 (0.1, 0.1)
		BSCC	1	2,224	0.0 (0, 0.3)	3.47 (0.22, 55.48)	0	148	0.0 (0, 2.5)	0.00 -	1	7,721	0.0 (0, 0.1)	1	7,573	0.0 (0, 0.1)	2	9,945	0.0 (0, 0.1)
		BSC	13	1,847	0.7 (0.4, 1.2)	1.22 (0.68, 2.16)	9	1,192	0.8 (0.4, 1.4)	1.34 (0.7, 2.64)	102	17,641	0.6 (0.5, 0.7)	93	16,449	0.6 (0.5, 0.7)	115	19,488	0.6 (0.5, 0.7)
		BSSL	0	517	0.0 (0, 0.7)	0.00 -	0	109	0.0 (0, 3.4)	0.00 -	8	6,565	0.1 (0.1, 0.2)	8	6,456	0.1 (0.1, 0.2)	8	7,082	0.1 (0.1, 0.2)
		BSOS	2	364	0.5 (0.2, 2)	1.45 (0.34, 6.09)	1	29	3.4 (0.6, 17.2)	9.43 (1.37, 67.43)	25	6,594	0.4 (0.3, 0.6)	24	6,565	0.4 (0.2, 0.5)	27	6,958	0.4 (0.3, 0.6)
		Total	21	12,872	0.2 (0.1, 0.2)	0.79 (0.5, 1.25)	15	4,990	0.3 (0.2, 0.5)	1.50 (0.91, 2.55)	169	82,025	0.2 (0.2, 0.2)	154	77,035	0.2 (0.2, 0.2)	190	94,897	0.2 (0.2, 0.2)
		45 to 69	Fixed	BSWN	2	6,264	0.0 (0, 0.1)	1.14 (0.26, 4.97)	2	3,347	0.1 (0, 0.2)	2.30 (0.58, 10.19)	15	53,381	0.0 (0, 0)	13	50,034	0.0 (0, 0)	17
BSCM	8			4,784	0.2 (0.1, 0.3)	1.41 (0.66, 2.99)	7	8,411	0.1 (0, 0.2)	0.64 (0.31, 1.44)	43	36,142	0.1 (0.1, 0.2)	36	27,731	0.1 (0.1, 0.2)	51	40,926	0.1 (0.1, 0.2)
BSAL	3			2,001	0.1 (0.1, 0.4)	0.92 (0.29, 2.93)	5	2,530	0.2 (0.1, 0.5)	1.23 (0.51, 3.08)	55	33,618	0.2 (0.1, 0.2)	50	31,088	0.2 (0.1, 0.2)	58	35,619	0.2 (0.1, 0.2)
BSM	17			10,070	0.2 (0.1, 0.3)	2.43 (1.36, 4.34)	0	884	0.0 (0, 0.4)	0.00 -	35	50,398	0.1 (0, 0.1)	35	49,514	0.1 (0.1, 0.1)	52	60,468	0.1 (0.1, 0.1)
BSCC	12			7,809	0.2 (0.1, 0.3)	2.13 (1.1, 4.13)	0	779	0.0 (0, 0.5)	0.00 -	33	45,842	0.1 (0.1, 0.1)	33	45,063	0.1 (0.1, 0.1)	45	53,651	0.1 (0.1, 0.1)
BSC	32			2,994	1.1 (0.8, 1.5)	1.24 (0.86, 1.79)	13	1,306	1.0 (0.6, 1.7)	1.16 (0.68, 2.03)	223	25,857	0.9 (0.8, 1)	210	24,551	0.9 (0.7, 1)	255	28,851	0.9 (0.8, 1)
BSSL	13			5,235	0.2 (0.1, 0.4)	1.23 (0.7, 2.16)	0	935	0.0 (0, 0.4)	0.00 -	167	82,777	0.2 (0.2, 0.2)	167	81,842	0.2 (0.2, 0.2)	180	88,012	0.2 (0.2, 0.2)
BSOS	7			1,959	0.4 (0.2, 0.7)	0.64 (0.3, 1.36)	2	296	0.7 (0.2, 2.4)	1.21 (0.3, 4.86)	142	25,335	0.6 (0.5, 0.7)	140	25,039	0.6 (0.5, 0.7)	149	27,294	0.5 (0.5, 0.6)
Total	94			41,116	0.2 (0.2, 0.3)	1.13 (0.91, 1.4)	29	18,488	0.2 (0.1, 0.2)	0.77 (0.53, 1.11)	713	353,350	0.2 (0.2, 0.2)	684	334,862	0.2 (0.2, 0.2)	807	394,466	0.2 (0.2, 0.2)
Mobile	BSWN			1	3,900	0.0 (0, 0.1)	0.72 (0.09, 6.01)	0	385	0.0 (0, 1)	0.00 -	6	16,933	0.0 (0, 0.1)	6	16,548	0.0 (0, 0.1)	7	20,833
	BSCM		3	1,421	0.2 (0.1, 0.6)	1.17 (0.35, 3.91)	4	1,920	0.2 (0.1, 0.5)	1.19 (0.45, 3.53)	21	11,611	0.2 (0.1, 0.3)	17	9,691	0.2 (0.1, 0.3)	24	13,032	0.2 (0.1, 0.3)
	BSAL		1	1,022	0.1 (0, 0.6)	0.86 (0.11, 6.63)	5	2,052	0.2 (0.1, 0.6)	3.08 (1.28, 10.08)	11	9,637	0.1 (0.1, 0.2)	6	7,585	0.1 (0, 0.2)	12	10,659	0.1 (0.1, 0.2)
	BSM		3	3,930	0.1 (0, 0.2)	0.62 (0.18, 2.09)	1	331	0.3 (0.1, 1.7)	2.53 (0.36, 18.85)	20	16,245	0.1 (0.1, 0.2)	19	15,914	0.1 (0.1, 0.2)	23	20,175	0.1 (0.1, 0.2)
	BSCC		2	2,780	0.1 (0, 0.3)	6.60 (0.6, 72.76)	0	193	0.0 (0, 2)	0.00 -	1	9,174	0.0 (0, 0.1)	1	8,981	0.0 (0, 0.1)	3	11,954	0.0 (0, 0.1)

2.c, Technical reject rate

Description: The number of images rejected as a percentage of total number of images taken, including technical recalls.

Target: ≤3% of images are rejected

Figure 46: 2.c.1, Technical reject rate, 50 to 69, fixed and mobile units



Technical reject rates were all well within the target range of 3% or less.

Figure 47: 2.c.3, Fixed sites 50 to 69, Technical reject rate, by LP




Figure 48: 2.c.5, Mobile units, 50 to 69, Technical reject rate, by LP




Table 8: 2.c.1, Technical reject rate


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Images Rejected	Images Taken	% of Images that were Rejected (95% CI)	Māori / Non-Māori Ratio	Images Rejected	Images Taken	% of Images that were Rejected (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Images Rejected	Images Taken	% of Images that were Rejected (95% CI)	Images Rejected	Images Taken	% of Images that were Rejected (95% CI)	Images Rejected	Images Taken	% of Images that were Rejected (95% CI)
45 to 49	Fixed	BSWN	81	7,133	1.1 (0.9, 1.4)	1.24 (0.98, 1.57)	30	3,277	0.9 (0.6, 1.3)	1.00 (0.7, 1.45)	465	50,906	0.9 (0.8, 1)	435	47,629	0.9 (0.8, 1)	546	58,039	0.9 (0.9, 1)
		BSCM	87	6,085	1.4 (1.2, 1.8)	1.01 (0.8, 1.26)	147	9,631	1.5 (1.3, 1.8)	1.10 (0.94, 1.33)	539	37,941	1.4 (1.3, 1.5)	392	28,310	1.4 (1.3, 1.5)	626	44,026	1.4 (1.3, 1.5)
		BSAL	5	2,619	0.2 (0.1, 0.4)	0.74 (0.3, 1.82)	8	2,726	0.3 (0.1, 0.6)	1.15 (0.58, 2.38)	88	34,085	0.3 (0.2, 0.3)	80	31,359	0.3 (0.2, 0.3)	93	36,704	0.3 (0.2, 0.3)
		BSM	99	10,647	0.9 (0.8, 1.1)	0.99 (0.79, 1.22)	16	979	1.6 (1, 2.6)	1.76 (1.08, 2.89)	425	45,030	0.9 (0.9, 1)	409	44,051	0.9 (0.8, 1)	524	55,677	0.9 (0.9, 1)
		BSCC	76	8,252	0.9 (0.7, 1.2)	1.09 (0.85, 1.4)	8	869	0.9 (0.5, 1.8)	1.09 (0.55, 2.2)	324	38,426	0.8 (0.8, 0.9)	316	37,557	0.8 (0.8, 0.9)	400	46,678	0.9 (0.8, 0.9)
		BSC	3	3,219	0.1 (0, 0.3)	0.55 (0.17, 1.79)	3	1,284	0.2 (0.1, 0.7)	1.42 (0.46, 4.6)	41	24,403	0.2 (0.1, 0.2)	38	23,119	0.2 (0.1, 0.2)	44	27,622	0.2 (0.1, 0.2)
		BSSL	52	6,026	0.9 (0.7, 1.1)	1.26 (0.95, 1.68)	10	1,208	0.8 (0.5, 1.5)	1.21 (0.66, 2.26)	545	79,695	0.7 (0.6, 0.7)	535	78,487	0.7 (0.6, 0.7)	597	85,721	0.7 (0.6, 0.8)
		BSOS	20	2,332	0.9 (0.6, 1.3)	0.78 (0.49, 1.22)	4	398	1.0 (0.4, 2.6)	0.91 (0.34, 2.43)	264	23,909	1.1 (1, 1.2)	260	23,511	1.1 (1, 1.2)	284	26,241	1.1 (1, 1.2)
		Total	423	46,313	0.9 (0.8, 1)	1.13 (1.02, 1.26)	226	20,372	1.1 (1, 1.3)	1.41 (1.24, 1.62)	2,691	334,395	0.8 (0.8, 0.8)	2,465	314,023	0.8 (0.8, 0.8)	3,114	380,708	0.8 (0.8, 0.8)
		Mobile	BSWN	37	3,676	1.0 (0.7, 1.4)	1.12 (0.77, 1.61)	4	416	1.0 (0.4, 2.4)	1.07 (0.4, 2.88)	123	13,648	0.9 (0.8, 1.1)	119	13,232	0.9 (0.8, 1.1)	160	17,324
	BSCM		26	1,535	1.7 (1.2, 2.5)	1.20 (0.79, 1.81)	38	2,192	1.7 (1.3, 2.4)	1.30 (0.95, 1.87)	156	11,037	1.4 (1.2, 1.7)	118	8,845	1.3 (1.1, 1.6)	182	12,572	1.4 (1.3, 1.7)
	BSAL		3	1,118	0.3 (0.1, 0.8)	1.09 (0.33, 3.62)	11	2,174	0.5 (0.3, 0.9)	2.95 (1.64, 6.58)	24	9,759	0.2 (0.2, 0.4)	13	7,585	0.2 (0.1, 0.3)	27	10,877	0.2 (0.2, 0.4)
	BSM		44	3,658	1.2 (0.9, 1.6)	1.29 (0.91, 1.83)	5	334	1.5 (0.6, 3.5)	1.64 (0.69, 3.99)	107	11,480	0.9 (0.8, 1.1)	102	11,146	0.9 (0.8, 1.1)	151	15,138	1.0 (0.9, 1.2)
	BSCC		27	2,411	1.1 (0.8, 1.6)	0.79 (0.51, 1.21)	9	204	4.4 (2.3, 8.2)	3.34 (1.76, 6.57)	87	6,111	1.4 (1.2, 1.8)	78	5,907	1.3 (1.1, 1.6)	114	8,522	1.3 (1.1, 1.6)
	BSC		0	2,333	0.0 (0, 0.2)	0.00 -	0	1,397	0.0 (0, 0.3)	0.00 -	9	17,099	0.1 (0, 0.1)	9	15,702	0.1 (0, 0.1)	9	19,432	0.0 (0, 0.1)
	BSSL		8	677	1.2 (0.6, 2.3)	1.33 (0.64, 2.76)	2	197	1.0 (0.3, 3.6)	1.14 (0.29, 4.65)	58	6,504	0.9 (0.7, 1.2)	56	6,307	0.9 (0.7, 1.2)	66	7,181	0.9 (0.7, 1.2)
	BSOS		2	364	0.5 (0.2, 2)	0.65 (0.16, 2.67)	1	30	3.3 (0.6, 16.7)	4.01 (0.58, 28.26)	40	4,724	0.8 (0.6, 1.2)	39	4,694	0.8 (0.6, 1.1)	42	5,088	0.8 (0.6, 1.1)
	Total		147	15,772	0.9 (0.8, 1.1)	1.24 (1.04, 1.48)	70	6,944	1.0 (0.8, 1.3)	1.39 (1.1, 1.78)	604	80,362	0.8 (0.7, 0.8)	534	73,418	0.7 (0.7, 0.8)	751	96,134	0.8 (0.7, 0.8)
	50 to 69	Fixed	BSWN	163	19,689	0.8 (0.7, 1)	1.10 (0.93, 1.29)	105	11,200	0.9 (0.8, 1.1)	1.26 (1.04, 1.54)	1,309	173,308	0.8 (0.7, 0.8)	1,204	162,108	0.7 (0.7, 0.8)	1,472	192,997
BSCM			191	14,519	1.3 (1.1, 1.5)	1.07 (0.92, 1.25)	327	26,281	1.2 (1.1, 1.4)	1.02 (0.91, 1.15)	1,418	115,574	1.2 (1.2, 1.3)	1,091	89,293	1.2 (1.2, 1.3)	1,609	130,093	1.2 (1.2, 1.3)
BSAL			16	5,930	0.3 (0.2, 0.4)	1.23 (0.74, 2.03)	19	8,116	0.2 (0.1, 0.4)	1.07 (0.68, 1.71)	234	106,352	0.2 (0.2, 0.3)	215	98,236	0.2 (0.2, 0.3)	250	112,282	0.2 (0.2, 0.3)
BSM			319	33,510	1.0 (0.9, 1.1)	1.07 (0.95, 1.2)	31	2,769	1.1 (0.8, 1.6)	1.26 (0.89, 1.8)	1,483	166,276	0.9 (0.8, 0.9)	1,452	163,507	0.9 (0.8, 0.9)	1,802	199,786	0.9 (0.9, 0.9)
BSCC			209	24,792	0.8 (0.7, 1)	0.99 (0.86, 1.15)	22	2,425	0.9 (0.6, 1.4)	1.07 (0.71, 1.63)	1,289	152,021	0.8 (0.8, 0.9)	1,267	149,596	0.8 (0.8, 0.9)	1,498	176,813	0.8 (0.8, 0.9)
BSC			11	10,296	0.1 (0.1, 0.2)	1.38 (0.73, 2.61)	2	4,587	0.0 (0, 0.2)	0.55 (0.14, 2.24)	66	85,094	0.1 (0.1, 0.1)	64	80,507	0.1 (0.1, 0.1)	77	95,390	0.1 (0.1, 0.1)
BSSL			119	16,917	0.7 (0.6, 0.8)	1.02 (0.85, 1.23)	30	3,016	1.0 (0.7, 1.4)	1.45 (1.02, 2.08)	1,841	267,600	0.7 (0.7, 0.7)	1,811	264,584	0.7 (0.7, 0.7)	1,960	284,517	0.7 (0.7, 0.7)
BSOS			63	6,086	1.0 (0.8, 1.3)	0.93 (0.72, 1.19)	9	899	1.0 (0.5, 1.9)	0.90 (0.47, 1.72)	920	82,357	1.1 (1, 1.2)	911	81,458	1.1 (1, 1.2)	983	88,443	1.1 (1, 1.2)
Total			1,091	131,739	0.8 (0.8, 0.9)	1.11 (1.04, 1.18)	545	59,293	0.9 (0.8, 1)	1.25 (1.15, 1.36)	8,560	1,148,582	0.7 (0.7, 0.8)	8,015	1,089,289	0.7 (0.7, 0.8)	9,651	1,280,321	0.8 (0.7, 0.8)
Mobile			BSWN	167	12,775	1.3 (1.1, 1.5)	1.45 (1.22, 1.72)	23	1,202	1.9 (1.3, 2.9)	2.17 (1.45, 3.29)	515	57,071	0.9 (0.8, 1)	492	55,869	0.9 (0.8, 1)	682	69,846
		BSCM	78	4,585	1.7 (1.4, 2.1)	1.29 (1.02, 1.63)	75	6,060	1.2 (1, 1.5)	0.93 (0.74, 1.18)	499	37,782	1.3 (1.2, 1.4)	424	31,722	1.3 (1.2, 1.5)	577	42,367	1.4 (1.3, 1.5)
		BSAL	18	3,253	0.6 (0.4, 0.9)	2.80 (1.66, 4.73)	10	6,623	0.2 (0.1, 0.3)	0.72 (0.39, 1.41)	60	30,355	0.2 (0.2, 0.3)	50	23,732	0.2 (0.2, 0.3)	78	33,608	0.2 (0.2, 0.3)
		BSM	135	13,113	1.0 (0.9, 1.2)	1.23 (1.02, 1.49)	16	1,112	1.4 (0.9, 2.3)	1.75 (1.08, 2.87)	468	56,134	0.8 (0.8, 0.9)	452	55,022	0.8 (0.7, 0.9)	603	69,247	0.9 (0.8, 0.9)
		BSCC	157	9,626	1.6 (1.4, 1.9)	1.29 (1.07, 1.54)	7	667	1.0 (0.5, 2.2)	0.82 (0.39, 1.73)	414	32,643	1.3 (1.2, 1.4)	407	31,976	1.3 (1.2, 1.4)	571	42,269	1.4 (1.2, 1.5)
		BSC	0	8,135	0.0 (0, 0)	0.00 -	0	5,422	0.0 (0, 0.1)	0.00 -	15	73,795	0.0 (0, 0)	15	68,373	0.0 (0, 0)	15	81,930	0.0 (0, 0)
		BSSL	21	2,203	1.0 (0.6, 1.5)	1.33 (0.85, 2.08)	6	494	1.2 (0.6, 2.6)	1.72 (0.78, 3.85)	197	27,510	0.7 (0.6, 0.8)	191	27,016	0.7 (0.6, 0.8)	218	29,713	0.7 (0.6, 0.8)
		BSOS	14	1,542	0.9 (0.5, 1.5)	1.12 (0.65, 1.92)	2	128	1.6 (0.4, 5.5)	1.94 (0.49, 7.71)	224	27,634	0.8 (0.7, 0.9)	222	27,506	0.8 (0.7, 0.9)	238	29,176	0.8 (0.7, 0.9)
		Total	590	55,232	1.1 (1, 1.2)	1.53 (1.4, 1.68)	139	21,708	0.6 (0.5, 0.8)	0.91 (0.77, 1.08)	2,392	342,924	0.7 (0.7, 0.7)	2,253	321,216	0.7 (0.7, 0.7)	2,982	398,156	0.7 (0.7, 0.8)
45 to 69		Fixed	BSWN	244	26,822	0.9 (0.8, 1)	1.15 (1.01, 1.31)	135	14,477	0.9 (0.8, 1.1)	1.19 (1.01, 1.42)	1,774	224,214	0.8 (0.8, 0.8)	1,639	209,737	0.8 (0.7, 0.8)	2,018	251,036
	BSCM		278	20,604	1.3 (1.2, 1.5)	1.06 (0.93, 1.2)	474	35,912	1.3 (1.2, 1.4)	1.05 (0.96, 1.16)	1,957	153,515	1.3 (1.2, 1.3)	1,483	117,603	1.3 (1.2, 1.3)	2,235	174,119	1.3 (1.2, 1.3)
	BSAL		21	8,549	0.2 (0.2, 0.4)	1.07 (0.69, 1.66)	27	10,842	0.2 (0.2, 0.4)	1.09 (0.75, 1.62)	322	140,437	0.2 (0.2, 0.3)	295	129,595	0.2 (0.2, 0.3)	343	148,986	0.2 (0.2, 0.3)
	BSM		418	44,157	0.9 (0.9, 1)	1.05 (0.94, 1.16)	47	3,748	1.3 (0.9, 1.7)	1.40 (1.05, 1.86)	1,908	211,306	0.9 (0.9, 0.9)	1,861	207,558	0.9 (0.9, 0.9)	2,326	255,463	0.9 (0.9, 0.9)
	BSCC		285	33,044	0.9 (0.8, 1)	1.02 (0.9, 1.15)	30	3,294	0.9 (0.6, 1.3)	1.08 (0.75, 1.54)	1,613	190,447	0.8 (0.8, 0.9)	1,583	187,153	0.8 (0.8, 0.9)	1,898	223,491	0.8 (0.8, 0.9)
	BSC		14	13,515	0.1 (0.1, 0.2)	1.06 (0.61, 1.85)	5	3,294	0.1 (0, 0.2)	0.87 (0.36, 2.12)	107	109,497	0.1 (0.1, 0.1)	102	103,626	0.1 (0.1, 0.1)	121	123,012	0.1 (0.1, 0.1)
	BSSL		171	22,943	0.7 (0.6, 0.9)	1.08 (0.93, 1.27)	40	4,224	0.9 (0.7, 1.3)	1.38 (1.02, 1.89)	2,386	347,295	0.7 (0.7, 0.7)	2,346	343,071	0.7 (0.7, 0.7)	2,557	370,238	0.7 (0.7, 0.7)
	BSOS		83	8,418	1.0 (0.8, 1.2)	0.88 (0.71, 1.1)	13	1,297	1.0 (0.6, 1.7)	0.90 (0.52, 1.55)	1,184	106,266	1.1 (1.1, 1.2)	1,171	104,969	1.1 (1.1, 1.2)	1,267	114,684	1.1 (1, 1.2)
	Total		1,514	178,052	0.9 (0.8, 0.9)	1.12 (1.06, 1.18)	771	79,665	1.0 (0.9, 1)	1.30 (1.21, 1.39)	11,251	1,482,977	0.8 (0.7, 0.8)	10,480	1,403,312	0.7 (0.7, 0.8)	12,765	1,661,029	0.8 (0.8, 0.8)
	Mobile		BSWN	204	16,451	1.2 (1.1, 1.4)	1.37 (1.18, 1.61)	27	1,618	1.7 (1.1, 2.4)	1.89 (1.3, 2.77)	638	70,719	0.9 (0.8, 1)	611	69,101	0.9 (0.8, 1)	842	87,170
		BSCM	104	6,120	1.7 (1.4, 2.1)	1.27 (1.03, 1.56)	113	8,252	1.4 (1.1, 1.6)	1.02 (0.85, 1.25)	655	48,819	1.3 (1.2,						

2.d, Assessment rate

Description: The number of women referred to assessment as a percentage of number of women screened.

Targets: Initial: expected value <10%. Subsequent: expected value <5% (45–49 and 50–69 age group).

Figure 49: 2.d.1, 50 to 69, Assessment rate, initial and subsequent screens



There were 20,712 referrals to assessment over the two-year period.

The proportion of Māori women aged 50–69 years referred for assessment from an initial screen was 12%, above the target of <10% but the positive predictive value for Māori women was high at 17.5%, indicating the higher assessment rate was appropriate. For Pacific and other women aged 50–69 having initial screens the assessment rates were on target at 10% and 9.2% respectively. Among women having subsequent screens, assessment rates were within the target range of <5% for all groups.

For women aged 45–49 years, rates of referral to assessment were within the expected ranges for initial (8.3%) and subsequent screens (4.4%).

Figure 50: 2.d.3, Initial, 50 to 69, Assessment rate, by LP




Figure 51: 2.d.5, Subsequent, 50 to 69, Assessment rate, by LP




Table 9: 2.d.1, Assessment rate


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to	Māori / Non-Māori Ratio	Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to	Pacific / Non-Māori Non-Pacific Ratio	Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to	Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to	Women Referred to Assessment	Women Screened	% of Women Screened who were Referred to	
45 to 49	Initial	BSWN	128	1,218	10.5 (8.9, 12.4)	1.27 (1.06, 1.52)	31	392	7.9 (5.6, 11)	0.95 (0.68, 1.35)	573	6,917	8.3 (7.7, 9)	542	6,525	8.3 (7.7, 9)	701	8,135	8.6 (8, 9.2)
		BSCM	59	798	7.4 (5.8, 9.4)	0.92 (0.7, 1.19)	102	1,324	7.7 (6.4, 9.3)	0.94 (0.78, 1.17)	386	4,787	8.1 (7.3, 8.9)	284	3,463	8.2 (7.3, 9.2)	445	5,585	8.0 (7.3, 8.7)
		BSAL	47	438	10.7 (8.2, 14)	1.26 (0.95, 1.68)	41	506	8.1 (6, 10.8)	0.95 (0.71, 1.29)	388	4,561	8.5 (7.7, 9.4)	347	4,055	8.6 (7.7, 9.5)	435	4,999	8.7 (8, 9.5)
		BSM	179	1,627	11.0 (9.6, 12.6)	1.36 (1.16, 1.6)	19	156	12.2 (7.9, 18.2)	1.53 (1, 2.35)	472	5,839	8.1 (7.4, 8.8)	453	5,683	8.0 (7.3, 8.7)	651	7,466	8.7 (8.1, 9.4)
		BSCC	79	1,172	6.7 (5.4, 8.3)	1.67 (1.29, 2.16)	5	128	3.9 (1.7, 8.8)	0.97 (0.41, 2.31)	179	4,432	4.0 (3.5, 4.7)	174	4,304	4.0 (3.5, 4.7)	258	5,604	4.6 (4.1, 5.2)
		BSC	44	532	8.3 (6.2, 10.9)	1.26 (0.93, 1.71)	16	264	6.1 (3.8, 9.6)	0.92 (0.57, 1.5)	252	3,837	6.6 (5.8, 7.4)	236	3,573	6.6 (5.8, 7.5)	296	4,369	6.8 (6.1, 7.6)
		BSSL	50	592	8.4 (6.5, 11)	0.97 (0.73, 1.27)	9	155	5.8 (3.1, 10.7)	0.66 (0.35, 1.25)	709	8,107	8.7 (8.1, 9.4)	700	7,952	8.8 (8.2, 9.4)	759	8,699	8.7 (8.2, 9.3)
		BSOS	40	252	15.9 (11.9, 20.9)	1.09 (0.81, 1.46)	6	38	15.8 (7.4, 30.4)	1.08 (0.52, 2.27)	411	2,813	14.6 (13.4, 16)	405	2,775	14.6 (13.3, 16)	451	3,065	14.7 (13.5, 16)
		Total	626	6,629	9.4 (8.8, 10.2)	1.16 (1.07, 1.26)	229	2,963	7.7 (6.8, 8.7)	0.94 (0.83, 1.07)	3,370	41,293	8.2 (7.9, 8.4)	3,141	38,330	8.2 (7.9, 8.5)	3,996	47,922	8.3 (8.1, 8.6)
	Subsequent	BSWN	69	1,325	5.2 (4.1, 6.5)	1.23 (0.96, 1.58)	18	465	3.9 (2.5, 6)	0.91 (0.58, 1.45)	357	8,430	4.2 (3.8, 4.7)	339	7,965	4.3 (3.8, 4.7)	426	9,755	4.4 (4, 4.8)
		BSCM	32	948	3.4 (2.4, 4.7)	0.83 (0.58, 1.18)	57	1,436	4.0 (3.1, 5.1)	0.96 (0.75, 1.28)	274	6,706	4.1 (3.6, 4.6)	217	5,270	4.1 (3.6, 4.7)	306	7,654	4.0 (3.6, 4.5)
		BSAL	22	431	5.1 (3.4, 7.6)	1.19 (0.78, 1.82)	32	608	5.3 (3.8, 7.3)	1.26 (0.9, 1.81)	250	5,817	4.3 (3.8, 4.8)	218	5,209	4.2 (3.7, 4.8)	272	6,248	4.4 (3.9, 4.9)
		BSM	82	1,720	4.8 (3.9, 5.9)	1.01 (0.8, 1.27)	6	152	3.9 (1.8, 8.3)	0.83 (0.38, 1.83)	364	7,683	4.7 (4.3, 5.2)	358	7,531	4.8 (4.3, 5.3)	446	9,403	4.7 (4.3, 5.2)
		BSCC	33	1,331	2.5 (1.8, 3.5)	1.04 (0.72, 1.51)	3	121	2.5 (1.0, 8.7)	1.04 (0.34, 3.22)	149	6,246	2.4 (2, 2.8)	146	6,125	2.4 (2, 2.8)	182	7,577	2.4 (2.1, 2.8)
		BSC	34	746	4.6 (3.3, 6.3)	1.11 (0.78, 1.58)	14	345	4.1 (2.4, 6.7)	0.99 (0.59, 1.68)	247	6,022	4.1 (3.6, 4.6)	233	5,677	4.1 (3.6, 4.7)	281	6,768	4.2 (3.7, 4.7)
		BSSL	59	965	6.1 (4.8, 7.8)	1.30 (1, 1.69)	6	165	3.6 (1.7, 7.7)	0.77 (0.35, 1.7)	579	12,337	4.7 (4.3, 5.1)	573	12,172	4.7 (4.3, 5.1)	638	13,302	4.8 (4.4, 5.2)
		BSOS	25	387	6.5 (4.4, 9.4)	0.93 (0.62, 1.38)	5	62	8.1 (3.5, 17.5)	1.16 (0.5, 2.71)	279	4,006	7.0 (6.2, 7.8)	274	3,944	6.9 (6.2, 7.8)	304	4,393	6.9 (6.2, 7.7)
Total		356	7,853	4.5 (4.1, 5)	1.04 (0.93, 1.16)	141	3,354	4.2 (3.6, 4.9)	0.96 (0.82, 1.13)	2,499	57,247	4.4 (4.2, 4.5)	2,358	53,893	4.4 (4.2, 4.6)	2,855	65,100	4.4 (4.2, 4.5)	
50 to 69	Initial	BSWN	40	277	14.4 (10.8, 19.1)	1.45 (1.06, 1.97)	12	121	9.9 (5.8, 16.5)	0.99 (0.58, 1.72)	235	2,354	10.0 (8.8, 11.3)	223	2,233	10.0 (8.8, 11.3)	275	2,631	10.5 (9.3, 11.7)
		BSCM	21	186	11.3 (7.5, 16.6)	1.14 (0.74, 1.76)	30	307	9.8 (6.9, 13.6)	0.98 (0.7, 1.44)	142	1,433	9.9 (8.5, 11.6)	112	1,126	9.9 (8.3, 11.8)	163	1,619	10.1 (8.7, 11.6)
		BSAL	9	109	8.3 (4.4, 15)	0.88 (0.46, 1.68)	14	157	8.9 (5.4, 14.4)	0.95 (0.57, 1.6)	141	1,506	9.4 (8, 10.9)	127	1,349	9.4 (8, 11.1)	150	1,615	9.3 (8, 10.8)
		BSM	79	539	14.7 (11.9, 17.9)	1.65 (1.28, 2.12)	9	49	18.4 (10, 31.4)	2.13 (1.18, 3.93)	155	1,744	8.9 (7.6, 10.3)	146	1,695	8.6 (7.4, 10)	234	2,283	10.2 (9.1, 11.6)
		BSCC	24	361	6.6 (4.5, 9.7)	1.31 (0.83, 2.07)	3	43	7.0 (2.4, 18.6)	1.40 (0.47, 4.28)	63	1,245	5.1 (4, 6.4)	60	1,202	5.0 (3.9, 6.4)	87	1,606	5.4 (4.4, 6.6)
		BSC	22	139	15.8 (10.7, 22.8)	2.18 (1.41, 3.37)	5	80	6.3 (2.7, 13.8)	0.85 (0.36, 2.05)	83	1,144	7.3 (5.9, 8.9)	78	1,064	7.3 (5.9, 9.1)	105	1,283	8.2 (6.8, 9.8)
		BSSL	11	107	10.3 (5.8, 17.5)	1.12 (0.62, 2.01)	6	44	13.6 (6.4, 26.7)	1.51 (0.72, 3.24)	124	1,350	9.2 (7.8, 10.8)	118	1,306	9.0 (7.6, 10.7)	135	1,457	9.3 (7.9, 10.9)
		BSOS	6	56	10.7 (5, 21.5)	0.61 (0.28, 1.32)	3	19	15.8 (5.5, 37.6)	0.89 (0.32, 2.55)	106	600	17.7 (14.8, 20.9)	103	581	17.7 (14.8, 21)	112	656	17.1 (14.4, 20.1)
		Total	212	1,774	12.0 (10.5, 13.5)	1.30 (1.13, 1.49)	82	820	10.0 (8.1, 12.2)	1.09 (0.89, 1.35)	1,049	11,376	9.2 (8.7, 9.8)	967	10,556	9.2 (8.6, 9.7)	1,261	13,150	9.6 (9.1, 10.1)
	Subsequent	BSWN	310	7,359	4.2 (3.8, 4.7)	1.24 (1.1, 1.39)	119	2,758	4.3 (3.6, 5.1)	1.29 (1.08, 1.54)	1,793	52,684	3.4 (3.3, 3.6)	1,674	49,926	3.4 (3.2, 3.5)	2,103	60,043	3.5 (3.4, 3.7)
		BSCM	154	4,275	3.6 (3.1, 4.2)	1.11 (0.94, 1.31)	246	7,275	3.4 (3, 3.8)	1.05 (0.93, 1.21)	1,134	34,872	3.3 (3.1, 3.4)	888	27,597	3.2 (3, 3.4)	1,288	39,147	3.3 (3.1, 3.5)
		BSAL	66	2,045	3.2 (2.5, 4.1)	1.07 (0.84, 1.37)	123	3,311	3.7 (3.1, 4.4)	1.22 (1.07, 1.53)	945	31,374	3.0 (2.8, 3.2)	827	28,063	2.9 (2.7, 3.1)	1,011	33,419	3.0 (2.8, 3.2)
		BSM	423	10,192	4.2 (3.8, 4.6)	1.22 (1.1, 1.36)	27	860	3.1 (2.2, 4.5)	0.92 (0.64, 1.34)	1,746	51,444	3.4 (3.2, 3.6)	1,719	50,584	3.4 (3.2, 3.6)	2,169	61,636	3.5 (3.4, 3.7)
		BSCC	166	7,735	2.1 (1.8, 2.5)	1.30 (1.1, 1.53)	12	680	1.8 (1, 3.1)	1.07 (0.61, 1.88)	713	43,104	1.7 (1.5, 1.8)	701	42,424	1.7 (1.5, 1.8)	879	50,839	1.7 (1.6, 1.8)
		BSC	141	4,004	3.5 (3, 4.1)	0.98 (0.83, 1.17)	79	2,144	3.7 (3, 4.6)	1.03 (0.83, 1.29)	1,311	36,609	3.6 (3.4, 3.8)	1,232	34,465	3.6 (3.4, 3.8)	1,452	40,613	3.6 (3.4, 3.8)
		BSSL	173	4,284	4.0 (3.5, 4.7)	1.21 (1.04, 1.41)	22	729	3.0 (2, 4.5)	0.91 (0.6, 1.37)	2,301	69,121	3.3 (3.2, 3.5)	2,279	68,392	3.3 (3.2, 3.5)	2,474	73,405	3.4 (3.2, 3.5)
		BSOS	84	1,732	4.8 (3.9, 6)	1.09 (0.88, 1.35)	13	216	6.0 (3.6, 10)	1.36 (0.8, 2.31)	1,140	25,650	4.4 (4.2, 4.7)	1,127	25,434	4.4 (4.2, 4.7)	1,224	27,382	4.5 (4.2, 4.7)
Total		1,517	41,626	3.6 (3.5, 3.8)	1.13 (1.08, 1.2)	641	17,973	3.6 (3.3, 3.8)	1.12 (1.03, 1.21)	11,083	344,858	3.2 (3.2, 3.3)	10,442	326,885	3.2 (3.1, 3.3)	12,600	386,484	3.3 (3.2, 3.3)	
45 to 69	Initial	BSWN	168	1,495	11.2 (9.7, 12.9)	1.29 (1.1, 1.51)	43	513	8.4 (6.3, 11.1)	0.96 (0.72, 1.29)	808	9,271	8.7 (8.2, 9.3)	765	8,758	8.7 (8.2, 9.3)	976	10,766	9.1 (8.5, 9.6)
		BSCM	80	984	8.1 (6.6, 10)	0.96 (0.76, 1.2)	132	1,631	8.1 (6.9, 9.5)	0.94 (0.8, 1.13)	528	6,220	8.5 (7.8, 9.2)	396	4,589	8.6 (7.9, 9.5)	608	7,204	8.4 (7.8, 9.1)
		BSAL	56	547	10.2 (8, 13.1)	1.17 (0.9, 1.52)	55	663	8.3 (6.4, 10.6)	0.95 (0.73, 1.24)	529	6,067	8.7 (8, 9.5)	474	5,404	8.8 (8, 9.6)	585	6,614	8.8 (8.2, 9.6)
		BSM	258	2,166	11.9 (10.6, 13.3)	1.44 (1.26, 1.65)	28	205	13.7 (9.6, 19)	1.68 (1.19, 2.39)	627	7,583	8.3 (7.7, 8.9)	599	7,378	8.1 (7.5, 8.8)	885	9,749	9.1 (8.5, 9.7)
		BSCC	103	1,533	6.7 (5.6, 8.1)	1.58 (1.26, 1.97)	8	171	4.7 (2.4, 9)	1.10 (0.56, 2.19)	242	5,677	4.3 (3.8, 4.8)	234	5,506	4.2 (3.7, 4.8)	345	7,210	4.8 (4.3, 5.3)
		BSC	66	671	9.8 (7.8, 12.3)	1.46 (1.14, 1.88)	21	344	6.1 (4, 9.2)	0.90 (0.6, 1.38)	335	4,981	6.7 (6.1, 7.5)	314	4,637	6.8 (6.1, 7.5)	401	5,652	7.1 (6.5, 7.8)
		BSSL	61	699	8.7 (6.9, 11.1)	0.99 (0.77, 1.27)	15	199	7.5 (4.6, 12.1)	0.85 (0.52, 1.39)	833	9,457	8.8 (8.3, 9.4)	818	9,258	8.8 (8.3, 9.4)	894	10,156	8.8 (8.3, 9.4)
		BSOS	46	308	14.9 (11.4, 19.3)	0.99 (0.75, 1.3)	9	57	15.8 (8.5, 27.4)	1.04 (0.57, 1.91)	517	3,413	15.1 (14, 16.4)	508	3,356	15.1 (14, 16.4)	563	3,721	15.1 (14, 16.3)
		Total	838	8,403	10.0 (9.4, 10.6)	1.19 (1.11, 1.28)	311	3,783	8.2 (7.4, 9.1)	0.98 (0.88, 1.09)	4,419	52,669	8.4 (8.2, 8.6)	4,108	48,886	8.4 (8.2, 8.7)	5,257	61,072	8.6 (8.4, 8.8)
	Subsequent	BSWN	379	8,684	4.4 (4, 4.8)	1.24 (1.11, 1.38)	137	3,223	4.3 (3.6, 5)	1.22 (1.04, 1.45)	2,150	61,114	3.5 (3.4, 3.7)	2,013	57,891	3.5 (3.3, 3.6)	2,529	69,798	3.6 (3.5, 3.8)
		BSCM	186	5,223	3.6 (3.1, 4.1)	1.05 (0.9, 1.22)	303	8,711	3.5 (3.1, 3.9)	1.03 (0.93, 1.17)	1,408	41,578	3.4 (3.2, 3.6)	1,105	32,867	3.4 (3.2, 3.6)	1,594	46,801	3.4 (3.2, 3.6)
		BSAL	88																

2.e, False positive rate

Description: The number with false positive screening results as a percentage of number of women screened.

Targets: Initial: <9% false positive screens. Subsequent: <4% false positive screens (50–69 age group only)

Figure 52: 2.e.1, 50 to 69, False positive rate



The false positive rates for initial screens were within the target range for BSA overall (7.4%). In BSOS the false positive rate for initial screens was outside the target range of <9% at 15% (95% CI 12.6%, 18%) for women aged 50–69 years.

The target for subsequent screens was met by all LPs for women aged 50–69 years, with an overall rate of 2.5%.

For women aged 45–49 years, the overall false positive rates were within the expected ranges for initial (7.2%) and subsequent screens (3.8%).

Figure 53: 2.e.3, Initial, 50 to 69, False positive rate, by LP




Figure 54: 2.e.5, Subsequent, 50 to 69, False positive rate, by LP




Table 10: 2.e.1, False positive rate

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)	Māori / Non-Māori Ratio	False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)	Pacific / Non-Pacific Ratio	False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)	False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)	False Positives	Women Screened	% of Women Screened who had a False Positive (95% CI)
45 to 49	Initial	BSWN	96	1,218	7.9 (6.5, 9.5)	1.64 (1.32, 2.04)	25	392	6.4 (4.4, 9.2)	1.36 (0.93, 2.01)	332	6,917	4.8 (4.3, 5.3)	307	6,525	4.7 (4.2, 5.2)	428	8,135	5.3 (4.8, 5.8)
		BSCM	49	798	6.1 (4.7, 8)	0.84 (0.63, 1.12)	86	1,324	6.5 (5.3, 8)	0.86 (0.7, 1.08)	349	4,787	7.3 (6.6, 8.1)	263	3,463	7.6 (6.8, 8.5)	398	5,585	7.1 (6.5, 7.8)
		BSAL	42	438	9.6 (7.2, 12.7)	1.26 (0.93, 1.7)	34	506	6.7 (4.8, 9.2)	0.87 (0.63, 1.22)	348	4,561	7.6 (6.9, 8.4)	314	4,055	7.7 (7, 8.6)	390	4,999	7.8 (7.1, 8.6)
		BSM	156	1,627	9.6 (8.3, 11.1)	1.28 (1.07, 1.52)	18	156	11.5 (7.4, 17.5)	1.56 (1.01, 2.43)	439	5,839	7.5 (6.9, 8.2)	421	5,683	7.4 (6.8, 8.1)	595	7,466	8.0 (7.4, 8.6)
		BSCC	63	1,172	5.4 (4.2, 6.8)	1.57 (1.18, 2.09)	5	128	3.9 (1.7, 8.8)	1.14 (0.48, 2.74)	152	4,432	3.4 (2.9, 4)	147	4,304	3.4 (2.9, 4)	215	5,604	3.8 (3.4, 4.4)
		BSC	37	532	7.0 (5.1, 9.4)	1.16 (0.83, 1.62)	13	264	4.9 (2.9, 8.2)	0.81 (0.48, 1.4)	230	3,837	6.0 (5.3, 6.8)	217	3,573	6.1 (5.3, 6.9)	267	4,369	6.1 (5.4, 6.9)
		BSSL	47	592	7.9 (6, 10.4)	0.98 (0.74, 1.3)	7	155	4.5 (2.2, 9)	0.55 (0.27, 1.14)	657	8,107	8.1 (7.5, 8.7)	650	7,952	8.2 (7.6, 8.8)	704	8,699	8.1 (7.5, 8.7)
		BSOS	39	252	15.5 (11.5, 20.5)	1.11 (0.82, 1.5)	3	38	7.9 (2.7, 20.8)	0.56 (0.19, 1.67)	392	2,813	13.9 (12.7, 15.3)	389	2,775	14.0 (12.8, 15.4)	431	3,065	14.1 (12.9, 15.3)
		Total	529	6,629	8.0 (7.4, 8.7)	1.14 (1.04, 1.24)	191	2,963	6.4 (5.6, 7.4)	0.91 (0.8, 1.05)	2,899	41,293	7.0 (6.8, 7.3)	2,708	38,330	7.1 (6.8, 7.3)	3,428	47,922	7.2 (6.9, 7.4)
			Subsequent	BSWN	36	1,325	2.7 (2, 3.7)	1.16 (0.81, 1.64)	15	465	3.2 (2, 5.3)	1.40 (0.85, 2.36)	198	8,430	2.3 (2, 2.7)	183	7,965	2.3 (2, 2.7)	234
BSCM	29			948	3.1 (2.1, 4.4)	0.82 (0.56, 1.2)	52	1,436	3.6 (2.8, 4.7)	0.96 (0.74, 1.3)	250	6,706	3.7 (3.3, 4.2)	198	5,270	3.8 (3.3, 4.3)	279	7,654	3.6 (3.2, 4.1)
BSAL	20			431	4.6 (3, 7.1)	1.17 (0.75, 1.83)	31	608	5.1 (3.6, 7.1)	1.33 (0.94, 1.92)	231	5,817	4.0 (3.5, 4.5)	200	5,209	3.8 (3.4, 4.4)	251	6,248	4.0 (3.6, 4.5)
BSM	73			1,720	4.2 (3.4, 5.3)	0.97 (0.76, 1.24)	6	152	3.9 (1.8, 8.3)	0.90 (0.41, 1.99)	336	7,683	4.4 (3.9, 4.9)	330	7,531	4.4 (3.9, 4.9)	409	9,403	4.3 (4, 4.8)
BSCC	27			1,331	2.0 (1.4, 2.9)	1.01 (0.67, 1.52)	2	121	1.7 (0.5, 5.8)	0.82 (0.21, 3.26)	126	6,246	2.0 (1.7, 2.4)	124	6,125	2.0 (1.7, 2.4)	153	7,577	2.0 (1.7, 2.4)
BSC	30			746	4.0 (2.8, 5.7)	1.06 (0.73, 1.54)	11	345	3.2 (1.8, 5.6)	0.83 (0.46, 1.51)	229	6,022	3.8 (3.3, 4.3)	218	5,677	3.8 (3.4, 4.4)	259	6,768	3.8 (3.4, 4.3)
BSSL	53			965	5.5 (4.2, 7.1)	1.30 (0.98, 1.71)	6	165	3.6 (1.7, 7.7)	0.86 (0.39, 1.89)	523	12,337	4.2 (3.9, 4.6)	517	12,172	4.2 (3.9, 4.6)	576	13,302	4.3 (4, 4.7)
BSOS	24			387	6.2 (4.2, 9.1)	0.94 (0.63, 1.42)	5	62	8.1 (3.5, 17.5)	1.23 (0.53, 2.88)	263	4,006	6.6 (5.8, 7.4)	258	3,944	6.5 (5.8, 7.4)	287	4,393	6.5 (5.8, 7.3)
Total	292			7,853	3.7 (3.3, 4.2)	0.99 (0.88, 1.11)	128	3,354	3.8 (3.2, 4.5)	1.01 (0.86, 1.21)	2,156	57,247	3.8 (3.6, 3.9)	2,028	53,893	3.8 (3.6, 3.9)	2,448	65,100	3.8 (3.6, 3.9)
50 to 69	Initial			BSWN	24	277	8.7 (5.9, 12.6)	1.47 (0.97, 2.22)	10	121	8.3 (4.6, 14.5)	1.43 (0.79, 2.65)	139	2,354	5.9 (5, 6.9)	129	2,233	5.8 (4.9, 6.8)	163
		BSCM	17	186	9.1 (5.8, 14.1)	1.18 (0.72, 1.92)	21	307	6.8 (4.5, 10.2)	0.86 (0.57, 1.35)	111	1,433	7.7 (6.5, 9.2)	90	1,126	8.0 (6.5, 9.7)	128	1,619	7.9 (6.7, 9.3)
		BSAL	7	109	6.4 (3.1, 12.7)	0.79 (0.38, 1.64)	12	157	7.6 (4.4, 12.9)	0.93 (0.54, 1.65)	123	1,506	8.2 (6.9, 9.7)	111	1,349	8.2 (6.9, 9.8)	130	1,615	8.0 (6.8, 9.5)
		BSM	58	539	10.8 (8.4, 13.7)	1.53 (1.13, 2.05)	4	49	8.2 (3.2, 19.2)	1.16 (0.45, 3.02)	123	1,744	7.1 (5.9, 8.4)	119	1,695	7.0 (5.9, 8.3)	181	2,283	7.9 (6.9, 9.1)
		BSCC	17	361	4.7 (3, 7.4)	1.11 (0.65, 1.89)	3	43	7.0 (2.4, 18.6)	1.68 (0.56, 5.16)	53	1,245	4.3 (3.3, 5.5)	50	1,202	4.2 (3.2, 5.4)	70	1,606	4.4 (3.5, 5.5)
		BSC	18	139	12.9 (8.4, 19.5)	2.24 (1.37, 3.67)	1	80	1.3 (0.2, 6.7)	0.20 (0.03, 1.46)	66	1,144	5.8 (4.6, 7.3)	65	1,064	6.1 (4.8, 7.7)	84	1,283	6.5 (5.3, 8)
		BSSL	10	107	9.3 (5.2, 16.4)	1.22 (0.66, 2.27)	6	44	13.6 (6.4, 26.7)	1.84 (0.87, 3.96)	103	1,350	7.6 (6.3, 9.2)	97	1,306	7.4 (6.1, 9)	113	1,457	7.8 (6.5, 9.2)
		BSOS	6	56	10.7 (5, 21.5)	0.69 (0.32, 1.51)	3	19	15.8 (5.5, 37.6)	1.02 (0.36, 2.93)	93	600	15.5 (12.8, 18.6)	90	581	15.5 (12.8, 18.7)	99	656	15.1 (12.6, 18)
		Total	157	1,774	8.9 (7.6, 10.3)	1.24 (1.05, 1.46)	60	820	7.4 (5.7, 9.3)	1.04 (0.82, 1.34)	811	11,376	7.1 (6.7, 7.6)	751	10,556	7.1 (6.6, 7.6)	968	13,150	7.4 (6.9, 7.8)
			Subsequent	BSWN	146	7,360	2.0 (1.7, 2.3)	1.11 (0.93, 1.32)	69	2,758	2.5 (2, 3.2)	1.43 (1.13, 1.82)	941	52,684	1.8 (1.7, 1.9)	872	49,926	1.7 (1.6, 1.9)	1,087
BSCM	117			4,275	2.7 (2.3, 3.3)	1.04 (0.86, 1.26)	188	7,275	2.6 (2.2, 3)	0.98 (0.85, 1.14)	918	34,872	2.6 (2.5, 2.8)	730	27,597	2.6 (2.5, 2.8)	1,035	39,147	2.6 (2.5, 2.8)
BSAL	49			2,045	2.4 (1.8, 3.2)	1.00 (0.75, 1.34)	97	3,311	2.9 (2.4, 3.6)	1.26 (1.04, 1.56)	749	31,374	2.4 (2.2, 2.6)	652	28,063	2.3 (2.2, 2.5)	798	33,419	2.4 (2.2, 2.6)
BSM	308			10,192	3.0 (2.7, 3.4)	1.08 (0.96, 1.22)	19	860	2.2 (1.4, 3.4)	0.79 (0.51, 1.24)	1,433	51,444	2.8 (2.6, 2.9)	1,414	50,584	2.8 (2.7, 2.9)	1,741	61,636	2.8 (2.7, 3)
BSCC	105			7,735	1.4 (1.1, 1.6)	1.22 (0.99, 1.5)	7	680	1.0 (0.5, 2.1)	0.92 (0.44, 1.94)	481	43,104	1.1 (1, 1.2)	474	42,424	1.1 (1, 1.2)	586	50,839	1.2 (1.1, 1.2)
BSC	123			4,005	3.1 (2.6, 3.7)	1.06 (0.88, 1.28)	59	2,144	2.8 (2.1, 3.5)	0.95 (0.74, 1.23)	1,059	36,609	2.9 (2.7, 3.1)	1,000	34,465	2.9 (2.7, 3.1)	1,182	40,614	2.9 (2.8, 3.1)
BSSL	136			4,284	3.2 (2.7, 3.7)	1.16 (0.98, 1.37)	16	729	2.2 (1.4, 3.5)	0.80 (0.49, 1.3)	1,895	69,121	2.7 (2.6, 2.9)	1,879	68,392	2.7 (2.6, 2.9)	2,031	73,405	2.8 (2.7, 2.9)
BSOS	75			1,732	4.3 (3.5, 5.4)	1.17 (0.93, 1.48)	10	216	4.6 (2.5, 8.3)	1.26 (0.69, 2.31)	947	25,650	3.7 (3.5, 3.9)	937	25,434	3.7 (3.5, 3.9)	1,022	27,382	3.7 (3.5, 4)
Total	1,059			41,628	2.5 (2.4, 2.7)	1.04 (0.98, 1.11)	465	17,973	2.6 (2.4, 2.8)	1.06 (0.97, 1.17)	8,423	344,858	2.4 (2.4, 2.5)	7,958	326,885	2.4 (2.4, 2.5)	9,482	386,486	2.5 (2.4, 2.5)
45 to 69	Initial			BSWN	120	1,495	8.0 (6.8, 9.5)	1.58 (1.3, 1.92)	35	513	6.8 (4.9, 9.3)	1.37 (1, 1.91)	471	9,271	5.1 (4.7, 5.5)	436	8,758	5.0 (4.5, 5.5)	591
		BSCM	66	984	6.7 (5.3, 8.4)	0.91 (0.71, 1.16)	107	1,631	6.6 (5.5, 7.9)	0.85 (0.71, 1.05)	460	6,220	7.4 (6.8, 8.1)	353	4,589	7.7 (7, 8.5)	526	7,204	7.3 (6.7, 7.9)
		BSAL	49	547	9.0 (6.8, 11.6)	1.15 (0.87, 1.53)	46	663	6.9 (5.2, 9.1)	0.88 (0.67, 1.18)	471	6,067	7.8 (7.1, 8.5)	425	5,404	7.9 (7.2, 8.6)	520	6,614	7.9 (7.2, 8.5)
		BSM	214	2,166	9.9 (8.7, 11.2)	1.33 (1.15, 1.55)	22	205	10.7 (7.2, 15.7)	1.47 (0.99, 2.19)	562	7,583	7.4 (6.8, 8)	540	7,378	7.3 (6.7, 7.9)	776	9,749	8.0 (7.4, 8.5)
		BSCC	80	1,533	5.2 (4.2, 6.4)	1.45 (1.12, 1.86)	8	171	4.7 (2.4, 9)	1.31 (0.66, 2.61)	205	5,677	3.6 (3.2, 4.1)	197	5,506	3.6 (3.1, 4.1)	285	7,210	4.0 (3.5, 4.4)
		BSC	55	671	8.2 (6.4, 10.5)	1.38 (1.05, 1.82)	14	344	4.1 (2.4, 6.7)	0.67 (0.4, 1.13)	296	4,981	5.9 (5.3, 6.6)	282	4,637	6.1 (5.4, 6.8)	351	5,652	6.2 (5.6, 6.9)
		BSSL	57	699	8.2 (6.3, 10.4)	1.01 (0.78, 1.31)	13	199	6.5 (3.9, 10.9)	0.81 (0.48, 1.38)	760	9,457	8.0 (7.5, 8.6)	747	9,258	8.1 (7.5, 8.6)	817	10,156	8.0 (7.5, 8.6)
		BSOS	45	308	14.6 (11.1, 19)	1.03 (0.78, 1.36)	6	57	10.5 (4.9, 21.1)	0.74 (0.35, 1.58)	485	3,413	14.2 (13.1, 15.4)	479	3,356	14.3 (13.1, 15.5)	530	3,721	14.2 (13.2, 15.4)
		Total	686	8,403	8.2 (7.6, 8.8)	1.16 (1.07, 1.25)	251	3,783	6.6 (5.9, 7.5)	0.94 (0.83, 1.06)	3,710	52,669	7.0 (6.8, 7.3)	3,459	48,886	7.1 (6.9, 7.3)	4,396	61,072	7.2 (7, 7.4)
			Subsequent	BSWN	182	6,685	2.1 (1.8, 2.4)	1.12 (0.96, 1.31)	84	3,223	2.6 (2.1, 3.2)	1.43 (1.16, 1.78)	1,139	61,114	1.9 (1.8, 2)	1,055	57,891	1.8 (1.7, 1.9)	1,321
BSCM	146			5,223	2.8 (2.4, 3.3)	1.00 (0.84, 1.18)	240	8,711	2.8 (2.4, 3.1)	0.98 (0.86, 1.12)	1,168	41,578	2.8 (2.7, 3)	928	32,867	2.8 (2.6, 3)	1,314	46,801	2.8 (2.7, 3)
BSAL	69																		


2.f, Positive predictive value

Description: The number of women diagnosed with cancer as a percentage of number of women referred to assessment.

Targets for 45–49 age group: >6% of women referred to assessment from an initial screen are diagnosed with cancer, >8% of women referred to assessment from a subsequent screen are diagnosed with cancer.

Targets for 50–69 age group: >9% of women referred to assessment from an initial or subsequent screen are diagnosed with cancer

Figure 55: 2.f.1, 50 to 69, Positive predictive value, initial and subsequent screens



For BSA overall, positive predictive values (PPV) were within the target ranges for initial and subsequent screens for each group aged 50–69 years, and within the expected ranges for women aged 45–49 years. PPVs were higher for Māori than for non-Māori women having initial and subsequent screens in both age groups. PPVs were also generally higher for Pacific women than for non-Māori non-Pacific women.

For initial screens, some providers show a zero PPV for Pacific or Māori women but the numbers of referrals for assessment in those LPs are low and the confidence intervals are very wide. For subsequent screens, all LPs were within the target range for Pacific and Māori women aged 50–69 years.

Further work is needed to determine appropriate targets for PPVs for women aged 50–69 years following an initial and subsequent screen.

Figure 56: 2.f.3, Initial, 50 to 69, Positive predictive value, by LP




Figure 57: 2.f.5, Subsequent, 50 to 69, Positive predictive value, by LP



Table 11: 2.f.1, Positive predictive value


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
			Cancers	Referrals	% of Referrals that were Cancers (95% CI)	Māori / Non-Māori Ratio	Cancers	Referrals	% of Referrals that were Cancers (95% CI)	Pacific / Non-Pacific Ratio	Cancers	Referrals	% of Referrals that were Cancers (95% CI)	Cancers	Referrals	% of Referrals that were Cancers (95% CI)	Cancers	Referrals	% of Referrals that were Cancers (95% CI)	
45 to 49	Initial	BSWN	8	128	6.3 (3.2, 11.8)	0.90 (0.43, 1.87)	1	31	3.2 (0.6, 16.2)	0.45 (0.07, 3.16)	40	573	7.0 (5.2, 9.4)	39	542	7.2 (5.3, 9.7)	48	701	6.8 (5.2, 9)	
		BSCM	9	59	15.3 (8.2, 26.5)	2.18 (1.08, 4.4)	11	102	10.8 (6.1, 18.3)	1.91 (1.1, 3.99)	27	386	7.0 (4.9, 10)	16	284	5.6 (3.5, 9)	36	445	8.1 (5.9, 11)	
		BSAL	4	47	8.5 (3.4, 19.9)	1.07 (0.39, 2.88)	5	41	12.2 (5.3, 25.5)	1.63 (0.72, 4.01)	31	388	8.0 (5.7, 11.1)	26	347	7.5 (5.2, 10.8)	35	435	8.0 (5.8, 11)	
		BSM	12	179	6.7 (3.9, 11.4)	1.51 (0.76, 3)	1	19	5.3 (0.9, 24.6)	1.19 (0.18, 8.42)	21	472	4.4 (2.9, 6.7)	20	453	4.4 (2.9, 6.7)	33	651	5.1 (3.6, 7)	
		BSCC	10	79	12.7 (7, 21.8)	0.91 (0.46, 1.8)	0	5	0.0 (0, 43.4)	NA (NA, NA)	25	179	14.0 (9.6, 19.8)	25	174	14.4 (9.9, 20.3)	35	258	13.6 (9.9, 18.3)	
		BSC	7	44	15.9 (7.9, 29.4)	1.82 (0.83, 4.01)	3	16	18.8 (6.6, 43)	2.33 (0.84, 7.05)	22	252	8.7 (5.8, 12.9)	19	236	8.1 (5.2, 12.2)	29	296	9.8 (6.9, 13.7)	
		BSSL	3	50	6.0 (2.1, 16.2)	0.87 (0.28, 2.69)	2	9	22.2 (6.3, 54.7)	3.31 (0.97, 11.59)	49	709	6.9 (5.3, 9)	47	700	6.7 (5.1, 8.8)	52	759	6.9 (5.3, 8.9)	
		BSOS	1	40	2.5 (0.4, 12.9)	0.69 (0.09, 5.05)	1	6	16.7 (3, 56.4)	4.82 (0.81, 31.03)	15	411	3.6 (2.2, 5.9)	14	405	3.5 (2.1, 5.7)	16	451	3.5 (2.2, 5.7)	
		Total	54	626	8.6 (6.7, 11.1)	1.26 (0.95, 1.68)	24	229	10.5 (7.1, 15.1)	1.60 (1.09, 2.39)	230	3,370	6.8 (6, 7.7)	206	3,141	6.6 (5.7, 7.5)	284	3,996	7.1 (6.4, 7.9)	
		Subsequent	BSWN	8	69	11.6 (6, 21.2)	1.48 (0.7, 3.11)	1	18	5.6 (1, 25.8)	0.70 (0.1, 4.85)	28	357	7.8 (5.5, 11.1)	27	339	8.0 (5.5, 11.3)	36	426	8.5 (6.2, 11.5)
	BSCM		3	32	9.4 (3.2, 24.2)	1.28 (0.4, 4.08)	5	57	8.8 (3.8, 18.9)	1.27 (0.55, 3.34)	20	274	7.3 (4.8, 11)	15	217	6.9 (4.2, 11.1)	23	306	7.5 (5.1, 11)	
	BSAL		2	22	9.1 (2.5, 27.8)	1.34 (0.33, 5.42)	1	32	3.1 (0.6, 15.7)	0.43 (0.06, 3.1)	17	250	6.8 (4.3, 10.6)	16	218	7.3 (4.6, 11.6)	19	272	7.0 (4.5, 10.7)	
	BSM		7	82	8.5 (4.2, 16.6)	1.29 (0.58, 2.9)	0	6	0.0 (0, 39)	0.00 (NA, NA)	24	364	6.6 (4.5, 9.6)	24	358	6.7 (4.5, 9.8)	31	446	7.0 (4.9, 9.7)	
	BSCC		6	33	18.2 (8.6, 34.4)	1.51 (0.65, 3.5)	1	3	33.3 (6.1, 79.2)	2.86 (0.58, 15.08)	18	149	12.1 (7.8, 18.3)	17	146	11.6 (7.4, 17.9)	24	182	13.2 (9, 18.9)	
	BSC		4	34	11.8 (4.7, 26.6)	1.71 (0.61, 4.78)	3	14	21.4 (7.6, 47.6)	3.57 (1.31, 10.98)	17	247	6.9 (4.3, 10.7)	14	233	6.0 (3.6, 9.8)	21	281	7.5 (4.9, 11.2)	
	BSSL		6	59	10.2 (4.7, 20.5)	1.13 (0.51, 2.52)	0	6	0.0 (0, 39)	0.00 (NA, NA)	52	579	9.0 (6.9, 11.6)	52	573	9.1 (7, 11.7)	58	638	9.1 (7.1, 11.6)	
	BSOS		1	25	4.0 (0.7, 19.5)	0.70 (0.1, 5.04)	0	5	0.0 (0, 43.4)	0.00 (NA, NA)	16	279	5.7 (3.6, 9.1)	16	274	5.8 (3.6, 9.3)	17	304	5.6 (3.5, 8.8)	
	Total		37	356	10.4 (7.6, 14)	1.35 (0.97, 1.89)	11	141	7.8 (4.4, 13.4)	1.02 (0.58, 1.82)	192	2,499	7.7 (6.7, 8.8)	181	2,358	7.7 (6.7, 8.8)	229	2,855	8.0 (7.1, 9.1)	
	50 to 69		Initial	BSWN	9	40	22.5 (12.3, 37.5)	2.12 (1.07, 4.19)	0	12	0.0 (0, 24.2)	0.00 (NA, NA)	25	235	10.6 (7.3, 15.2)	25	223	11.2 (7.7, 16)	34	275
		BSCM		2	21	9.5 (2.7, 28.9)	0.64 (0.16, 2.55)	7	30	23.3 (11.8, 40.9)	1.87 (0.98, 4.21)	21	142	14.8 (9.9, 21.6)	14	112	12.5 (7.6, 19.9)	23	163	14.1 (9.6, 20.3)
BSAL		1		9	11.1 (2, 43.5)	1.42 (0.21, 9.84)	1	14	7.1 (1.3, 31.5)	0.91 (0.14, 6.57)	11	141	7.8 (4.4, 13.4)	10	127	7.9 (4.3, 13.9)	12	150	8.0 (4.6, 13.5)	
BSM		15		79	19.0 (11.9, 29)	1.34 (0.74, 2.43)	1	9	11.1 (2, 43.5)	0.77 (0.12, 5.11)	22	155	14.2 (9.6, 20.6)	21	146	14.4 (9.6, 21)	37	234	15.8 (11.7, 21)	
BSCC		7		24	29.2 (14.9, 49.2)	2.30 (0.93, 5.64)	0	3	0.0 (0, 56.1)	0.00 (NA, NA)	8	63	12.7 (6.6, 23.1)	8	60	13.3 (6.9, 24.2)	15	87	17.2 (10.7, 26.5)	
BSC		3		22	13.6 (4.7, 33.3)	0.75 (0.24, 2.38)	3	5	60.0 (23.1, 88.2)	3.90 (1.91, 9.45)	15	83	18.1 (11.3, 27.7)	12	78	15.4 (9, 25)	18	105	17.1 (11.1, 25.5)	
BSSL		0		11	0.0 (0, 25.9)	0.00 (NA, NA)	0	6	0.0 (0, 39)	0.00 (NA, NA)	16	124	12.9 (8.1, 19.9)	16	118	13.6 (8.5, 20.9)	16	135	11.9 (7.4, 18.4)	
BSOS		0		6	0.0 (0, 39)	0.00 (NA, NA)	0	3	0.0 (0, 56.1)	0.00 (NA, NA)	9	106	8.5 (4.5, 15.4)	9	103	8.7 (4.7, 15.8)	9	112	8.0 (4.3, 14.6)	
Total		37		212	17.5 (12.9, 23.1)	1.44 (1.03, 2.02)	12	82	14.6 (8.6, 23.9)	1.23 (0.73, 2.13)	127	1,049	12.1 (10.3, 14.2)	115	967	11.9 (10, 14.1)	164	1,261	13.0 (11.3, 15)	
Subsequent		BSWN		77	311	24.8 (20.3, 29.8)	1.50 (1.21, 1.88)	22	119	18.5 (12.5, 26.4)	1.13 (0.78, 1.68)	295	1,793	16.5 (14.8, 18.2)	273	1,674	16.3 (14.6, 18.2)	372	2,104	17.7 (16.1, 19.4)
		BSCM	35	154	22.7 (16.8, 30)	1.38 (1, 1.9)	46	246	18.7 (14.3, 24)	1.18 (0.91, 1.59)	187	1,134	16.5 (14.4, 18.8)	141	888	15.9 (13.6, 18.4)	222	1,288	17.2 (15.3, 19.4)	
		BSAL	15	66	22.7 (14.3, 34.2)	1.27 (0.8, 2.02)	22	123	17.9 (12.1, 25.6)	1.00 (0.68, 1.5)	169	945	17.9 (15.6, 20.5)	147	822	17.9 (15.4, 20.7)	184	1,011	18.2 (15.9, 20.7)	
		BSM	100	423	23.6 (19.8, 27.9)	1.41 (1.15, 1.72)	7	27	25.9 (13.2, 44.7)	1.56 (0.82, 2.97)	293	1,746	16.8 (15.1, 18.6)	286	1,719	16.6 (15, 18.5)	393	2,169	18.1 (16.6, 19.8)	
		BSCC	58	166	34.9 (28.1, 42.5)	1.18 (0.93, 1.5)	4	12	33.3 (13.8, 60.9)	1.13 (0.51, 2.53)	211	713	29.6 (26.4, 33)	207	701	29.5 (26.3, 33)	269	879	30.6 (27.6, 33.7)	
		BSC	16	142	11.3 (7.1, 17.5)	0.61 (0.38, 0.98)	18	79	22.8 (14.9, 33.2)	1.25 (0.83, 1.9)	243	1,311	18.5 (16.5, 20.7)	225	1,232	18.3 (16.2, 20.5)	259	1,453	17.8 (15.9, 19.9)	
		BSSL	35	173	20.2 (14.9, 26.8)	1.20 (0.88, 1.63)	6	22	27.3 (13.2, 48.2)	1.62 (0.82, 3.23)	389	2,301	16.9 (15.4, 18.5)	383	2,279	16.8 (15.3, 18.4)	424	2,474	17.1 (15.7, 18.7)	
		BSOS	9	84	10.7 (5.7, 19.1)	0.66 (0.35, 1.24)	3	13	23.1 (8.2, 50.3)	1.43 (0.53, 3.89)	185	1,140	16.2 (14.2, 18.5)	182	1,127	16.1 (14.1, 18.4)	194	1,224	15.8 (13.9, 18)	
		Total	345	1,519	22.7 (20.7, 24.9)	1.28 (1.15, 1.41)	128	641	20.0 (17.1, 23.2)	1.13 (0.97, 1.33)	1,972	11,083	17.8 (17.1, 18.5)	1,844	10,442	17.7 (16.9, 18.4)	2,317	12,602	18.4 (17.7, 19.1)	
		45 to 69	Initial	BSWN	17	168	10.1 (6.4, 15.6)	1.26 (0.76, 2.09)	1	43	2.3 (0.4, 12.1)	0.28 (0.04, 1.96)	65	808	8.0 (6.4, 10.1)	64	765	8.4 (6.6, 10.5)	82	976
BSCM				11	80	13.8 (7.9, 23)	1.51 (0.82, 2.79)	18	132	13.6 (8.8, 20.5)	1.80 (1.17, 3.12)	48	528	9.1 (6.9, 11.8)	30	396	7.6 (5.4, 10.6)	59	608	9.7 (7.6, 12.3)
BSAL	5			56	8.9 (3.9, 19.3)	1.12 (0.46, 2.73)	6	55	10.9 (5.1, 21.8)	1.44 (0.67, 3.25)	42	529	7.9 (5.9, 10.6)	36	474	7.6 (5.5, 10.3)	47	585	8.0 (6.1, 10.5)	
BSM	27			258	10.5 (7.3, 14.8)	1.53 (0.96, 2.41)	2	28	7.1 (2, 22.6)	1.04 (0.27, 4.1)	43	627	6.9 (5.1, 9.1)	41	599	6.8 (5.1, 9.2)	70	885	7.9 (6.3, 9.9)	
BSCC	17			103	16.5 (10.6, 24.9)	1.21 (0.71, 2.07)	0	8	0.0 (0, 32.4)	0.00 (NA, NA)	33	242	13.6 (9.9, 18.5)	33	234	14.1 (10.2, 19.1)	50	345	14.5 (11.2, 18.6)	
BSC	10			66	15.2 (8.4, 25.7)	1.37 (0.72, 2.62)	6	21	28.6 (13.8, 50)	2.89 (1.47, 6.15)	37	335	11.0 (8.1, 14.9)	31	314	9.9 (7, 13.7)	47	401	11.7 (8.9, 15.2)	
BSSL	3			61	4.9 (1.7, 13.5)	0.63 (0.2, 1.95)	2	15	13.3 (3.7, 37.9)	1.73 (0.48, 6.43)	65	833	7.8 (6.2, 9.8)	63	818	7.7 (6.1, 9.7)	68	894	7.6 (6, 9.5)	
BSOS	1			46	2.2 (0.4, 11.3)	0.47 (0.06, 3.38)	1	9	11.1 (2, 43.5)	2.45 (0.39, 16.25)	24	517	4.6 (3.1, 6.7)	23	508	4.5 (3, 7)	25	563	4.4 (3, 6.5)	
Total	91			838	10.9 (8.9, 13.1)	1.34 (1.08, 1.67)	36	311	11.6 (8.5, 15.6)	1.48 (1.09, 2.05)	357	4,419	8.1 (7.3, 8.9)	321	4,108	7.8 (7, 8.7)	448	5,257	8.5 (7.8, 9.3)	
Subsequent	BSWN			85	380	22.4 (18.5, 26.8)	1.49 (1.2, 1.84)	23	137	16.8 (11.5, 23.9)	1.13 (0.78, 1.66)	323	2,150	15.0 (13.6, 16.6)	300	2,013	14.9 (13.4, 16.5)	408	2,530	16.1 (14.7, 17.6)
	BSCM		38	186	20.4 (15.3, 26.8)	1.39 (1.02, 1.9)	51	303	16.8 (13, 21.5)	1.19 (0.93, 1.59)	207	1,408	14.7 (12.9, 16.6)	156	1,105	14.1 (12.2, 16.3)	245	1,594	15.4 (13.7, 17.2)	
	BSAL		17	88	19.3 (12.4, 28.8)	1.24 (0.79, 1.94)	23	155	14.8 (10.1, 21.3)	0.95 (0.65, 1.42)	186	1,195	15.6 (13.6, 17.7)	163	1,040	15.7 (13.6, 18)	203	1,283	15.8 (13.9, 17.9)	
	BSM		107	505	21.2 (17.8, 25)	1.41 (1.16, 1.72)	7	33	21.2 (10.7, 37.8)	1.42 (0.74, 2.76)	317	2,110	15.0 (13.6, 16.6)	310	2,077	14.9 (13.5, 16.5)	424	2,615	16.2 (

2.g, Benign open biopsy weight

Description: The percentage of benign open biopsies where the specimen weight is less than 30g.

Target: >90% of open biopsies which prove benign, will weigh <30g (50–69 age group only)

Figure 58: 2.g.1, 50 to 69, Benign open biopsy weight



BSA aims to have more than 90% of open biopsies that prove to be benign weighing less than 30g. Overall, 85% of women aged 45–69 years who had a benign open biopsy had biopsies less than 30 g. The target was met or within the confidence interval for most LPs, apart from BSM (81%) and BSCC (53% of 17 open biopsies).

Figure 59: 2.g.3, 50 to 69, Benign open biopsy weight, by LP




Table 12: 2.g.1, Benign open biopsy weight


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)	Māori / Non-Māori Ratio	Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)	Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)	Benign Open Biopsies <30g	Benign Open Biopsies	% of Benign Open Biopsies <30g (95% CI)
45 to 49	BSWN	6	6	100.0 (61, 100)	1.05 (0.95, 1.16)	3	3	100.0 (43.9, 100)	1.06 (1.06, 1.2)	19	20	95.0 (76.4, 99.1)	16	17	94.1 (73, 99)	25	26	96.2 (81.1, 99.3)
	BSCM	2	4	50.0 (15, 85)	0.54 (0.2, 1.46)	2	2	100.0 (34.2, 100)	1.10 (1.1, 1.33)	12	13	92.3 (66.7, 98.6)	10	11	90.9 (62.3, 98.4)	14	17	82.4 (59, 93.8)
	BSAL	0	0	NA (NA, NA)	NA (NA, NA)	2	2	100.0 (34.2, 100)	1.00 (1, 1)	16	16	100.0 (80.6, 100)	14	14	100.0 (78.5, 100)	16	16	100.0 (80.6, 100)
	BSM	10	12	83.3 (55.2, 95.3)	0.97 (0.7, 1.35)	0	0	NA (NA, NA)	NA (NA, NA)	12	14	85.7 (60.1, 96)	12	14	85.7 (60.1, 96)	22	26	84.6 (66.5, 93.8)
	BSCC	3	3	100.0 (43.9, 100)	2.33 (0.99, 5.49)	0	1	0.0 (0, 79.3)	NA (NA, NA)	3	7	42.9 (15.8, 75)	3	6	50.0 (18.8, 81.2)	6	10	60.0 (31.3, 83.2)
	BSC	2	2	100.0 (34.2, 100)	1.30 (0.97, 1.75)	0	0	NA (NA, NA)	NA (NA, NA)	10	13	76.9 (49.7, 91.8)	10	13	76.9 (49.7, 91.8)	12	15	80.0 (54.8, 93)
	BSSL	3	4	75.0 (30.1, 95.4)	0.99 (0.54, 1.8)	0	0	NA (NA, NA)	NA (NA, NA)	22	29	75.9 (57.9, 87.8)	22	29	75.9 (57.9, 87.8)	25	33	75.8 (59, 87.2)
	BSOS	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (20.7, 100)	1.33 (1.33, 1.77)	13	17	76.5 (52.7, 90.4)	12	16	75.0 (50.5, 89.8)	13	17	76.5 (52.7, 90.4)
	Total	26	31	83.9 (67.4, 92.9)	1.01 (0.85, 1.2)	8	9	88.9 (56.5, 98)	1.08 (0.86, 1.38)	107	129	82.9 (75.5, 88.5)	99	120	82.5 (74.7, 88.3)	133	160	83.1 (76.6, 88.1)
50 to 69	BSWN	10	13	76.9 (49.7, 91.8)	0.93 (0.67, 1.29)	1	1	100.0 (20.7, 100)	1.22 (1.22, 1.39)	38	46	82.6 (69.3, 90.9)	37	45	82.2 (68.7, 90.7)	48	59	81.4 (69.6, 89.3)
	BSCM	5	6	83.3 (43.6, 97)	0.92 (0.63, 1.34)	8	9	88.9 (56.5, 98)	0.97 (0.77, 1.27)	29	32	90.6 (75.8, 96.8)	21	23	91.3 (73.2, 97.6)	34	38	89.5 (75.9, 95.8)
	BSAL	2	2	100.0 (34.2, 100)	1.16 (1, 1.34)	4	5	80.0 (37.6, 96.4)	0.91 (0.59, 1.45)	25	29	86.2 (69.4, 94.5)	21	24	87.5 (69, 95.7)	27	31	87.1 (71.1, 94.9)
	BSM	15	18	83.3 (60.8, 94.2)	1.07 (0.82, 1.4)	0	0	NA (NA, NA)	NA (NA, NA)	28	36	77.8 (61.9, 88.3)	28	36	77.8 (61.9, 88.3)	43	54	79.6 (67.1, 88.2)
	BSCC	0	1	0.0 (0, 79.3)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	3	6	50.0 (18.8, 81.2)	3	6	50.0 (18.8, 81.2)	3	7	42.9 (15.8, 75)
	BSC	3	3	100.0 (43.9, 100)	1.13 (0.96, 1.32)	1	2	50.0 (9.5, 90.5)	0.53 (0.13, 2.14)	16	18	88.9 (67.2, 96.9)	15	16	93.8 (71.7, 98.9)	19	21	90.5 (71.1, 97.3)
	BSSL	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (20.7, 100)	1.06 (1.06, 1.15)	35	37	94.6 (82.3, 98.5)	34	36	94.4 (81.9, 98.5)	35	37	94.6 (82.3, 98.5)
	BSOS	2	2	100.0 (34.2, 100)	1.05 (0.95, 1.16)	1	1	100.0 (20.7, 100)	1.06 (1.06, 1.17)	19	20	95.0 (76.4, 99.1)	18	19	94.7 (75.4, 99.1)	21	22	95.5 (78.2, 99.2)
	Total	37	45	82.2 (68.7, 90.7)	0.95 (0.82, 1.1)	16	19	84.2 (62.4, 94.5)	0.98 (0.8, 1.19)	193	224	86.2 (81, 90.1)	177	205	86.3 (81, 90.4)	230	269	85.5 (80.8, 89.2)
45 to 69	BSWN	16	19	84.2 (62.4, 94.5)	0.98 (0.78, 1.21)	4	4	100.0 (51, 100)	1.17 (1.17, 1.3)	57	66	86.4 (76.1, 92.7)	53	62	85.5 (74.7, 92.2)	73	85	85.9 (76.9, 91.7)
	BSCM	7	10	70.0 (39.7, 89.2)	0.77 (0.51, 1.16)	10	11	90.9 (62.3, 98.4)	1.00 (0.83, 1.24)	41	45	91.1 (79.3, 96.5)	31	34	91.2 (77, 97)	48	55	87.3 (76, 93.7)
	BSAL	2	2	100.0 (34.2, 100)	1.10 (1, 1.2)	6	7	85.7 (48.7, 97.4)	0.93 (0.69, 1.28)	41	45	91.1 (79.3, 96.5)	35	38	92.1 (79.2, 97.3)	43	47	91.5 (80.1, 96.6)
	BSM	25	30	83.3 (66.4, 92.7)	1.04 (0.84, 1.29)	0	0	NA (NA, NA)	NA (NA, NA)	40	50	80.0 (67, 88.8)	40	50	80.0 (67, 88.8)	65	80	81.3 (71.3, 88.3)
	BSCC	3	4	75.0 (30.1, 95.4)	1.63 (0.72, 3.67)	0	1	0.0 (0, 79.3)	0.00 (NA, NA)	6	13	46.2 (23.2, 70.9)	6	12	50.0 (25.4, 74.6)	9	17	52.9 (31, 73.8)
	BSC	5	5	100.0 (56.6, 100)	1.19 (1.02, 1.39)	1	2	50.0 (9.5, 90.5)	0.58 (0.15, 2.34)	26	31	83.9 (67.4, 92.9)	25	29	86.2 (69.4, 94.5)	31	36	86.1 (71.3, 93.9)
	BSSL	3	4	75.0 (30.1, 95.4)	0.87 (0.49, 1.54)	1	1	100.0 (20.7, 100)	1.16 (1.16, 1.28)	57	66	86.4 (76.1, 92.7)	56	65	86.2 (75.7, 92.5)	60	70	85.7 (75.7, 92.1)
	BSOS	2	2	100.0 (34.2, 100)	1.16 (1.02, 1.31)	2	2	100.0 (34.2, 100)	1.17 (1.17, 1.34)	32	37	86.5 (72, 94.1)	30	35	85.7 (70.6, 93.7)	34	39	87.2 (73.3, 94.4)
	Total	63	76	82.9 (72.9, 89.7)	0.98 (0.87, 1.09)	24	28	85.7 (68.5, 94.3)	1.01 (0.87, 1.18)	300	353	85.0 (80.9, 88.3)	276	325	84.9 (80.6, 88.4)	363	429	84.6 (80.9, 87.7)

2.h, Preoperative diagnosis rate

Description: The percentage of women who are diagnosed with breast cancer by percutaneous biopsy, prior to any surgery.

Target: >90% of screen detected cancers are diagnosed pre-operatively (50–69 age group only)

Figure 60: 2.h.1, 50 to 69, Preoperative diagnosis rate



All LPs met the target of >90% for the proportion of women whose screen detected cancer was diagnosed pre-operatively.

Figure 61: 2.h.3, 50 to 69, Preoperative diagnosis rate, by LP




Table 13: 2.h.1, Preoperative diagnosis rate


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)	Māori / Non-Māori Ratio	Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)	Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)	Pre-Operative Diagnosis of Cancer	Cancers	% of Cancers with a Pre-Operative Diagnosis of Cancer (95% CI)
45 to 49	BSWN	14	16	87.5 (64, 96.5)	0.92 (0.76, 1.11)	2	2	100.0 (34.2, 100)	1.05 (1.05, 1.1)	65	68	95.6 (87.8, 98.5)	63	66	95.5 (87.5, 98.4)	79	84	94.0 (86.8, 97.4)
	BSCM	11	12	91.7 (64.6, 98.5)	0.94 (0.79, 1.12)	15	16	93.8 (71.7, 98.9)	0.94 (0.83, 1.06)	46	47	97.9 (88.9, 99.6)	31	31	100.0 (89, 100)	57	59	96.6 (88.5, 99.1)
	BSAL	6	6	100.0 (61, 100)	1.14 (1.03, 1.27)	6	6	100.0 (61, 100)	1.17 (1.17, 1.32)	42	48	87.5 (75.3, 94.1)	36	42	85.7 (72.2, 93.3)	48	54	88.9 (77.8, 94.8)
	BSM	16	19	84.2 (62.4, 94.5)	0.88 (0.72, 1.08)	1	1	100.0 (20.7, 100)	1.05 (1.05, 1.12)	43	45	95.6 (85.2, 98.8)	42	44	95.5 (84.9, 98.7)	59	64	92.2 (83, 96.6)
	BSCC	14	16	87.5 (64, 96.5)	0.92 (0.75, 1.12)	1	1	100.0 (20.7, 100)	1.05 (1.05, 1.12)	41	43	95.3 (84.5, 98.7)	40	42	95.2 (84.2, 98.7)	55	59	93.2 (83.8, 97.3)
	BSC	11	11	100.0 (74.1, 100)	1.15 (1.02, 1.29)	4	6	66.7 (30, 90.3)	0.73 (0.42, 1.3)	34	39	87.2 (73.3, 94.4)	30	33	90.9 (76.4, 96.9)	45	50	90.0 (78.6, 95.7)
	BSSL	7	9	77.8 (45.3, 93.7)	0.83 (0.58, 1.18)	2	2	100.0 (34.2, 100)	1.06 (1.06, 1.12)	95	101	94.1 (87.6, 97.2)	93	99	93.9 (87.4, 97.2)	102	110	92.7 (86.3, 96.3)
	BSOS	2	2	100.0 (34.2, 100)	1.11 (0.99, 1.24)	1	1	100.0 (20.7, 100)	1.11 (1.11, 1.25)	28	31	90.3 (75.1, 96.7)	27	30	90.0 (74.4, 96.5)	30	33	90.9 (76.4, 96.9)
	Total	81	91	89.0 (80.9, 93.9)	0.95 (0.88, 1.03)	32	35	91.4 (77.6, 97)	0.98 (0.88, 1.09)	394	422	93.4 (90.6, 95.4)	362	387	93.5 (90.6, 95.6)	475	513	92.6 (90, 94.6)
50 to 69	BSWN	84	86	97.7 (91.9, 99.4)	1.02 (0.98, 1.07)	21	22	95.5 (78.2, 99.2)	1.00 (0.91, 1.1)	305	320	95.3 (92.4, 97.1)	284	298	95.3 (92.3, 97.2)	389	406	95.8 (93.4, 97.4)
	BSCM	37	37	100.0 (90.6, 100)	1.04 (1.01, 1.07)	52	53	98.1 (90.1, 99.7)	1.03 (0.99, 1.08)	200	208	96.2 (92.6, 98)	148	155	95.5 (91, 97.8)	237	245	96.7 (93.7, 98.3)
	BSAL	15	16	93.8 (71.7, 98.9)	1.02 (0.89, 1.17)	19	23	82.6 (62.9, 93)	0.89 (0.74, 1.08)	165	180	91.7 (86.7, 94.9)	146	157	93.0 (87.9, 96)	180	196	91.8 (87.2, 94.9)
	BSM	109	115	94.8 (89.1, 97.6)	1.00 (0.95, 1.05)	8	8	100.0 (67.6, 100)	1.06 (1.06, 1.09)	298	315	94.6 (91.5, 96.6)	290	307	94.5 (91.3, 96.5)	407	430	94.7 (92.1, 96.4)
	BSCC	64	65	98.5 (91.8, 99.7)	1.01 (0.97, 1.05)	3	4	75.0 (30.1, 95.4)	0.76 (0.43, 1.35)	214	219	97.7 (94.8, 99)	211	215	98.1 (95.3, 99.3)	278	284	97.9 (95.5, 99)
	BSC	19	19	100.0 (83.2, 100)	1.04 (1.02, 1.07)	21	21	100.0 (84.5, 100)	1.04 (1.04, 1.07)	248	258	96.1 (93, 97.9)	227	237	95.8 (92.4, 97.7)	267	277	96.4 (93.5, 98)
	BSSL	34	35	97.1 (85.5, 99.5)	1.01 (0.95, 1.08)	6	6	100.0 (61, 100)	1.04 (1.04, 1.07)	388	405	95.8 (93.4, 97.4)	382	399	95.7 (93.3, 97.3)	422	440	95.9 (93.6, 97.4)
	BSOS	7	9	77.8 (45.3, 93.7)	0.80 (0.57, 1.14)	3	3	100.0 (43.9, 100)	1.03 (1.03, 1.06)	188	194	96.9 (93.4, 98.6)	185	191	96.9 (93.3, 98.6)	195	203	96.1 (92.4, 98)
	Total	369	382	96.6 (94.3, 98)	1.01 (0.99, 1.03)	133	140	95.0 (90, 97.6)	0.99 (0.96, 1.03)	2,006	2,099	95.6 (94.6, 96.4)	1,873	1,959	95.6 (94.6, 96.4)	2,375	2,481	95.7 (94.9, 96.5)
45 to 69	BSWN	98	102	96.1 (90.3, 98.5)	1.01 (0.96, 1.05)	23	24	95.8 (79.8, 99.3)	1.01 (0.92, 1.1)	370	388	95.4 (92.8, 97)	347	364	95.3 (92.6, 97.1)	468	490	95.5 (93.3, 97)
	BSCM	48	49	98.0 (89.3, 99.6)	1.02 (0.97, 1.06)	67	69	97.1 (90, 99.2)	1.01 (0.97, 1.06)	246	255	96.5 (93.4, 98.1)	179	186	96.2 (92.4, 98.2)	294	304	96.7 (94.1, 98.2)
	BSAL	21	22	95.5 (78.2, 99.2)	1.05 (0.95, 1.16)	25	29	86.2 (69.4, 94.5)	0.94 (0.81, 1.1)	207	228	90.8 (86.3, 93.9)	182	199	91.5 (86.7, 94.6)	228	250	91.2 (87, 94.1)
	BSM	125	134	93.3 (87.7, 96.4)	0.98 (0.94, 1.04)	9	9	100.0 (70.1, 100)	1.06 (1.06, 1.08)	341	360	94.7 (91.9, 96.6)	332	351	94.6 (91.7, 96.5)	466	494	94.3 (91.9, 96)
	BSCC	78	81	96.3 (89.7, 98.7)	0.99 (0.94, 1.04)	4	5	80.0 (37.6, 96.4)	0.82 (0.53, 1.27)	255	262	97.3 (94.6, 98.7)	251	257	97.7 (95, 98.9)	333	343	97.1 (94.7, 98.4)
	BSC	30	30	100.0 (88.6, 100)	1.05 (1.03, 1.08)	25	27	92.6 (76.6, 97.9)	0.97 (0.87, 1.09)	282	297	94.9 (91.8, 96.9)	257	270	95.2 (91.9, 97.2)	312	327	95.4 (92.6, 97.2)
	BSSL	41	44	93.2 (81.8, 97.7)	0.98 (0.9, 1.06)	8	8	100.0 (67.6, 100)	1.05 (1.05, 1.07)	483	506	95.5 (93.3, 97)	475	498	95.4 (93.2, 96.9)	524	550	95.3 (93.2, 96.8)
	BSOS	9	11	81.8 (52.3, 94.9)	0.85 (0.64, 1.13)	4	4	100.0 (51, 100)	1.04 (1.04, 1.07)	216	225	96.0 (92.6, 97.9)	212	221	95.9 (92.4, 97.8)	225	236	95.3 (91.8, 97.4)
	Total	450	473	95.1 (92.8, 96.7)	1.00 (0.98, 1.02)	165	175	94.3 (89.8, 96.9)	0.99 (0.95, 1.03)	2,400	2,521	95.2 (94.3, 96)	2,235	2,346	95.3 (94.3, 96.1)	2,850	2,994	95.2 (94.4, 95.9)

2.i, Specificity

Description: The number with negative screening results as a percentage of number with negative screening results plus number with false positive screening results.

Target: >93% (50–69 age group only)

Figure 62: 2.i.1, 50 to 69, Specificity



Specificity was outside the target range of >93% for initial screens for BSA overall (90.4% for women aged 50–69 years), with LPs ranging from 82.9% to 94.6%.

For subsequent screens, all LPs were above the target, ranging from 93.7% to 97.9%.

Figure 63: 2.i.3, Initial, 50 to 69, Specificity, by LP




Figure 64: 2.i.5, Subsequent, 50 to 69, Specificity, by LP




Table 14: 2.i.1, Specificity


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
		Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)	Māori / Non-Māori Ratio	Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)	Pacific / Non-Pacific Ratio	Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)	Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)	Negative Screens (RRS* from Screen)	Negative Screens Plus False Positives	Estimated Specificity (95% CI)		
45 to 49	Initial	BSWN	1,090	1,218	89.5 (87.6, 91.1)	0.98 (0.96, 1)	361	392	92.1 (89, 94.4)	1.00 (0.98, 1.03)	6,344	6,917	91.7 (91, 92.3)	5,983	6,525	91.7 (91, 92.3)	7,434	8,135	91.4 (90.8, 92)	
		BSCM	739	798	92.6 (90.6, 94.2)	1.01 (0.99, 1.03)	1,222	1,324	92.3 (90.7, 93.6)	1.01 (0.99, 1.02)	4,401	4,787	91.9 (91.1, 92.7)	3,179	3,463	91.8 (90.8, 92.7)	5,140	5,585	92.0 (91.3, 92.7)	
		BSAL	391	438	89.3 (86, 91.8)	0.98 (0.94, 1.01)	465	506	91.9 (89.2, 94)	1.00 (0.98, 1.03)	4,173	4,561	91.5 (90.6, 92.3)	3,708	4,055	91.4 (90.5, 92.3)	4,564	4,999	91.3 (90.5, 92)	
		BSM	1,448	1,627	89.0 (87.4, 90.4)	0.97 (0.95, 0.99)	137	156	87.8 (81.8, 92.1)	0.95 (0.9, 1.01)	5,367	5,839	91.9 (91.2, 92.6)	5,230	5,683	92.0 (91.3, 92.7)	6,815	7,466	91.3 (90.6, 91.9)	
		BSCC	1,093	1,172	93.3 (91.7, 94.6)	0.97 (0.96, 0.99)	123	128	96.1 (91.2, 98.3)	1.00 (0.97, 1.04)	4,253	4,432	96.0 (95.3, 96.5)	4,130	4,304	96.0 (95.3, 96.5)	5,346	5,604	95.4 (94.8, 95.9)	
		BSC	488	532	91.7 (89.1, 93.8)	0.98 (0.96, 1.01)	248	264	93.9 (90.4, 96.2)	1.01 (0.98, 1.04)	3,585	3,837	93.4 (92.6, 94.2)	3,337	3,573	93.4 (92.5, 94.2)	4,073	4,369	93.2 (92.4, 93.9)	
		BSSL	542	592	91.6 (89, 93.5)	1.00 (0.98, 1.03)	146	155	94.2 (89.3, 96.9)	1.03 (0.99, 1.07)	7,398	8,107	91.3 (90.6, 91.9)	7,252	7,952	91.2 (90.6, 91.8)	7,940	8,699	91.3 (90.7, 91.8)	
		BSOS	212	252	84.1 (79.1, 88.1)	0.99 (0.93, 1.04)	32	38	84.2 (69.6, 92.6)	0.99 (0.86, 1.13)	2,402	2,813	85.4 (84, 86.6)	2,370	2,775	85.4 (84, 86.7)	2,614	3,065	85.3 (84, 86.5)	
		Total	6,003	6,629	90.6 (89.8, 91.2)	0.99 (0.98, 0.99)	2,734	2,963	92.3 (91.3, 93.2)	1.01 (0.99, 1.02)	37,923	41,293	91.8 (91.6, 92.1)	35,189	38,330	91.8 (91.5, 92.1)	43,926	47,922	91.7 (91.4, 91.9)	
		Subsequent	BSWN	1,256	1,325	94.8 (93.5, 95.9)	0.99 (0.98, 1)	447	465	96.1 (94, 97.5)	1.00 (0.99, 1.02)	8,073	8,430	95.8 (95.3, 96.2)	7,626	7,965	95.7 (95.3, 96.2)	9,329	9,755	95.6 (95.2, 96)
	BSCM		916	948	96.6 (95.3, 97.6)	1.01 (0.99, 1.02)	1,379	1,436	96.0 (94.9, 96.9)	1.00 (0.99, 1.01)	6,432	6,706	95.9 (95.4, 96.4)	5,053	5,270	95.9 (95.3, 96.4)	7,348	7,654	96.0 (95.5, 96.4)	
	BSAL		409	431	94.9 (92.4, 96.6)	0.99 (0.97, 1.01)	576	608	94.7 (92.7, 96.2)	0.99 (0.97, 1.01)	5,567	5,817	95.7 (95.2, 96.2)	4,991	5,209	95.8 (95.2, 96.3)	5,976	6,248	95.6 (95.1, 96.1)	
	BSM		1,638	1,720	95.2 (94.1, 96.1)	1.00 (0.99, 1.01)	146	152	96.1 (91.7, 98.2)	1.01 (0.98, 1.04)	7,319	7,683	95.3 (94.8, 95.7)	7,173	7,531	95.2 (94.7, 95.7)	8,957	9,403	95.3 (94.8, 95.7)	
	BSCC		1,298	1,331	97.5 (96.5, 98.2)	1.00 (0.99, 1.01)	118	121	97.5 (93, 99.2)	1.00 (0.97, 1.03)	6,097	6,246	97.6 (97.2, 98)	5,979	6,125	97.6 (97.2, 98)	7,395	7,577	97.6 (97.2, 97.9)	
	BSC		712	746	95.4 (93.7, 96.7)	1.00 (0.98, 1.01)	331	345	95.9 (93.3, 97.6)	1.00 (0.98, 1.02)	5,775	6,022	95.9 (95.4, 96.4)	5,444	5,677	95.9 (95.3, 96.4)	6,487	6,768	95.8 (95.3, 96.3)	
	BSSL		906	965	93.9 (92.2, 95.2)	0.99 (0.97, 1)	159	165	96.4 (92.3, 98.3)	1.01 (0.98, 1.04)	11,758	12,337	95.3 (94.9, 95.7)	11,599	12,172	95.3 (94.9, 95.7)	12,664	13,302	95.2 (94.8, 95.6)	
	BSOS		362	387	93.5 (90.6, 95.6)	1.01 (0.98, 1.03)	57	62	91.9 (82.5, 96.5)	0.99 (0.92, 1.06)	3,727	4,006	93.0 (92.2, 93.8)	3,670	3,944	93.1 (92.2, 93.8)	4,089	4,393	93.1 (92.3, 93.8)	
	Total		7,497	7,853	95.5 (95, 95.9)	1.00 (0.99, 1)	3,213	3,354	95.8 (95.1, 96.4)	1.00 (0.99, 1.01)	54,748	57,247	95.6 (95.5, 95.8)	51,535	53,893	95.6 (95.4, 95.8)	62,245	65,100	95.6 (95.5, 95.8)	
	50 to 69		Initial	BSWN	237	277	85.6 (80.9, 89.2)	0.95 (0.9, 1)	109	121	90.1 (83.5, 94.2)	1.00 (0.94, 1.06)	2,119	2,354	90.0 (88.7, 91.2)	2,010	2,233	90.0 (88.7, 91.2)	2,356	2,631
		BSCM		165	186	88.7 (83.4, 92.5)	0.98 (0.93, 1.04)	277	307	90.2 (86.4, 93.1)	1.00 (0.97, 1.04)	1,291	1,433	90.1 (88.4, 91.5)	1,014	1,126	90.1 (88.2, 91.7)	1,456	1,619	89.9 (88.4, 91.3)
BSAL		100		109	91.7 (85, 95.6)	1.01 (0.95, 1.07)	143	157	91.1 (85.6, 94.6)	1.01 (0.96, 1.06)	1,365	1,506	90.6 (89.1, 92)	1,222	1,349	90.6 (88.9, 92)	1,465	1,615	90.7 (89.2, 92)	
BSM		460		539	85.3 (82.1, 88.1)	0.94 (0.9, 0.97)	40	49	81.6 (68.6, 90)	0.89 (0.78, 1.02)	1,589	1,744	91.1 (89.7, 92.4)	1,549	1,695	91.4 (90, 92.6)	2,049	2,283	89.8 (88.4, 90.9)	
BSCC		337		361	93.4 (90.3, 95.5)	0.98 (0.95, 1.01)	40	43	93.0 (81.4, 97.6)	0.98 (0.9, 1.06)	1,182	1,245	94.9 (93.6, 96)	1,142	1,202	95.0 (93.6, 96.1)	1,519	1,606	94.6 (93.4, 95.6)	
BSC		117		139	84.2 (77.2, 89.3)	0.91 (0.84, 0.98)	75	80	93.8 (86.2, 97.3)	1.01 (0.96, 1.07)	1,061	1,144	92.7 (91.1, 94.1)	986	1,064	92.7 (90.9, 94.1)	1,178	1,283	91.8 (90.2, 93.2)	
BSSL		96		107	89.7 (82.5, 94.2)	0.99 (0.92, 1.06)	38	44	86.4 (73.3, 93.6)	0.95 (0.84, 1.07)	1,226	1,350	90.8 (89.2, 92.2)	1,188	1,306	91.0 (89.3, 92.4)	1,322	1,457	90.7 (89.1, 92.1)	
BSOS		50		56	89.3 (78.5, 95)	1.08 (0.98, 1.2)	16	19	84.2 (62.4, 94.5)	1.02 (0.84, 1.25)	494	600	82.3 (79.1, 85.2)	478	581	82.3 (79, 85.2)	544	656	82.9 (79.9, 85.6)	
Total		1,562		1,774	88.0 (86.5, 89.5)	0.97 (0.95, 0.99)	738	820	90.8 (87.8, 91.9)	0.99 (0.97, 1.01)	10,327	11,376	90.8 (90.2, 91.3)	9,589	10,556	90.8 (90.3, 91.4)	11,889	13,150	90.4 (89.9, 90.9)	
Subsequent		BSWN		7,049	7,359	95.8 (95.3, 96.2)	1.00 (0.99, 1.01)	2,639	2,758	95.7 (94.9, 96.4)	1.00 (0.99, 1.01)	10,265	10,723	95.7 (95.3, 96.1)	7,626	7,965	95.7 (95.3, 96.2)	17,314	18,082	95.8 (95.4, 96)
		BSCM	4,121	4,275	96.4 (95.8, 96.9)	1.00 (0.99, 1.01)	7,029	7,275	96.6 (96.2, 97)	1.01 (1, 1.01)	12,082	12,545	96.3 (96, 96.6)	5,053	5,270	95.9 (95.3, 96.4)	16,203	16,820	96.3 (96, 96.6)	
		BSAL	1,979	2,045	96.8 (95.9, 97.5)	1.01 (1, 1.02)	3,188	3,311	96.3 (95.6, 96.9)	1.00 (1, 1.01)	8,179	8,520	96.0 (95.6, 96.4)	4,991	5,209	95.8 (95.2, 96.3)	10,158	10,565	96.1 (95.8, 96.5)	
		BSM	9,769	10,192	95.8 (95.4, 96.2)	1.00 (1, 1.01)	833	860	96.9 (95.5, 97.8)	1.02 (1, 1.03)	8,006	8,391	95.4 (94.9, 95.8)	7,173	7,531	95.2 (94.7, 95.7)	17,775	18,583	95.7 (95.3, 95.9)	
		BSCC	7,569	7,735	97.9 (97.5, 98.2)	1.00 (1, 1.01)	668	680	98.2 (96.9, 99)	1.01 (1, 1.02)	6,647	6,805	97.7 (97.3, 98)	5,979	6,125	97.6 (97.2, 98)	14,216	14,540	97.8 (97.5, 98)	
		BSC	3,863	4,004	96.5 (95.9, 97)	1.00 (1, 1.01)	2,065	2,144	96.3 (95.4, 97)	1.00 (1, 1.01)	7,509	7,821	96.0 (95.6, 96.4)	5,444	5,677	95.9 (95.3, 96.4)	11,372	11,825	96.2 (95.8, 96.5)	
		BSSL	4,111	4,284	96.0 (95.3, 96.5)	1.01 (1, 1.01)	707	729	97.0 (95.5, 98)	1.02 (1, 1.03)	12,306	12,901	95.4 (95, 95.7)	11,599	12,172	95.3 (94.9, 95.7)	16,417	17,185	95.5 (95.2, 95.8)	
		BSOS	1,648	1,732	95.2 (94, 96.1)	1.02 (1.01, 1.04)	203	216	94.0 (90, 96.4)	1.01 (0.98, 1.05)	3,873	4,160	93.1 (92.3, 93.8)	3,670	3,944	93.1 (92.2, 93.8)	5,521	5,892	93.7 (93.1, 94.3)	
		Total	40,109	41,626	96.4 (96.2, 96.5)	1.01 (1, 1.01)	17,332	17,973	96.4 (96.2, 96.7)	1.01 (1.01, 1.01)	68,867	71,866	95.8 (95.7, 96)	51,535	53,893	95.6 (95.4, 95.8)	108,976	113,492	96.0 (95.9, 96.1)	
		45 to 69	Initial	BSWN	1,327	1,495	88.8 (87.1, 90.3)	0.97 (0.95, 0.99)	470	513	91.6 (88.9, 93.7)	1.00 (0.98, 1.03)	8,463	9,271	91.3 (90.7, 91.8)	7,993	8,758	91.3 (90.7, 91.8)	9,790	10,766
BSCM				904	984	91.9 (90, 93.4)	1.00 (0.98, 1.02)	1,499	1,631	91.9 (90.5, 93.1)	1.01 (0.99, 1.02)	5,692	6,220	91.5 (90.8, 92.2)	4,193	4,589	91.4 (90.5, 92.1)	6,596	7,204	91.6 (90.9, 92.2)
BSAL	491			547	89.8 (86.9, 92)	0.98 (0.95, 1.01)	608	663	91.7 (89.4, 93.6)	1.01 (0.98, 1.03)	5,538	6,067	91.3 (90.4, 92)	4,930	5,404	91.2 (90.4, 92)	6,029	6,614	91.2 (90.4, 91.8)	
BSM	1,908			2,166	88.1 (86.7, 89.4)	0.96 (0.94, 0.98)	177	205	86.3 (81, 90.4)	0.94 (0.89, 0.99)	6,956	7,583	91.7 (91.1, 92.3)	6,779	7,378	91.9 (91.2, 92.5)	8,864	9,749	90.9 (90.3, 91.5)	
BSCC	1,430			1,533	93.3 (91.9, 94.4)	0.97 (0.96, 0.99)	163	171	95.3 (91, 97.6)	1.00 (0.96, 1.03)	5,435	5,677	95.7 (95.2, 96.2)	5,272	5,506	95.8 (95.2, 96.3)	6,865	7,210	95.2 (94.7, 95.7)	
BSC	605			671	90.2 (87.7, 92.2)	0.97 (0.94, 0.99)	323	344	93.9 (90.8, 96)	1.01 (0.98, 1.04)	4,646	4,981	93.3 (92.5, 93.9)	4,323	4,637	93.2 (92.5, 93.9)	5,251	5,652	92.9 (92.3, 93.5)	
BSSL	638			699	91.3 (88.9, 93.1)	1.00 (0.98, 1.02)	184	199	92.5 (87.9, 95.4)	1.01 (0.97, 1.06)	8,624	9,457	91.2 (90.6, 91.7)	8,440	9,258	91.2 (90.6, 91.7)	9,262	10,156	91.2 (90.6, 91.7)	
BSOS	262			308	85.1 (80.7, 88.6)	1.00 (0.95, 1.05)	48	57	84.2 (72.6, 91.5)	0.99 (0.89, 1.11)	2,896	3,413	84.9 (83.6, 86)	2,848	3,356	84.9 (83.6, 86)	3,158	3,721	84.9 (83.7, 86)	

2.m, Benign open biopsy rate

Description: The number of women with benign open biopsy per number of women screened.

Targets: Initial: ≤ 3.5 per 1,000 women screened. Subsequent: ≤ 1.6 per 1,000 women screened (50–69 age group only)

Figure 65: 2.m.1, 50 to 69, Benign open biopsy rate, total BSA



Over the two years, out of 512,498 screens 419 open biopsies were performed that turned out to be benign. For BSA overall, the benign open biopsy rate for initial screens was 2.0 per 1,000 women screened aged 45–69 years, while the rate for subsequent screens was 0.7 per 1,000 women screened. The targets were met or were within the confidence interval for each LP.

Figure 66: 2.m.3, Initial, 50 to 69, Benign open biopsy rate, by LP




Figure 67: 2.m.5, Subsequent, 50 to 69, Benign open biopsy rate, by LP




Table 15: 2.m.1, Benign open biopsy rate

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)	Māori / Non-Māori Ratio	Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)	Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)	Benign Open Biopsies	Women Screened	Benign Biopsies per 1,000 Women Screened (95% CI)	
45 to 49	Initial	BSWN	5	1,218	4.1 (1.8, 9.5)	1.89 (0.69, 5.2)	1	392	2.6 (0.5, 14.3)	1.19 (0.17, 9.02)	15	6,917	2.2 (1.3, 3.6)	14	6,525	2.1 (1.3, 3.6)	20	8,135	2.5 (1.6, 3.8)
		BSCM	3	798	3.8 (1.3, 10.9)	2.00 (0.54, 7.37)	1	1,324	0.8 (0.1, 4.3)	0.33 (0.05, 2.61)	9	4,787	1.9 (1.3, 3.6)	8	3,463	2.3 (1.2, 4.5)	12	5,585	2.1 (1.2, 3.7)
		BSAL	0	438	0.0 (0, 0.7)	NA (NA, NA)	0	506	2.0 (0.4, 11.1)	1.60 (0.23, 13.69)	6	4,561	1.3 (0.6, 2.9)	5	4,055	1.2 (0.5, 2.9)	6	4,999	1.2 (0.6, 2.6)
		BSM	11	1,627	6.8 (3.9, 11.9)	5.64 (2.19, 14.52)	1	156	0.0 (0, 24)	NA (NA, NA)	7	5,839	1.2 (0.6, 2.5)	7	5,683	1.2 (0.6, 2.5)	18	7,466	2.4 (1.5, 3.8)
		BSCC	1	1,172	0.9 (0.2, 4.8)	0.54 (0.07, 4.39)	1	128	7.8 (1.8, 42.5)	5.60 (0.8, 46.21)	7	4,432	1.6 (0.8, 3.2)	6	4,304	1.4 (0.6, 3)	8	5,604	1.4 (0.7, 2.8)
		BSC	1	532	1.9 (0.4, 10.5)	1.20 (0.14, 9.97)	0	264	0.0 (0, 14.3)	NA (NA, NA)	6	3,837	1.6 (0.7, 3.4)	6	3,573	1.7 (0.8, 3.6)	7	4,369	1.6 (0.8, 3.3)
		BSSL	1	592	1.7 (0.3, 9.5)	0.81 (0.11, 6.04)	0	155	0.0 (0, 24.2)	NA (NA, NA)	17	8,107	2.1 (1.3, 3.3)	17	7,952	2.1 (1.3, 3.4)	18	8,699	2.1 (1.3, 3.3)
		BSOS	0	252	0.0 (0, 15)	NA (NA, NA)	0	38	0.0 (0, 91.8)	NA (NA, NA)	14	2,813	5.0 (3, 8.3)	14	2,775	5.0 (3, 8.4)	14	3,065	4.6 (2.8, 7.6)
		Total	22	6,629	3.3 (2.2, 5)	1.69 (1.06, 2.71)	4	2,963	1.3 (0.5, 3.5)	0.67 (0.25, 1.83)	81	41,293	2.0 (1.6, 2.4)	77	38,330	2.0 (1.6, 2.5)	103	47,922	2.1 (1.8, 2.6)
		Subsequent	BSWN	1	1,325	0.8 (0.1, 4.3)	1.59 (0.18, 14.22)	2	465	4.3 (1.3, 15.5)	17.12 (4.3, 121.29)	4	8,427	0.5 (0.2, 1.2)	2	7,962	0.3 (0.1, 0.9)	5	9,752
	BSCM		1	948	1.1 (0.2, 5.9)	1.77 (0.2, 15.8)	1	1,436	0.7 (0.1, 3.9)	1.22 (0.17, 11.75)	4	6,703	0.6 (0.2, 1.5)	3	5,267	0.6 (0.2, 1.7)	5	7,651	0.7 (0.3, 1.5)
	BSAL		0	431	0.0 (0, 0.8)	NA (NA, NA)	1	608	1.6 (0.3, 9.2)	0.95 (0.13, 7.5)	10	5,817	1.7 (0.9, 3.2)	9	5,209	1.7 (0.9, 3.3)	10	6,248	1.6 (0.9, 2.9)
	BSM		1	1,719	0.6 (0.1, 3.3)	0.64 (0.08, 5.18)	0	152	0.0 (0, 24.6)	NA (NA, NA)	7	7,679	0.9 (0.4, 1.9)	7	7,527	0.9 (0.5, 1.9)	8	9,398	0.9 (0.4, 1.7)
	BSCC		2	1,331	1.5 (0.4, 5.5)	NA (NA, NA)	0	121	0.0 (0, 30.8)	NA (NA, NA)	0	6,246	0.0 (0, 0.6)	0	6,125	0.0 (0, 0.6)	2	7,577	0.3 (0.1, 1)
	BSC		1	745	1.3 (0.2, 7.6)	1.15 (0.14, 9.37)	0	345	0.0 (0, 11)	NA (NA, NA)	7	6,022	1.2 (0.6, 2.4)	7	5,677	1.2 (0.6, 2.5)	8	6,767	1.2 (0.6, 2.3)
	BSSL		3	961	3.1 (1.1, 9.1)	3.85 (1.06, 13.97)	0	164	0.0 (0, 22.9)	NA (NA, NA)	10	12,335	0.8 (0.4, 1.5)	10	12,171	0.8 (0.4, 1.5)	13	13,296	1.0 (0.6, 1.7)
	BSOS		0	386	0.0 (0, 9.9)	NA (NA, NA)	1	62	16.1 (4.4, 84.3)	31.79 (4.55, 346.03)	3	4,004	0.7 (0.3, 2.2)	2	3,942	0.5 (0.1, 1.8)	3	4,390	0.7 (0.2, 2)
Total	9	7,846	1.1 (0.6, 2.2)	1.46 (0.71, 2.98)	5	3,353	1.5 (0.6, 3.5)	2.01 (0.84, 5.09)	45	57,233	0.8 (0.6, 1.1)	40	53,880	0.7 (0.5, 1)	54	65,079	0.8 (0.6, 1.1)		
50 to 69	Initial	BSWN	1	277	3.6 (0.7, 20.1)	2.83 (0.3, 27.14)	0	121	0.0 (0, 30.8)	NA (NA, NA)	3	2,354	1.3 (0.4, 3.7)	3	2,233	1.3 (0.5, 3.9)	4	2,631	1.5 (0.6, 3.9)
		BSCM	0	186	0.0 (0, 20.2)	NA (NA, NA)	0	307	0.0 (0, 12.4)	NA (NA, NA)	2	1,433	1.4 (0.4, 5.1)	2	1,126	1.8 (0.5, 6.4)	2	1,619	1.2 (0.3, 4.5)
		BSAL	0	109	0.0 (0, 34)	NA (NA, NA)	2	157	12.7 (4.3, 44.4)	5.73 (1.45, 34.02)	5	1,506	3.3 (1.5, 7.7)	3	1,349	2.2 (0.8, 6.5)	5	1,615	3.1 (1.4, 7.2)
		BSM	1	539	1.9 (0.3, 10.4)	0.65 (0.08, 5.53)	0	49	0.0 (0, 72.7)	NA (NA, NA)	5	1,744	2.9 (1.3, 6.7)	5	1,695	2.9 (1.3, 6.9)	6	2,283	2.6 (1.2, 5.7)
		BSCC	0	361	0.0 (0, 10.5)	NA (NA, NA)	0	43	0.0 (0, 82)	NA (NA, NA)	0	1,245	0.0 (0, 3.1)	0	1,202	0.0 (0, 3.2)	0	1,606	0.0 (0, 2.4)
		BSC	0	139	0.0 (0, 26.9)	NA (NA, NA)	0	80	0.0 (0, 45.8)	NA (NA, NA)	0	1,144	0.0 (0, 3.3)	0	1,064	0.0 (0, 3.6)	0	1,283	0.0 (0, 3)
		BSSL	0	107	0.0 (0, 34.7)	NA (NA, NA)	0	44	0.0 (0, 80.3)	NA (NA, NA)	2	1,350	1.5 (0.4, 5.4)	2	1,306	1.5 (0.4, 5.6)	2	1,457	1.4 (0.4, 5)
		BSOS	0	56	0.0 (0, 64.2)	NA (NA, NA)	0	19	0.0 (0, 168.2)	NA (NA, NA)	3	600	5.0 (1.9, 14.5)	3	581	5.2 (1.9, 15)	3	656	4.6 (1.6, 13.3)
		Total	2	1,774	1.1 (0.3, 4.1)	0.64 (0.15, 2.74)	2	820	2.4 (0.7, 8.8)	1.43 (0.36, 6.15)	20	11,376	1.8 (1.1, 2.7)	18	10,556	1.7 (1.1, 2.7)	22	13,150	1.7 (1.1, 2.5)
		Subsequent	BSWN	12	7,355	1.6 (0.9, 2.8)	2.10 (1.1, 3.99)	1	2,756	0.4 (0.1, 2.1)	0.45 (0.06, 3.29)	41	52,660	0.8 (0.6, 1.1)	40	49,904	0.8 (0.6, 1.1)	53	60,015
	BSCM		6	4,275	1.4 (0.6, 3.1)	1.63 (0.68, 3.92)	9	7,273	1.2 (0.7, 2.3)	1.63 (0.85, 3.55)	30	34,860	0.9 (0.6, 1.2)	21	27,587	0.8 (0.5, 1.2)	36	39,135	0.9 (0.7, 1.3)
	BSAL		2	2,045	1.0 (0.3, 3.6)	1.28 (0.3, 5.41)	3	3,311	0.9 (0.3, 2.7)	1.21 (0.39, 4.06)	24	31,374	0.9 (0.5, 1.1)	21	28,063	0.7 (0.5, 1.1)	26	33,419	0.8 (0.5, 1.1)
	BSM		16	10,173	1.6 (1, 2.5)	2.79 (1.52, 5.13)	0	860	0.0 (0, 4.4)	NA (NA, NA)	29	51,422	0.6 (0.4, 0.8)	29	50,562	0.6 (0.4, 0.8)	45	61,595	0.7 (0.5, 1)
	BSCC		1	7,734	0.1 (0, 0.7)	0.93 (0.11, 7.71)	0	680	0.0 (0, 5.6)	NA (NA, NA)	6	43,101	0.1 (0.1, 0.3)	6	42,421	0.1 (0.1, 0.3)	7	50,835	0.1 (0.1, 0.3)
	BSC		3	3,992	0.8 (0.3, 2.2)	1.62 (0.47, 5.52)	2	2,141	0.9 (0.3, 3.4)	2.15 (0.54, 9.38)	17	36,599	0.5 (0.3, 0.7)	15	34,458	0.4 (0.3, 0.7)	20	40,591	0.5 (0.3, 0.8)
	BSSL		0	4,275	0.0 (0, 0.9)	NA (NA, NA)	1	727	1.4 (0.3, 7.7)	2.77 (0.39, 20.18)	35	69,107	0.5 (0.4, 0.7)	34	68,380	0.5 (0.4, 0.7)	35	73,382	0.5 (0.3, 0.7)
	BSOS		2	1,730	1.2 (0.3, 4.2)	1.85 (0.43, 8.05)	1	215	4.7 (1, 25.7)	7.89 (1.12, 59.43)	16	25,645	0.6 (0.4, 1)	15	25,430	0.6 (0.4, 1)	18	27,375	0.7 (0.4, 1)
Total	42	41,579	1.0 (0.7, 1.4)	1.76 (1.26, 2.45)	17	17,963	0.9 (0.6, 1.5)	1.71 (1.06, 2.81)	198	344,768	0.6 (0.5, 0.7)	181	326,805	0.6 (0.5, 0.6)	240	386,347	0.6 (0.5, 0.7)		
45 to 69	Initial	BSWN	6	1,495	4.0 (1.9, 8.7)	2.07 (0.82, 5.2)	1	513	1.9 (0.4, 10.9)	1.00 (0.14, 7.53)	18	9,271	1.9 (1.2, 3.1)	17	8,758	1.9 (1.2, 3.1)	24	10,766	2.2 (1.5, 3.3)
		BSCM	3	984	3.0 (1.1, 8.9)	1.72 (0.48, 6.17)	1	1,631	0.6 (0.1, 3.5)	0.28 (0.04, 2.2)	11	6,220	1.8 (1, 3.2)	10	4,589	2.2 (1.2, 4)	14	7,204	1.9 (1.2, 3.3)
		BSAL	0	547	0.0 (0, 7)	NA (NA, NA)	3	663	4.5 (1.6, 13.1)	3.06 (0.99, 11.49)	11	6,067	1.8 (1, 3.2)	8	5,404	1.5 (0.8, 2.9)	11	6,614	1.7 (0.9, 3)
		BSM	12	2,166	5.5 (3.2, 9.6)	3.50 (1.58, 7.78)	0	205	0.0 (0, 18.4)	NA (NA, NA)	12	7,583	1.6 (0.9, 2.8)	12	7,378	1.6 (0.9, 2.8)	24	9,749	2.5 (1.7, 3.6)
		BSCC	1	1,533	0.7 (0.1, 3.7)	0.53 (0.07, 4.3)	1	171	5.8 (1.2, 32.2)	5.37 (0.76, 44.33)	7	5,677	1.2 (0.6, 2.5)	6	5,506	1.1 (0.5, 2.4)	8	7,210	1.1 (0.6, 2.2)
		BSC	1	671	1.5 (0.3, 8.4)	1.24 (0.15, 10.26)	0	344	0.0 (0, 11)	NA (NA, NA)	6	4,981	1.2 (0.6, 2.6)	6	4,637	1.3 (0.6, 2.8)	7	5,652	1.2 (0.6, 2.5)
		BSSL	1	699	1.4 (0.3, 8)	0.71 (0.1, 5.31)	0	199	0.0 (0, 18.9)	NA (NA, NA)	19	9,457	2.0 (1.3, 3.1)	19	9,258	2.1 (1.3, 3.2)	20	10,156	2.0 (1.3, 3)
		BSOS	0	308	0.0 (0, 12.3)	NA (NA, NA)	0	57	0.0 (0, 63.1)	NA (NA, NA)	17	3,413	5.0 (3.2, 7.9)	17	3,356	5.1 (3.2, 8)	17	3,721	4.6 (2.9, 7.3)
		Total	24	8,403	2.9 (1.9, 4.2)	1.49 (0.95, 2.32)	6	3,783	1.6 (0.7, 3.4)	0.82 (0.37, 1.86)	101	52,669	1.9 (1.6, 2.3)	95	48,886	1.9 (1.6, 2.4)	125	61,072	2.0 (1.7, 2.4)
		Subsequent	BSWN	13	8,680	1.5 (0.9, 2.6)	2.03 (1.1, 3.77)	3	3,221	0.9 (0.3, 2.7)	1.28 (0.41, 4.14)	45	61,087	0.7 (0.6, 1)	42	57,866	0.7 (0.5, 1)	58	69,767
	BSCM		7	5,223	1.3 (0.7, 2.8)	1.64 (0.73, 3.69)	10	8,709	1.1 (0.6, 2.1)	1.57 (0.85, 3.29)	34	41,563	0.8 (0.6, 1.1)	24	32,854	0.7 (0.5, 1.1)	41	46,786	0.9 (0.6, 1.2)
	BSAL		2	2,476	0.8 (0.2, 2.9)	0.88 (0.21, 3.68)	4	3,919	1.0 (0.4, 2.6)	1.13 (0.43, 3.21)	34	37,191	0.9 (0.7, 1.3)	30	33,272	0.9 (0.6, 1.3)	36	39,667	0.9 (0.7, 1.3)
	BSM		17	11,892	1.4 (0.9, 2.3)	2.35 (1.32, 4.18)	0	1,012	0.0 (0, 3.8)	NA (NA, NA)	36	59,101	0.6 (0.4, 0.8)	36	58,089	0.6 (0.4, 0.9)	53	70,993	0.7 (0.6, 1)
	BSCC		3	9,065	0.3 (0.1, 1)	2.72 (0.68, 10.88)	0	801	0.0 (0, 4.8)	NA (NA, NA)	6	49,347	0.1 (0.1, 0.3)	6	48,546	0.1 (0.1, 0.3)	9	58,412	0.2 (0.1, 0.3)
	BSC		4	4,737	0.8 (0.3, 2.2)	1.50 (0.52, 4.32)													


Breast Cancer Detection

3.a.1, DCIS and invasive cancer detection

Description: The number of women who have breast cancer detected, expressed as a rate per 1,000 screens.

Target: No target

Figure 68: 3.a.1.1, 50 to 69, breast cancer detection rates (DCIS and invasive combined), initial and subsequent screens



The total number of breast cancers detected by BSA among women aged 45–69 years was 2,994 over two years. 513 cancers were detected in women aged 45–49 years and 2,481 in women aged 50–69 years.

The cancer detection rates for women aged 45–49 years were 5.9 per 1,000 initial screens and 3.5 per 1,000 subsequent screens. For women aged 50–69 years the rates were higher at 12.5 per 1,000 initial screens and 6.0 per 1,000 subsequent screens.

Māori women were more likely to have a breast cancer detected from an initial or subsequent screen than non-Māori women in both age groups. Pacific women were also more likely than non-Māori non-Pacific women to have a cancer detected (apart from subsequent screens in the 45–49 age group).

Figure 69: 3.a.1.3, Initial, 50 to 69 breast cancer detection rates (DCIS and invasive combined), by LP




Figure 70: 3.a.1.5, Subsequent, 50 to 69, breast cancer detection rates (DCIS and invasive combined), by LP




Table 16: 3.a.1.1, Breast cancer detection rates (DCIS and invasive combined)

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Māori / Non-Māori Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Pacific / Non-Pacific Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)
45 to 49	Initial	BSWN	8	1,218	6.6 (3.5, 12.8)	1.14 (0.53, 2.42)	1	392	2.6 (0.5, 14.3)	0.43 (0.06, 3.1)	40	6,917	5.8 (4.3, 7.8)	39	6,525	6.0 (4.4, 8.1)	48	8,135	5.9 (4.5, 7.8)
		BSCM	9	798	11.3 (6.3, 20.9)	2.00 (0.94, 4.24)	11	1,324	8.3 (4.8, 14.6)	1.80 (1, 3.86)	27	4,787	5.6 (3.9, 8.1)	16	3,463	4.6 (2.9, 7.4)	36	5,585	6.4 (4.7, 8.8)
		BSAL	4	438	9.1 (3.9, 22.9)	1.34 (0.48, 3.79)	5	506	9.9 (4.6, 22.6)	1.54 (0.64, 4)	31	4,561	6.8 (4.9, 9.6)	26	4,055	6.4 (4.5, 9.3)	35	4,999	7.0 (5.1, 9.6)
		BSM	12	1,627	7.4 (4.4, 12.7)	2.05 (1.01, 4.16)	1	156	6.4 (1.4, 35.2)	1.82 (0.26, 13.49)	21	5,839	3.6 (2.4, 5.5)	20	5,683	3.5 (2.3, 5.4)	33	7,466	4.4 (3.2, 6.2)
		BSCC	10	1,172	8.5 (4.8, 15.4)	1.51 (0.73, 3.14)	0	128	0.0 (0, 29.1)	NA (NA, NA)	25	4,432	5.6 (3.9, 8.3)	25	4,304	5.8 (4.8, 8.5)	35	5,604	6.2 (4.6, 8.6)
		BSC	7	532	13.2 (6.9, 26.4)	2.29 (0.99, 5.35)	3	264	11.4 (4.5, 32.3)	2.14 (0.69, 7.18)	22	3,837	5.7 (3.9, 8.6)	19	3,573	5.3 (3.5, 8.2)	29	4,369	6.6 (4.7, 9.4)
		BSSL	3	592	5.1 (1.8, 14.7)	0.84 (0.26, 2.68)	2	155	12.9 (4.4, 45)	2.18 (0.55, 8.91)	49	8,107	6.0 (4.6, 7.9)	47	7,952	5.9 (4.5, 7.8)	52	8,699	6.0 (4.6, 7.8)
		BSOS	1	252	4.0 (0.8, 22)	0.74 (0.1, 5.61)	1	38	26.3 (8.8, 130.8)	5.22 (0.75, 38.67)	15	2,813	5.3 (3.3, 8.7)	14	2,775	5.0 (3.1, 8.4)	16	3,065	5.2 (3.3, 8.4)
		Total	54	6,629	8.1 (6.3, 10.5)	1.46 (1.09, 1.96)	24	2,963	8.1 (5.6, 11.9)	1.51 (1.01, 2.3)	230	41,293	5.6 (4.9, 6.3)	206	38,330	5.4 (4.7, 6.1)	284	47,922	5.9 (5.3, 6.6)
		Subsequent	BSWN	8	1,338	6.0 (3.1, 11.6)	1.81 (0.82, 3.95)	1	468	2.1 (0.4, 12)	0.63 (0.09, 4.64)	28	8,455	3.3 (2.3, 4.8)	27	7,987	3.4 (2.3, 4.9)	36	9,793
	BSCM		3	951	3.2 (1.1, 9.2)	1.06 (0.32, 3.56)	5	1,440	3.5 (1.5, 8.1)	1.22 (0.51, 3.36)	20	6,723	3.0 (1.9, 4.6)	15	5,283	2.8 (1.7, 4.7)	23	7,674	3.0 (2, 4.5)
	BSAL		2	431	4.6 (1.4, 16.6)	1.59 (0.37, 6.85)	1	608	1.6 (0.3, 9.2)	0.54 (0.08, 4.03)	17	5,819	2.9 (1.8, 4.7)	16	5,211	3.1 (1.9, 5)	19	6,250	3.0 (2, 4.7)
	BSM		7	1,767	4.0 (2, 8.1)	1.27 (0.55, 2.95)	0	152	0.0 (0, 24.6)	NA (NA, NA)	24	7,703	3.1 (2.1, 4.6)	24	7,551	3.2 (2.2, 4.7)	31	9,470	3.3 (2.3, 4.6)
	BSCC		6	1,333	4.5 (2.1, 9.7)	1.56 (0.62, 3.93)	1	122	8.2 (1.9, 44.6)	2.96 (0.42, 22.03)	18	6,251	2.9 (1.8, 4.5)	17	6,129	2.8 (1.7, 4.4)	24	7,584	3.2 (2.1, 4.7)
	BSC		4	765	5.2 (2.1, 13.3)	1.85 (0.63, 5.49)	3	349	8.6 (3.3, 24.6)	3.49 (1.13, 12.07)	17	6,026	2.8 (1.8, 4.5)	14	5,677	2.5 (1.5, 4.1)	21	6,791	3.1 (2, 4.7)
	BSSL		6	981	6.1 (2.9, 13.2)	1.45 (0.63, 3.37)	0	165	0.0 (0, 22.8)	NA (NA, NA)	52	12,349	4.2 (3.2, 5.5)	52	12,184	4.3 (3.3, 5.6)	58	13,300	4.4 (3.4, 5.6)
	BSOS		1	391	2.6 (0.5, 14.3)	0.64 (0.09, 4.82)	0	63	0.0 (0, 57.5)	NA (NA, NA)	16	4,011	4.0 (2.5, 6.4)	16	3,948	4.1 (2.5, 6.5)	17	4,402	3.9 (2.4, 6.1)
	Total		37	7,957	4.6 (3.4, 6.4)	1.39 (0.98, 1.97)	11	3,367	3.3 (1.9, 5.8)	0.97 (0.54, 1.79)	192	57,337	3.3 (2.9, 3.8)	181	53,970	3.4 (2.9, 3.9)	229	65,294	3.5 (3.1, 4)
	50 to 69	Initial	BSWN	9	277	32.5 (20.4, 57.4)	3.06 (1.44, 6.49)	0	121	0.0 (0, 30.8)	0.00 #NUM!	25	2,354	10.6 (7.4, 15.4)	25	2,233	11.2 (7.8, 16.3)	34	2,631
BSCM			2	186	10.8 (3.5, 37.8)	0.73 (0.17, 3.1)	7	307	22.8 (12.8, 44.6)	1.83 (0.88, 4.5)	21	1,433	14.7 (10, 21.9)	14	1,126	12.4 (7.8, 20.4)	23	1,619	14.2 (9.9, 20.9)
BSAL			1	109	9.2 (2.1, 49.6)	1.26 (0.16, 9.64)	1	157	6.4 (1.4, 34.9)	0.86 (0.12, 6.67)	11	1,506	7.3 (4.2, 12.9)	10	1,349	7.4 (4.2, 13.4)	12	1,615	7.4 (4.4, 12.8)
BSM			15	539	27.8 (18.8, 43.6)	2.21 (1.15, 4.22)	1	49	20.4 (6.1, 104.4)	1.65 (0.24, 12)	22	1,744	12.6 (8.6, 18.7)	21	1,695	12.4 (8.4, 18.6)	37	2,283	16.2 (12.2, 21.9)
BSCC			7	361	19.4 (10.6, 38.3)	3.02 (1.1, 8.27)	0	43	0.0 (0, 8.2)	NA (NA, NA)	8	1,245	6.4 (3.4, 12.5)	8	1,202	6.7 (3.5, 12.9)	15	1,606	9.3 (5.9, 15.2)
BSC			3	139	21.6 (9.5, 59.4)	1.65 (0.48, 5.61)	3	80	37.5 (19.3, 98.1)	3.33 (1.1, 11.54)	15	1,144	13.1 (8.4, 21.1)	12	1,064	11.3 (6.8, 19.3)	18	1,283	14.0 (9.3, 21.7)
BSSL			0	107	0.0 (0, 34.7)	NA (NA, NA)	0	44	0.0 (0, 80.3)	NA (NA, NA)	16	1,350	11.9 (7.6, 18.9)	16	1,306	12.3 (7.9, 19.5)	16	1,457	11.0 (7, 17.5)
BSOS			0	56	0.0 (0, 64.2)	NA (NA, NA)	0	19	0.0 (0, 168.2)	NA (NA, NA)	9	600	15.0 (8.6, 27.6)	9	581	15.5 (8.9, 28.5)	9	656	13.7 (7.8, 25.3)
Total			37	1,774	20.9 (15.8, 28)	1.87 (1.3, 2.69)	12	820	14.6 (8.9, 24.9)	1.34 (0.77, 2.42)	127	11,376	11.0 (9.5, 13.2)	115	10,556	10.9 (9.2, 13)	164	13,150	12.5 (10.8, 14.4)
Subsequent			BSWN	77	7,430	10.4 (8.4, 12.8)	1.86 (1.45, 2.39)	22	2,785	7.9 (5.3, 11.8)	1.45 (0.96, 2.24)	295	52,987	5.6 (5, 6.2)	273	50,202	5.4 (4.8, 6.1)	372	60,417
		BSCM	35	4,282	8.2 (6, 11.2)	1.53 (1.07, 2.19)	46	7,299	6.3 (4.8, 8.3)	1.24 (0.93, 1.73)	187	34,995	5.3 (4.7, 6.1)	141	27,696	5.1 (4.3, 6)	222	39,277	5.7 (5, 6.4)
		BSAL	15	2,048	7.3 (4.6, 11.9)	1.36 (0.8, 2.3)	22	3,311	6.6 (4.5, 10)	1.27 (0.84, 1.98)	169	31,382	5.4 (4.7, 6.2)	147	28,071	5.2 (4.5, 6.1)	184	33,430	5.5 (4.8, 6.3)
		BSM	100	10,512	9.5 (7.9, 11.5)	1.68 (1.34, 2.11)	7	865	8.1 (4.1, 16.4)	1.44 (0.69, 3.05)	293	51,870	5.6 (5.1, 6.3)	286	51,005	5.6 (5, 6.3)	393	62,382	6.3 (5.7, 6.9)
		BSCC	58	7,758	7.5 (5.9, 9.6)	1.53 (1.15, 2.05)	4	682	5.9 (2.4, 14.8)	1.20 (0.45, 3.23)	211	43,208	4.9 (4.3, 5.6)	207	42,526	4.9 (4.3, 5.6)	269	50,966	5.3 (4.7, 5.9)
		BSC	16	4,165	3.8 (2.4, 6.2)	0.58 (0.35, 0.97)	18	2,227	8.1 (5.3, 12.6)	1.24 (0.79, 2.01)	243	36,857	6.6 (5.8, 7.4)	225	34,630	6.5 (5.7, 7.4)	259	41,022	6.3 (5.6, 7.1)
		BSSL	35	4,395	8.0 (5.8, 11)	1.42 (1, 2)	6	757	7.9 (3.9, 17)	1.42 (0.64, 3.17)	389	69,273	5.6 (5.1, 6.2)	383	68,516	5.6 (5.1, 6.2)	424	73,668	5.8 (5.2, 6.3)
		BSOS	9	1,762	5.1 (2.8, 9.6)	0.71 (0.36, 1.38)	3	220	13.6 (5.5, 38.5)	1.91 (0.62, 5.93)	185	25,691	7.2 (6.3, 8.3)	182	25,471	7.1 (6.2, 8.2)	194	27,453	7.1 (6.2, 8.1)
		Total	345	42,352	8.1 (7.4, 9)	1.43 (1.28, 1.6)	128	18,146	7.1 (6, 8.3)	1.26 (1.06, 1.5)	1,972	346,263	5.7 (5.5, 5.9)	1,844	328,117	5.6 (5.4, 5.9)	2,317	388,615	6.0 (5.7, 6.2)
45 to 69		Initial	BSWN	17	1,495	11.4 (7.4, 17.9)	1.62 (0.95, 2.76)	1	513	1.9 (0.4, 10.9)	0.27 (0.04, 1.92)	65	9,271	7.0 (5.6, 8.9)	64	8,758	7.3 (5.8, 9.3)	82	10,766
	BSCM		11	984	11.2 (6.6, 19.6)	1.45 (0.75, 2.78)	18	1,631	11.0 (7.2, 17.1)	1.69 (1.07, 3.02)	48	6,220	7.7 (5.9, 10.1)	30	4,589	6.5 (4.7, 9.2)	59	7,204	8.2 (6.4, 10.5)
	BSAL		5	547	9.1 (4.2, 20.9)	1.32 (0.52, 3.32)	6	663	9.0 (4.4, 19.3)	1.36 (0.61, 3.21)	42	6,067	6.9 (5.2, 9.3)	36	5,404	6.7 (4.9, 9.1)	47	6,614	7.1 (5.4, 9.4)
	BSM		27	2,166	12.5 (8.8, 17.8)	2.20 (1.36, 3.55)	2	205	9.8 (3.2, 34.4)	1.76 (0.44, 7.21)	43	7,583	5.7 (4.3, 7.6)	41	7,378	5.6 (4.1, 7.5)	70	9,749	7.2 (5.7, 9)
	BSCC		17	1,533	11.1 (7.2, 17.4)	1.91 (1.07, 3.42)	0	171	0.0 (0, 22)	NA (NA, NA)	33	5,677	5.8 (4.2, 8.1)	33	5,506	6.0 (4.3, 8.3)	50	7,210	6.9 (5.3, 9.1)
	BSC		10	671	14.9 (8.7, 26.6)	2.01 (1, 4.02)	6	344	17.4 (9.1, 36.5)	2.61 (1.18, 6.21)	37	4,981	7.4 (5.5, 10.1)	31	4,637	6.7 (4.8, 9.4)	47	5,652	8.3 (6.3, 10.9)
	BSSL		3	699	4.3 (1.5, 12.5)	0.62 (0.2, 1.98)	2	199	10.1 (3.3, 35.4)	1.48 (0.37, 5.99)	65	9,457	6.9 (5.4, 8.7)	63	9,258	6.8 (5.4, 8.6)	68	10,156	6.7 (5.3, 8.4)
	BSOS		1	308	3.2 (0.6, 18.1)	0.46 (0.06, 3.4)	1	57	17.5 (5, 91)	2.56 (0.37, 18.63)	24	3,413	7.0 (4.8, 10.4)	23	3,356	6.9 (4.7, 10.2)	25	3,721	6.7 (4.6, 9.8)
	Total		91	8,403	10.8 (8.9, 13.2)	1.60 (1.27, 2.01)	36	3,783	9.5 (7, 13)	1.45 (1.05, 2.04)	357	52,669	6.8 (6.1, 7.5)	321	48,886	6.6 (5.9, 7.3)	448	61,072	7.3 (6.7, 8)
	Subsequent		BSWN	85	8,768	9.7 (7.9, 11.9)	1.84 (1.45, 2.34)	23	3,253	7.1 (4.8, 10.5)	1.37 (0.91, 2.09)	323	61,442	5.3 (4.7, 5.8)	300	58,189	5.2 (4.6, 5.8)	408	70,210
		BSCM	38	5,233	7.3 (5.4, 9.9)	1.46 (1.04, 2.07)	51	8,739	5.8 (4.5, 7.6)	1.23 (0.94, 1.69)	207	41,718	5.0 (4.3, 5.7)	156	32,979	4.7 (4.1, 5.5)	245	46,951	5.2 (4.6, 5.9)
		BSAL	17	2,479	6.9 (4.4, 10.9)	1.37 (0.84, 2.25)	23	3,919	5.9 (4, 8.7)	1.20 (0.8, 1.85)	186	37,201	5.0 (4.3, 5.8)	163	33,282	4.9 (4.2, 5.7)	203	39,680	5.1 (4.5, 5.9)
		BSM																	


3.a.2, Invasive breast cancer detection

Description: The number of women with diagnosed invasive cancer per number of women screened.

Targets for 45–49 age group: Initial: ≥ 3.8 per 1,000 women screened. Subsequent: ≥ 2.4 per 1,000 women screened

Targets for 50–69 age group: Initial: ≥ 6.1 per 1,000 women screened. Subsequent: ≥ 3.45 per 1,000 women screened

Figure 71: 3.a.2.1, 50 to 69, Invasive breast cancer detection, initial and subsequent screens



Over the two-year period, BSA detected 2,235 invasive breast cancers among women aged 45–69 years, 322 from initial screens and 1,913 from subsequent screens. 349 invasive cancers were detected among women aged 45–49 years (191 from initial screens) and 1,886 among women aged 50–69 years (131 from initial screens).

Invasive breast cancer detection rates were within the target ranges for initial and subsequent screens for women in both age groups. For BSA overall, the invasive cancer detection rates for women aged 45–49 were 4.0 per 1,000 initial screens and 2.4 per 1,000 subsequent screens. For women aged 50–69 years the rates were 10.0 per 1,000 initial screens and 4.5 per 1,000 subsequent screens. Targets were met or within the confidence interval for all LPs.

Māori women aged 45–69 were more likely than non-Māori women to have an invasive breast cancer detected from an initial screen (71% higher rate) or subsequent screen (57% higher). Pacific women aged 45–69 were also more likely to have an invasive breast cancer detected from an initial (35% higher) or subsequent screen (26% higher).

Figure 72: 3.a.2.3, Initial, 50 to 69, Invasive breast cancer detection, by LP




Figure 73: 3.a.2.5, Subsequent, 50 to 69, Invasive breast cancer detection, by LP




Table 17: 3.a.2.1, Invasive breast cancer detection

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Māori / Non-Māori Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Pacific / Non-Pacific Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)
45 to 49	Initial	BSWN	6	1,218	4.93 (2.3, 10.6)	1.26 (0.52, 3.05)	1	392	2.55 (0.5, 14.3)	0.64 (0.09, 4.71)	27	6,917	3.90 (2.7, 5.6)	26	6,525	3.98 (2.7, 5.8)	33	8,135	4.06 (2.9, 5.7)
		BSCM	7	798	8.77 (4.5, 17.8)	2.10 (0.89, 4.95)	8	1,324	6.04 (3.2, 11.8)	1.74 (0.87, 4.26)	20	4,787	4.18 (2.7, 6.4)	12	3,463	3.47 (2, 6)	27	5,585	4.83 (3.4, 7)
		BSAL	4	438	9.13 (3.9, 22.9)	2.45 (0.83, 7.25)	4	506	7.91 (3.3, 19.9)	2.47 (0.93, 7.53)	17	4,561	3.73 (2.4, 5.9)	13	4,055	3.21 (1.9, 5.5)	21	4,999	4.20 (2.8, 6.4)
		BSM	6	1,627	3.69 (1.7, 8)	1.54 (0.59, 4)	1	156	6.41 (1.4, 35.2)	2.80 (0.4, 21.29)	14	5,839	2.40 (1.4, 4)	13	5,683	2.29 (1.3, 3.9)	20	7,466	2.68 (1.7, 4.1)
		BSCC	8	1,172	6.83 (3.6, 13.3)	1.68 (0.73, 3.86)	0	128	0.00 (0, 29.1)	NA (NA, NA)	18	4,432	4.06 (2.6, 6.4)	18	4,304	4.18 (2.7, 6.6)	26	5,604	4.64 (3.2, 6.8)
		BSC	7	532	13.16 (6.9, 26.4)	3.88 (1.56, 9.69)	1	264	3.79 (0.8, 21.1)	1.13 (0.16, 8.64)	13	3,837	3.39 (2, 5.8)	12	3,573	3.36 (2, 5.8)	20	4,369	4.58 (3, 7)
		BSSL	0	592	0.00 (0, 6.4)	NA (NA, NA)	2	155	12.90 (4.4, 45)	3.02 (0.76, 12.45)	36	8,107	4.44 (3.2, 6.1)	34	7,952	4.28 (3.1, 5.9)	36	8,699	4.14 (3, 5.7)
		BSOS	0	252	0.00 (0, 15)	NA (NA, NA)	1	38	26.32 (8.8, 130.8)	10.43 (1.51, 82.73)	8	2,813	2.84 (1.5, 5.6)	7	2,775	2.52 (1.2, 5.2)	8	3,065	2.61 (1.3, 5.1)
	Total	38	6,629	5.73 (4.2, 7.8)	1.55 (1.09, 2.2)	18	2,963	6.07 (3.9, 9.5)	1.72 (1.09, 2.82)	153	41,293	3.71 (3.2, 4.3)	135	38,330	3.52 (3, 4.2)	191	47,922	3.99 (3.5, 4.6)	
	Subsequent	BSWN	6	1,325	4.53 (2.1, 9.8)	1.73 (0.7, 4.27)	0	465	0.00 (0, 8.2)	NA (NA, NA)	22	8,427	2.61 (1.7, 3.9)	22	7,962	2.76 (1.8, 4.2)	28	9,752	2.87 (2, 4.1)
		BSCM	3	948	3.16 (1.1, 9.2)	1.93 (0.54, 6.9)	3	1,436	2.09 (0.7, 6.1)	1.38 (0.44, 5.18)	11	6,703	1.64 (0.9, 2.9)	8	5,267	1.52 (0.8, 3)	14	7,651	1.83 (1.1, 3.1)
		BSAL	1	431	2.32 (0.4, 13)	1.69 (0.21, 13.46)	1	608	1.64 (0.3, 9.2)	1.22 (0.17, 9.93)	8	5,817	1.38 (0.7, 2.7)	7	5,209	1.34 (0.7, 2.8)	9	6,248	1.44 (0.8, 2.7)
		BSM	4	1,719	2.33 (0.9, 5.9)	0.89 (0.31, 2.61)	0	152	0.00 (0, 24.6)	NA (NA, NA)	20	7,679	2.60 (1.7, 4)	20	7,527	2.66 (1.7, 4.1)	24	9,398	2.55 (1.7, 3.8)
		BSCC	3	1,331	2.25 (0.8, 6.6)	1.01 (0.29, 3.49)	1	121	8.26 (1.9, 44.9)	3.89 (0.55, 29.53)	14	6,246	2.24 (1.3, 3.7)	13	6,125	2.12 (1.3, 3.6)	17	7,577	2.24 (1.4, 3.6)
		BSC	4	745	5.37 (2.2, 13.6)	2.69 (0.87, 8.33)	2	345	5.80 (1.8, 20.7)	3.29 (0.83, 14.96)	12	6,022	1.99 (1.2, 3.5)	10	5,677	1.76 (1, 3.2)	16	6,767	2.36 (1.5, 3.8)
BSSL		5	961	5.20 (2.3, 12)	1.94 (0.76, 4.97)	0	164	0.00 (0, 22.9)	NA (NA, NA)	33	12,335	2.68 (1.9, 3.7)	33	12,171	2.71 (1.9, 3.8)	38	13,296	2.86 (2.1, 3.9)	
BSOS		1	386	2.59 (0.5, 14.5)	0.94 (0.12, 7.28)	0	62	0.00 (0, 58.3)	NA (NA, NA)	11	4,004	2.75 (1.6, 4.9)	11	3,942	2.79 (1.6, 5)	12	4,390	2.73 (1.6, 4.8)	
Total	27	7,846	3.44 (2.4, 5)	1.50 (0.99, 2.27)	7	3,353	2.09 (1, 4.3)	0.91 (0.43, 1.94)	131	57,233	2.29 (1.9, 2.7)	124	53,880	2.30 (1.9, 2.7)	158	65,079	2.43 (2.1, 2.8)		
50 to 69	Initial	BSWN	8	277	28.88 (17.3, 53.3)	2.83 (1.29, 6.24)	0	121	0.00 (0, 30.8)	NA (NA, NA)	24	2,354	10.20 (7, 14.9)	24	2,233	10.75 (7.4, 15.7)	32	2,631	12.16 (8.9, 16.9)
		BSCM	2	186	10.75 (3.5, 37.8)	1.03 (0.24, 4.46)	3	307	9.77 (3.8, 27.9)	0.92 (0.3, 3.23)	15	1,433	10.47 (6.6, 17)	12	1,126	10.66 (6.4, 18.2)	17	1,619	10.50 (6.8, 16.5)
		BSAL	0	109	0.00 (0, 34)	NA (NA, NA)	0	157	0.00 (0, 23.9)	NA (NA, NA)	9	1,506	5.98 (3.2, 11.2)	9	1,349	6.67 (3.6, 12.5)	9	1,615	5.57 (3, 10.5)
		BSM	11	539	20.41 (12.5, 35.1)	2.09 (0.99, 4.44)	0	49	0.00 (0, 72.7)	NA (NA, NA)	17	1,744	9.75 (6.3, 15.4)	17	1,695	10.03 (6.5, 15.8)	28	2,283	12.26 (8.8, 17.4)
		BSCC	7	361	19.39 (10.6, 38.3)	4.02 (1.36, 11.9)	0	43	0.00 (0, 82)	NA (NA, NA)	6	1,245	4.82 (2.3, 10.4)	6	1,202	4.99 (2.4, 10.8)	13	1,606	8.09 (4.9, 13.6)
		BSC	3	139	21.58 (9.5, 59.4)	1.76 (0.51, 6.06)	3	80	37.50 (19.3, 98.1)	3.63 (1.2, 12.74)	14	1,144	12.24 (7.7, 20.1)	11	1,064	10.34 (6.1, 18.1)	17	1,283	13.25 (8.7, 20.7)
		BSSL	0	107	0.00 (0, 34.7)	NA (NA, NA)	0	44	0.00 (0, 80.3)	NA (NA, NA)	6	1,350	4.44 (2.1, 9.6)	6	1,306	4.59 (2.2, 9.9)	6	1,457	4.12 (1.9, 8.9)
		BSOS	0	56	0.00 (0, 64.2)	NA (NA, NA)	0	19	0.00 (0, 168.2)	NA (NA, NA)	9	600	15.00 (8.6, 27.6)	9	581	15.49 (8.9, 28.5)	9	656	13.72 (7.8, 25.3)
		Total	31	1,774	17.47 (12.8, 24.2)	1.99 (1.33, 2.97)	6	820	7.32 (3.5, 15.7)	0.82 (0.37, 1.87)	100	11,376	8.79 (7.3, 10.6)	94	10,556	8.90 (7.4, 10.8)	131	13,150	9.76 (8.5, 11.7)
	Subsequent	BSWN	63	7,356	8.56 (6.8, 10.9)	2.07 (1.56, 2.74)	15	2,756	5.44 (3.4, 8.9)	1.34 (0.81, 2.26)	218	52,661	4.14 (3.6, 4.7)	203	49,905	4.07 (3.6, 4.7)	281	60,017	4.68 (4.2, 5.2)
		BSCM	26	4,275	6.08 (4.2, 8.8)	1.46 (0.96, 2.22)	39	7,273	5.36 (4, 7.3)	1.40 (1.02, 2.01)	145	34,860	4.16 (3.5, 4.9)	106	27,587	3.84 (3.2, 4.6)	171	39,135	4.37 (3.8, 5.1)
		BSAL	13	2,045	6.36 (3.8, 10.7)	1.76 (1, 3.13)	17	3,311	5.13 (3.3, 8.2)	1.50 (0.93, 2.51)	113	31,374	3.60 (3, 4.3)	96	28,063	3.42 (2.8, 4.2)	126	33,419	3.77 (3.2, 4.5)
		BSM	83	10,176	8.16 (6.7, 10)	1.91 (1.48, 2.45)	4	860	4.65 (1.9, 11.8)	1.09 (0.41, 2.92)	220	51,422	4.28 (3.8, 4.9)	216	50,562	4.27 (3.8, 4.9)	303	61,598	4.92 (4.4, 5.5)
		BSCC	43	7,734	5.56 (4.2, 7.4)	1.54 (1.1, 2.15)	4	680	5.88 (2.4, 14.9)	1.64 (0.62, 4.42)	156	43,102	3.62 (3.1, 4.2)	152	42,422	3.58 (3.1, 4.2)	199	50,836	3.91 (3.4, 4.5)
		BSC	15	3,994	3.76 (2.3, 6.2)	0.73 (0.43, 1.23)	13	2,142	6.07 (3.6, 10.3)	1.19 (0.69, 2.08)	189	36,602	5.16 (4.5, 5.9)	176	34,460	5.11 (4.4, 5.9)	204	40,596	5.03 (4.4, 5.7)
BSSL	32	4,275	7.49 (5.4, 10.5)	1.80 (1.25, 2.59)	4	727	5.50 (2.3, 13.9)	1.33 (0.5, 3.56)	287	69,107	4.15 (3.7, 4.7)	283	68,380	4.14 (3.7, 4.6)	319	73,382	4.35 (3.9, 4.8)		
BSOS	8	1,731	4.62 (2.4, 9)	0.82 (0.4, 1.67)	3	216	13.89 (5.6, 39.2)	2.50 (0.81, 7.8)	144	25,646	5.61 (4.8, 6.6)	141	25,430	5.54 (4.7, 6.5)	152	27,377	5.55 (4.8, 6.5)		
Total	283	41,586	6.81 (6.1, 7.6)	1.59 (1.4, 1.81)	99	17,965	5.51 (4.6, 6.7)	1.31 (1.08, 1.61)	1,472	344,774	4.27 (4.1, 4.5)	1,373	326,809	4.20 (4, 4.4)	1,755	386,360	4.54 (4.3, 4.8)		
45 to 69	Initial	BSWN	14	1,495	9.36 (5.8, 15.5)	1.70 (0.94, 3.07)	1	513	1.95 (0.4, 10.9)	0.34 (0.05, 2.47)	51	9,271	5.50 (4.2, 7.2)	50	8,758	5.71 (4.4, 7.5)	65	10,766	6.04 (4.8, 7.6)
		BSCM	9	984	9.15 (5.1, 17.1)	1.63 (0.78, 3.37)	11	1,631	6.74 (3.9, 11.9)	1.29 (0.72, 2.63)	35	6,220	5.63 (4.1, 7.8)	24	4,589	5.23 (3.6, 7.7)	44	7,204	6.11 (4.6, 8.1)
		BSAL	4	547	7.31 (3.1, 18.4)	1.71 (0.6, 4.87)	4	663	6.03 (2.5, 15.3)	1.48 (0.56, 4.29)	26	6,067	4.29 (3, 6.2)	22	5,404	4.07 (2.7, 6.1)	30	6,614	4.54 (3.2, 6.4)
		BSM	17	2,166	7.85 (5, 12.4)	1.92 (1.06, 3.46)	1	205	4.88 (1, 27)	1.20 (0.17, 8.75)	31	7,583	4.09 (2.9, 5.8)	30	7,378	4.07 (2.9, 5.8)	48	9,749	4.92 (3.7, 6.5)
		BSCC	15	1,533	9.78 (6.2, 15.9)	2.31 (1.22, 4.4)	0	171	0.00 (0, 22)	NA (NA, NA)	24	5,677	4.23 (2.9, 6.3)	24	5,506	4.36 (3, 6.4)	39	7,210	5.41 (4, 7.3)
		BSC	10	671	14.90 (8.7, 26.6)	2.75 (1.34, 5.65)	4	344	11.63 (5.1, 29)	2.34 (0.88, 6.74)	27	4,981	5.42 (3.8, 7.8)	23	4,637	4.96 (3.4, 7.4)	37	5,652	6.55 (4.8, 8.9)
		BSSL	0	699	0.00 (0, 5.5)	NA (NA, NA)	2	199	10.05 (3.3, 35.4)	2.33 (0.59, 9.56)	42	9,457	4.44 (3.3, 6)	40	9,258	4.32 (3.2, 5.9)	42	10,156	4.14 (3.1, 5.6)
		BSOS	0	308	0.00 (0, 12.3)	NA (NA, NA)	1	57	17.54 (5, 91)	3.68 (0.53, 27.28)	17	3,413	4.98 (3.2, 7.9)	16	3,356	4.77 (3, 7.7)	17	3,721	4.57 (2.9, 7.3)
		Total	69	8,403	8.21 (6.6, 10.3)	1.71 (1.31, 2.23)	24	3,783	6.34 (4.3, 9.4)	1.35 (0.91, 2.06)	253	52,669	4.80 (4.3, 5.4)	229	48,886	4.68 (4.1, 5.3)	322	61,072	5.27 (4.7, 5.9)
		Subsequent	BSWN	69	8,681	7.95 (6.4, 10)	2.02 (1.55, 2.64)	15	3,221	4.66 (2.9, 7.6)	1.20 (0.72, 2.02)	240	61,088	3.93 (3.5, 4.4)	225	57,867	3.89 (3.4, 4.4)	309	69,769
	BSCM		29	5,223	5.55 (3.9, 7.9)	1.48 (1, 2.2)	42	8,709	4.82 (3.6, 6.5)	1.39 (1.03, 1.98)	156	41,563	3.75 (3.2, 4.4)	114	32,854	3.47 (2.9, 4.2)	185	46,786	3.95 (3.4, 4.6)
	BSAL		14	2,476	5.65 (3.4, 9.4)	1.74 (1, 3.02)	18	3,919	4.59 (3, 7.2)	1.48 (0.94, 2.45)	121	37,191	3.25 (2.7, 3.9)	103	33,272	3.10 (2.6, 3.7)			

3.a.3, Summary of assessment outcomes

Description: See definitions for referral to assessment (2d); specificity (2l); positive prediction value(2f); detection rate of DCIS and invasive cancer (3a1).

Targets (50–69 only): Assessment: Initial: expected value <10%. Subsequent: expected value <5%; **Specificity >93%; Positive predictive value: >9%; Detection** no target.

Table 18: 3.a.3.1, Summary of assessment outcomes

		Māori				Pacific				Non-Māori				Non-Māori Non-Pacific				All				
		% of Women Screened Referred for Assessment	Estimated Specificity %	Positive Predictive Value %	Detection Rate per 1,000 Screens	% of Women Screened Referred for Assessment	Estimated Specificity	Positive Predictive Value	Detection Rate per 1,000 Screens	% of Women Screened Referred for Assessment	Estimated Specificity	Positive Predictive Value	Detection Rate per 1,000 Screens	% of Women Screened Referred for Assessment	Estimated Specificity	Positive Predictive Value	Detection Rate per 1,000 Screens	% of Women Screened Referred for Assessment	Estimated Specificity	Positive Predictive Value	Detection Rate per 1,000 Screens	
45 to 49	Initial	BSWN	10.5	89.5	6.3	6.6	7.9	92.1	3.2	2.6	8.3	91.7	7.0	5.8	8.3	91.7	7.2	6.0	8.6	91.4	6.8	5.9
		BSCM	7.4	92.6	15.3	11.3	7.7	92.3	10.8	8.3	8.1	91.9	7.0	5.6	8.2	91.8	5.6	4.6	8.0	92.0	8.1	6.4
		BSAL	10.7	89.3	8.5	9.1	8.1	91.9	12.2	9.9	8.5	91.5	8.0	6.8	8.6	91.4	7.5	6.4	8.7	91.3	8.0	7.0
		BSM	11.0	89.0	6.7	7.4	12.2	87.8	5.3	6.4	8.1	91.9	4.4	3.6	8.0	92.0	4.4	3.5	8.7	91.3	5.1	4.4
		BSCC	6.7	93.3	12.7	8.5	3.9	96.1	0.0	0.0	4.0	96.0	14.0	5.6	4.0	96.0	14.4	5.8	4.6	95.4	13.6	6.2
		BSC	8.3	91.7	15.9	13.2	6.1	93.9	18.8	11.4	6.6	93.4	8.7	5.7	6.6	93.4	8.1	5.3	6.8	93.2	9.8	6.6
		BSSL	8.4	91.6	6.0	5.1	5.8	94.2	22.2	12.9	8.7	91.3	6.9	6.0	8.8	91.2	6.7	5.9	8.7	91.3	6.9	6.0
		BSOS	15.9	84.1	2.5	4.0	15.8	84.2	16.7	26.3	14.6	85.4	3.6	5.3	14.6	85.4	3.5	5.0	14.7	85.3	3.5	5.2
	Total	9.4	90.6	8.6	8.1	7.7	92.3	10.5	8.1	8.2	91.8	6.8	5.6	8.2	91.8	6.6	5.4	8.3	91.7	7.1	5.9	
	Subsequent	BSWN	5.2	94.8	11.6	6.0	3.9	96.1	5.6	2.1	4.2	95.8	7.8	3.3	4.3	95.7	8.0	3.4	4.4	95.6	8.5	3.7
		BSCM	3.4	96.6	9.4	3.2	4.0	96.0	8.8	3.5	4.1	95.9	7.3	3.0	4.1	95.9	6.9	2.8	4.0	96.0	7.5	3.0
		BSAL	5.1	94.9	9.1	4.6	5.3	94.7	3.1	1.6	4.3	95.7	6.8	2.9	4.2	95.8	7.3	3.1	4.4	95.6	7.0	3.0
		BSM	4.8	95.2	8.5	4.0	3.9	96.1	0.0	0.0	4.7	95.3	6.6	3.1	4.8	95.2	6.7	3.2	4.7	95.3	7.0	3.3
		BSCC	2.5	97.5	18.2	4.5	2.5	97.5	33.3	8.2	2.4	97.6	12.1	2.9	2.4	97.6	11.6	2.8	2.4	97.6	13.2	3.2
		BSC	4.6	95.4	11.8	5.2	4.1	95.9	21.4	8.6	4.1	95.9	6.9	2.8	4.1	95.9	6.0	2.5	4.2	95.8	7.5	3.1
BSSL		6.1	93.9	10.2	6.1	3.6	96.4	0.0	0.0	4.7	95.3	9.0	4.2	4.7	95.3	9.1	4.3	4.8	95.2	9.1	4.4	
BSOS		6.5	93.5	4.0	2.6	8.1	91.9	0.0	0.0	7.0	93.0	5.7	4.0	6.9	93.1	5.8	4.1	6.9	93.1	5.6	3.9	
Total	4.5	95.5	10.4	4.6	4.2	95.8	7.8	3.3	4.4	95.6	7.7	3.3	4.4	95.6	7.7	3.4	4.4	95.6	8.0	3.5		
50 to 69	Initial	BSWN	14.4	85.6	22.5	32.5	9.9	90.1	0.0	0.0	10.0	90.0	10.6	10.6	10.0	90.0	11.2	11.2	10.5	89.5	12.4	12.9
		BSCM	11.3	88.7	9.5	10.8	9.8	90.2	23.3	22.8	9.9	90.1	14.8	14.7	9.9	90.1	12.5	12.4	10.1	89.9	14.1	14.2
		BSAL	8.3	91.7	11.1	9.2	8.9	91.1	7.1	6.4	9.4	90.6	7.8	7.3	9.4	90.6	7.9	7.4	9.3	90.7	8.0	7.4
		BSM	14.7	85.3	19.0	27.8	18.4	81.6	11.1	20.4	8.9	91.1	14.2	12.6	8.6	91.4	14.4	12.4	10.2	89.8	15.8	16.2
		BSCC	6.6	93.4	29.2	19.4	7.0	93.0	0.0	0.0	5.1	94.9	12.7	6.4	5.0	95.0	13.3	6.7	5.4	94.6	17.2	9.3
		BSC	15.8	84.2	13.6	21.6	6.3	93.8	60.0	37.5	7.3	92.7	18.1	13.1	7.3	92.7	15.4	11.3	8.2	91.8	17.1	14.0
		BSSL	10.3	89.7	0.0	0.0	13.6	86.4	0.0	0.0	9.2	90.8	12.9	11.9	9.0	91.0	13.6	12.3	9.3	90.7	11.9	11.0
		BSOS	10.7	89.3	0.0	0.0	15.8	84.2	0.0	0.0	17.7	82.3	8.5	15.0	17.7	82.3	8.7	15.5	17.1	82.9	8.0	13.7
	Total	12.0	88.0	17.5	20.9	10.0	90.0	14.6	14.6	9.2	90.8	12.1	11.2	9.2	90.8	11.9	10.9	9.6	90.4	13.0	12.5	
	Subsequent	BSWN	4.2	95.8	24.8	10.4	4.3	95.7	18.5	7.9	3.4	95.7	16.5	5.6	3.4	95.7	16.3	5.4	3.5	95.8	17.7	6.2
		BSCM	3.6	96.4	22.7	8.2	3.4	96.6	18.7	6.3	3.3	96.3	16.5	5.3	3.2	95.9	15.9	5.1	3.3	96.3	17.2	5.7
		BSAL	3.2	96.8	22.7	7.3	3.7	96.3	17.9	6.6	3.0	96.0	17.9	5.4	2.9	95.8	17.9	5.2	3.0	96.1	18.2	5.5
		BSM	4.2	95.8	23.6	9.5	3.1	96.9	25.9	8.1	3.4	95.4	16.8	5.6	3.4	95.2	16.6	5.6	3.5	95.7	18.1	6.3
		BSCC	2.1	97.9	34.9	7.5	1.8	98.2	33.3	5.9	1.7	97.7	29.6	4.9	1.7	97.6	29.5	4.9	1.7	97.8	30.6	5.3
		BSC	3.5	96.5	11.3	3.8	3.7	96.3	22.8	8.1	3.6	96.0	18.5	6.6	3.6	95.9	18.3	6.5	3.6	96.2	17.8	6.3
BSSL		4.0	96.0	20.2	8.0	3.0	97.0	27.3	7.9	3.3	95.4	16.9	5.6	3.3	95.3	16.8	5.6	3.4	95.5	17.1	5.8	
BSOS		4.8	95.2	10.7	5.1	6.0	94.0	23.1	13.6	4.4	93.1	16.2	7.2	4.4	93.1	16.1	7.1	4.5	93.7	15.8	7.1	
Total	3.6	96.4	22.7	8.1	3.6	96.4	20.0	7.1	3.2	95.8	17.8	5.7	3.2	95.6	17.7	5.6	3.3	96.0	18.4	6.0		


3.c.p, Detection of invasive breast cancer less than or equal to 15mm (percentage)

Description: The number with an invasive cancer of diameter $\leq 15\text{mm}$ as a percentage of the number with invasive cancer .

Targets for women aged 45–49 years: Initial: $>50\%$ of all invasive cancers detected will be $\leq 15\text{mm}$. Subsequent: $>50\%$ of all invasive cancers detected will be $\leq 15\text{mm}$.

Targets for women aged 50–69 years: Initial: $>50\%$ of all invasive cancers detected are $\leq 15\text{mm}$. Subsequent: $> 50\%$ of all invasive cancers detected are $\leq 15\text{mm}$.

Figure 74: 3.c.p.1, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), initial and subsequent screens



Of 2,158 invasive cancers detected by BSA among women aged 45–69 years, 1,338 (62%) were small ($\leq 15\text{mm}$ diameter). The percentage of small cancers was lower in initial screens (54%) than in subsequent screens (63%). These proportions were similar in the two age groups. The targets were met or within the confidence interval for all LPs. The proportions of invasive cancers that were small were lower for Pacific women aged 45–69 years, at 41% for initial (not statistically significant) and 49% for subsequent screens (significantly lower).

Figure 75: 3.c.p.3, Initial, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), by LP



Figure 76: 3.c.p.5, Subsequent, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (percentage), by LP




Table 19: 3.c.p.1, Detection of invasive breast cancer less than or equal to 15mm (percentage)

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
		Invasive Cancers ≤15Mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers ≤15Mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers ≤15Mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Invasive Cancers ≤15Mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Invasive Cancers ≤15Mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)		
45 to 49	Initial	BSWN	2	5	40.0 (11.8, 76.9)	0.80 (0.25, 2.53)	0	1	0.0 (0, 79.3)	NA (NA, NA)	11	22	50.0 (30.7, 69.3)	11	21	52.4 (32.4, 71.7)	13	27	48.1 (30.7, 66)	
		BSCM	3	7	42.9 (15.8, 75)	1.36 (0.46, 4)	3	8	37.5 (13.7, 69.4)	1.38 (0.56, 5.13)	6	19	31.6 (15.4, 54)	3	11	27.3 (9.7, 56.6)	9	26	34.6 (19.4, 53.8)	
		BSAL	3	4	75.0 (30.1, 95.4)	1.71 (0.78, 3.79)	1	4	25.0 (4.6, 69.9)	0.50 (0.09, 2.99)	7	16	43.8 (23.1, 66.8)	6	12	50.0 (25.4, 74.6)	10	20	50.0 (29.9, 70.1)	
		BSM	4	6	66.7 (30, 90.3)	0.80 (0.43, 1.49)	0	0	NA (NA, NA)	NA (NA, NA)	10	12	83.3 (55.2, 95.3)	10	12	83.3 (55.2, 95.3)	14	18	77.8 (54.8, 91)	
		BSCC	6	8	75.0 (40.9, 92.9)	1.71 (0.86, 3.4)	0	0	NA (NA, NA)	NA (NA, NA)	7	16	43.8 (23.1, 66.8)	7	16	43.8 (23.1, 66.8)	13	24	54.2 (35.1, 72.1)	
		BSC	2	7	28.6 (8.2, 64.1)	0.52 (0.14, 1.9)	1	1	100.0 (20.7, 100)	2.00 (2, 3.72)	6	11	54.5 (28, 78.7)	5	10	50.0 (23.7, 76.3)	8	18	44.4 (24.6, 66.3)	
		BSSL	0	0	NA (NA, NA)	NA (NA, NA)	1	2	50.0 (9.5, 90.5)	0.86 (0.22, 3.55)	19	33	57.6 (40.8, 72.8)	18	31	58.1 (40.8, 73.6)	19	33	57.6 (40.8, 72.8)	
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (20.7, 100)	1.40 (1.4, 2.24)	6	8	75.0 (40.9, 92.9)	5	7	71.4 (35.9, 91.8)	6	8	75.0 (40.9, 92.9)	
		Total	20	37	54.1 (38.4, 69)	1.03 (0.73, 1.44)	7	17	41.2 (21.6, 64)	0.76 (0.43, 1.37)	72	137	52.6 (44.2, 60.7)	65	120	54.2 (45.3, 62.8)	92	174	52.9 (45.5, 60.1)	
		Subsequent	BSWN	5	6	83.3 (43.6, 97)	1.02 (0.68, 1.53)	0	0	NA (NA, NA)	NA (NA, NA)	18	22	81.8 (61.5, 92.7)	18	22	81.8 (61.5, 92.7)	23	28	82.1 (64.4, 92.1)
	BSCM		1	3	33.3 (6.1, 79.2)	0.67 (0.12, 3.71)	1	3	33.3 (6.1, 79.2)	0.58 (0.12, 3.27)	5	10	50.0 (23.7, 76.3)	4	7	57.1 (25, 84.2)	6	13	46.2 (23.2, 70.9)	
	BSAL		0	1	0.0 (0, 79.3)	NA (NA, NA)	1	1	100.0 (20.7, 100)	1.75 (1.75, 3.32)	5	8	62.5 (30.6, 86.3)	4	7	57.1 (25, 84.2)	5	9	55.6 (26.7, 81.1)	
	BSM		1	3	33.3 (6.1, 79.2)	0.51 (0.1, 2.62)	0	0	NA (NA, NA)	NA (NA, NA)	13	20	65.0 (43.3, 81.9)	13	20	65.0 (43.3, 81.9)	14	23	60.9 (40.8, 77.8)	
	BSCC		1	2	50.0 (9.5, 90.5)	0.93 (0.21, 4.06)	0	1	0.0 (0, 79.3)	NA (NA, NA)	7	13	53.8 (29.1, 76.8)	7	12	58.3 (32, 80.7)	8	15	53.3 (31, 75.2)	
	BSC		2	4	50.0 (15, 85)	0.69 (0.24, 1.95)	1	2	50.0 (9.5, 90.5)	0.64 (0.16, 2.68)	8	11	72.7 (43.4, 90.3)	7	9	77.8 (45.3, 93.7)	10	15	66.7 (41.7, 84.8)	
	BSSL		4	5	80.0 (37.6, 96.4)	1.26 (0.75, 2.12)	0	0	NA (NA, NA)	NA (NA, NA)	19	30	63.3 (45.5, 78.1)	19	30	63.3 (45.5, 78.1)	23	35	65.7 (49.2, 79.2)	
	BSOS		0	1	0.0 (0, 79.3)	0.00 #NUM!	0	0	NA (NA, NA)	NA (NA, NA)	6	11	54.5 (28, 78.7)	6	11	54.5 (28, 78.7)	6	12	50.0 (25.4, 74.6)	
	Total		14	25	56.0 (37.1, 73.3)	0.86 (0.6, 1.25)	3	7	42.9 (15.8, 75)	0.65 (0.28, 1.54)	81	125	64.8 (56.1, 72.6)	78	118	66.1 (57.2, 74)	95	150	63.0 (50.3, 70.6)	
	50 to 69		Initial	BSWN	4	7	57.1 (25, 84.2)	0.91 (0.45, 1.86)	0	0	NA (NA, NA)	NA (NA, NA)	15	24	62.5 (42.7, 78.8)	15	24	62.5 (42.7, 78.8)	19	31
		BSCM		1	2	50.0 (9.5, 90.5)	1.75 (0.35, 8.79)	0	2	0.0 (0, 65.8)	0.00 #NUM!	4	14	28.6 (11.7, 54.6)	4	12	33.3 (13.8, 60.9)	5	16	31.3 (14.2, 55.6)
BSAL		0		0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	6	9	66.7 (35.4, 87.9)	6	9	66.7 (35.4, 87.9)	6	9	66.7 (35.4, 87.9)	
BSM		6		11	54.5 (28, 78.7)	1.16 (0.55, 2.43)	0	0	NA (NA, NA)	NA (NA, NA)	8	17	47.1 (26.2, 69)	8	17	47.1 (26.2, 69)	14	28	50.0 (32.6, 67.4)	
BSCC		3		7	42.9 (15.8, 75)	0.57 (0.2, 1.59)	0	0	NA (NA, NA)	NA (NA, NA)	3	4	75.0 (30.1, 95.4)	3	4	75.0 (30.1, 95.4)	6	11	54.5 (28, 78.7)	
BSC		3		3	100.0 (43.9, 100)	2.00 (1.18, 3.38)	2	3	66.7 (20.8, 93.9)	1.47 (0.66, 4.11)	7	14	50.0 (26.8, 73.2)	5	11	45.5 (21.3, 72)	10	17	58.8 (36, 78.4)	
BSSL		0		0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	5	6	83.3 (43.6, 97)	5	6	83.3 (43.6, 97)	5	6	83.3 (43.6, 97)	
BSOS		0		0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	5	8	62.5 (30.6, 86.3)	5	8	62.5 (30.6, 86.3)	5	8	62.5 (30.6, 86.3)	
Total		17		30	56.7 (39.2, 72.6)	1.03 (0.72, 1.47)	2	5	40.0 (11.8, 76.9)	0.71 (0.24, 2.12)	53	96	55.2 (45.3, 64.8)	51	91	56.0 (45.8, 65.8)	70	126	55.6 (46.8, 63.9)	
Subsequent		BSWN		39	59	66.1 (53.4, 76.9)	0.97 (0.79, 1.19)	5	15	33.3 (15.2, 58.3)	0.47 (0.23, 0.97)	147	215	68.4 (61.9, 74.2)	142	200	71.0 (64.4, 76.8)	186	274	67.9 (62.1, 73.1)
		BSCM	16	26	61.5 (42.5, 77.6)	1.11 (0.79, 1.56)	18	38	47.4 (32.5, 62.7)	0.81 (0.58, 1.18)	78	141	55.3 (47.1, 63.3)	60	103	58.3 (48.6, 67.3)	94	167	56.3 (48.7, 63.6)	
		BSAL	6	13	46.2 (23.2, 70.9)	0.66 (0.36, 1.2)	12	17	70.6 (46.9, 86.7)	1.01 (0.74, 1.41)	77	110	70.0 (60.9, 77.8)	65	93	69.9 (59.9, 78.3)	83	123	67.5 (58.8, 75.1)	
		BSM	52	82	63.4 (52.6, 73)	0.99 (0.82, 1.2)	1	3	33.3 (6.1, 79.2)	0.52 (0.1, 2.58)	138	216	63.9 (57.3, 70)	137	213	64.3 (57.7, 70.4)	190	298	63.8 (58.2, 69)	
		BSCC	25	41	61.0 (45.7, 74.3)	1.05 (0.79, 1.39)	1	3	33.3 (6.1, 79.2)	0.57 (0.11, 2.83)	89	153	58.2 (50.2, 65.7)	88	150	58.7 (50.7, 66.2)	114	194	58.8 (51.7, 65.5)	
		BSC	8	15	53.3 (30.1, 75.2)	0.92 (0.56, 1.5)	5	12	41.7 (19.3, 68)	0.71 (0.36, 1.4)	103	178	57.9 (50.5, 64.9)	98	166	59.0 (51.4, 66.2)	111	193	57.5 (50.5, 64.3)	
		BSSL	16	31	51.6 (34.8, 68)	0.77 (0.54, 1.09)	3	4	75.0 (30.1, 95.4)	1.11 (0.63, 1.97)	190	282	67.4 (61.7, 72.6)	187	278	67.3 (61.5, 72.5)	206	313	65.8 (60.4, 70.8)	
		BSOS	7	8	87.5 (52.9, 97.8)	1.34 (1.01, 1.79)	2	3	66.7 (20.8, 93.9)	1.02 (0.46, 2.3)	90	138	65.2 (57, 72.7)	88	135	65.2 (56.8, 72.7)	97	146	66.4 (58.4, 73.6)	
		Total	169	275	61.5 (55.6, 67)	0.97 (0.87, 1.07)	47	95	49.5 (39.6, 59.4)	0.77 (0.62, 0.94)	912	1,433	63.6 (61.1, 66.1)	865	1,338	64.6 (62, 67.2)	1,081	1,708	63.3 (61, 65.5)	
		45 to 69	Initial	BSWN	6	12	50.0 (25.4, 74.6)	0.76 (0.41, 1.39)	0	1	0.0 (0, 79.3)	NA (NA, NA)	29	44	65.9 (51.1, 78.1)	26	45	57.8 (43.3, 71)	32	58
BSCM				4	9	44.4 (18.9, 73.3)	1.17 (0.49, 2.79)	3	10	30.0 (10.8, 60.3)	0.99 (0.38, 3.05)	11	29	37.9 (22.7, 56)	7	23	30.4 (15.6, 50.9)	14	42	33.3 (21, 48.4)
BSAL	3			4	75.0 (30.1, 95.4)	1.50 (0.75, 3)	1	4	25.0 (4.6, 69.9)	0.44 (0.08, 2.49)	12	24	50.0 (31.4, 68.6)	12	21	57.1 (36.5, 75.5)	16	29	55.2 (37.5, 71.6)	
BSM	10			17	58.8 (36, 78.4)	0.82 (0.52, 1.29)	0	0	NA (NA, NA)	NA (NA, NA)	23	32	71.9 (54.6, 84.4)	18	29	62.1 (44, 77.3)	28	46	60.9 (46.5, 73.6)	
BSCC	9			15	60.0 (35.7, 80.2)	1.24 (0.71, 2.17)	0	0	NA (NA, NA)	NA (NA, NA)	14	29	48.3 (31.4, 65.6)	10	20	50.0 (29.9, 70.1)	19	35	54.3 (38.2, 69.5)	
BSC	5			10	50.0 (23.7, 76.3)	0.79 (0.39, 1.58)	3	4	75.0 (30.1, 95.4)	1.58 (0.89, 3.24)	14	22	63.6 (43, 80.3)	10	21	47.6 (28.3, 67.6)	18	35	51.4 (35.6, 67)	
BSSL	0			0	NA (NA, NA)	NA (NA, NA)	1	2	50.0 (9.5, 90.5)	0.80 (0.2, 3.29)	38	63	60.3 (48, 71.5)	23	37	62.2 (46.1, 75.9)	24	39	61.5 (45.9, 75.1)	
BSOS	0			0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (20.7, 100)	1.50 (1.5, 2.15)	12	19	63.2 (41, 80.9)	10	15	66.7 (41.7, 84.8)	11	16	68.8 (44.4, 85.8)	
Total	37			67	55.2 (43.4, 66.5)	0.95 (0.74, 1.2)	9	22	40.9 (23.3, 61.3)	0.74 (0.45, 1.25)	153	262	58.4 (52.3, 64.2)	116	211	55.0 (48.2, 61.5)	162	300	54.0 (48.3, 59.6)	
Subsequent	BSWN			44	65	67.7 (55.6, 77.8)	0.97 (0.81, 1.17)	5	15	33.3 (15.2, 58.3)	0.46 (0.23, 0.95)	165	237	69.6 (63.5, 75.1)	160	222	72.1 (65.8, 77.6)	209	302	69.2 (63.8, 74.1)
	BSCM		17	29	58.6 (40.7, 74.5)	1.07 (0.76, 1.5)	19	41	46.3 (32.1, 61.3)	0.80 (0.57, 1.15)	83	151	55.0 (47, 62.7)	64	110	58.2 (48.8, 67)	100	180	55.6 (48.3, 62.6)	
	BSAL		6	14	42.9 (21.4, 67.4)	0.62 (0.33, 1.14)	13	18	72.2 (49.1, 87.5)	1.05 (0.79, 1.43)	82	118	69.5 (60.7, 77.1)	69	100	69.0 (59.4, 77.2)	88	132	66.7 (58.3, 74.1)	
	BSM		53	85	62.4 (51.7, 71.9)	0.97 (0.81, 1.18)	1	3	33.3 (6.1, 79.2)	0.52 (0.1, 2.57)	151	236	64.0 (57.7, 69.8)	150	233	64.4 (58, 70.2)	204	321	63.6 (58.2, 68.6)	
	BSCC		26	43	60.5 (45.6, 73.6)	1.05 (0.79, 1.38)	1	4	25.0 (4.6, 69.9)	0.43 (0.08, 2.34)	96	166	57.8 (50.2, 65.1)	95	162	58.6 (50.9, 65.9)	122	209	58.4 (51.6, 64.8)	
	BSC		10	19	52.6 (31.7, 72.7)	0.90 (0.58, 1.4)	6	14	42.9 (21.4, 67.4)	0.71 (0.39, 1.32)	111	189	58.7 (51.6,							


3.c.r, Detection of invasive breast cancer less than or equal to 15mm (rate)

Description: The number with an invasive cancer of diameter $\leq 15\text{mm}$ as a rate per 10,000 women screened.

Targets for women aged 45 to 49 years: Initial: The rate of small invasive cancers ($\leq 15\text{mm}$) detected will be greater than or equal to 19.0 per 10,000 women screened. Subsequent: The rate of small invasive cancers ($\leq 15\text{mm}$) detected will be greater than or equal to 12.0 per 10,000 women screened.

Targets for women aged 50 to 69 years: Initial: The rate of small invasive cancers ($\leq 15\text{mm}$) detected will be greater than or equal to 30.5 per 10,000 women screened. Subsequent: The rate of small invasive cancers ($\leq 15\text{mm}$) detected will be greater than or equal to 17.3 per 10,000 women screened.

Figure 77: 3.c.r.1, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate per 10,000), initial and subsequent screens



Among women aged 45–49 years, the rate of small cancers per 10,000 women screened was on target for initial screens overall (19.3), higher for Māori women (30.6) than for other women (17.0), with Pacific women at 24.0. The target was also met for subsequent screens overall at 14.6 per 10,000, 17.9 for Māori, 9.0 for Pacific women.

Among women aged 50–69 years, the target for initial screens was exceeded at a rate of 53.6 per 10,000 overall, twice as high for Māori (98.0) than non-Māori (46.8), and about half as high for Pacific women (24.7). For subsequent screens the rate of small cancers was also in the target range at 28.1 per 10,000 overall, also higher in Māori women (41.1), but similar in Pacific (26.3) and other women (26.5). All LPs met all targets.

Figure 78: 3.c.r.3, Initial, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate), by LP




Figure 79: 3.c.r.5, Subsequent, 50 to 69, Detection of invasive breast cancer less than or equal to 15mm (rate), by LP



Table 20: 3.c.r.1, Detection of invasive breast cancer less than or equal to 15mm (rate)


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
			Invasive Cancers ≤15Mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers ≤15Mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers ≤15Mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Invasive Cancers ≤15Mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Invasive Cancers ≤15Mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	
			45 to 49	Initial	BSWN	2	1,207	16.6 (6.13, 58.63)	1.04 (0.23, 4.66)	0	390	0.0 (0, 97.5)	NA (NA, NA)	11	6,871	16.0 (9.7, 27.9)	11	6,481	17.0 (10.3, 29.5)	13
BSCM	3	796	37.7 (20.3, 102.74)		2.98 (0.75, 11.9)	3	1,313	22.8 (10.4, 64.3)	2.62 (0.84, 12.95)	6	4,748	12.6 (6.4, 26.9)	3	3,435	8.7 (3.3, 25.3)	9	5,544	16.2 (9.4, 30)		
		BSAL	3	436	68.8 (50.51, 173.24)	4.47 (1.16, 17.24)	1	506	19.8 (6.2, 108.3)	1.33 (0.19, 11.05)	7	4,552	15.4 (8.3, 30.9)	6	4,046	14.8 (7.6, 31.5)	10	4,988	20.0 (12.1, 35.6)	
		B5M	4	1,565	25.6 (12.95, 62.53)	1.48 (0.46, 4.71)	0	153	0.0 (0, 244.9)	NA (NA, NA)	10	5,784	17.3 (10.3, 30.9)	10	5,631	17.8 (10.6, 31.7)	14	7,349	19.1 (12.3, 31)	
		B5CC	6	1,169	51.3 (34.61, 100.46)	3.24 (1.09, 9.63)	0	128	0.0 (0, 291.4)	NA (NA, NA)	7	4,422	15.8 (8.6, 31.7)	7	4,294	16.3 (8.8, 32.7)	13	5,591	23.3 (15.1, 38.3)	
		B5C	2	497	40.2 (20.83, 135.74)	2.56 (0.52, 12.63)	1	241	41.5 (19.8, 218.8)	2.96 (0.42, 25.27)	6	3,812	15.7 (8.2, 33.4)	5	3,571	14.0 (6.8, 31.9)	8	4,309	18.6 (10.6, 35.4)	
		B5SL	0	565	0.0 (0, 67.53)	NA (NA, NA)	1	150	66.7 (44.9, 334.8)	2.94 (0.42, 21.87)	19	8,085	23.5 (16.3, 35.4)	18	7,935	22.7 (15.6, 34.6)	19	8,650	22.0 (15.2, 33.2)	
		B5OS	0	240	0.0 (0, 157.54)	NA (NA, NA)	1	37	270.3 (NA, NA)	14.95 (2.16, 124.86)	6	2,803	21.4 (11.6, 44.9)	5	2,766	18.1 (9.1, 40.9)	6	3,043	19.7 (10.5, 41.5)	
		Total	20	6,475	30.9 (22.2, 45.47)	1.76 (1.07, 2.89)	7	2,918	24.0 (13.7, 47.3)	1.41 (0.67, 3.07)	72	41,077	17.5 (14.3, 21.7)	65	38,159	17.0 (13.7, 21.3)	92	47,552	19.3 (16.2, 23.3)	
	Subsequent	BSWN	5	1,321	37.9 (22.4, 82.08)	1.77 (0.66, 4.76)	0	465	0.0 (0, 81.9)	NA (NA, NA)	18	8,420	21.4 (14.6, 32.7)	18	7,955	22.6 (15.5, 34.5)	23	9,741	23.6 (16.9, 34.2)	
		BSCM	1	947	10.6 (2.64, 58.79)	1.41 (0.17, 12.09)	1	1,434	7.0 (1.6, 39.1)	0.92 (0.13, 8.2)	5	6,696	7.5 (3.4, 17.2)	4	5,262	7.6 (3.2, 19.3)	6	7,643	7.9 (3.8, 16.9)	
		BSAL	0	430	0.0 (0, 88.55)	NA (NA, NA)	1	608	16.4 (4.8, 90.7)	2.14 (0.3, 19.12)	5	5,814	8.6 (4, 19.8)	4	5,206	7.7 (3.2, 19.5)	5	6,244	8.0 (3.7, 18.5)	
		B5M	1	1,711	5.8 (1.27, 32.79)	0.34 (0.05, 2.63)	0	152	0.0 (0, 246.5)	NA (NA, NA)	13	7,672	16.9 (10.7, 28.2)	13	7,520	17.3 (10.9, 28.7)	14	9,383	14.9 (9.5, 24.5)	
		B5CC	1	1,329	7.5 (1.72, 42.1)	0.67 (0.08, 5.45)	0	121	0.0 (0, 307.7)	NA (NA, NA)	7	6,244	11.2 (5.9, 22.7)	7	6,123	11.4 (6, 23.1)	8	7,573	10.6 (5.7, 20.5)	
		B5C	2	743	26.9 (11.66, 93.34)	2.02 (0.43, 9.52)	1	344	29.1 (11.2, 156.8)	2.36 (0.33, 19.1)	8	6,018	13.3 (7.3, 25.6)	7	5,674	12.3 (6.5, 24.9)	10	6,761	14.8 (8.7, 26.5)	
		B5SL	4	958	41.8 (24.59, 98.52)	2.71 (0.92, 7.95)	0	164	0.0 (0, 228.9)	NA (NA, NA)	19	12,329	15.4 (10.4, 23.5)	19	12,165	15.6 (10.6, 23.8)	23	13,287	17.3 (12.2, 25.3)	
		B5OS	0	386	0.0 (0, 98.54)	NA (NA, NA)	0	62	0.0 (0, 583.4)	NA (NA, NA)	6	4,001	15.0 (7.7, 31.8)	6	3,939	15.2 (7.9, 32.3)	6	4,387	13.7 (7, 29.1)	
			Total	14	7,825	17.9 (11.5, 29.17)	1.26 (0.72, 2.23)	3	3,350	9.0 (3.4, 25.9)	0.62 (0.2, 1.96)	81	57,194	14.2 (11.6, 17.4)	78	53,844	14.5 (11.8, 17.8)	95	65,019	14.6 (12.2, 17.6)
50 to 69		Initial	BSWN	4	275	145.5 (56.71, 367.96)	2.27 (0.76, 6.79)	0	121	0.0 (0, 307.7)	NA (NA, NA)	15	2,339	64.1 (51.2, 93.3)	15	2,218	67.6 (54.9, 97.4)	19	2,614	72.7 (61.3, 98.5)
	BSCM		1	184	54.3 (31.29, 279.69)	1.94 (0.22, 17.24)	0	304	0.0 (0, 124.8)	NA (NA, NA)	4	1,426	28.1 (14.6, 68.3)	4	1,122	35.7 (19.9, 85.3)	5	1,610	31.1 (17.4, 68.4)	
	BSAL		0	108	0.0 (0, 343.47)	NA (NA, NA)	0	157	0.0 (0, 238.8)	NA (NA, NA)	6	1,505	39.9 (24.7, 80.3)	6	1,348	44.5 (28.6, 88.6)	6	1,613	37.2 (22.6, 75.3)	
	B5M		6	524	114.5 (138.91, 161.21)	2.48 (0.86, 7.11)	0	48	0.0 (0, 741)	NA (NA, NA)	8	1,731	46.2 (31.3, 83.1)	8	1,683	47.5 (32.4, 85.2)	14	2,255	62.1 (48.8, 92.2)	
	B5CC		3	355	84.5 (71.92, 202.33)	3.49 (0.71, 17.2)	0	44	0.0 (0, 803)	NA (NA, NA)	3	1,238	24.2 (11.2, 68)	3	1,194	25.1 (11.8, 70.4)	6	1,593	37.7 (23, 76.2)	
	B5C		3	131	229.0 (78.18, 651.67)	3.72 (0.97, 14.21)	2	74	270.3 (NA, NA)	5.75 (1.46, 29.12)	7	1,137	61.6 (45.4, 111)	5	1,063	47.0 (30, 99.8)	10	1,268	78.9 (66.7, 120.7)	
	B5SL		0	104	0.0 (0, 356.21)	NA (NA, NA)	0	44	0.0 (0, 803)	NA (NA, NA)	5	1,347	37.1 (21.8, 80.6)	5	1,303	38.4 (22.8, 83.1)	5	1,451	34.5 (19.8, 75.3)	
	B5OS		0	53	0.0 (0, 675.82)	NA (NA, NA)	0	18	0.0 (0, 1758.8)	NA (NA, NA)	5	595	84.0 (72.2, 159)	5	577	86.7 (76.1, 162.2)	5	648	77.2 (62.6, 149.8)	
			Total	17	1,734	98.0 (96.05, 121.7)	2.09 (1.22, 3.61)	2	810	24.7 (10.4, 86)	0.51 (0.13, 2.09)	53	11,318	46.8 (39.2, 57.9)	51	10,508	48.5 (40.6, 60.1)	70	13,052	53.6 (46.4, 63.8)
	Subsequent		BSWN	39	7,311	53.3 (44.21, 67.67)	1.90 (1.34, 2.71)	5	2,738	18.3 (9.2, 41.3)	0.64 (0.27, 1.56)	147	52,436	28.0 (24.5, 32.3)	142	49,698	28.6 (25, 32.9)	186	59,747	31.1 (27.7, 35.2)
		BSCM	16	4,256	37.6 (26.85, 57.29)	1.67 (0.98, 2.86)	18	7,256	24.8 (17.2, 37.7)	1.13 (0.72, 1.92)	78	34,695	25.5 (18.6, 27.5)	60	27,439	21.9 (17.6, 27.5)	94	38,951	24.1 (20.3, 28.9)	
		BSAL	6	2,037	29.5 (16.93, 60.7)	1.20 (0.52, 2.75)	12	3,310	36.3 (24.7, 59.4)	1.56 (0.89, 2.89)	77	31,349	24.6 (20.4, 30.2)	65	28,039	23.2 (18.9, 28.8)	83	33,386	24.9 (20.8, 30.1)	
		B5M	52	9,973	52.1 (44.06, 64.03)	1.93 (1.41, 2.66)	1	856	11.7 (3, 64.9)	0.43 (0.06, 3.06)	138	51,179	27.0 (23.5, 31.2)	137	50,323	27.2 (23.7, 31.5)	190	61,152	31.1 (27.7, 35.1)	
		B5CC	25	7,715	32.4 (24.15, 45.61)	1.57 (1.01, 2.44)	1	679	14.7 (4.1, 81.4)	0.71 (0.1, 5.08)	89	43,022	20.7 (17.3, 25)	88	42,343	20.8 (17.3, 25.1)	114	50,737	22.5 (19.2, 26.8)	
		B5C	8	3,898	20.5 (11.84, 39.01)	0.73 (0.35, 1.49)	5	2,084	24.0 (12.7, 53.6)	0.84 (0.35, 2.06)	103	36,460	28.3 (24.1, 33.4)	98	34,376	28.5 (24.3, 33.9)	111	40,358	27.5 (23.6, 32.4)	
		B5SL	16	4,208	38.0 (27.2, 57.9)	1.38 (0.83, 2.3)	3	720	41.7 (23.4, 112.6)	1.52 (0.49, 4.75)	190	69,029	27.5 (24.5, 31.1)	187	68,309	27.4 (24.3, 31)	206	73,237	28.1 (25.1, 31.7)	
		B5OS	7	1,717	40.8 (26.1, 77.58)	1.16 (0.54, 2.5)	2	211	94.8 (88.4, 276.6)	2.73 (0.69, 11.03)	90	25,599	35.2 (30, 41.8)	88	25,388	34.7 (29.5, 41.3)	97	27,316	35.5 (30.5, 41.9)	
			Total	169	41,115	41.1 (36.79, 46.35)	1.55 (1.32, 1.83)	47	17,854	26.3 (20.8, 33.9)	0.99 (0.75, 1.33)	912	343,769	26.5 (25.1, 28.1)	865	325,915	26.5 (25.1, 28.1)	1,081	384,884	28.1 (26.7, 29.6)
45 to 69		Initial	BSWN	6	1,482	40.5 (25.23, 81.39)	1.43 (0.59, 3.48)	0	511	0.0 (0, 74.6)	NA (NA, NA)	26	9,210	28.2 (20.9, 39.7)	26	8,699	29.9 (22.2, 41.9)	32	10,692	29.9 (22.9, 40.6)
	BSCM		4	980	40.8 (23.84, 96.52)	2.52 (0.79, 8.02)	3	1,617	18.6 (8, 52.7)	1.21 (0.39, 4.67)	10	6,174	16.2 (9.6, 29)	7	4,557	15.4 (8.3, 30.8)	14	7,154	19.6 (12.7, 31.8)	
	BSAL		3	544	55.1 (35.49, 144.15)	2.57 (0.73, 8.99)	1	663	15.1 (4.3, 83.3)	0.68 (0.1, 5.21)	13	6,057	21.5 (13.8, 35.4)	12	5,394	22.2 (14.1, 37.4)	16	6,601	24.2 (16.4, 37.9)	
	B5M		10	2,089	47.9 (33.69, 80.23)	2.00 (0.92, 4.32)	0	201	0.0 (0, 187.5)	NA (NA, NA)	18	7,515	24.0 (16.5, 36.5)	18	7,314	24.6 (17, 37.4)	28	9,604	29.2 (21.8, 40.4)	
	B5CC		9	1,524	59.1 (43.83, 99.13)	3.34 (1.36, 8.21)	0	172	0.0 (0, 218.5)	NA (NA, NA)	10	5,660	17.7 (10.6, 31.5)	10	5,488	18.2 (10.9, 32.5)	19	7,184	26.4 (18.6, 39.6)	
	B5C		5	628	79.6 (65.89, 153.18)	3.03 (1.08, 8.47)	3	315	95.2 (89.8, 218.9)	4.41 (1.43, 15.96)	13	4,949	26.3 (17.3, 43)	10	4,634	21.6 (13.2, 38.2)	18	5,577	32.3 (23, 48.4)	
	B5SL		0	669	0.0 (0, 57.09)	NA (NA, NA)	1	194	51.5 (28.5, 266.7)	2.07 (0.29, 15.25)	24	9,432	25.4 (18.5, 36.5)	23	9,238	24.9 (17.9, 36)	24	10,101	23.8 (17.1, 34.2)	
	B5OS		0	293	0.0 (0, 129.41)	NA (NA, NA)	1	55	181.8 (370.8, 622)	6.08 (0.87, 46.67)	11	3,398	32.4 (21.3, 54.7)	10	3,343	29.9 (19.1, 52.1)	11	3,691	29.8 (19.3, 50.6)	
			Total	37	20,909	45.1 (36.38, 58.4)	1.89 (1.31, 2.72)	9	3,728	24.1 (14.6, 43.9)	1.01 (0.53, 1.99)	125	52,395	23.9 (20.6, 27.9)	116	48,667	23.8 (20.4, 28)	162	60,604	26.7 (23.5, 30.6)
	Subsequent		BSWN	44	8,632	51.0 (42.4, 63.95)	1.88 (1.35, 2.62)	5	3,203	15.6 (7.7, 35.5)	0.56 (0.23, 1.37)	165	60,856	27.1 (23.						

3.d, Nodal involvement

Description: The inverse of the proportion of women with invasive screened detected breast cancer who do have nodal involvement. Positive sentinel nodes are included in the node positive group. Nodes identified with only isolated tumour cell (ITC) are not included.

Targets: Initial: >70%. Subsequent: >75% (50–69 years only)

Figure 80: 3.d.1, 50 to 69, Nodal involvement



Among 2,236 women aged 45–69 years with invasive cancer detected by BSA, 1,754 (78%) had no nodal involvement. Of 322 women with cancer detected at their first screen 223 (69.3%) had no nodal involvement. Of 1,914 women with cancer detected at a subsequent screen, 1,513 (80%) had no nodal involvement.

Among women aged 45–49 years, the proportions of invasive cancers without nodal involvement were 68% of those detected at an initial screen and 75% of those detected at a subsequent screen. Among Māori women these proportions were 71% and 63% respectively, and 67% and 71% respectively for Pacific women.

For women aged 50–69 years, the percentages were 72% (initial screens) and 80% (subsequent screens) with no significant differences between groups. The targets were met or were within the confidence interval for all LPs.

Figure 81: 3.d.3, Initial, 50 to 69, Nodal involvement, by LP



Figure 82: 3.d.3, Subsequent, 50 to 69, Nodal involvement, by LP



Table 21: 3.d.1, Nodal involvement

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
			Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Māori / Non-Māori Ratio	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	
45 to 49	Initial	BSWN	4	6	66.7 (30, 90.3)	1.13 (0.59, 2.15)	0	1	- (0, 79.3)	NA (NA, NA)	16	27	59.3 (40.7, 75.5)	16	26	61.5 (42.5, 77.6)	20	33	60.6 (43.7, 75.3)	
		BSCM	4	7	57.1 (25, 84.2)	0.71 (0.36, 1.41)	6	8	75.0 (40.9, 92.9)	0.90 (0.6, 1.44)	16	20	80.0 (58.4, 91.9)	16	12	83.3 (55.2, 95.3)	20	27	74.1 (55.3, 86.8)	
		BSAL	3	4	75.0 (30.1, 95.4)	1.42 (0.69, 2.92)	3	4	75.0 (30.1, 95.4)	1.63 (0.92, 3.67)	9	17	52.9 (31, 73.8)	6	13	46.2 (23.2, 70.9)	12	21	57.1 (36.5, 75.5)	
		BSM	4	6	66.7 (30, 90.3)	1.17 (0.56, 2.41)	1	1	100.0 (20.7, 100)	1.86 (1.86, 3.07)	8	14	57.1 (32.6, 78.6)	7	13	53.8 (29.1, 76.8)	12	20	60.0 (38.7, 78.1)	
		BSCC	6	8	75.0 (40.9, 92.9)	1.23 (0.71, 2.11)	0	0	NA (NA, NA)	NA (NA, NA)	11	18	61.1 (38.6, 79.7)	11	18	61.1 (38.6, 79.7)	17	26	65.4 (46.2, 80.6)	
		BSC	6	7	85.7 (48.7, 97.4)	1.01 (0.69, 1.48)	1	1	100.0 (20.7, 100)	1.20 (1.2, 1.55)	11	13	84.6 (57.8, 95.7)	10	12	83.3 (55.2, 95.3)	17	20	85.0 (64, 94.8)	
		BSSL	0	0	NA (NA, NA)	NA (NA, NA)	0	2	- (0, 65.8)	NA (NA, NA)	23	36	63.9 (47.6, 77.5)	23	34	67.6 (50.8, 80.9)	23	36	63.9 (47.6, 77.5)	
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (20.7, 100)	1.00 (1, 1)	8	8	100.0 (67.6, 100)	7	7	100.0 (64.6, 100)	8	8	100.0 (67.6, 100)	
		Total	27	38	71.1 (55.2, 83)	1.07 (0.85, 1.34)	12	18	66.7 (43.7, 83.7)	1.00 (0.72, 1.42)	102	153	66.7 (58.9, 73.6)	90	135	66.7 (58.4, 74.1)	129	191	67.5 (60.6, 73.8)	
		Subsequent	BSWN	5	6	83.3 (43.6, 97)	1.22 (0.77, 1.93)	0	0	NA (NA, NA)	NA (NA, NA)	15	22	68.2 (47.3, 83.6)	15	22	68.2 (47.3, 83.6)	20	28	71.4 (52.9, 84.7)
	BSCM		1	3	33.3 (6.1, 79.2)	0.52 (0.1, 2.76)	1	3	33.3 (6.1, 79.2)	0.44 (0.09, 2.31)	7	11	63.6 (35.4, 84.8)	6	8	75.0 (40.9, 92.9)	8	14	57.1 (32.6, 78.6)	
	BSAL		0	1	- (0, 79.3)	NA (NA, NA)	1	1	100.0 (20.7, 100)	1.40 (1.4, 2.24)	6	8	75.0 (40.9, 92.9)	5	7	71.4 (35.9, 91.8)	6	9	66.7 (35.4, 87.9)	
	BSM		3	4	75.0 (30.1, 95.4)	0.88 (0.49, 1.6)	0	0	NA (NA, NA)	NA (NA, NA)	17	20	85.0 (64, 94.8)	17	20	85.0 (64, 94.8)	20	24	83.3 (64.1, 93.3)	
	BSCC		0	3	- (0, 56.1)	NA (NA, NA)	1	1	100.0 (20.7, 100)	1.30 (1.3, 1.75)	11	14	78.6 (52.4, 92.4)	10	13	76.9 (49.7, 91.8)	11	17	64.7 (41.3, 82.7)	
	BSC		2	4	50.0 (15, 85)	0.60 (0.22, 1.65)	2	2	100.0 (34.2, 100)	1.25 (1.25, 1.7)	10	12	83.3 (55.2, 95.3)	8	10	80.0 (49, 94.3)	12	16	75.0 (50.5, 89.8)	
	BSSL		5	5	100.0 (56.6, 100)	1.27 (1.06, 1.52)	0	0	NA (NA, NA)	NA (NA, NA)	26	33	78.8 (62.2, 89.3)	26	33	78.8 (62.2, 89.3)	31	38	81.6 (66.6, 90.8)	
	BSOS		1	1	100.0 (20.7, 100)	1.10 (0.91, 1.33)	0	0	NA (NA, NA)	NA (NA, NA)	10	11	90.9 (62.3, 98.4)	10	11	90.9 (62.3, 98.4)	11	12	91.7 (64.6, 98.5)	
	Total		17	27	63.0 (44.2, 78.5)	0.81 (0.6, 1.1)	5	7	71.4 (35.9, 91.8)	0.91 (0.57, 1.47)	102	131	77.9 (70, 84.1)	97	124	78.2 (70.2, 84.6)	119	158	75.3 (68, 81.4)	
	50 to 69		Initial	BSWN	6	8	75.0 (40.9, 92.9)	0.95 (0.6, 1.49)	0	0	NA (NA, NA)	NA (NA, NA)	19	24	79.2 (59.5, 90.8)	19	24	79.2 (59.5, 90.8)	25	32
		BSCM		2	2	100.0 (34.2, 100)	1.88 (1.17, 3.01)	2	3	66.7 (20.8, 93.9)	1.33 (0.6, 3.55)	8	15	53.3 (30.1, 75.2)	6	12	50.0 (25.4, 74.6)	10	17	58.8 (36, 78.4)
BSAL		0		0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	6	9	66.7 (35.4, 87.9)	6	9	66.7 (35.4, 87.9)	5	9	55.6 (26.7, 81.1)	
BSM		7		11	63.6 (35.4, 84.8)	0.98 (0.56, 1.74)	0	0	NA (NA, NA)	NA (NA, NA)	11	17	64.7 (41.3, 82.7)	11	17	64.7 (41.3, 82.7)	18	28	64.3 (45.8, 79.3)	
BSCC		5		7	71.4 (35.9, 91.8)	1.07 (0.51, 2.23)	0	0	NA (NA, NA)	NA (NA, NA)	4	6	66.7 (30, 90.3)	4	6	66.7 (30, 90.3)	9	13	69.2 (42.4, 87.3)	
BSC		3		3	100.0 (43.9, 100)	1.17 (0.94, 1.44)	2	3	66.7 (20.8, 93.9)	0.73 (0.33, 1.67)	12	14	85.7 (60.1, 96)	10	11	90.9 (62.3, 98.4)	15	17	88.2 (65.7, 96.7)	
BSSL		0		0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	6	6	100.0 (61, 100)	6	6	100.0 (61, 100)	6	6	100.0 (61, 100)	
BSOS		0		0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	6	9	66.7 (35.4, 87.9)	6	9	66.7 (35.4, 87.9)	6	9	66.7 (35.4, 87.9)	
Total		22		31	71.0 (53.4, 83.9)	0.99 (0.76, 1.27)	4	6	66.7 (30, 90.3)	0.92 (0.52, 1.65)	72	100	72.0 (62.5, 79.9)	68	94	72.3 (62.6, 80.4)	94	131	71.8 (63.5, 78.8)	
Subsequent		BSWN		52	63	82.5 (71.4, 90)	0.99 (0.87, 1.12)	11	15	73.3 (48, 89.1)	0.87 (0.64, 1.19)	182	218	83.5 (78, 87.8)	171	203	84.2 (78.6, 88.6)	234	281	83.3 (78.5, 87.2)
		BSCM	23	26	88.5 (71, 96)	1.10 (0.93, 1.29)	31	39	79.5 (64.5, 89.2)	0.98 (0.84, 1.18)	117	145	80.7 (73.5, 86.3)	86	106	81.1 (72.6, 87.4)	140	171	81.9 (75.4, 86.9)	
		BSAL	9	13	69.2 (42.4, 87.3)	0.89 (0.61, 1.29)	16	17	94.1 (73, 99)	1.25 (1.11, 1.48)	88	113	77.9 (69.4, 84.5)	72	96	75.0 (65.5, 82.6)	97	126	77.0 (68.9, 83.5)	
		BSM	56	83	67.5 (56.8, 76.6)	0.87 (0.74, 1.03)	2	4	50.0 (15, 85)	0.64 (0.24, 1.72)	170	220	77.3 (71.3, 82.3)	168	216	77.8 (71.8, 82.8)	226	303	74.6 (69.4, 79.2)	
		BSCC	30	43	69.8 (54.9, 81.4)	0.84 (0.68, 1.04)	3	4	75.0 (30.1, 95.4)	0.90 (0.51, 1.6)	129	156	82.7 (76, 87.8)	126	152	82.9 (76.1, 88.1)	159	199	79.7 (73.8, 84.9)	
		BSC	13	15	86.7 (62.1, 96.3)	1.08 (0.88, 1.34)	10	13	76.9 (49.7, 91.8)	0.96 (0.71, 1.3)	152	190	80.0 (73.7, 85.1)	142	177	80.2 (73.7, 85.4)	165	205	80.5 (74.5, 85.3)	
		BSSL	26	32	81.3 (64.7, 91.1)	0.97 (0.82, 1.16)	4	4	100.0 (51, 100)	1.20 (1.2, 1.26)	240	287	83.6 (78.9, 87.5)	236	283	83.4 (78.6, 87.3)	266	319	83.4 (78.9, 87.1)	
		BSOS	8	8	100.0 (67.6, 100)	1.23 (1.14, 1.33)	3	3	100.0 (43.9, 100)	1.24 (1.24, 1.34)	117	144	81.3 (74.1, 86.8)	114	141	80.9 (73.6, 86.5)	125	152	82.2 (75.4, 87.5)	
		Total	217	283	76.7 (71.4, 81.2)	0.95 (0.88, 1.01)	80	99	80.8 (72, 87.4)	1.00 (0.9, 1.1)	1,195	1,473	81.1 (79, 83)	1,115	1,374	81.1 (79, 83.1)	1,412	1,756	80.4 (78.5, 82.2)	
		45 to 69	Initial	BSWN	10	14	71.4 (45.4, 88.3)	1.04 (0.71, 1.52)	0	1	- (0, 79.3)	NA (NA, NA)	35	51	68.6 (55, 79.7)	35	50	70.0 (56.2, 80.9)	45	65
BSCM				6	9	66.7 (35.4, 87.9)	0.97 (0.58, 1.62)	8	11	72.7 (43.4, 90.3)	1.09 (0.76, 1.73)	24	35	68.6 (52, 81.4)	16	24	66.7 (46.7, 82)	30	44	68.2 (53.4, 80)
BSAL	2			4	50.0 (15, 85)	0.87 (0.31, 2.44)	3	4	75.0 (30.1, 95.4)	1.38 (0.78, 2.72)	15	26	57.7 (38.9, 74.5)	12	22	54.5 (34.7, 73.1)	17	30	56.7 (39.2, 72.6)	
BSM	11			17	64.7 (41.3, 82.7)	1.06 (0.67, 1.65)	1	1	100.0 (20.7, 100)	1.67 (1.67, 2.23)	19	31	61.3 (43.8, 76.3)	18	30	60.0 (42.3, 75.4)	30	48	62.5 (48.4, 74.8)	
BSCC	11			15	73.3 (48, 89.1)	1.17 (0.76, 1.81)	0	0	NA (NA, NA)	NA (NA, NA)	15	24	62.5 (42.7, 78.8)	15	24	62.5 (42.7, 78.8)	26	39	66.7 (51, 79.4)	
BSC	9			10	90.0 (59.6, 98.2)	1.06 (0.81, 1.37)	3	4	75.0 (30.1, 95.4)	0.86 (0.49, 1.55)	23	27	85.2 (67.5, 94.1)	20	23	80.0 (67.9, 95.5)	32	37	86.5 (72, 94.1)	
BSSL	0			0	NA (NA, NA)	NA (NA, NA)	0	2	- (0, 65.8)	NA (NA, NA)	29	42	69.0 (54, 80.9)	29	40	72.5 (57.2, 83.9)	29	42	69.0 (54, 80.9)	
BSOS	0			0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 (20.7, 100)	1.23 (1.23, 1.56)	14	17	82.4 (59, 93.8)	13	16	81.3 (57, 93.4)	14	17	82.4 (59, 93.8)	
Total	49			69	71.0 (59.4, 80.4)	1.03 (0.87, 1.23)	16	24	66.7 (46.7, 82)	0.97 (0.73, 1.3)	174	253	68.8 (62.8, 74.2)	158	229	69.0 (62.7, 74.6)	223	322	69.3 (64, 74)	
Subsequent	BSWN			57	69	82.6 (72, 89.8)	1.01 (0.89, 1.14)	11	15	73.3 (48, 89.1)	0.89 (0.65, 1.21)	197	240	82.1 (76.7, 86.4)	186	225	82.7 (77.2, 87.1)	254	309	82.2 (77.5, 86.1)
	BSCM		24	29	82.8 (65.5, 92.4)	1.04 (0.87, 1.25)	32	42	76.2 (61.5, 86.5)	0.94 (0.8, 1.14)	124	156	79.5 (72.5, 85.1)	92	114	80.7 (72.5, 86.9)	148	185	80.0 (73.7, 85.1)	
	BSAL		9	14	64.3 (38.8, 83.7)	0.83 (0.55, 1.24)	17	18	94.4 (74.2, 99)	1.26 (1.13, 1.48)	94	121	77.7 (69.5, 84.2)	77	103	74.8 (65.6, 82.2)	103	135	76.3 (68.5, 82.7)	
	BSM		59	87	67.8 (57.4, 76.7)	0.87 (0.74, 1.02)	2	4	50.0 (15, 85)	0.64 (0.24, 1.7)	187	240	77.9 (72.3, 82.7)	185	236	78.4 (72.7, 83.2)	246	327	75.2 (70.3, 79.6)	
	BSCC		30	46	65.2 (50.8, 77.3)	0.79 (0.63, 0.99)	4	5	80.0 (37.6, 96.4)	0.97 (0.63, 1.51)	140	170	82.4 (75.9, 87.3)	136	165	82.4 (75.9, 87.5)	170	216	78.7 (72.8, 83.6)	
	BSC		15	19	78.9 (56.7, 91.5)	1.00 (0.77, 1.25)	12	15	80.0 (54.8, 93)											


3.e, Ductal carcinoma in situ diagnosis

Description: The percentage of all women with screen detected cancer who are diagnosed as having ductal carcinoma in situ (DCIS) as their primary lesion.


Target: 10-25% of all cancers detected by the BSA programme are DCIS (50–69 age group only)

Figure 83: 3.e.1, 45 to 49 and 50 to 69, Ductal carcinoma in situ diagnosis

45–49 years



50–69 years



Of 2,746 cancers detected by BSA among women aged 45–69 years, 669 (24%) were DCIS.

Among women aged 50–69 years the proportion was 22.9%. For Māori women DCIS made up a smaller proportion of screen-detected cancers at 12.7%. For Pacific and other women, the proportions were similar (25.6% and 24.6% respectively). The target range was met or was within the confidence interval for all LPs.

Among women aged 45–49 years the proportion of cancers detected that were DCIS was higher at 31% overall, similar for Māori (31%), and lower for Pacific women (21%).

Figure 84: 3.e.3, 50 to 69, Ductal carcinoma in situ diagnosis, by LP



Table 22: 3.e.1, Ductal carcinoma in situ diagnosis

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			DCIS	Cancers	% of Cancers that were DCIS (95% CI)	Māori / Non-Māori Ratio	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	DCIS	Cancers	% of Cancers that were DCIS (95% CI)
45 to 49	BSWN	4	13	30.8 (12.7, 57.6)	1.12 (0.45, 2.79)	1	2	50.0 (9.5, 90.5)	1.88 (0.47, 7.98)	17	62	27.4 (17.9, 39.6)	16	60	26.7 (17.1, 39)	21	75	28.0 (19.1, 39)	
	BSCM	2	9	22.2 (6.3, 54.7)	0.68 (0.19, 2.48)	4	16	25.0 (10.2, 49.5)	0.68 (0.29, 1.8)	15	46	32.6 (20.9, 47)	11	30	36.7 (21.9, 54.5)	17	55	30.9 (20.3, 44)	
	BSAL	1	5	20.0 (3.6, 62.4)	0.46 (0.08, 2.74)	1	5	20.0 (3.6, 62.4)	0.43 (0.07, 2.57)	20	46	43.5 (30.2, 57.8)	19	41	46.3 (32.1, 61.3)	21	51	41.2 (28.8, 54.8)	
	BSM	8	18	44.4 (24.6, 66.3)	1.88 (0.87, 4.05)	0	1	0.0 (0, 79.3)	NA (NA, NA)	9	38	23.7 (13, 39.2)	9	37	24.3 (13.4, 40.1)	17	56	30.4 (19.9, 43.3)	
	BSCC	4	15	26.7 (10.9, 52)	1.33 (0.47, 3.78)	0	1	0.0 (0, 79.3)	NA (NA, NA)	8	40	20.0 (10.5, 34.8)	8	39	20.5 (10.8, 35.5)	12	55	21.8 (12.9, 34.4)	
	BSC	0	9	0.0 (0, 29.9)	NA (NA, NA)	1	5	20.0 (3.6, 62.4)	0.66 (0.11, 4.11)	11	38	28.9 (17, 44.8)	10	33	30.3 (17.4, 47.3)	11	47	23.4 (13.6, 37.2)	
	BSSL	4	8	50.0 (21.5, 78.5)	1.50 (0.71, 3.17)	0	2	0.0 (0, 65.8)	NA (NA, NA)	32	96	33.3 (24.7, 43.2)	32	94	34.0 (25.3, 44.1)	36	104	34.6 (26.2, 44.2)	
	BSOS	1	1	100.0 (20.7, 100)	2.42 (1.57, 3.73)	0	1	0.0 (0, 79.3)	NA (NA, NA)	12	29	41.4 (25.5, 59.3)	12	28	42.9 (26.5, 60.9)	13	30	43.3 (27.4, 60.8)	
	Total	24	78	30.8 (21.6, 41.7)	0.98 (0.68, 1.41)	7	33	21.2 (10.7, 37.8)	0.66 (0.34, 1.29)	124	395	31.4 (27, 36.1)	117	362	32.3 (27.7, 37.3)	148	473	31.3 (27.3, 35.6)	
50 to 69	BSWN	15	83	18.1 (11.3, 27.7)	0.70 (0.42, 1.15)	6	17	35.3 (17.3, 58.7)	1.39 (0.73, 2.73)	74	285	26.0 (21.2, 31.4)	68	268	25.4 (20.5, 30.9)	89	368	24.2 (20.1, 28.8)	
	BSCM	8	34	23.5 (12.4, 40)	1.00 (0.52, 1.93)	11	48	22.9 (13.3, 36.5)	0.96 (0.57, 1.75)	45	191	23.6 (18.1, 30.1)	34	143	23.8 (17.5, 31.4)	53	225	23.6 (18.5, 29.5)	
	BSAL	0	11	0.0 (0, 25.9)	NA (NA, NA)	6	23	26.1 (12.5, 46.5)	0.80 (0.4, 1.65)	53	167	31.7 (25.2, 39.1)	47	144	32.6 (25.5, 40.7)	53	178	29.8 (23.5, 36.9)	
	BSM	12	102	11.8 (6.9, 19.4)	0.51 (0.29, 0.9)	3	5	60.0 (23.1, 88.2)	2.66 (1.3, 5.63)	65	280	23.2 (18.7, 28.5)	62	275	22.5 (18, 27.8)	77	382	20.2 (16.4, 24.5)	
	BSCC	4	54	7.4 (2.9, 17.6)	0.35 (0.13, 0.94)	0	3	0.0 (0, 56.1)	NA (NA, NA)	41	196	20.9 (15.8, 27.1)	41	193	21.2 (16.1, 27.5)	45	250	18.0 (13.7, 23.2)	
	BSC	0	16	0.0 (0, 19.4)	NA (NA, NA)	4	20	20.0 (8.1, 41.6)	0.97 (0.41, 2.43)	50	244	20.5 (15.9, 26)	46	224	20.5 (15.8, 26.3)	50	260	19.2 (14.9, 24.5)	
	BSSL	3	30	10.0 (3.5, 25.6)	0.35 (0.12, 1.04)	2	6	33.3 (9.7, 70)	1.17 (0.38, 3.67)	109	382	28.5 (24.2, 33.3)	107	376	28.5 (24.1, 33.2)	112	412	27.2 (23.1, 31.7)	
	BSOS	1	8	12.5 (2.2, 47.1)	0.58 (0.09, 3.7)	0	3	0.0 (0, 56.1)	NA (NA, NA)	41	190	21.6 (16.3, 28)	41	187	21.9 (16.6, 28.4)	42	198	21.2 (16.1, 27.4)	
	Total	43	338	12.7 (9.6, 16.7)	0.51 (0.39, 0.69)	32	125	25.6 (18.8, 33.9)	1.04 (0.77, 1.42)	478	1,935	24.7 (22.8, 26.7)	446	1,810	24.6 (22.7, 26.7)	521	2,273	22.9 (21.2, 24.7)	
45 to 69	BSWN	19	96	19.8 (13.1, 28.9)	0.75 (0.49, 1.17)	7	19	36.8 (19.1, 59)	1.44 (0.8, 2.67)	91	347	26.2 (21.9, 31.1)	84	328	25.6 (21.2, 30.6)	110	443	24.8 (21, 29.1)	
	BSCM	10	43	23.3 (13.2, 37.7)	0.92 (0.51, 1.65)	15	64	23.4 (14.7, 35.1)	0.90 (0.58, 1.5)	60	237	25.3 (20.2, 31.2)	45	173	26.0 (20, 33)	70	280	25.0 (20.3, 30.4)	
	BSAL	1	16	6.3 (1.1, 28.3)	0.18 (0.03, 1.23)	7	28	25.0 (12.7, 43.4)	0.70 (0.37, 1.37)	73	213	34.3 (28.2, 40.9)	66	185	35.7 (29.1, 42.8)	74	229	32.3 (26.6, 38.6)	
	BSM	20	120	16.7 (11.1, 24.3)	0.72 (0.46, 1.12)	3	6	50.0 (18.8, 81.2)	2.20 (0.99, 5.02)	74	318	23.3 (19, 28.2)	71	312	22.8 (18.5, 27.7)	94	438	21.5 (17.9, 25.5)	
	BSCC	8	69	11.6 (6, 21.2)	0.56 (0.28, 1.12)	0	4	0.0 (0, 49)	NA (NA, NA)	49	236	20.8 (16.1, 26.4)	49	232	21.1 (16.4, 26.8)	57	305	18.7 (14.7, 23.4)	
	BSC	0	25	0.0 (0, 13.3)	NA (NA, NA)	5	25	20.0 (8.9, 39.1)	0.92 (0.42, 2.08)	61	282	21.6 (17.2, 26.8)	56	257	21.8 (17.2, 27.2)	61	307	19.9 (15.8, 24.7)	
	BSSL	7	38	18.4 (9.2, 33.4)	0.62 (0.32, 1.24)	2	8	25.0 (7.1, 59.1)	0.85 (0.25, 2.83)	141	478	29.5 (25.6, 33.7)	139	470	29.6 (25.6, 33.9)	148	516	28.7 (24.9, 32.7)	
	BSOS	2	9	22.2 (6.3, 54.7)	0.92 (0.26, 3.19)	0	4	0.0 (0, 49)	NA (NA, NA)	53	219	24.2 (19, 30.3)	53	215	24.7 (19.4, 30.8)	55	228	24.1 (19, 30.1)	
	Total	67	416	16.1 (12.9, 19.9)	0.62 (0.5, 0.78)	39	158	24.7 (18.6, 32)	0.95 (0.73, 1.26)	602	2,330	25.8 (24.1, 27.7)	563	2,172	25.9 (24.1, 27.8)	669	2,746	24.4 (22.8, 26)	

Treatment: Early detection of DCIS or invasive breast cancer

3.a.2.t, Detection of invasive breast cancer, women screened during the 4 years to December 2019

Table 23: 3.a.2.t, Detection of invasive cancer, women screened during the 4 years to December 2019

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Māori / Non-Māori Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Pacific / Non-Māori Ratio	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)	Screens with Breast Cancer	Screens	Rate of Breast Cancers Detected per 1,000 Screens (95% CI)
45 to 49	Initial	BSWN	8	2,439	3.3 (1.7, 6.4)	0.86 (0.41, 1.8)	1	777	1.3 (0.2, 7.2)	0.32 (0.05, 2.34)	56	14,636	3.8 (3.4, 4.9)	55	13,859	4.0 (3.1, 5.1)	64	17,075	3.7 (3.4, 4.8)
		BSCM	13	1,861	7.0 (4.1, 11.9)	1.99 (1.06, 3.72)	15	2,837	5.3 (3.3, 8.6)	1.82 (1.1, 3.47)	39	11,104	3.5 (2.6, 4.8)	24	8,267	2.9 (2.4, 3)	52	12,965	4.0 (3.1, 5.2)
		BSAL	5	792	6.3 (2.7, 14.7)	1.34 (0.53, 3.37)	7	1,126	6.2 (3.1, 12.7)	1.38 (0.66, 3.08)	45	9,551	4.7 (3.6, 6.3)	38	8,425	4.5 (3.3, 6.2)	50	10,343	4.8 (3.7, 6.3)
		B5M	15	3,468	4.3 (2.6, 7.1)	1.56 (0.86, 2.85)	1	341	2.9 (0.6, 16.4)	1.06 (0.15, 7.73)	37	13,384	2.8 (2.3, 3.8)	36	13,043	2.8 (2.3, 3.8)	52	16,852	3.1 (2.4, 4)
		BSCC	20	2,596	7.7 (5, 11.9)	2.25 (1.3, 3.91)	2	237	8.4 (2.7, 29.9)	2.56 (0.64, 10.63)	34	9,951	3.4 (2.5, 4.8)	32	9,714	3.3 (2.4, 4.6)	54	12,547	4.3 (3.3, 5.6)
		B5C	9	1,246	7.2 (3.8, 13.7)	2.11 (1.02, 4.4)	1	601	1.7 (0.3, 9.3)	0.47 (0.07, 3.44)	34	9,947	3.4 (2.5, 4.8)	33	9,346	3.5 (2.5, 4.9)	43	11,193	3.8 (2.9, 5.2)
		B5SL	3	1,394	2.2 (0.7, 6.3)	0.50 (0.16, 1.59)	3	310	9.7 (3.7, 27.6)	2.30 (0.75, 7.26)	80	18,640	4.3 (3.5, 5.3)	77	18,330	4.2 (3.4, 5.2)	83	20,034	4.1 (3.4, 5.1)
		BSOS	2	593	3.4 (0.9, 12.2)	0.81 (0.19, 3.38)	2	99	20.2 (7.7, 68.6)	5.14 (1.3, 21.39)	27	6,456	4.2 (2.9, 6)	25	6,357	3.9 (2.7, 5.8)	29	7,049	4.1 (2.9, 5.9)
		Total	75	14,389	5.2 (4.2, 6.5)	1.39 (1.08, 1.78)	32	6,328	5.1 (3.6, 7.1)	1.38 (0.98, 1.98)	352	93,669	3.8 (3.4, 4.2)	320	87,341	3.7 (3.3, 4.1)	427	108,058	4.0 (3.6, 4.3)
	Subsequent	BSWN	10	2,719	3.7 (2.6, 8)	1.16 (0.59, 2.26)	0	999	0.0 (0, 3.8)	NA (NA, NA)	59	18,576	3.2 (2.5, 4.1)	59	17,577	3.4 (2.6, 4.3)	69	21,295	3.2 (2.6, 4.1)
		BSCM	7	1,951	3.6 (1.7, 7.4)	1.41 (0.63, 3.16)	8	3,044	2.6 (1.4, 5.2)	1.04 (0.52, 2.28)	58	14,115	2.6 (1.9, 3.5)	28	11,071	2.5 (1.8, 3.6)	43	16,066	2.7 (2, 3.6)
		BSAL	2	925	2.2 (0.6, 7.8)	0.72 (0.17, 2.97)	7	1,371	5.1 (2.6, 10.4)	1.85 (0.88, 4.2)	38	12,619	3.0 (2.2, 4.1)	31	11,248	2.8 (2, 3.9)	40	13,544	3.0 (2.2, 4)
		B5M	12	3,384	3.5 (2.2, 6.2)	1.39 (0.73, 2.65)	1	315	3.2 (0.6, 17.7)	1.25 (0.18, 9.1)	40	15,714	2.5 (1.9, 3.5)	39	15,399	2.5 (1.9, 3.5)	52	19,098	2.7 (2.1, 3.6)
		BSCC	7	2,896	2.4 (1.2, 5)	0.95 (0.42, 2.14)	2	277	7.2 (2.2, 25.7)	2.95 (0.74, 12.25)	34	13,350	2.5 (1.8, 3.5)	32	13,073	2.4 (1.7, 3.4)	41	16,246	2.5 (1.9, 3.4)
		B5C	7	1,561	4.5 (2.2, 9.2)	2.88 (1.22, 6.81)	1	772	1.3 (0.2, 7.3)	0.82 (0.12, 6.15)	20	12,863	1.6 (1, 2.4)	19	12,091	1.6 (1, 2.4)	27	14,424	1.9 (1.3, 2.7)
		B5SL	7	2,064	3.4 (1.6, 7)	1.40 (0.64, 3.04)	1	325	3.1 (0.6, 17.2)	1.27 (0.18, 9.14)	65	26,777	2.4 (1.9, 3.1)	64	26,452	2.4 (1.9, 3.1)	72	28,841	2.5 (2, 3.1)
		BSOS	1	779	1.3 (0.2, 7.2)	0.38 (0.05, 2.76)	0	123	0.0 (0, 30.3)	NA (NA, NA)	30	8,792	3.4 (2.4, 4.8)	30	8,669	3.5 (2.4, 4.9)	31	9,571	3.2 (2.3, 4.6)
		Total	53	16,279	3.3 (2.5, 4.3)	1.24 (0.93, 1.66)	20	7,226	2.8 (1.8, 4.3)	1.06 (0.68, 1.66)	322	122,806	2.6 (2.4, 2.9)	302	115,580	2.6 (2.3, 2.9)	375	139,085	2.7 (2.4, 3)
		50 to 69	Initial	BSWN	10	512	19.5 (10.6, 35.6)	2.51 (1.26, 5)	0	209	0.0 (0, 18)	NA (NA, NA)	39	5,016	7.8 (5.8, 10.5)	39	4,807	8.1 (6, 11)	49
BSCM	5			372	13.4 (5.8, 31.1)	1.81 (0.7, 4.67)	5	763	6.6 (3, 15.1)	0.86 (0.36, 2.25)	28	3,776	7.4 (5.2, 10.6)	23	3,013	7.6 (5.2, 11.3)	33	4,148	8.0 (5.8, 11.1)
BSAL	4			182	22.0 (8.6, 55.1)	2.48 (0.88, 7)	2	292	6.8 (2.1, 24.4)	0.76 (0.19, 3.17)	28	3,163	8.9 (6.3, 12.6)	26	2,871	9.1 (6.3, 13.1)	32	3,345	9.6 (6.9, 13.3)
B5M	21			1,245	16.9 (11.1, 25.6)	1.70 (1.01, 2.85)	1	134	7.5 (1.7, 40.7)	0.75 (0.11, 5.38)	43	4,331	9.9 (7.5, 13.2)	42	4,197	10.0 (7.6, 13.4)	64	5,576	11.5 (9.1, 14.5)
BSCC	15			910	16.5 (10, 27)	2.06 (1.09, 3.91)	1	90	11.1 (2.7, 59.5)	1.41 (0.2, 10.3)	24	3,001	8.0 (5.5, 11.8)	23	2,911	7.9 (5.4, 11.7)	39	3,911	10.0 (7.4, 13.5)
B5C	5			355	14.1 (6, 32.5)	1.30 (0.51, 3.3)	3	199	15.1 (6.2, 42.4)	1.43 (0.46, 4.63)	33	3,036	10.9 (7.9, 15)	30	2,837	10.6 (7.6, 14.9)	38	3,391	11.2 (8.4, 15.2)
B5SL	4			217	18.4 (7.2, 46.4)	2.74 (0.95, 7.93)	0	79	0.0 (0, 46.4)	NA (NA, NA)	21	3,127	6.7 (4.5, 10.2)	21	3,048	6.9 (4.6, 10.4)	25	3,344	7.5 (5.2, 10.9)
BSOS	0			123	0.0 (0, 30.3)	NA (NA, NA)	0	41	0.0 (0, 85.7)	NA (NA, NA)	11	1,411	7.8 (4.5, 13.7)	11	1,370	8.0 (4.7, 14.2)	11	1,534	7.2 (4.1, 12.7)
Total	64			3,916	16.3 (12.8, 20.8)	1.93 (1.47, 2.55)	12	1,807	6.6 (3.9, 11.5)	0.77 (0.44, 1.38)	227	26,861	8.5 (7.5, 9.6)	215	25,054	8.6 (7.6, 9.8)	291	30,777	9.5 (8.5, 10.6)
Subsequent	BSWN		118	14,992	7.9 (6.6, 9.4)	1.75 (1.43, 2.14)	34	5,428	6.3 (4.5, 8.7)	1.42 (1.02, 2.01)	503	111,823	4.5 (4.1, 4.9)	469	106,395	4.4 (4, 4.8)	621	126,815	4.9 (4.5, 5.3)
	BSCM		59	9,097	6.5 (5, 8.4)	1.49 (1.13, 1.97)	78	14,950	5.2 (4.2, 6.5)	1.27 (1.02, 1.64)	315	72,533	4.3 (3.9, 4.8)	237	57,583	4.1 (3.6, 4.7)	374	81,630	4.6 (4.2, 5.1)
	BSAL		28	4,199	6.7 (4.6, 9.6)	1.55 (1.05, 2.29)	42	6,780	6.2 (4.6, 8.3)	1.52 (1.12, 2.11)	283	65,878	4.3 (3.8, 4.8)	241	59,098	4.1 (3.6, 4.6)	311	70,077	4.4 (4, 4.9)
	B5M		174	20,155	8.6 (7.4, 10)	1.81 (1.53, 2.15)	11	1,678	6.6 (3.8, 11.6)	1.39 (0.77, 2.51)	521	109,515	4.8 (4.4, 5.2)	510	107,837	4.7 (4.3, 5.1)	695	129,670	5.4 (5, 5.8)
	BSCC		109	16,229	6.7 (5.6, 8.1)	1.65 (1.33, 2.03)	9	1,420	6.3 (3.5, 11.9)	1.57 (0.82, 3.03)	382	93,583	4.1 (3.7, 4.5)	373	92,163	4.0 (3.7, 4.5)	491	109,812	4.5 (4.1, 4.9)
	B5C		51	7,985	6.4 (4.9, 8.4)	1.40 (1.04, 1.87)	17	4,233	4.0 (2.5, 6.4)	0.87 (0.54, 1.42)	364	79,547	4.6 (4.1, 5.1)	347	75,314	4.6 (4.2, 5.1)	415	87,532	4.7 (4.3, 5.2)
	B5SL		55	8,439	6.5 (5, 8.5)	1.52 (1.15, 2)	5	1,455	3.4 (1.5, 8)	0.80 (0.33, 1.92)	641	149,366	4.3 (4, 4.6)	636	147,911	4.3 (4, 4.6)	696	157,805	4.4 (4.1, 4.7)
	BSOS		15	3,412	4.4 (2.7, 7.2)	0.82 (0.49, 1.38)	5	397	12.6 (6, 28.6)	2.37 (0.99, 5.71)	301	56,178	5.4 (4.8, 6)	296	55,781	5.3 (4.8, 5.9)	316	59,590	5.3 (4.8, 5.9)
	Total		609	84,508	7.2 (6.7, 7.8)	1.61 (1.47, 1.75)	201	36,341	5.5 (4.8, 6.3)	1.25 (1.09, 1.44)	3,310	738,423	4.5 (4.3, 4.6)	3,109	702,082	4.4 (4.3, 4.6)	3,919	822,931	4.8 (4.6, 4.9)
	45 to 69		Initial	BSWN	18	2,951	6.1 (3.9, 9.6)	1.26 (0.76, 2.09)	1	986	1.0 (0.2, 5.7)	0.20 (0.03, 1.44)	95	19,652	4.8 (4, 5.9)	94	18,666	5.0 (4.1, 6.1)	113
BSCM		18		2,233	8.1 (5.1, 12.7)	1.79 (1.07, 3.01)	20	3,600	5.6 (3.7, 8.5)	1.33 (0.86, 2.25)	67	14,880	4.5 (3.6, 5.7)	47	11,280	4.2 (3.2, 5.5)	85	17,113	5.0 (4, 6.1)
BSAL		9		974	9.2 (4.9, 17.5)	1.61 (0.81, 3.21)	9	1,418	6.3 (3.5, 11.9)	1.12 (0.58, 2.25)	73	12,714	5.7 (4.6, 7.2)	64	11,296	5.7 (4.5, 7.2)	82	13,688	6.0 (4.9, 7.4)
B5M		36		4,713	7.6 (5.5, 10.6)	1.69 (1.14, 2.5)	2	475	4.2 (1.2, 15.1)	0.93 (0.23, 3.78)	80	17,715	4.5 (3.7, 5.6)	78	17,240	4.5 (3.6, 5.6)	116	22,428	5.2 (4.3, 6.2)
BSCC		35		3,506	10.0 (7.2, 13.9)	2.23 (1.47, 3.39)	3	327	9.2 (3.5, 26.2)	2.11 (0.68, 6.7)	58	12,952	4.5 (3.5, 5.8)	55	12,625	4.4 (3.4, 5.6)	93	16,458	5.7 (4.6, 6.9)
B5C		14		1,601	8.7 (5.2, 14.6)	1.69 (0.95, 3.01)	4	800	5.0 (2, 12.7)	0.97 (0.36, 2.65)	67	12,983	5.2 (4.1, 6.5)	63	12,183	5.2 (4.1, 6.6)	81	14,584	5.6 (4.5, 6.9)
B5SL		7		1,611	4.3 (2.1, 8.9)	0.94 (0.44, 2.01)	3	389	7.7 (2.9, 22.2)	1.68 (0.53, 5.28)	101	21,767	4.6 (3.8, 5.6)	98	21,378	4.6 (3.8, 5.6)	108	23,378	4.6 (3.8, 5.6)
BSOS		2		716	2.8 (0.8, 10.1)	0.58 (0.14, 2.39)	2	140	14.3 (5, 49.5)	3.07 (0.77, 12.61)	38	7,867	4.8 (3.6, 6.6)	36	7,727	4.7 (3.4, 6.4)	40	8,583	4.7 (3.5, 6.3)
Total		139		18,305	7.6 (6.4, 9)	1.58 (1.31, 1.9)	44	8,135	5.4 (4.1, 7.2)	1.14 (0.85, 1.54)	579	120,530	4.8 (4.4, 5.2)	535	112,395	4.8 (4.4, 5.2)	718	138,835	5.2 (4.8, 5.6)
Subsequent		BSWN	128	17,711	7.2 (6.1, 8.6)	1.68 (1.38, 2.03)	34	6,427	5.3 (3.8, 7.3)	1.24 (0.89, 1.76)	562	130,399	4.3 (4, 4.7)	528	123,972	4.3 (3.9, 4.6)	690	148,110	4.7 (4.3, 5)
		BSCM	66	11,048	6.0 (4.7, 7.6)	1.47 (1.13, 1.92)	86	17,994	4.8 (3.9, 5.9)	1.24 (1, 1.58)	351	86,648							

3.a.3.t, Treatment Data Completeness, women screened during the 4 years to December 2019

Description: Lead Providers have 9 months to complete Staging and Surgery data entry for women referred to treatment. Lead Providers have 6 months to complete Endocrine, Radiotherapy, and Chemotherapy data entry for women referred to treatment. The 't' in the indicator id marks it as a treatment indicator.

Target: ≥ 90%

Table 24: 3.a.3.t.1, Treatment Data Completeness, women screened during the 4 years to December 2019

		Staging Data Target Met	Staging Data Collected	Surgery Data Target Met	Surgery Data Collected	Endocrine Data Target Met	Endocrine Data Collected	Radiotherapy Data Target Met	Radiotherapy Data Collected	Chemotherapy Data Target Met	Chemotherapy Data Collected
45 - 49	BSWN	0.65	1.00	0.99	1.00	0.79	0.76	0.68	1.00	0.87	1.00
	BSCM	0.58	1.00	0.91	1.00	0.79	0.75	0.76	1.00	0.81	1.00
	BSAL	0.68	1.00	0.93	1.00	0.78	0.79	0.75	1.00	0.87	1.00
	BSM	0.88	0.99	0.99	1.00	0.64	0.56	0.63	0.99	0.63	0.99
	BSCC	0.59	1.00	0.87	1.00	0.77	0.77	0.77	1.00	0.85	1.00
	BSC	0.35	1.00	0.88	1.00	0.74	0.72	0.66	1.00	0.83	1.00
	BSSL	0.93	1.00	1.00	1.00	0.90	0.90	0.90	1.00	0.99	1.00
	BSOS	0.74	1.00	1.00	1.00	0.90	0.95	0.93	1.00	0.95	1.00
50 - 69	BSWN	0.71	1.00	0.96	1.00	0.80	1.00	0.78	1.00	0.85	1.00
	BSCM	0.65	1.00	0.99	1.00	0.79	1.00	0.70	1.00	0.87	1.00
	BSAL	0.65	1.00	0.93	1.00	0.81	0.99	0.78	0.98	0.83	0.99
	BSM	0.62	0.98	0.92	1.00	0.77	1.00	0.76	1.00	0.83	1.00
	BSCC	0.87	1.00	0.98	1.00	0.62	1.00	0.63	1.00	0.63	1.00
	BSC	0.63	1.00	0.91	1.00	0.81	1.00	0.81	0.99	0.88	1.00
	BSSL	0.31	1.00	0.89	1.00	0.77	1.00	0.74	1.00	0.86	1.00
	BSOS	0.96	1.00	1.00	1.00	0.93	1.00	0.94	1.00	0.99	1.00

3.c.p.t, Detection of invasive breast cancer less than or equal to 15mm (percentage), women screened during the 4 years to December 2019

Table 25: 3.c.p.t Detection of invasive breast cancer less than or equal to 15mm (percentage), women screened during the 4 years to December 2019

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
		Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)	Invasive Cancers ≤15mm	Invasive Cancers	% of Invasive Cancers ≤15mm (95% CI)		
45 to 49	Initial	B5WN	4	8	50.0 (21.5, 78.5)	0.67 (0.33, 1.36)	1	1	100.0 (20.7, 100)	1.26 (1.26, 1.46)	39	52	75.0 (61.8, 84.8)	38	48	79.2 (65.7, 88.3)	43	57	75.4 (62.9, 84.8)	
		B5CM	3	13	23.1 (8.2, 50.3)	1.23 (0.39, 3.9)	5	15	33.3 (15.2, 58.3)	2.75 (1.34, 8.81)	9	48	18.8 (10.2, 31.9)	4	33	12.1 (4.8, 27.3)	12	61	19.7 (11.6, 31.3)	
		B5AL	3	5	60.0 (23.1, 88.2)	0.64 (0.31, 1.32)	3	7	42.9 (15.8, 75)	0.43 (0.18, 1.01)	30	32	93.8 (79.9, 98.3)	27	27	100.0 (87.5, 100)	33	39	84.6 (70.3, 92.8)	
		B5M	5	15	33.3 (15.2, 58.3)	0.59 (0.27, 1.28)	0	1	0.0 (0, 79.3)	NA (NA, NA)	17	30	56.7 (39.2, 72.6)	17	30	56.7 (39.2, 72.6)	22	46	47.8 (34.1, 61.9)	
		B5CC	6	20	30.0 (14.5, 51.9)	0.81 (0.35, 1.86)	1	2	50.0 (9.5, 90.5)	1.39 (0.35, 6.11)	10	27	37.0 (21.5, 55.8)	9	25	36.0 (20.2, 55.5)	16	47	34.0 (22.2, 48.3)	
		B5C	2	9	22.2 (6.3, 54.7)	0.48 (0.13, 1.73)	1	1	100.0 (20.7, 100)	2.25 (2.25, 3.43)	13	28	46.4 (29.5, 64.2)	12	27	44.4 (27.6, 62.7)	15	37	40.5 (26.3, 56.5)	
		B5SL	1	3	33.3 (6.1, 79.2)	0.68 (0.13, 3.42)	1	3	33.3 (6.1, 79.2)	0.67 (0.13, 3.37)	32	65	49.2 (37.5, 61.1)	31	62	50.0 (37.9, 62.1)	33	68	48.5 (37.1, 60.2)	
		B5OS	1	2	50.0 (9.5, 90.5)	3.17 (0.66, 15.2)	1	2	50.0 (9.5, 90.5)	3.70 (0.93, 18.47)	6	38	15.8 (7.4, 30.4)	5	37	13.5 (5.9, 28)	7	41	17.1 (8.5, 31.3)	
		Total	25	75	33.3 (23.7, 44.6)	0.68 (0.49, 0.96)	13	32	40.6 (25.5, 57.7)	0.82 (0.54, 1.27)	156	320	48.8 (43.3, 54.2)	143	289	49.5 (43.8, 55.2)	181	396	45.7 (40.9, 50.6)	
		Subsequent	B5WN	7	10	70.0 (39.7, 89.2)	0.88 (0.57, 1.34)	0	0	NA (NA, NA)	NA (NA, NA)	44	55	80.0 (67.6, 88.4)	44	52	84.6 (72.5, 92)	51	62	82.3 (71, 89.8)
	B5CM		1	7	14.3 (2.6, 51.3)	0.59 (0.09, 3.93)	1	8	12.5 (2.2, 47.1)	0.47 (0.07, 3.22)	9	37	24.3 (13.4, 40.1)	8	30	26.7 (14.2, 44.4)	10	45	22.2 (12.5, 36.3)	
	B5AL		1	2	50.0 (9.5, 90.5)	0.61 (0.15, 2.47)	3	7	42.9 (15.8, 75)	0.43 (0.18, 1.01)	27	33	81.8 (65.6, 91.4)	24	24	100.0 (86.2, 100)	28	33	84.8 (69.1, 92.3)	
	B5M		3	12	25.0 (8.9, 53.2)	0.59 (0.21, 1.69)	0	1	0.0 (0, 79.3)	NA (NA, NA)	16	38	42.1 (27.9, 57.8)	16	37	43.2 (28.7, 59.1)	19	50	38.0 (25.9, 51.8)	
	B5CC		3	7	42.9 (15.8, 75)	1.06 (0.41, 2.71)	1	2	50.0 (9.5, 90.5)	1.21 (0.3, 5.14)	15	37	40.5 (26.3, 56.5)	14	34	41.2 (26.4, 57.8)	18	43	41.9 (28.4, 56.7)	
	B5C		2	7	28.6 (8.2, 64.1)	0.54 (0.15, 1.89)	1	1	100.0 (20.7, 100)	2.00 (2, 3.26)	9	17	52.9 (31, 73.8)	8	16	50.0 (28, 72)	11	24	45.8 (27.9, 64.9)	
	B5SL		2	7	28.6 (8.2, 64.1)	0.75 (0.22, 2.53)	0	1	0.0 (0, 79.3)	NA (NA, NA)	21	55	38.2 (26.5, 51.4)	21	54	38.9 (27, 52.2)	23	62	37.1 (26.2, 49.5)	
	B5OS		0	1	- (0, 79.3)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	14	21	66.7 (45.4, 82.8)	14	21	66.7 (45.4, 82.8)	14	22	63.6 (43, 80.3)	
	Total		19	53	35.8 (24.3, 49.3)	0.68 (0.47, 0.99)	6	20	30.0 (14.5, 51.9)	0.54 (0.28, 1.06)	155	293	52.9 (47.2, 58.5)	149	268	55.6 (49.6, 61.4)	174	341	51.0 (45.7, 56.3)	
	50 to 69		Initial	B5WN	8	10	80.0 (49, 94.3)	1.20 (0.82, 1.75)	0	0	NA (NA, NA)	NA (NA, NA)	28	42	66.7 (51.6, 79)	28	39	71.8 (56.2, 83.5)	36	49
		B5CM		2	5	40.0 (11.8, 76.9)	3.70 (0.9, 15.27)	0	5	0.0 (0, 43.4)	NA (NA, NA)	4	37	10.8 (4.3, 24.7)	4	24	16.7 (6.7, 35.9)	6	34	17.6 (8.3, 33.5)
B5AL		3		4	75.0 (30.1, 95.4)	1.13 (0.6, 2.12)	0	2	0.0 (0, 65.8)	NA (NA, NA)	16	24	66.7 (46.7, 82)	16	22	72.7 (51.8, 86.8)	19	28	67.9 (49.3, 82.1)	
B5M		8		21	38.1 (20.8, 59.1)	1.31 (0.65, 2.63)	1	1	100.0 (20.7, 100)	3.62 (3.62, 5.74)	14	48	29.2 (18.2, 43.2)	13	47	27.7 (16.9, 41.8)	22	69	31.9 (22.1, 43.6)	
B5CC		8		15	53.3 (30.1, 75.2)	1.70 (0.86, 3.35)	0	1	0.0 (0, 79.3)	NA (NA, NA)	11	35	31.4 (18.6, 48)	11	33	33.3 (19.8, 50.4)	19	49	38.8 (26.4, 52.8)	
B5C		3		5	60.0 (23.1, 88.2)	2.20 (0.89, 5.45)	1	3	33.3 (6.1, 79.2)	1.29 (0.26, 7.13)	9	33	27.3 (15.1, 44.2)	8	31	25.8 (13.7, 43.2)	12	39	30.8 (18.6, 46.4)	
B5SL		2		4	50.0 (15, 85)	0.96 (0.34, 2.74)	0	0	NA (NA, NA)	NA (NA, NA)	14	27	51.9 (34, 69.3)	14	27	51.9 (34, 69.3)	16	31	51.6 (34.8, 68)	
B5OS		0		0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	7	9	0.0 (45.3, 93.7)	7	9	77.8 (45.3, 93.7)	7	9	77.8 (45.3, 93.7)	
Total		34		64	53.1 (41.1, 64.8)	1.32 (1, 1.73)	2	12	16.7 (4.7, 44.8)	0.38 (0.11, 1.37)	103	255	40.4 (34.6, 46.5)	101	232	43.5 (37.3, 50)	137	308	44.5 (39, 50.1)	
Subsequent		B5WN		94	118	79.7 (71.5, 85.9)	0.94 (0.85, 1.04)	26	34	76.5 (60, 87.6)	0.91 (0.75, 1.1)	416	492	84.6 (81.1, 87.5)	390	463	84.2 (80.6, 87.3)	510	615	82.9 (79.8, 85.7)
		B5CM	21	59	35.6 (24.6, 48.3)	0.77 (0.53, 1.1)	32	78	41.0 (30.8, 52.1)	0.88 (0.67, 1.18)	145	313	46.3 (40.9, 51.9)	113	242	46.7 (40.5, 53)	166	379	43.8 (38.9, 48.8)	
		B5AL	19	28	67.9 (49.3, 82.1)	0.95 (0.73, 1.25)	29	42	69.0 (54, 80.9)	0.99 (0.81, 1.23)	187	263	71.1 (65.4, 76.2)	158	226	69.9 (63.6, 75.5)	206	296	69.6 (64.1, 74.6)	
		B5M	87	174	50.0 (42.7, 57.3)	0.89 (0.75, 1.05)	3	11	27.3 (9.7, 56.6)	0.48 (0.18, 1.27)	287	512	56.1 (51.7, 60.3)	284	501	56.7 (52.3, 61)	374	686	54.5 (50.8, 58.2)	
		B5CC	50	109	45.9 (36.8, 55.2)	1.10 (0.87, 1.39)	2	9	22.2 (6.3, 54.7)	0.53 (0.16, 1.8)	164	392	41.8 (37.1, 46.8)	162	385	42.1 (37.2, 47.1)	214	503	42.5 (38.3, 46.9)	
		B5C	18	51	35.3 (23.6, 49)	0.74 (0.5, 1.09)	4	17	23.5 (9.6, 47.3)	0.48 (0.2, 1.14)	158	330	47.9 (42.5, 53.3)	154	314	49.0 (43.6, 54.6)	176	382	46.1 (41.1, 51.1)	
		B5SL	21	55	38.2 (26.5, 51.4)	0.81 (0.58, 1.15)	1	5	20.0 (3.6, 62.4)	0.43 (0.07, 2.47)	297	633	46.9 (43.1, 50.8)	296	631	46.9 (43, 50.8)	318	691	46.0 (42.3, 49.7)	
		B5OS	7	15	46.7 (24.8, 69.9)	0.91 (0.52, 1.57)	1	5	20.0 (3.6, 62.4)	0.39 (0.07, 2.24)	150	291	51.5 (45.8, 57.2)	149	288	51.7 (46, 57.4)	157	308	51.0 (45.4, 56.5)	
		Total	317	609	52.1 (48.1, 56)	0.93 (0.86, 1.01)	98	201	48.8 (41.9, 55.6)	0.87 (0.76, 1.01)	1,804	3,226	55.9 (54.2, 57.6)	1,706	3,050	55.9 (54.2, 57.7)	2,121	3,860	54.9 (53.4, 56.5)	
		45 to 69	Initial	B5WN	12	18	66.7 (43.7, 83.7)	0.94 (0.66, 1.33)	1	1	100.0 (20.7, 100)	1.32 (1.32, 1.48)	67	94	71.3 (61.4, 79.4)	66	87	75.9 (65.9, 83.6)	79	106
B5CM				5	18	27.8 (12.5, 50.9)	1.82 (0.74, 4.46)	5	20	25.0 (11.2, 46.9)	1.78 (0.83, 4.82)	13	85	15.3 (9.2, 24.4)	8	57	14.0 (7.3, 25.3)	18	95	18.9 (12.3, 28)
B5AL	6			9	66.7 (35.4, 87.9)	0.81 (0.5, 1.31)	3	9	33.3 (12.1, 64.6)	0.38 (0.15, 0.96)	46	56	82.1 (70.2, 90)	43	49	87.8 (75.8, 94.3)	52	67	77.6 (66.3, 85.9)	
B5M	13			36	36.1 (22.5, 52.4)	0.91 (0.54, 1.52)	1	2	50.0 (9.5, 90.5)	1.28 (0.32, 5.28)	31	78	39.7 (29.6, 50.8)	30	77	39.0 (28.8, 50.1)	44	115	38.3 (29.9, 47.4)	
B5CC	14			35	40.0 (25.6, 56.4)	1.18 (0.69, 2.02)	1	3	33.3 (6.1, 79.2)	0.97 (0.2, 4.98)	21	62	33.9 (23.3, 46.3)	20	58	34.5 (23.6, 47.3)	35	96	36.5 (27.5, 46.4)	
B5C	5			14	35.7 (16.3, 61.2)	0.99 (0.45, 2.16)	2	4	50.0 (15, 85)	1.45 (0.54, 4.11)	22	61	36.1 (25.2, 48.6)	20	58	34.5 (23.6, 47.3)	27	76	35.5 (25.7, 46.7)	
B5SL	3			7	42.9 (15.8, 75)	0.86 (0.36, 2.07)	1	3	33.3 (6.1, 79.2)	0.66 (0.13, 3.31)	46	92	50.0 (40, 60)	45	89	50.6 (40.4, 60.7)	49	99	49.5 (39.9, 59.2)	
B5OS	1			2	0.0 (9.5, 90.5)	NA (NA, NA)	1	2	50.0 (9.5, 90.5)	1.92 (0.48, 8.33)	13	47	0.0 (16.9, 41.8)	12	46	26.1 (15.6, 40.3)	14	50	28.0 (17.5, 41.7)	
Total	59			139	42.4 (34.5, 50.8)	0.94 (0.76, 1.17)	15	44	34.1 (21.9, 48.9)	0.73 (0.48, 1.11)	259	575	45.0 (41, 49.1)	244	521	46.8 (42.6, 51.1)	318	704	45.2 (41.5, 48.9)	
Subsequent	B5WN			101	128	78.9 (71, 85.1)	0.94 (0.85, 1.03)	26	34	76.5 (60, 87.6)	0.91 (0.75, 1.1)	460	547	84.1 (80.8, 86.9)	434	515	84.3 (80.9, 87.2)	561	677	82.9 (79.8, 85.5)
	B5CM		22	66	33.3 (23.2, 45.3)	0.76 (0.53, 1.09)	33	86	38.4 (28.8, 48.9)	0.86 (0.66, 1.16)	154	350	44.0 (38.9, 49.2)	121	272	44.5 (38.7, 50.4)	176	424	41.5 (36.9, 46.3)	
	B5AL		20	30	66.7 (48.8, 80.8)	0.92 (0.71, 1.2)	32	49	65.3 (51.3, 77.1)	0.90 (0.73, 1.12)	214	296	72.3 (66.9, 77.1)	182	250	72.8 (67, 77.9)	234	329	71.1 (66, 75.8)	
	B5M		90	186	48.4 (41.3, 55.5)	0.88 (0.74, 1.04)	3	12	25.0 (8.9, 53.2)	0.45 (0.17, 1.2)	303	550	55.1 (50.9, 59.2)	30						

3.c.r.t, Detection of invasive breast cancer less than or equal to 15mm (rate), women screened during the 4 years to December 2019

Table 26: 3.c.r.t Detection of invasive breast cancer less than or equal to 15mm (rate per 10,000 screens), women screened during the 4 years to December 2019

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
		Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Pacific / Non-Pacific Ratio	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)	Invasive Cancers ≤15mm	Women Screened	Rate of Invasive Cancers per 10,000 (95% CI)		
45 to 49	Initial	BSWN	4	2,439	16.4 (7.6, 40.9)	0.62 (0.22, 1.72)	1	777	12.9 (3.4, 71.4)	0.47 (0.07, 3.41)	39	14,636	26.6 (20.7, 35.2)	38	13,859	27.4 (21.2, 36.4)	43	17,075	25.2 (19.7, 32.9)	
		BSCM	3	1,861	16.1 (6.8, 46)	1.99 (0.54, 7.34)	5	2,837	17.6 (8.8, 39.9)	3.64 (1.52, 13.56)	9	11,104	8.1 (4.5, 15.2)	4	8,267	4.8 (2, 12.3)	12	12,965	9.3 (5.5, 15.9)	
		BSAL	3	792	37.9 (20.4, 103.2)	1.21 (0.37, 3.94)	3	1,126	26.6 (12.7, 74.4)	0.83 (0.27, 2.74)	30	9,551	31.4 (23.9, 42.9)	27	8,425	32.0 (24.1, 44.5)	33	10,343	31.9 (24.6, 42.9)	
		BSM	5	3,468	14.4 (7, 32.9)	1.14 (0.42, 3.07)	0	341	0.0 (0, 111.4)	NA (NA, NA)	17	13,384	12.7 (8.3, 20)	17	13,043	13.0 (8.5, 20.5)	22	16,852	13.1 (9, 19.4)	
		BSCC	6	2,596	23.1 (12.7, 48.3)	2.30 (0.84, 6.32)	1	237	42.2 (20.3, 222.2)	4.55 (0.64, 35.8)	10	9,951	10.0 (5.8, 18.2)	9	9,714	9.3 (5.1, 17.3)	16	12,547	12.8 (8.2, 20.3)	
		BSC	2	1,246	16.1 (5.9, 56.8)	1.23 (0.28, 5.44)	1	601	16.6 (4.9, 91.7)	1.30 (0.18, 9.95)	13	9,947	13.1 (8.1, 21.9)	12	9,346	12.8 (7.8, 22)	15	11,193	13.4 (8.6, 21.7)	
		BSSL	1	1,394	7.2 (1.6, 40.2)	0.42 (0.06, 3.06)	1	310	32.3 (13.1, 173)	1.91 (0.27, 13.93)	32	18,640	17.2 (12.7, 23.7)	31	18,330	16.9 (12.4, 23.5)	33	20,034	16.5 (12.2, 22.7)	
		BSOS	1	593	16.9 (5, 92.9)	1.81 (0.22, 15.05)	1	99	101.0 (98.2, 469.8)	12.84 (1.83, 108.92)	6	6,456	9.3 (4.6, 19.9)	5	6,357	7.9 (3.6, 18.2)	7	7,049	9.9 (5.2, 20.1)	
		Total	25	14,389	17.4 (12.4, 25)	1.04 (0.68, 1.59)	13	6,328	20.5 (13.2, 34)	1.25 (0.73, 2.21)	156	93,669	16.7 (14.5, 19.3)	143	87,341	16.4 (14.1, 19.1)	181	108,058	16.8 (14.7, 19.2)	
		Subsequent	BSWN	7	2,719	25.7 (14.9, 50.6)	1.09 (0.49, 2.41)	0	999	0.0 (0, 38.3)	NA (NA, NA)	44	18,576	23.7 (18.5, 30.9)	44	17,577	25.0 (19.6, 32.6)	51	21,295	23.9 (19, 30.6)
	BSCM		1	1,951	5.1 (1.1, 28.8)	0.80 (0.1, 6.34)	1	3,044	3.3 (0.7, 18.5)	0.45 (0.06, 3.63)	9	14,115	6.4 (3.5, 12)	8	11,071	7.2 (3.8, 14.1)	10	16,066	6.2 (3.5, 11.3)	
	BSAL		1	925	10.8 (2.7, 60.2)	0.51 (0.07, 3.71)	3	1,371	21.9 (9.9, 61.7)	1.03 (0.33, 3.4)	27	12,619	21.4 (15.6, 30.2)	24	11,248	21.3 (15.3, 30.8)	28	13,544	20.7 (15.1, 29)	
	BSM		3	3,384	8.9 (3.4, 25.6)	0.87 (0.25, 2.99)	0	315	0.0 (0, 120.5)	NA (NA, NA)	16	15,714	10.2 (6.5, 16.3)	16	15,399	10.4 (6.7, 16.6)	19	19,098	9.9 (6.6, 15.3)	
	BSCC		3	2,896	10.4 (4.1, 29.9)	0.92 (0.27, 3.18)	1	277	36.1 (15.7, 192.3)	3.37 (0.48, 25.55)	15	13,350	11.2 (7.1, 18.2)	14	13,073	10.7 (6.7, 17.7)	18	16,246	11.1 (7.3, 17.2)	
	BSC		2	1,561	12.8 (4.5, 45.7)	1.83 (0.4, 8.47)	1	772	13.0 (3.5, 71.8)	1.96 (0.28, 15.63)	9	12,863	7.0 (3.8, 13.1)	8	12,091	6.6 (3.5, 12.9)	11	14,424	7.6 (4.4, 13.5)	
	BSSL		2	2,064	9.7 (3.2, 34.7)	1.24 (0.29, 5.27)	0	325	0.0 (0, 116.8)	NA (NA, NA)	21	26,777	7.8 (5.3, 11.9)	21	26,452	7.9 (5.3, 12)	23	28,841	8.0 (5.4, 11.8)	
	BSOS		0	779	0.0 (0, 49.1)	NA (NA, NA)	0	123	0.0 (0, 302.9)	NA (NA, NA)	14	8,792	15.9 (10.1, 26.1)	14	8,669	16.1 (10.3, 26.4)	14	9,571	14.6 (9.3, 24)	
	Total		19	16,279	11.7 (7.8, 17.9)	0.92 (0.57, 1.49)	6	7,226	8.3 (4.1, 17.8)	0.64 (0.29, 1.46)	155	122,806	12.6 (10.9, 14.6)	149	115,580	12.9 (11.1, 15)	174	139,085	12.5 (10.9, 14.4)	
	50 to 69		Initial	BSWN	8	512	156.3 (126.79, 322.04)	2.80 (1.28, 6.11)	0	209	0.0 (0, 180.5)	NA (NA, NA)	28	5,016	55.8 (45.3, 73.9)	28	4,807	58.2 (47.7, 76.7)	36	5,528
		BSCM		2	372	53.8 (32.7, 175.9)	5.08 (0.93, 27.62)	0	763	0.0 (0, 50.1)	NA (NA, NA)	4	3,776	10.6 (4.6, 26.7)	4	3,013	13.3 (6, 33.3)	6	4,148	14.5 (7.4, 30.7)
BSAL		3		182	164.8 (129.01, 524.38)	3.26 (0.96, 11.08)	0	292	0.0 (0, 129.8)	NA (NA, NA)	16	3,163	50.6 (38.2, 75)	16	2,871	55.7 (43, 81.7)	19	3,345	56.8 (44.8, 80.2)	
BSM		8		1,245	64.3 (48.8, 110.1)	1.99 (0.84, 4.73)	1	134	74.6 (55.2, 368.6)	2.41 (0.34, 18.28)	14	4,331	32.3 (22.1, 51.3)	13	4,197	31.0 (20.8, 50.2)	22	5,576	39.5 (29.6, 56.1)	
BSCC		8		910	87.9 (78.8, 138.3)	2.40 (0.97, 5.94)	0	90	0.0 (0, 409.4)	NA (NA, NA)	11	3,001	36.7 (24.6, 61.4)	11	2,911	37.8 (25.5, 63.1)	19	3,911	48.6 (37, 69.8)	
BSC		3		355	84.5 (71.9, 202.3)	2.85 (0.78, 10.48)	1	199	50.3 (27.3, 260.7)	1.78 (0.25, 14.18)	9	3,036	29.6 (18.5, 53.3)	8	2,837	28.2 (17.1, 52.8)	12	3,391	35.4 (24, 58)	
BSSL		2		217	92.2 (83.7, 271.3)	2.06 (0.47, 9)	0	79	0.0 (0, 463.7)	NA (NA, NA)	14	3,127	44.8 (32.4, 69.3)	14	3,048	45.9 (33.4, 70.9)	16	3,344	47.8 (35.7, 71.4)	
BSOS		0		123	0.0 (0, 302.9)	NA (NA, NA)	0	41	0.0 (0, 856.7)	NA (NA, NA)	7	1,411	49.6 (33.7, 92.4)	7	1,370	51.1 (35.1, 94.8)	7	1,534	45.6 (30.2, 85.8)	
Total		34		3,916	86.6 (80, 103.3)	2.26 (1.54, 3.33)	2	1,807	11.1 (3.7, 39.6)	0.27 (0.07, 1.11)	103	26,861	38.3 (33.2, 44.9)	101	25,054	40.3 (35, 47.2)	137	30,777	44.5 (39.5, 50.7)	
Subsequent		BSWN		94	14,992	62.7 (56.1, 71.8)	1.69 (1.35, 2.11)	26	5,428	47.9 (37.7, 65.1)	1.01 (0.89, 1.94)	416	111,823	37.2 (34.5, 40.2)	390	106,395	36.7 (33.9, 39.7)	510	126,815	40.2 (37.7, 43.1)
		BSCM	21	9,097	23.1 (16.3, 34.1)	1.15 (0.73, 1.82)	32	14,950	21.4 (16, 29.4)	1.39 (0.77, 1.61)	145	72,533	20.0 (17.3, 23.2)	113	57,583	19.6 (16.7, 23.2)	166	81,630	20.2 (17.8, 23.3)	
		BSAL	19	4,199	45.2 (34.3, 65.5)	1.59 (1, 2.55)	29	6,780	42.8 (33.5, 57.7)	1.60 (1.11, 2.38)	187	65,878	28.4 (25.2, 32.1)	158	59,098	26.7 (23.5, 30.6)	206	70,077	29.4 (26.3, 33.1)	
		BSM	87	20,155	43.2 (37.2, 51)	1.65 (1.3, 2.09)	3	1,678	17.9 (7.7, 50.8)	0.68 (0.22, 2.12)	287	109,515	26.2 (23.8, 29)	284	107,837	26.3 (23.9, 29.1)	374	129,670	28.8 (26.5, 31.5)	
		BSCC	50	16,229	30.8 (24.8, 39.2)	1.76 (1.28, 2.41)	2	1,420	14.1 (5, 50.1)	0.80 (0.2, 3.23)	164	93,583	17.5 (15.3, 20.2)	162	92,163	17.6 (15.3, 20.3)	214	109,812	19.5 (17.3, 22)	
		BSC	18	7,985	22.5 (15.5, 34.4)	1.13 (0.7, 1.85)	4	4,233	9.4 (4.1, 23.9)	0.46 (0.17, 1.25)	158	79,547	19.9 (17.3, 22.9)	154	75,314	20.4 (17.8, 23.6)	176	87,532	20.1 (17.7, 23)	
		BSSL	21	8,439	24.9 (17.7, 36.6)	1.25 (0.8, 1.95)	1	1,455	6.9 (1.5, 38.5)	0.34 (0.05, 2.44)	297	149,366	19.9 (18, 22)	296	147,911	20.0 (18.1, 22.2)	318	157,805	20.2 (18.3, 22.3)	
		BSOS	7	3,412	20.5 (11.5, 40.8)	0.77 (0.36, 1.64)	1	397	25.2 (9, 136.8)	0.94 (0.13, 6.72)	150	56,178	26.7 (23.4, 30.7)	149	55,781	26.7 (23.4, 30.7)	157	59,590	26.3 (23.1, 30.2)	
		Total	317	84,508	37.5 (34.5, 41)	1.54 (1.36, 1.73)	98	36,341	27.0 (22.9, 32.1)	1.11 (0.91, 1.36)	1,804	738,423	24.4 (23.5, 25.4)	1,706	702,082	24.3 (23.3, 25.3)	2,121	822,931	25.8 (24.9, 26.7)	
		45 to 69	Initial	BSWN	12	2,951	40.7 (23.3, 70.9)	1.19 (0.65, 2.2)	1	986	10.1 (2.5, 56.5)	0.29 (0.04, 2.06)	67	19,652	34.1 (28.4, 41.8)	66	18,666	35.4 (29.4, 43.3)	79	22,603
BSCM				5	2,233	22.4 (9.6, 52.3)	2.56 (0.91, 7.18)	5	3,600	13.9 (6.7, 31.7)	1.96 (0.82, 5.98)	13	14,880	8.7 (5.3, 14.7)	8	11,280	7.1 (3.8, 13.8)	18	17,113	10.5 (6.9, 16.4)
BSAL	6			974	61.6 (28.3, 133.7)	1.70 (0.73, 3.98)	3	1,418	21.2 (9.5, 59.7)	0.56 (0.18, 1.79)	46	12,714	36.2 (29.2, 46.2)	43	11,296	38.1 (30.6, 48.9)	52	13,688	38.0 (31.1, 47.6)	
BSM	13			4,713	27.6 (16.1, 47.1)	1.58 (0.83, 3.01)	1	475	21.1 (6.9, 115.1)	1.21 (0.17, 8.85)	31	17,715	17.5 (12.9, 24.3)	30	17,240	17.4 (12.7, 24.3)	44	22,428	19.6 (15.2, 25.7)	
BSCC	14			3,506	39.9 (23.8, 66.9)	2.46 (1.25, 4.84)	1	327	30.6 (12.1, 164.5)	1.93 (0.27, 14.34)	21	12,952	16.2 (11.2, 24.2)	20	12,625	15.8 (10.8, 23.9)	35	16,458	21.3 (16.1, 28.8)	
BSC	5			1,601	31.2 (13.3, 72.9)	1.84 (0.7, 4.86)	2	800	25.0 (10.5, 87)	1.52 (0.38, 6.5)	22	12,983	16.9 (11.8, 25)	20	12,183	16.4 (11.2, 24.7)	27	14,584	18.5 (13.4, 26.3)	
BSSL	3			1,611	18.6 (6.3, 54.6)	0.88 (0.27, 2.83)	1	389	25.7 (9.2, 139.5)	1.22 (0.17, 8.84)	46	21,767	21.1 (16.5, 27.5)	45	21,378	21.0 (16.4, 27.5)	49	23,378	21.0 (16.5, 27.1)	
BSOS	1			716	14.0 (2.5, 78.7)	0.85 (0.11, 6.45)	1	140	71.4 (50.9, 355.2)	4.60 (0.65, 35.13)	13	7,867	16.5 (10.4, 27.5)	12	7,727	15.5 (9.6, 26.5)	14	8,583	16.3 (10.4, 26.7)	
Total	59			18,305	32.2 (25, 41.6)	1.50 (1.13, 1.99)	15	8,135	18.4 (12, 29.5)	0.85 (0.51, 1.43)	259	120,530	21.5 (19.3, 24)	244	112,395	21.7 (19.5, 24.3)	318	138,835	22.9 (20.8, 25.3)	
Subsequent	BSWN			101	17,711	57.0 (47, 69.2)	1.62 (1.3, 2)	26	6,427	40.5 (31.1, 55.8)	1.16 (0.79, 1.72)									

3.d.t, Nodal involvement, women screened during the 4 years to December 2019

Table 27: 3.d.t, Nodal involvement, women screened during the 4 years to December 2019

			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Māori / Non-Māori Ratio	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)	Node Negative Invasive Cancers	Invasive Cancers	% of Invasive Cancers with no Nodal Involvement (95% CI)
45 to 49	Initial	BSWN	6	8	75.0 (40.9, 92.9)	1.00 (0.65, 1.54)	0	1	0.0 (0, 79.3)	NA (NA, NA)	39	52	75.0 (61.8, 84.8)	39	55	70.9 (57.9, 81.2)	45	64	70.3 (58.2, 80.1)
		BSCM	7	13	53.8 (29.1, 76.8)	0.83 (0.48, 1.44)	10	15	66.7 (41.7, 84.8)	0.76 (0.53, 1.12)	31	48	64.6 (50.4, 76.6)	21	24	87.5 (69.9, 95.7)	38	52	73.1 (59.7, 83.2)
		BSAL	3	5	60.0 (23.1, 88.2)	0.64 (0.31, 1.32)	4	7	57.1 (25, 84.2)	0.84 (0.44, 1.64)	30	32	93.8 (79.9, 98.3)	26	38	68.4 (52.5, 80.9)	33	50	66.0 (52.2, 77.6)
		BSM	8	15	53.3 (30.1, 75.2)	0.64 (0.39, 1.05)	1	1	100.0 (20.7, 100)	1.50 (1.5, 1.89)	25	30	83.3 (66.4, 92.7)	24	36	66.7 (50.3, 79.8)	33	52	63.5 (49.9, 75.2)
		BSCC	12	20	60.0 (38.7, 78.1)	0.74 (0.49, 1.1)	2	2	100.0 (34.2, 100)	1.60 (1.6, 2.09)	22	27	81.5 (63.3, 91.8)	20	32	62.5 (45.3, 77.1)	34	54	63.0 (49.6, 74.6)
		BSC	5	9	55.6 (26.7, 81.1)	0.62 (0.34, 1.13)	1	1	100.0 (20.7, 100)	1.38 (1.38, 1.69)	25	28	89.3 (72.8, 96.3)	24	33	72.7 (55.8, 84.9)	30	43	69.8 (54.9, 81.4)
		BSSL	2	3	66.7 (20.8, 93.9)	0.77 (0.35, 1.73)	1	3	33.3 (6.1, 79.2)	0.47 (0.09, 2.33)	56	65	86.2 (75.7, 92.5)	55	77	71.4 (60.5, 80.3)	58	83	69.9 (59.3, 78.7)
		BSOS	1	2	50.0 (9.5, 90.5)	0.79 (0.19, 3.23)	2	2	100.0 (34.2, 100)	1.14 (1.14, 1.31)	24	38	63.2 (47.3, 76.6)	22	25	88.0 (70.9, 95.8)	25	29	86.2 (69.4, 94.5)
		Total	44	75	58.7 (47.4, 69.1)	0.74 (0.61, 0.91)	21	32	65.6 (48.3, 79.6)	0.91 (0.71, 1.18)	252	320	78.8 (73.9, 82.9)	231	320	72.2 (67, 76.8)	296	427	69.3 (64.8, 73.5)
		Subsequent	BSWN	8	10	80.0 (49, 94.3)	1.13 (0.79, 1.61)	0	0	NA (NA, NA)	NA (NA, NA)	39	55	70.9 (57.9, 81.2)	39	59	66.1 (53.4, 76.9)	47	69
	BSCM		3	7	42.9 (15.8, 75)	0.69 (0.28, 1.68)	2	8	25.0 (7.1, 59.1)	0.33 (0.1, 1.13)	23	37	62.2 (46.1, 75.9)	21	28	75.0 (56.6, 87.3)	26	43	60.5 (45.6, 73.6)
	BSAL		1	2	50.0 (9.5, 90.5)	0.52 (0.13, 2.06)	6	7	85.7 (48.7, 97.4)	1.02 (0.76, 1.44)	32	33	97.0 (84.7, 99.5)	26	31	83.9 (67.4, 92.9)	33	40	82.5 (68.3, 91.3)
	BSM		9	12	75.0 (46.8, 91.1)	0.81 (0.58, 1.14)	1	1	100.0 (20.7, 100)	1.15 (1.15, 1.29)	35	38	92.1 (79.2, 97.3)	34	39	87.2 (73.3, 94.4)	44	52	84.6 (72.5, 92)
	BSCC		5	7	71.4 (35.9, 91.8)	0.98 (0.59, 1.63)	2	2	100.0 (34.2, 100)	1.28 (1.28, 1.54)	27	37	73.0 (57, 84.6)	25	32	78.1 (61.2, 89)	32	41	78.0 (63.3, 88)
	BSC		2	7	28.6 (8.2, 64.1)	0.32 (0.1, 1.06)	1	1	100.0 (20.7, 100)	1.36 (1.36, 1.78)	15	17	88.2 (65.7, 96.7)	14	19	73.7 (51.2, 88.2)	17	27	63.0 (44.2, 78.5)
	BSSL		4	7	57.1 (25, 84.2)	0.65 (0.34, 1.25)	0	1	0.0 (0, 79.3)	NA (NA, NA)	48	55	87.3 (76.9, 93.7)	48	64	75.0 (63.2, 84)	52	72	72.2 (61, 81.2)
	BSOS		1	1	100.0 (20.7, 100)	0.91 (0.56, 1.48)	0	0	NA (NA, NA)	NA (NA, NA)	23	21	109.5 #NUM!	23	30	76.7 (59.1, 88.2)	24	31	77.4 (60.2, 88.6)
	Total		33	53	62.3 (48.8, 74.1)	0.75 (0.61, 0.94)	12	20	60.0 (38.7, 78.1)	0.79 (0.55, 1.13)	242	293	82.6 (77.8, 86.5)	230	302	76.2 (71, 80.6)	275	375	73.3 (68.6, 77.6)
	50 to 69	Initial	BSWN	6	10	60.0 (31.3, 83.2)	0.87 (0.5, 1.5)	0	0	NA (NA, NA)	NA (NA, NA)	29	42	69.0 (54, 80.9)	29	39	74.4 (58.9, 85.4)	35	49
BSCM			3	5	60.0 (23.1, 88.2)	1.23 (0.56, 2.71)	3	5	60.0 (23.1, 88.2)	0.92 (0.45, 2)	18	37	48.6 (33.4, 64.1)	15	23	65.2 (44.9, 81.2)	21	33	63.6 (46.6, 77.8)
BSAL			3	4	75.0 (30.1, 95.4)	1.06 (0.57, 1.97)	0	2	0.0 (0, 65.8)	NA (NA, NA)	17	24	70.8 (50.8, 85.1)	17	26	62.5 (45.2, 80.6)	20	32	62.5 (45.3, 77.1)
BSM			12	21	57.1 (36.5, 75.5)	0.91 (0.59, 1.41)	1	1	100.0 (20.7, 100)	1.45 (1.45, 1.77)	30	48	62.5 (48.4, 74.8)	29	42	69.0 (54, 80.9)	42	64	65.6 (53.4, 76.1)
BSCC			12	15	80.0 (54.8, 93)	1.56 (1.03, 2.34)	0	1	0.0 (0, 79.3)	NA (NA, NA)	18	35	51.4 (35.6, 67)	18	23	78.3 (58.1, 90.3)	30	39	76.9 (61.7, 87.4)
BSC			4	5	80.0 (37.6, 96.4)	1.36 (0.65, 1.7)	3	3	100.0 (43.9, 100)	1.36 (1.36, 1.69)	25	33	75.8 (59, 87.2)	22	30	73.3 (55.6, 85.8)	29	38	76.3 (60.8, 87)
BSSL			3	4	75.0 (30.1, 95.4)	1.27 (0.66, 2.42)	0	0	NA (NA, NA)	NA (NA, NA)	16	27	59.3 (40.7, 75.5)	16	21	76.2 (54.9, 89.4)	19	25	76.0 (56.6, 88.5)
BSOS			0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	9	9	100.0 (70.1, 100)	9	11	81.8 (52.3, 94.9)	9	11	81.8 (52.3, 94.9)
Total			43	64	62.2 (55, 77.4)	1.06 (0.87, 1.29)	7	12	58.3 (32, 80.7)	0.81 (0.5, 1.31)	162	255	63.5 (57.5, 69.2)	155	215	72.1 (65.7, 77.7)	205	291	70.4 (65, 75.4)
Subsequent			BSWN	96	118	81.4 (73.4, 87.4)	0.99 (0.9, 1.09)	25	34	73.5 (56.9, 85.4)	0.91 (0.74, 1.12)	404	492	82.1 (78.5, 85.2)	379	469	80.8 (77, 84.1)	500	621
		BSCM	44	59	74.6 (62.2, 83.9)	0.94 (0.8, 1.1)	64	78	82.1 (72.1, 89)	1.06 (0.95, 1.2)	248	313	79.2 (74.4, 83.4)	184	237	77.6 (71.9, 82.5)	292	374	78.1 (73.6, 82)
		BSAL	19	28	67.9 (49.3, 82.1)	0.79 (0.61, 1.02)	36	42	85.7 (72.2, 93.3)	1.08 (0.96, 1.24)	227	263	86.3 (81.6, 89.9)	191	241	79.3 (73.7, 83.9)	246	311	79.1 (74.2, 83.2)
		BSM	124	174	71.3 (64.1, 77.5)	0.85 (0.76, 0.94)	8	11	72.7 (43.4, 90.3)	0.88 (0.61, 1.26)	431	512	84.2 (80.8, 87.1)	423	510	82.9 (79.4, 86)	555	695	79.9 (76.7, 82.7)
		BSCC	72	109	66.1 (56.8, 74.3)	0.92 (0.79, 1.06)	5	9	55.6 (26.7, 81.1)	0.75 (0.42, 1.35)	282	392	71.9 (67.3, 76.2)	277	373	74.3 (69.6, 78.4)	354	491	72.1 (68, 75.9)
		BSC	42	51	82.4 (69.7, 90.4)	0.95 (0.83, 1.08)	13	17	76.5 (52.7, 90.4)	0.97 (0.74, 1.27)	287	330	87.0 (82.9, 90.2)	274	347	79.0 (74.4, 82.9)	329	415	79.3 (75.1, 82.9)
		BSSL	46	55	83.6 (71.7, 91.1)	0.99 (0.88, 1.12)	5	5	100.0 (56.6, 100)	1.20 (1.2, 1.25)	533	633	84.2 (81.2, 86.8)	528	636	83.0 (79.9, 85.7)	579	696	83.2 (80.3, 85.8)
		BSOS	13	15	86.7 (62.1, 96.3)	1.05 (0.86, 1.29)	4	5	80.0 (37.6, 96.4)	1.00 (0.65, 1.56)	240	291	82.5 (77.7, 86.4)	236	296	79.7 (74.8, 83.9)	253	316	80.1 (75.3, 84.1)
		Total	456	609	74.9 (71.3, 78.2)	0.91 (0.87, 0.96)	160	201	79.6 (73.5, 84.6)	0.99 (0.93, 1.07)	2,652	3,226	82.2 (80.8, 83.5)	2,492	3,109	80.2 (78.7, 81.5)	3,108	3,919	79.3 (78, 80.5)
45 to 69		Initial	BSWN	12	18	66.7 (43.7, 83.7)	0.92 (0.65, 1.31)	0	1	0.0 (0, 79.3)	NA (NA, NA)	68	94	72.3 (62.6, 80.4)	68	94	72.3 (62.6, 80.4)	80	113
	BSCM		10	18	55.6 (33.7, 75.4)	0.96 (0.61, 1.51)	13	20	65.0 (43.3, 81.9)	0.85 (0.62, 1.21)	49	85	57.6 (47, 67.6)	36	47	76.6 (62.8, 86.4)	59	85	69.4 (59, 78.2)
	BSAL		6	9	66.7 (35.4, 87.9)	0.79 (0.49, 1.28)	4	9	44.4 (18.9, 73.3)	0.66 (0.32, 1.4)	47	56	83.9 (72.2, 91.3)	43	64	67.2 (55, 77.4)	53	82	64.6 (53.8, 74.1)
	BSM		20	36	55.6 (39.6, 70.5)	0.79 (0.57, 1.09)	2	2	100.0 (34.2, 100)	1.47 (1.47, 1.71)	55	78	70.5 (59.6, 79.5)	53	78	67.9 (57, 77.3)	75	116	64.7 (55.6, 72.8)
	BSCC		24	35	68.6 (52, 81.4)	1.06 (0.79, 1.42)	2	3	100.0 (20.8, 93.9)	0.96 (0.43, 2.19)	40	62	64.5 (52.1, 75.3)	38	55	69.1 (56, 79.7)	64	93	68.8 (58.8, 77.3)
	BSC		9	14	64.3 (38.8, 83.7)	0.78 (0.52, 1.18)	4	4	100.0 (51, 100)	1.37 (1.37, 1.59)	50	61	82.0 (70.5, 89.6)	46	63	73.0 (61, 82.4)	59	81	72.8 (62.3, 81.3)
	BSSL		5	7	71.4 (35.9, 91.8)	0.91 (0.56, 1.48)	1	3	33.3 (6.1, 79.2)	0.46 (0.09, 2.29)	72	92	78.3 (68.8, 85.5)	71	98	72.4 (62.9, 80.3)	77	108	71.3 (62.9, 80.3)
	BSOS		1	2	50.0 (9.5, 90.5)	0.71 (0.18, 2.88)	2	2	100.0 (34.2, 100)	1.16 (1.16, 1.32)	33	47	70.2 (56, 81.3)	31	36	86.1 (71.3, 93.9)	34	40	85.0 (70.9, 92.9)
	Total		87	139	62.6 (54.3, 70.2)	0.87 (0.76, 1)	28	44	63.6 (48.9, 76.2)	0.88 (0.71, 1.11)	414	575	72.0 (68.2, 75.5)	386	535	72.1 (68.2, 75.8)	501	718	69.8 (66.3, 73)
	Subsequent		BSWN	104	128	81.3 (73.6, 87.1)	1.00 (0.91, 1.1)	25	34	73.5 (56.9, 85.4)	0.93 (0.76, 1.14)	443	547	81.0 (77.5, 84.1)	418	528	79.2 (75.5, 82.4)	547	690
		BSCM	47	66	71.2 (59.4, 80.7)	0.92 (0.78, 1.08)	66	86	76.7 (66.8, 84.4)	0.99 (0.88, 1.13)	271	350	77.4 (72.8, 81.5)	205	265	77.4 (71.9, 82)	318	417	76.3 (71.9, 80.1)
		BSAL	20	30	66.7 (48.8, 80.8)	0.76 (0.59, 0.98)	42	49	85.7 (73.3, 92.9)	1.07 (0.96, 1.22)	259	296	87.5 (83.2, 90.8)	217	272	79.8 (74.6, 84.1)	279	351	79.5 (75, 83.4)
		BSM	133	186	71.5 (64.6, 77.5)	0.84 (0.77, 0.93)	9	12	75.0 (46.										

3.e.t, Ductal carcinoma in situ diagnosis, women screened during the 4 years to December 2019

Table 28: 3.e.t.1, Ductal carcinoma in situ diagnosis, women screened during the 4 years to December 2019



			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			DCIS	Cancers	% of Cancers that were DCIS (95% CI)	Māori / Non-Māori Ratio	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	Pacific / Non-Pacific Ratio	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	DCIS	Cancers	% of Cancers that were DCIS (95% CI)	DCIS	Cancers	% of Cancers that were DCIS (95% CI)
45 to 49		BSWN	9	27	33.3 (18.6, 52.2)	1.22 (0.68, 2.21)	2	3	66.7 (20.8, 93.9)	2.52 (1.13, 5.85)	43	158	27.2 (20.9, 34.6)	41	155	26.5 (20.1, 33.9)	52	185	28.1 (22.1, 35)
		BSCM	3	23	13.0 (4.5, 32.1)	0.37 (0.13, 1.1)	12	35	34.3 (20.8, 50.8)	1.03 (0.65, 1.79)	38	108	35.2 (26.8, 44.6)	26	78	33.3 (23.9, 44.4)	41	136	30.1 (23.1, 38.3)
		BSAL	2	9	22.2 (6.3, 54.7)	0.58 (0.17, 2.02)	3	17	17.6 (6.2, 41)	0.56 (0.2, 1.62)	35	91	38.5 (29.1, 48.7)	32	101	31.7 (23.4, 41.3)	37	127	29.1 (21.9, 37.6)
		BSM	14	41	34.1 (21.6, 49.5)	1.07 (0.65, 1.77)	0	2	0.0 (0, 65.8)	NA (NA, NA)	36	113	31.9 (24, 40.9)	36	111	32.4 (24.4, 41.6)	50	154	32.5 (25.6, 40.2)
		BSCC	6	33	18.2 (8.6, 34.4)	0.56 (0.26, 1.22)	1	5	20.0 (3.6, 62.4)	0.61 (0.11, 3.62)	32	99	32.3 (23.9, 42)	31	95	32.6 (24, 42.6)	38	133	28.6 (21.6, 36.8)
		BSC	3	19	15.8 (5.5, 37.6)	0.35 (0.12, 1.04)	2	4	50.0 (15, 85)	1.46 (0.55, 4.08)	29	65	44.6 (33.2, 56.7)	27	79	34.2 (24.7, 45.2)	32	102	31.4 (23.2, 40.9)
		BSSL	5	15	33.3 (15.2, 58.3)	0.96 (0.46, 2.01)	1	5	20.0 (3.6, 62.4)	0.65 (0.11, 3.83)	63	181	34.8 (28.2, 42)	62	203	30.5 (24.6, 37.2)	68	223	30.5 (24.8, 36.8)
		BSOS	1	4	25.0 (4.6, 69.9)	0.82 (0.15, 4.64)	0	2	0.0 (0, 65.8)	NA (NA, NA)	24	79	30.4 (21.3, 41.2)	24	79	30.4 (21.3, 41.2)	25	85	29.4 (20.8, 39.8)
		Total	43	171	25.1 (19.2, 32.1)	0.75 (0.57, 0.99)	21	73	43.8 (19.7, 40)	1.41 (0.98, 2.05)	300	894	33.6 (30.5, 36.7)	279	901	31.0 (28, 34.1)	343	1,145	30.0 (28.8, 31.3)
50 to 69		BSWN	27	122	22.1 (15.7, 30.3)	0.91 (0.64, 1.3)	14	48	29.2 (18.2, 43.2)	1.29 (0.83, 2.05)	162	666	24.3 (21.2, 27.7)	148	656	22.6 (19.5, 25.9)	189	788	24.0 (20.1, 25.9)
		BSCM	13	72	18.1 (10.9, 28.5)	0.79 (0.47, 1.33)	23	106	21.7 (14.9, 30.5)	0.96 (0.67, 1.45)	99	433	22.9 (19.2, 27)	76	336	22.6 (18.5, 27.4)	112	505	22.2 (18.4, 25.6)
		BSAL	6	29	20.7 (9.8, 38.4)	0.71 (0.34, 1.47)	8	52	15.4 (8, 27.5)	0.58 (0.31, 1.13)	104	356	29.2 (24.7, 34.1)	96	363	26.4 (22.2, 31.2)	110	385	28.6 (21, 29)
		BSM	37	208	17.8 (13.2, 23.6)	0.80 (0.58, 1.11)	6	18	33.3 (16.3, 56.3)	1.59 (0.83, 3.11)	152	683	22.3 (19.3, 25.5)	146	698	20.9 (18.1, 24.1)	189	891	21.2 (18, 23.2)
		BSCC	28	129	21.7 (15.5, 29.6)	0.92 (0.64, 1.32)	0	10	0.0 (0, 27.8)	NA (NA, NA)	123	520	23.7 (20.2, 27.5)	123	519	23.7 (20.2, 27.5)	151	649	23.3 (19.9, 26.3)
		BSC	9	64	14.1 (7.6, 24.6)	0.51 (0.27, 0.95)	6	26	23.1 (11, 42.1)	0.96 (0.47, 1.96)	126	456	27.6 (23.7, 31.9)	120	497	24.1 (20.6, 28.1)	135	520	26.0 (19.8, 26.6)
		BSSL	15	61	24.6 (15.5, 36.7)	0.88 (0.56, 1.39)	3	8	37.5 (13.7, 69.4)	1.41 (0.58, 3.48)	240	863	27.8 (24.9, 30.9)	237	894	26.5 (23.7, 29.5)	255	924	27.6 (23.8, 29.4)
		BSOS	2	14	14.3 (4, 39.9)	0.56 (0.15, 2.05)	1	6	16.7 (3, 56.4)	0.68 (0.11, 4.12)	100	393	25.4 (21.4, 30)	99	406	24.4 (20.5, 28.8)	102	407	25.1 (20.1, 28.2)
		Total	137	699	19.6 (16.8, 22.7)	0.77 (0.66, 0.91)	61	274	22.3 (17.7, 27.6)	0.93 (0.75, 1.17)	1,106	4,370	25.3 (24, 26.6)	1,045	4,369	23.9 (22.7, 25.2)	1,243	5,069	24.5 (22.2, 24.4)
45 to 69		BSWN	36	149	24.2 (18, 31.6)	0.97 (0.71, 1.32)	16	51	31.4 (20.3, 45)	1.35 (0.9, 2.06)	205	824	24.9 (22, 27.9)	189	811	23.3 (20.5, 26.3)	241	973	24.8 (21.3, 26.6)
		BSCM	16	95	16.8 (10.6, 25.6)	0.67 (0.42, 1.06)	35	141	24.8 (18.4, 32.6)	1.01 (0.76, 1.41)	137	541	25.3 (21.8, 29.2)	102	414	24.6 (20.7, 29)	153	641	23.9 (20.4, 26.9)
		BSAL	8	38	21.1 (11.1, 36.3)	0.68 (0.36, 1.27)	11	69	15.9 (9.1, 26.3)	0.58 (0.34, 1.01)	139	447	31.1 (27, 35.5)	128	464	27.6 (23.7, 31.8)	147	512	28.7 (22.3, 29.5)
		BSM	51	249	20.5 (15.9, 25.9)	0.87 (0.66, 1.14)	6	20	30.0 (14.5, 51.9)	1.33 (0.68, 2.64)	188	796	23.6 (20.8, 26.7)	182	809	22.5 (19.8, 25.5)	239	1,045	22.9 (19.8, 24.7)
		BSCC	34	162	21.0 (15.4, 27.9)	0.84 (0.6, 1.16)	1	15	6.7 (1.2, 29.8)	0.27 (0.04, 1.77)	155	619	25.0 (21.8, 28.6)	154	614	25.1 (21.8, 28.7)	189	782	24.2 (21.1, 27)
		BSC	12	83	14.5 (8.5, 23.6)	0.49 (0.28, 0.83)	8	30	26.7 (14.2, 44.4)	1.04 (0.58, 1.92)	155	521	29.8 (26, 33.8)	147	576	25.5 (22.1, 29.2)	167	622	26.8 (21.2, 27.6)
		BSSL	20	76	26.3 (17.7, 37.2)	0.91 (0.62, 1.34)	4	13	30.8 (12.7, 57.6)	1.13 (0.5, 2.57)	303	1,044	29.0 (26.4, 31.8)	299	1,097	27.3 (24.7, 30)	323	1,147	28.2 (24.8, 29.8)
		BSOS	3	18	16.7 (5.8, 39.2)	0.63 (0.22, 1.8)	1	8	12.5 (2.2, 47.1)	0.49 (0.08, 3.1)	124	472	26.3 (22.5, 30.4)	123	485	25.4 (21.7, 29.4)	127	492	25.8 (21.3, 28.8)
		Total	180	870	20.7 (18.1, 23.5)	0.77 (0.68, 0.89)	82	347	23.6 (19.5, 28.4)	0.94 (0.78, 1.14)	1,406	5,264	26.7 (25.5, 27.9)	1,324	5,270	25.1 (24, 26.3)	1,586	6,214	25.5 (23.4, 25.5)

4.a.1.t, Women with invasive breast cancers $\leq 30\text{mm}$ who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to December 2019

Description: The proportion of women with invasive breast cancers less than or equal to 30mm who have sentinel node biopsy as their first axillary procedure. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Figure 85: 4.a.1.t.1, 50 to 69, Women with invasive breast cancers $\leq 30\text{mm}$ who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2019



Among women aged 45–69 years whose invasive breast cancer was detected during the four years to 30 June 2019, 82% had a sentinel node biopsy as their first axillary procedure. The proportion was slightly lower for Māori women (77%) and similar for Pacific women (80%).

(Note the graphs above and below present data for 2-year time periods to 31 December 2019, while the table presents data for a 4-year period to 30 December 2019).

Figure 86: 4.a.1.t.2, 50 to 69, Women with invasive breast cancers $\leq 30\text{mm}$ who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2019, by LP



Table 29: 4.a.1.t.1, Women with invasive breast cancers ≤30mm who have sentinel node biopsy as their first axillary procedure, women screened during the 4 years to 31 December 2019


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure	Māori / Non-Māori Ratio	Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure	Pacific / Non-Māori Non-Pacific Ratio	Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure	Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure	Number Having Sentinel Node Biopsy as First Axillary Procedure	Number with Invasive Breast Cancer ≤ 30mm	% of Cancers having Sentinel Node Biopsy as First Axillary Procedure
45 to 49	BSWN	14	16	87.5 (61.7, 98.4)	1.08 (0.88, 1.33)	0	0	NA (NA, NA)	NA (NA, NA)	77	95	81.1 (71.7, 88.4)	77	95	81.1 (71.7, 88.4)	91	111	82.0 (73.6, 88.6)
	BSCM	10	14	71.4 (41.9, 91.6)	0.88 (0.61, 1.25)	11	15	73.3 (44.9, 92.2)	0.87 (0.64, 1.21)	44	54	81.5 (68.6, 90.7)	33	39	84.6 (69.5, 94.1)	54	68	79.4 (67.9, 88.3)
	BSAL	5	5	100.0	- 1.24 (1.1, 1.4)	8	11	72.7 (39.0, 94.0)	0.89 (0.62, 1.3)	54	67	80.6 (69.1, 89.2)	46	56	82.1 (69.6, 91.1)	59	72	81.9 (71.1, 90.0)
	BSM	15	24	62.5 (40.6, 81.2)	0.70 (0.51, 0.96)	1	1	100.0	- 1.11 (1.11, 1.21)	62	69	89.9 (80.2, 95.8)	61	68	89.7 (79.9, 95.8)	77	93	82.8 (73.6, 89.8)
	BSCC	16	25	64.0 (42.5, 82.0)	0.80 (0.58, 1.1)	3	4	75.0 (19.4, 99.4)	0.93 (0.53, 1.67)	48	60	80.0 (67.7, 89.2)	45	56	80.4 (67.6, 89.8)	64	85	75.3 (64.7, 84.0)
	BSC	8	11	72.7 (39.0, 94.0)	0.78 (0.54, 1.13)	2	2	100.0	- 1.08 (1.08, 1.18)	40	43	93.0 (80.9, 98.5)	38	41	92.7 (80.1, 98.5)	48	54	88.9 (77.4, 95.8)
	BSSL	4	8	50.0 (15.7, 84.3)	0.62 (0.31, 1.24)	2	4	50.0 (6.8, 93.2)	0.61 (0.23, 1.63)	104	128	81.3 (73.4, 87.6)	102	124	82.3 (74.4, 88.5)	108	136	79.4 (71.6, 85.9)
	BSOS	2	2	100.0	- 1.32 (1.13, 1.55)	1	2	50.0 (1.3, 98.7)	0.65 (0.16, 2.63)	37	49	75.5 (61.1, 86.7)	36	47	76.6 (62.0, 87.7)	39	51	76.5 (62.5, 87.2)
	Total	74	105	70.5 (60.8, 79.0)	0.85 (0.75, 0.97)	28	39	71.8 (55.1, 85.0)	0.86 (0.71, 1.05)	466	565	82.5 (79.1, 85.5)	438	526	83.3 (79.8, 86.4)	540	670	80.6 (77.4, 83.5)
	50 to 69	BSWN	85	115	73.9 (64.9, 81.7)	0.91 (0.81, 1.03)	22	28	78.6 (59.0, 91.7)	0.97 (0.8, 1.18)	404	499	81.0 (77.2, 84.3)	382	471	81.1 (77.3, 84.5)	489	614
BSCM		44	60	73.3 (60.3, 83.9)	0.87 (0.74, 1.02)	60	71	84.5 (74.0, 92.0)	1.00 (0.91, 1.12)	255	302	84.4 (79.8, 88.3)	195	231	84.4 (79.1, 88.8)	299	362	82.6 (78.3, 86.4)
BSAL		25	26	96.2 (80.4, 99.9)	1.08 (0.99, 1.18)	32	37	86.5 (71.2, 95.5)	0.97 (0.85, 1.11)	239	269	88.8 (84.5, 92.3)	207	232	89.2 (84.5, 92.9)	264	295	89.5 (85.4, 92.7)
BSM		136	173	78.6 (71.7, 84.5)	0.92 (0.84, 1)	8	11	72.7 (39.0, 94.0)	0.85 (0.59, 1.22)	454	531	85.5 (82.2, 88.4)	446	520	85.8 (82.5, 88.7)	590	704	83.8 (80.9, 86.5)
BSCC		79	112	70.5 (61.2, 78.8)	0.86 (0.76, 0.98)	5	8	62.5 (24.5, 91.5)	0.76 (0.44, 1.3)	294	359	81.9 (77.5, 85.7)	289	351	82.3 (77.9, 86.2)	373	471	79.2 (75.2, 82.8)
BSC		43	51	84.3 (71.4, 93.0)	1.00 (0.88, 1.14)	16	19	84.2 (60.4, 96.6)	1.00 (0.83, 1.23)	304	362	84.0 (79.8, 87.6)	288	343	84.0 (79.6, 87.7)	347	413	84.0 (80.1, 87.4)
BSSL		47	53	88.7 (77.0, 95.7)	1.07 (0.96, 1.18)	5	5	100.0	- 1.21 (1.21, 1.25)	517	622	83.1 (79.9, 86.0)	512	617	83.0 (79.8, 85.9)	564	675	83.6 (80.5, 86.3)
BSOS		10	13	76.9 (46.2, 95.0)	0.97 (0.72, 1.32)	2	5	40.0 (5.3, 85.3)	0.50 (0.17, 1.47)	224	283	79.2 (73.9, 83.7)	222	278	79.9 (74.7, 84.4)	234	296	79.1 (74.0, 83.5)
Total		469	603	77.8 (74.2, 81.0)	0.93 (0.89, 0.98)	150	184	81.5 (75.1, 86.9)	0.98 (0.91, 1.05)	2,691	3,227	83.4 (82.1, 84.7)	2,541	3,043	83.5 (82.1, 84.8)	3,160	3,830	82.5 (81.3, 83.7)
45 to 69		BSWN	99	131	75.6 (67.3, 82.7)	0.93 (0.84, 1.04)	22	28	78.6 (59.0, 91.7)	0.97 (0.8, 1.18)	481	594	81.0 (77.6, 84.1)	459	566	81.1 (77.6, 84.2)	580	725
	BSCM	54	74	73.0 (61.4, 82.6)	0.87 (0.75, 1.01)	71	86	82.6 (72.9, 89.9)	0.98 (0.89, 1.09)	299	356	84.0 (79.8, 87.6)	228	270	84.4 (79.6, 88.6)	353	430	82.1 (78.1, 85.6)
	BSAL	30	31	96.8 (83.3, 99.9)	1.11 (1.03, 1.2)	40	48	83.3 (69.8, 92.5)	0.95 (0.84, 1.08)	293	336	87.2 (83.2, 90.6)	253	288	87.8 (83.5, 91.4)	323	367	88.0 (84.2, 91.2)
	BSM	151	197	76.6 (70.1, 82.4)	0.89 (0.82, 0.97)	9	12	75.0 (42.8, 94.5)	0.87 (0.63, 1.21)	516	600	86.0 (83.0, 88.7)	507	588	86.2 (83.2, 88.9)	667	797	83.7 (80.9, 86.2)
	BSCC	95	137	69.3 (60.9, 76.9)	0.85 (0.75, 0.96)	8	12	66.7 (34.9, 90.1)	0.81 (0.54, 1.22)	342	419	81.6 (77.6, 85.2)	334	407	82.1 (78.0, 85.7)	437	556	78.6 (75.0, 81.9)
	BSC	51	62	82.3 (70.5, 90.8)	0.97 (0.86, 1.09)	18	21	85.7 (63.7, 97.0)	1.01 (0.85, 1.21)	344	405	84.9 (81.1, 88.3)	326	384	84.9 (80.9, 88.3)	395	467	84.6 (81.0, 87.7)
	BSSL	51	61	83.6 (71.9, 91.8)	1.01 (0.9, 1.13)	7	9	77.8 (40.0, 97.2)	0.94 (0.66, 1.33)	621	750	82.8 (79.9, 85.4)	614	741	82.9 (80.0, 85.5)	672	811	82.9 (80.1, 85.4)
	BSOS	12	15	80.0 (51.9, 95.7)	1.02 (0.79, 1.32)	3	7	42.9 (9.9, 81.6)	0.54 (0.23, 1.27)	261	332	78.6 (73.8, 82.9)	258	325	79.4 (74.6, 83.7)	273	347	78.7 (74.0, 82.9)
	Total	543	708	76.7 (73.4, 79.8)	0.92 (0.88, 0.96)	178	223	79.8 (73.9, 84.9)	0.96 (0.9, 1.02)	3,157	3,792	83.3 (82.0, 84.4)	2,979	3,569	83.5 (82.2, 84.7)	3,700	4,500	82.2 (81.1, 83.3)

4.b.t, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2019

Description: The percentage of women with invasive cancer who have a single excisional breast treatment procedure. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Figure 87: 4.b.t.1, 50 to 69, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2019



Among women aged 45–69 years whose invasive breast cancer was detected during the 4 years to December 2019, 86% had a single excisional breast treatment procedure, with little variation between LP regions.

Figure 88: 4.b.t.3, 50 to 69, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2019, by LP




Table 30: 4.b.t.1, Invasive cancers having a single excisional procedure, women screened during the 4 years to December 2019


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)	Māori / Non-Māori Ratio	Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)	Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)	Single Excisional Procedures For Invasive Cancer	Invasive Cancers Gaving Surgical Breast Procedure	% of Invasive Cancers Having a Single Excisional Breast Treatment Procedure (95% CI)
45 to 49	BSWN	18	18	100.0 -	1.17 (1.08, 1.26)	1	1	100.00 -	1.20 (1.2, 1.3)	95	111	85.6 (77.6, 91.5)	94	110	83.3 (77.5, 91.5)	113	129	84.7 (80.6, 92.7)
	BSCM	17	20	85.0 (62.1, 96.8)	0.96 (0.78, 1.17)	18	20	90.0 (68.3, 98.8)	0.97 (0.84, 1.16)	63	71	88.7 (79.0, 95.0)	45	51	92.6 (76.1, 95.6)	80	91	92.0 (79.4, 93.8)
	BSAL	6	6	100.0 -	1.06 (1, 1.12)	13	13	100.0 -	1.04 (1.04, 1.12)	70	74	94.6 (86.7, 98.5)	57	61	95.8 (84.1, 98.2)	76	80	97.0 (87.7, 98.6)
	BSM	17	24	70.8 (48.9, 87.4)	0.91 (0.69, 1.21)	2	2	100.0 -	1.24 (1.24, 1.4)	60	77	77.9 (67.0, 86.6)	58	75	81.0 (66.2, 86.2)	77	101	81.4 (66.7, 84.1)
	BSCC	20	27	74.1 (53.7, 88.9)	0.91 (0.71, 1.17)	3	3	100.0 -	1.38 (1.38, 1.56)	53	65	81.5 (70.0, 90.1)	50	62	72.2 (68.6, 89.6)	73	92	71.6 (69.6, 87.1)
	BSC	12	16	75.0 (47.6, 92.7)	1.04 (0.75, 1.44)	2	2	100.0 -	1.35 (1.35, 1.61)	39	54	72.2 (58.4, 83.5)	37	52	74.1 (56.9, 82.9)	51	70	74.6 (60.9, 82.8)
	BSSL	8	8	100.0 -	1.15 (1.08, 1.23)	3	4	75.0 (19.4, 99.4)	0.85 (0.48, 1.51)	120	138	87.0 (80.2, 92.1)	117	134	87.9 (80.5, 92.4)	128	146	88.6 (81.2, 92.5)
	BSOS	2	3	66.7 (9.4, 99.2)	0.78 (0.35, 1.75)	2	2	100.0 -	1.11 (1.11, 1.24)	47	55	85.5 (73.3, 93.5)	45	53	90.0 (72.4, 93.3)	49	58	88.4 (72.6, 92.7)
	Total	100	122	82.0 (74.0, 88.3)	0.97 (0.88, 1.06)	44	47	93.6 (82.5, 98.7)	1.11 (1.03, 1.21)	547	645	84.8 (81.8, 87.5)	503	598	84.1 (80.9, 87.0)	647	767	84.7 (81.6, 86.9)
50 to 69	BSWN	107	120	89.2 (82.2, 94.1)	1.00 (0.93, 1.07)	30	32	93.8 (79.2, 99.2)	1.06 (0.97, 1.17)	470	526	89.4 (86.4, 91.9)	440	494	88.1 (86.0, 91.7)	577	646	89.2 (86.7, 91.6)
	BSCM	53	58	91.4 (81.0, 97.1)	1.00 (0.92, 1.09)	73	79	92.4 (84.2, 97.2)	1.03 (0.96, 1.1)	302	331	91.2 (87.7, 94.1)	229	252	90.1 (86.6, 94.1)	355	389	90.2 (88.0, 93.9)
	BSAL	26	28	92.9 (76.5, 99.1)	1.05 (0.94, 1.17)	35	41	85.4 (70.8, 94.4)	1.00 (0.88, 1.15)	254	287	88.5 (84.2, 92.0)	219	246	85.2 (84.4, 92.6)	280	315	85.5 (84.9, 92.1)
	BSM	162	190	85.3 (79.4, 90.0)	1.04 (0.97, 1.12)	10	12	83.3 (51.6, 97.9)	1.03 (0.8, 1.33)	452	552	81.9 (78.4, 85.0)	442	540	81.0 (78.3, 85.0)	614	742	81.7 (79.8, 85.4)
	BSCC	99	119	83.2 (75.2, 89.4)	0.97 (0.88, 1.06)	9	10	90.0 (55.5, 99.7)	1.04 (0.84, 1.28)	340	395	86.1 (82.3, 89.3)	331	385	87.0 (82.1, 89.3)	439	514	86.7 (82.1, 88.3)
	BSC	42	54	77.8 (64.4, 88.0)	0.90 (0.78, 1.05)	15	19	78.9 (54.4, 93.9)	0.90 (0.71, 1.14)	335	389	86.1 (82.3, 89.4)	320	370	87.8 (82.6, 89.8)	377	443	86.7 (81.4, 88.3)
	BSSL	54	59	91.5 (81.3, 97.2)	1.06 (0.98, 1.15)	5	5	100.0 -	1.17 (1.17, 1.21)	548	636	86.2 (83.2, 88.8)	543	631	85.6 (83.1, 88.7)	602	695	86.0 (83.9, 89.1)
	BSOS	13	15	86.7 (59.5, 98.3)	1.02 (0.83, 1.25)	4	4	100.0 -	1.21 (1.21, 1.27)	261	308	84.7 (80.2, 88.6)	257	304	82.8 (80.0, 88.4)	274	323	82.8 (80.4, 88.6)
	Total	556	643	86.5 (83.6, 89.0)	1.00 (0.97, 1.03)	181	202	89.6 (84.5, 93.4)	1.05 (1, 1.1)	2,962	3,424	86.5 (85.3, 87.6)	2,781	3,222	85.7 (85.1, 87.5)	3,518	4,067	86.0 (85.4, 87.5)
45 to 69	BSWN	125	138	90.6 (84.4, 94.9)	1.02 (0.96, 1.08)	31	33	93.9 (79.8, 99.3)	1.08 (0.99, 1.18)	565	637	88.7 (86.0, 91.1)	534	604	87.3 (85.6, 90.9)	690	775	88.4 (86.6, 91.1)
	BSCM	70	78	89.7 (80.8, 95.5)	0.99 (0.91, 1.07)	91	99	91.9 (84.7, 96.4)	1.02 (0.96, 1.09)	365	402	90.8 (87.5, 93.4)	274	303	90.5 (86.5, 93.5)	435	480	90.6 (87.7, 93.1)
	BSAL	32	34	94.1 (80.3, 99.3)	1.05 (0.96, 1.15)	48	54	88.9 (77.4, 95.8)	1.02 (0.93, 1.13)	324	361	89.8 (86.1, 92.7)	276	307	87.0 (86.0, 93.0)	356	395	87.6 (86.8, 92.9)
	BSM	179	214	83.6 (78.0, 88.3)	1.03 (0.96, 1.1)	12	14	85.7 (57.2, 98.2)	1.06 (0.85, 1.31)	512	629	81.4 (78.1, 84.4)	500	615	81.0 (78.0, 84.3)	691	843	81.7 (79.2, 84.5)
	BSCC	119	146	81.5 (74.2, 87.4)	0.95 (0.88, 1.04)	12	13	92.3 (64.0, 99.8)	1.09 (0.93, 1.28)	393	460	85.4 (81.9, 88.5)	381	447	84.5 (81.6, 88.4)	512	606	84.2 (81.4, 87.3)
	BSC	54	70	77.1 (65.6, 86.3)	0.91 (0.8, 1.04)	17	21	81.0 (58.1, 94.6)	0.94 (0.76, 1.16)	374	443	84.4 (80.7, 87.7)	357	422	86.2 (80.8, 87.9)	428	513	85.0 (79.9, 86.5)
	BSSL	62	67	92.5 (83.4, 97.5)	1.07 (1, 1.15)	8	9	88.9 (51.8, 99.7)	1.03 (0.82, 1.3)	668	774	86.3 (83.7, 88.6)	660	765	86.0 (83.6, 88.6)	730	841	86.4 (84.3, 89.0)
	BSOS	15	18	83.3 (58.6, 96.4)	0.98 (0.8, 1.21)	6	6	100.0 -	1.20 (1.2, 1.25)	308	363	84.8 (80.7, 88.4)	302	357	83.6 (80.4, 88.2)	323	381	83.5 (80.8, 88.2)
	Total	656	765	85.8 (83.1, 88.2)	0.99 (0.96, 1.03)	225	249	90.4 (86.0, 93.7)	1.06 (1.02, 1.1)	3,509	4,069	86.2 (85.1, 87.3)	3,284	3,820	85.5 (84.8, 87.1)	4,165	4,834	85.8 (85.2, 87.1)

4.e.t, DCIS having breast conserving surgery, women screened during the 4 years to December 2019

Description: The percentage of women diagnosed with sole DCIS of pathological diameter $\leq 20\text{mm}$ who have breast conserving surgery (BCS). The 't' in the indicator id marks it as a treatment indicator.

Target: $>50\%$ of screen-detected DCIS $\leq 20\text{mm}$ are treated by BCS.

Figure 89: 4.e.t.3, 50 to 69, DCIS having breast conserving surgery, women screened during the 4 years to December 2019



The majority (88%) of women aged 45–69 years who were diagnosed with DCIS with a diameter 20mm or less had breast conserving surgery. The proportions were over 80% in most LPs apart from BSCM (71%).

Figure 90: 4.e.t.3, 50 to 69, DCIS having breast conserving surgery, women screened during the 4 years to December 2019, by LP




Table 31: 4.e.t.1, DCIS having breast conserving surgery, women screened during the 4 years to December 2019


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)	Māori / Non-Māori Ratio	DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)	DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)	DCIS ≤20mm Having BCS	DCIS ≤ 20mm who are Operated on	% of DCIS ≤20mm who have BCS (95% CI)
45 to 49	BSWN	5	5	100.0 -	1.11 (0.96, 1.27)	1	1	100.0 -	1.11 (1.11, 1.29)	19	21	90.5 (69.6, 98.8)	18	20	90.0 (68.3, 98.8)	24	26	92.3 (74.9, 99.1)	
	BSCM	1	1	100.0 -	1.33 (1, 1.77)	2	3	66.7 (9.4, 99.2)	0.87 (0.39, 2.04)	12	16	75.0 (47.6, 92.7)	10	13	76.9 (46.2, 95.0)	13	17	76.5 (50.1, 93.2)	
	BSAL	1	1	100.0 -	1.00 (1, 1)	0	0	NA (NA, NA)	NA (NA, NA)	11	11	100.0 -	11	11	100.0 -	12	12	100.0 -	
	BSM	7	7	100.0 -	1.18 (1, 1.39)	0	0	NA (NA, NA)	NA (NA, NA)	22	26	84.6 (65.1, 95.6)	22	26	84.6 (65.1, 95.6)	29	33	87.9 (71.8, 96.6)	
	BSCC	3	4	75.0 (19.4, 99.4)	0.79 (0.44, 1.39)	1	1	100.0 -	1.05 (1.05, 1.16)	21	22	95.5 (77.2, 99.9)	20	21	95.2 (76.2, 99.9)	24	26	92.3 (74.9, 99.1)	
	BSC	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	10	10	100.0 -	10	10	100.0 -	10	10	100.0 -	
	BSSL	2	2	100.0 -	1.00 (1, 1)	0	0	NA (NA, NA)	NA (NA, NA)	26	26	100.0 -	26	26	100.0 -	28	28	100.0 -	
	BSOS	1	1	100.0 -	1.09 (0.92, 1.29)	0	0	NA (NA, NA)	NA (NA, NA)	11	12	91.7 (61.5, 99.8)	11	12	91.7 (61.5, 99.8)	12	13	92.3 (64.0, 99.8)	
	Total	20	21	95.2 (76.2, 99.9)	1.04 (0.93, 1.16)	4	5	80.0 (28.4, 99.5)	0.87 (0.56, 1.35)	132	144	91.7 (85.9, 95.6)	128	139	92.1 (86.3, 96.0)	152	165	92.1 (86.9, 95.7)	
	50 to 69	BSWN	19	21	90.5 (69.6, 98.8)	1.06 (0.9, 1.25)	4	4	100.0 -	1.18 (1.18, 1.3)	75	88	85.2 (76.1, 91.9)	71	84	84.5 (75.0, 91.5)	94	109	86.2 (78.3, 92.1)
BSCM		6	6	100.0 -	1.54 (1.23, 1.91)	4	5	80.0 (28.4, 99.5)	1.27 (0.82, 2.09)	28	43	65.1 (49.1, 79.0)	24	38	63.2 (46.0, 78.2)	34	49	69.4 (54.6, 81.7)	
BSAL		1	2	50.0 (1.3, 98.7)	0.61 (0.15, 2.47)	0	0	NA (NA, NA)	NA (NA, NA)	31	38	81.6 (65.7, 92.3)	31	38	81.6 (65.7, 92.3)	32	40	80.0 (64.4, 90.9)	
BSM		16	16	100.0 -	1.09 (1.02, 1.17)	1	1	100.0 -	1.09 (1.09, 1.17)	67	73	91.8 (83.0, 96.9)	66	72	91.7 (82.7, 96.9)	83	89	93.3 (85.9, 97.5)	
BSCC		6	6	100.0 -	1.28 (1.12, 1.46)	0	0	NA (NA, NA)	NA (NA, NA)	50	64	78.1 (66.0, 87.5)	50	64	78.1 (66.0, 87.5)	56	70	80.0 (68.7, 88.6)	
BSC		4	4	100.0 -	1.04 (0.98, 1.11)	1	1	100.0 -	1.04 (1.04, 1.11)	46	48	95.8 (85.7, 99.5)	45	47	95.7 (85.5, 99.5)	50	52	96.2 (86.8, 99.5)	
BSSL		8	8	100.0 -	1.11 (1.05, 1.17)	0	0	NA (NA, NA)	NA (NA, NA)	111	123	90.2 (83.6, 94.9)	111	123	90.2 (83.6, 94.9)	119	131	90.8 (84.5, 95.2)	
BSOS		1	1	100.0 -	1.20 (1.06, 1.35)	1	1	100.0 -	1.20 (1.2, 1.36)	41	49	83.7 (70.3, 92.7)	40	48	83.3 (69.8, 92.5)	42	50	84.0 (70.9, 92.8)	
Total		61	64	95.3 (86.9, 99.0)	1.12 (1.05, 1.19)	11	12	91.7 (61.5, 99.8)	1.08 (0.91, 1.28)	449	526	85.4 (82.0, 88.3)	438	514	85.2 (81.8, 88.2)	510	590	86.4 (83.4, 89.1)	
45 to 69		BSWN	24	26	92.3 (74.9, 99.1)	1.07 (0.94, 1.22)	5	5	100.0 -	1.17 (1.17, 1.26)	94	109	86.2 (78.3, 92.1)	89	104	85.6 (77.3, 91.7)	118	135	87.4 (80.6, 92.5)
	BSCM	7	7	100.0 -	1.48 (1.24, 1.76)	6	8	75.0 (34.9, 96.8)	1.13 (0.75, 1.75)	40	59	67.8 (54.4, 79.4)	34	51	66.7 (52.1, 79.2)	47	66	71.2 (58.7, 81.7)	
	BSAL	2	3	66.7 (9.4, 99.2)	0.78 (0.35, 1.75)	0	0	NA (NA, NA)	NA (NA, NA)	42	49	85.7 (72.8, 94.1)	42	49	85.7 (72.8, 94.1)	44	52	84.6 (71.9, 93.1)	
	BSM	23	23	100.0 -	1.11 (1.04, 1.19)	1	1	100.0 -	1.11 (1.11, 1.19)	89	99	89.9 (82.2, 95.0)	88	98	89.8 (82.0, 95.0)	112	122	91.8 (85.4, 96.0)	
	BSCC	9	10	90.0 (55.5, 99.7)	1.09 (0.87, 1.37)	1	1	100.0 -	1.21 (1.21, 1.34)	71	86	82.6 (72.9, 89.9)	70	85	82.4 (72.6, 89.8)	80	96	83.3 (74.4, 90.2)	
	BSC	4	4	100.0 -	1.04 (0.99, 1.09)	1	1	100.0 -	1.04 (1.04, 1.09)	56	58	96.6 (88.1, 99.6)	55	57	96.5 (87.9, 99.6)	60	62	96.8 (88.8, 99.6)	
	BSSL	10	10	100.0 -	1.09 (1.04, 1.14)	0	0	NA (NA, NA)	NA (NA, NA)	137	149	91.9 (86.4, 95.8)	137	149	91.9 (86.4, 95.8)	147	159	92.5 (87.2, 96.0)	
	BSOS	2	2	100.0 -	1.17 (1.06, 1.3)	1	1	100.0 -	1.18 (1.18, 1.31)	52	61	85.2 (73.8, 93.0)	51	60	85.0 (73.4, 92.9)	54	63	85.7 (74.6, 93.3)	
	Total	81	85	95.3 (88.4, 98.7)	1.10 (1.04, 1.16)	15	17	88.2 (63.6, 98.5)	1.02 (0.86, 1.21)	581	670	86.7 (83.9, 89.2)	566	653	86.7 (83.8, 89.2)	662	755	87.7 (85.1, 89.9)	

4.f.t, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2019

Description: The percentage of women diagnosed with invasive cancer, without a DCIS component, of pathological diameter $\leq 20\text{mm}$ who have breast conserving surgery (BCS). The 't' in the indicator id marks it as a treatment indicator.

Target: $>50\%$ of screen-detected invasive cancers $\leq 20\text{mm}$ are treated by BCS

Figure 91: 4.f.t.3, 50 to 69, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2019



Most women aged 45–69 years who were diagnosed with invasive breast cancer with a diameter 20mm or less had breast conserving surgery (84%). All LPs had proportions of 75% or more.

Figure 92: 4.f.t.3, 50 to 69, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2019, by LP




Table 32: 4.f.t.1, Invasive cancers having breast conserving surgery, women screened during the 4 years to December 2019


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)	Pacific / Non-Pacific Ratio	Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)	Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)	Invasive Cancers Without DCIS ≤20mm Having BCS	Invasive Cancers Without DCIS ≤20mm who are Operated on	% of Invasive Cancers Without DCIS ≤20mm who have BCS (95% CI)
45 to 49	BSWN	2	2	100.0 -	1.40 (0.88, 2.24)	0	0	NA (NA, NA)	NA (NA, NA)	5	7	71.4 (29.0, 96.3)	5	7	71.4 (29.0, 96.3)	7	9	77.8 (40.0, 97.2)
	BSCM	0	0	0.0 -	NA (NA, NA)	2	2	100.0 -	2.00 (2, 8)	3	4	75.0 (19.4, 99.4)	1	2	50.0 (1.3, 98.7)	3	4	75.0 (19.4, 99.4)
	BSAL	2	2	100.0 -	1.14 (0.88, 1.49)	0	0	NA (NA, NA)	NA (NA, NA)	7	8	87.5 (47.3, 99.7)	7	8	87.5 (47.3, 99.7)	9	10	90.0 (55.5, 99.7)
	BSM	2	2	100.0 -	1.20 (0.93, 1.55)	0	0	NA (NA, NA)	NA (NA, NA)	10	12	83.3 (51.6, 97.9)	10	12	83.3 (51.6, 97.9)	12	14	85.7 (57.2, 98.2)
	BSCC	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	2.50 (2.5, 7.31)	3	6	50.0 (11.8, 88.2)	2	5	40.0 (5.3, 85.3)	3	6	50.0 (11.8, 88.2)
	BSC	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	1.00 (1, 1)	6	6	100.0 -	5	5	100.0 -	6	6	100.0 -
	BSSL	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	5	6	83.3 (35.9, 99.6)	5	6	83.3 (35.9, 99.6)	5	6	83.3 (35.9, 99.6)
	BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	7	7	100.0 -	7	7	100.0 -	7	7	100.0 -
	Total	6	6	100.0 -	1.22 (1.08, 1.38)	4	4	100.0 -	1.24 (1.24, 1.41)	46	56	82.1 (69.6, 91.1)	42	52	80.8 (67.5, 90.4)	52	62	83.9 (72.3, 92.0)
50 to 69	BSWN	28	32	87.5 (71.0, 96.5)	1.05 (0.9, 1.23)	4	5	80.0 (28.4, 99.5)	0.96 (0.62, 1.49)	86	103	83.5 (74.9, 90.1)	82	98	83.7 (74.8, 90.4)	114	135	84.4 (77.2, 90.1)
	BSCM	2	4	50.0 (6.8, 93.2)	0.62 (0.23, 1.66)	4	5	80.0 (28.4, 99.5)	0.98 (0.64, 1.57)	30	37	81.1 (64.8, 92.0)	26	32	81.3 (63.6, 92.8)	32	41	78.0 (62.4, 89.4)
	BSAL	4	5	80.0 (28.4, 99.5)	0.93 (0.59, 1.46)	7	10	70.0 (34.8, 93.3)	0.79 (0.52, 1.19)	55	64	85.9 (75.0, 93.4)	48	54	88.9 (77.4, 95.8)	59	69	85.5 (75.0, 92.8)
	BSM	27	34	79.4 (62.1, 91.3)	0.86 (0.72, 1.03)	1	1	100.0 -	1.08 (1.08, 1.15)	97	105	92.4 (85.5, 96.7)	96	104	92.3 (85.4, 96.6)	124	139	89.2 (82.8, 93.8)
	BSCC	18	24	75.0 (53.3, 90.2)	0.98 (0.75, 1.27)	0	1	0.0 -	NA (NA, NA)	56	73	76.7 (65.4, 85.8)	56	72	77.8 (66.4, 86.7)	74	97	76.3 (66.6, 84.3)
	BSC	6	7	85.7 (42.1, 99.6)	0.96 (0.7, 1.31)	0	0	NA (NA, NA)	NA (NA, NA)	43	48	89.6 (77.3, 96.5)	43	48	89.6 (77.3, 96.5)	49	55	89.1 (77.8, 95.9)
	BSSL	10	12	83.3 (51.6, 97.9)	1.04 (0.79, 1.37)	1	1	100.0 -	1.25 (1.25, 1.4)	61	76	80.3 (69.5, 88.5)	60	75	80.0 (69.2, 88.4)	71	88	80.7 (70.9, 88.3)
	BSOS	4	4	100.0 -	1.16 (1.05, 1.28)	1	1	100.0 -	1.16 (1.16, 1.28)	56	65	86.2 (75.3, 93.5)	55	64	85.9 (75.0, 93.4)	60	69	87.0 (76.7, 93.9)
	Total	99	122	81.1 (73.1, 87.7)	0.96 (0.87, 1.05)	18	24	75.0 (53.3, 90.2)	0.88 (0.7, 1.11)	484	571	84.8 (81.5, 87.6)	466	547	85.2 (81.9, 88.1)	583	693	84.1 (81.2, 86.8)
45 to 69	BSWN	30	34	88.2 (72.5, 96.7)	1.07 (0.92, 1.24)	4	5	80.0 (28.4, 99.5)	0.97 (0.62, 1.51)	91	110	82.7 (74.3, 89.3)	87	105	82.9 (74.3, 89.5)	121	144	84.0 (77.0, 89.6)
	BSCM	2	4	50.0 (6.8, 93.2)	0.62 (0.23, 1.67)	6	7	85.7 (42.1, 99.6)	1.08 (0.8, 1.53)	33	41	80.5 (65.1, 91.2)	27	34	79.4 (62.1, 91.3)	35	45	77.8 (62.9, 88.8)
	BSAL	6	7	85.7 (42.1, 99.6)	1.00 (0.73, 1.37)	7	10	70.0 (34.8, 93.3)	0.79 (0.53, 1.2)	62	72	86.1 (75.9, 93.1)	55	62	88.7 (78.1, 95.3)	68	79	86.1 (76.5, 92.8)
	BSM	29	36	80.6 (64.0, 91.8)	0.88 (0.74, 1.04)	1	1	100.0 -	1.09 (1.09, 1.16)	107	117	91.5 (84.8, 95.8)	106	116	91.4 (84.7, 95.8)	136	153	88.9 (82.8, 93.4)
	BSCC	18	24	75.0 (53.3, 90.2)	1.00 (0.77, 1.31)	1	2	50.0 (1.3, 98.7)	0.66 (0.17, 2.67)	59	79	74.7 (63.6, 83.8)	58	77	75.3 (64.2, 84.4)	77	103	74.8 (65.2, 82.8)
	BSC	6	7	85.7 (42.1, 99.6)	0.94 (0.69, 1.29)	1	1	100.0 -	1.10 (1.1, 1.2)	49	54	90.7 (79.7, 96.9)	48	53	90.6 (79.3, 96.9)	55	61	90.2 (79.8, 96.3)
	BSSL	10	12	83.3 (51.6, 97.9)	1.04 (0.79, 1.36)	1	1	100.0 -	1.25 (1.25, 1.39)	66	82	80.5 (70.3, 88.4)	65	81	80.2 (69.9, 88.3)	76	94	80.9 (71.4, 88.2)
	BSOS	4	4	100.0 -	1.14 (1.05, 1.25)	1	1	100.0 -	1.15 (1.15, 1.25)	63	72	87.5 (77.6, 94.1)	62	71	87.3 (77.3, 94.0)	67	76	88.2 (78.7, 94.4)
	Total	105	128	82.0 (74.3, 88.3)	0.97 (0.89, 1.06)	22	28	78.6 (59.0, 91.7)	0.93 (0.76, 1.13)	530	627	84.5 (81.5, 87.3)	508	599	84.8 (81.7, 87.6)	635	755	84.1 (81.3, 86.6)

4.g.t, Invasive cancer having radiotherapy, women screened during the 4 years to December 2019

Description: The percentage of women diagnosed with invasive cancer, who have breast conserving surgery (BCS) who go on to have radiotherapy. The 't' in the indicator id marks it as a treatment indicator.

Target: $\geq 95\%$

Figure 93: 4.g.t.3, 50 to 69, Invasive cancer having radiotherapy, women screened during the 4 years to December 2019



Among women aged 45–69 years, most women who were diagnosed with invasive breast cancer and had breast conserving surgery went on to have radiotherapy (target 95% or more). The target was met or within the confidence interval for women screened by three LPs: BSC, BSSL, and BSOS, and lowest in BSAL (82%), BSCM (83%) and BSM (84%).

Figure 94: 4.g.t.3, 50 to 69, Invasive cancer having radiotherapy, women screened during the 4 years to December 2019, by LP



Table 33: 4.g.t.1, Invasive cancer having radiotherapy, women screened during the 4 years to December 2019


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Invasive Cancers Having Bcs Who Have Radiotherapy	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers Having Bcs Who Have Radiotherapy	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers Having Bcs Who Have Radiotherapy	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)	Invasive Cancers Having Bcs Who Have Radiotherapy	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)	Invasive Cancers Having Bcs Who Have Radiotherapy	Invasive Cancers Having BCS	% of Invasive Cancers Having BCS who have Radiotherapy (95% CI)
45 to 49	BSWN	11	12	91.7 (61.5, 99.8)	1.01 (0.84, 1.22)	0	0	NA (NA, NA)	NA (NA, NA)	58	64	90.6 (80.7, 96.5)	58	64	90.6 (80.7, 96.5)	69	76	90.8 (81.9, 96.2)
	BSCM	10	12	83.3 (51.6, 97.9)	0.90 (0.68, 1.19)	6	7	85.7 (42.1, 99.6)	0.90 (0.67, 1.25)	24	26	92.3 (74.9, 99.1)	18	19	94.7 (74.0, 99.9)	34	38	89.5 (75.2, 97.1)
	BSAL	3	3	100.0 -	1.19 (1.05, 1.35)	5	7	71.4 (29.0, 96.3)	0.83 (0.52, 1.34)	37	44	84.1 (69.9, 93.4)	32	37	86.5 (71.2, 95.5)	40	47	85.1 (71.7, 93.8)
	BSM	19	19	100.0 -	1.23 (1.09, 1.4)	2	2	100.0 -	1.24 (1.24, 1.42)	47	58	81.0 (68.6, 90.1)	45	56	80.4 (67.6, 89.8)	66	77	85.7 (75.9, 92.6)
	BSCC	5	5	100.0 -	1.06 (0.98, 1.15)	3	3	100.0 -	1.06 (1.06, 1.16)	34	36	94.4 (81.3, 99.3)	31	33	93.9 (79.8, 99.3)	39	41	95.1 (83.5, 99.4)
	BSC	9	9	NA (NA, NA)	NA (NA, NA)	2	2	100.0 -	1.03 (1.03, 1.1)	34	35	97.1 (85.1, 99.9)	32	33	97.0 (84.2, 99.9)	43	44	97.7 (88.0, 99.9)
	BSSL	5	5	100.0 -	1.06 (1, 1.13)	1	1	100.0 -	1.06 (1.06, 1.13)	64	68	94.1 (85.6, 98.4)	63	67	94.0 (85.4, 98.3)	69	73	94.5 (86.6, 98.5)
	BSOS	5	5	100.0 -	1.03 (0.97, 1.09)	1	1	100.0 -	1.03 (1.03, 1.1)	33	34	97.1 (84.7, 99.9)	32	33	97.0 (84.2, 99.9)	38	39	97.4 (86.5, 99.9)
	Total	67	70	95.7 (88.0, 99.1)	1.06 (0.99, 1.12)	20	23	87.0 (66.4, 97.2)	0.96 (0.82, 1.12)	331	365	90.7 (87.2, 93.5)	311	342	90.9 (87.4, 93.8)	398	435	91.5 (88.5, 93.9)
50 to 69	BSWN	73	81	90.1 (81.5, 95.6)	0.98 (0.9, 1.06)	19	23	82.6 (61.2, 95.0)	0.89 (0.74, 1.08)	340	369	92.1 (88.9, 94.7)	321	346	92.8 (89.5, 95.3)	413	450	91.8 (88.8, 94.1)
	BSCM	27	34	79.4 (62.1, 91.3)	0.96 (0.8, 1.15)	34	46	73.9 (58.9, 85.7)	0.87 (0.73, 1.04)	157	190	82.6 (76.5, 87.7)	123	144	85.4 (78.6, 90.7)	184	224	82.1 (76.5, 86.9)
	BSAL	16	22	72.7 (49.8, 89.3)	0.89 (0.68, 1.15)	20	24	83.3 (62.6, 95.3)	1.02 (0.85, 1.23)	173	211	82.0 (76.1, 86.9)	153	187	81.8 (75.5, 87.1)	189	233	81.1 (75.5, 85.9)
	BSM	105	140	75.0 (67.0, 81.9)	0.87 (0.78, 0.96)	9	9	100.0 -	1.16 (1.16, 1.21)	399	462	86.4 (82.9, 89.4)	390	453	86.1 (82.6, 89.1)	504	602	83.7 (80.5, 86.6)
	BSCC	63	76	82.9 (72.5, 90.6)	0.89 (0.8, 0.99)	2	3	66.7 (9.4, 99.2)	0.71 (0.32, 1.59)	224	240	93.3 (89.4, 96.1)	222	237	93.7 (89.8, 96.4)	287	316	90.8 (87.1, 93.8)
	BSC	37	38	97.4 (86.2, 99.9)	1.03 (0.97, 1.09)	13	14	92.9 (66.1, 99.8)	0.98 (0.85, 1.14)	284	300	94.7 (91.5, 96.9)	271	286	94.8 (91.5, 97.0)	321	338	95.0 (92.1, 97.0)
	BSSL	32	35	91.4 (76.9, 98.2)	0.97 (0.88, 1.08)	4	4	100.0 -	1.06 (1.06, 1.09)	383	407	94.1 (91.4, 96.2)	379	403	94.0 (91.3, 96.1)	415	442	93.9 (91.2, 95.9)
	BSOS	12	12	100.0 -	1.07 (1.03, 1.11)	3	3	100.0 -	1.07 (1.07, 1.11)	191	204	93.6 (89.3, 96.6)	188	201	93.5 (89.2, 96.5)	203	216	94.0 (89.9, 96.8)
	Total	365	438	83.3 (79.5, 86.7)	0.92 (0.88, 0.96)	104	126	82.5 (74.8, 88.7)	0.91 (0.84, 0.99)	2,151	2,383	90.3 (89.0, 91.4)	2,047	2,257	90.7 (89.4, 91.9)	2,516	2,821	89.2 (88.0, 90.3)
45 to 69	BSWN	84	93	90.3 (82.4, 95.5)	0.98 (0.91, 1.06)	19	23	82.6 (61.2, 95.0)	0.89 (0.74, 1.08)	398	433	91.9 (88.9, 94.3)	379	410	92.4 (89.4, 94.8)	482	526	91.6 (88.9, 93.9)
	BSCM	37	46	80.4 (66.1, 90.6)	0.96 (0.82, 1.12)	40	53	75.5 (61.7, 86.2)	0.87 (0.75, 1.03)	181	216	83.8 (78.2, 88.4)	141	163	86.5 (80.3, 91.3)	218	262	83.2 (78.1, 87.5)
	BSAL	19	25	76.0 (54.9, 90.6)	0.92 (0.74, 1.16)	25	31	80.6 (62.5, 92.5)	0.98 (0.82, 1.17)	210	255	82.4 (77.1, 86.8)	185	224	82.6 (77.0, 87.3)	229	280	81.8 (76.8, 86.1)
	BSM	124	159	78.0 (70.7, 84.2)	0.91 (0.83, 0.99)	11	11	100.0 -	1.17 (1.17, 1.21)	446	520	85.8 (82.5, 88.7)	435	509	85.5 (82.1, 88.4)	570	679	83.9 (81.0, 86.6)
	BSCC	68	81	84.0 (74.1, 91.2)	0.90 (0.81, 0.99)	5	6	83.3 (35.9, 99.6)	0.89 (0.62, 1.27)	258	276	93.5 (89.9, 96.1)	253	270	93.7 (90.1, 96.3)	326	357	91.3 (87.9, 94.0)
	BSC	46	47	97.9 (88.7, 99.9)	1.03 (0.98, 1.08)	15	16	93.8 (69.8, 99.8)	0.99 (0.87, 1.12)	318	335	94.9 (92.0, 97.0)	303	319	95.0 (92.0, 97.1)	364	382	95.3 (92.7, 97.2)
	BSSL	37	40	92.5 (79.6, 98.4)	0.98 (0.9, 1.08)	5	5	100.0 -	1.06 (1.06, 1.09)	447	475	94.1 (91.6, 96.0)	442	470	94.0 (91.5, 96.0)	484	515	94.0 (91.6, 95.9)
	BSOS	17	17	100.0 -	1.06 (1.03, 1.1)	4	4	100.0 -	1.06 (1.06, 1.1)	224	238	94.1 (90.3, 96.7)	220	234	94.0 (90.2, 96.7)	241	255	94.5 (91.0, 97.0)
	Total	432	508	85.0 (81.6, 88.0)	0.94 (0.91, 0.98)	124	149	83.2 (76.2, 88.8)	0.92 (0.85, 0.99)	2,482	2,748	90.3 (89.2, 91.4)	2,358	2,599	90.7 (89.5, 91.8)	2,914	3,256	89.5 (88.4, 90.5)

4.h.t, DCIS having radiotherapy, women screened during the 4 years to December 2019

Description: The percentage of women diagnosed solely with DCIS, who have Breast Conserving Surgery (BCS), who go on to have radiotherapy. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Figure 95: 4.h.t.3, 50 to 69, DCIS having radiotherapy, women screened during the 4 years to December 2019



Among women aged 45–69 who were diagnosed with DCIS and had breast conserving surgery, 59% went on to have radiotherapy, lowest in BSOS (46%) and BSAL (49%), and highest in BSM (76%).

Māori women (68%) were more likely than non-Māori (58%) to have radiotherapy. Pacific women (41%) were less likely to have radiotherapy than non-Māori non-Pacific women (58%).

Figure 96: 4.h.t.3, 50 to 69, DCIS having radiotherapy, women screened during the 4 years to December 2019, by LP




Table 34: 4.h.t.1, DCIS having radiotherapy, women screened during the 4 years to December 2019

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)	Māori / Non-Māori Ratio	DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)	DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)	DCIS Having BCS who have Radiotherapy	DCIS, Having BCS	% of DCIS, Having BCS, who have Radiotherapy (95% CI)
45 to 49	BSWN	3	7	42.9 (9.9, 81.6)	0.72 (0.29, 1.8)	1	2	50.0 (1.3, 98.7)	0.83 (0.21, 3.46)	16	27	59.3 (38.8, 77.6)	15	25	60.0 (38.7, 78.9)	19	34	55.9 (37.9, 72.8)
	BSCM	3	3	100.0 -	2.00 (1.23, 3.26)	1	3	33.3 (0.8, 90.6)	0.62 (0.12, 3.31)	8	16	50.0 (24.7, 75.3)	7	13	53.8 (25.1, 80.8)	11	19	57.9 (33.5, 79.7)
	BSAL	0	1	0.0 -	NA (NA, NA)	1	1	100.0 -	1.78 (1.78, 2.74)	10	17	58.8 (32.9, 81.6)	9	16	56.3 (29.9, 80.2)	10	18	55.6 (30.8, 78.5)
	BSM	7	9	77.8 (40.0, 97.2)	1.05 (0.69, 1.59)	0	0	NA (NA, NA)	NA (NA, NA)	20	27	74.1 (53.7, 88.9)	20	27	74.1 (53.7, 88.9)	27	36	75.0 (57.8, 87.9)
	BSCC	2	4	50.0 (6.8, 93.2)	0.92 (0.32, 2.62)	0	1	0.0 -	NA (NA, NA)	12	22	54.5 (32.2, 75.6)	12	21	57.1 (34.0, 78.2)	14	26	53.8 (33.4, 73.4)
	BSC	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	15	18	83.3 (58.6, 96.4)	15	18	83.3 (58.6, 96.4)	15	18	83.3 (58.6, 96.4)
	BSSL	3	3	100.0 -	1.33 (1.11, 1.59)	0	1	0.0 -	NA (NA, NA)	30	40	75.0 (58.8, 87.3)	30	39	76.9 (60.7, 88.9)	33	43	76.7 (61.4, 88.2)
	BSOS	0	1	0.0 -	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	4	14	28.6 (8.4, 58.1)	4	14	28.6 (8.4, 58.1)	4	15	26.7 (7.8, 55.1)
	Total	18	28	64.3 (44.1, 81.4)	1.01 (0.75, 1.36)	3	8	37.5 (8.5, 75.5)	0.58 (0.24, 1.43)	115	181	63.5 (56.1, 70.5)	112	173	64.7 (57.1, 71.8)	133	209	63.6 (56.7, 70.2)
50 to 69	BSWN	17	22	77.3 (54.6, 92.2)	1.32 (1, 1.75)	4	7	57.1 (18.4, 90.1)	0.98 (0.51, 1.9)	59	101	58.4 (48.2, 68.1)	55	94	58.5 (47.9, 68.6)	76	123	61.8 (52.6, 70.4)
	BSCM	2	7	28.6 (3.7, 71.0)	0.54 (0.16, 1.8)	5	11	45.5 (16.7, 76.6)	0.83 (0.44, 1.68)	29	55	52.7 (38.8, 66.3)	24	44	54.5 (38.8, 69.6)	31	62	50.0 (37.0, 63.0)
	BSAL	3	3	100.0 -	2.24 (1.67, 3)	1	4	25.0 (0.6, 80.6)	0.54 (0.1, 3.03)	25	56	44.6 (31.3, 58.5)	24	52	46.2 (32.2, 60.5)	28	59	47.5 (34.3, 60.9)
	BSM	21	26	80.8 (60.6, 93.4)	1.08 (0.87, 1.35)	3	3	100.0 -	1.36 (1.36, 1.52)	79	106	74.5 (65.1, 82.5)	76	103	73.8 (64.2, 82.0)	100	132	75.8 (67.5, 82.8)
	BSCC	7	10	70.0 (34.8, 93.3)	1.26 (0.79, 2)	0	0	NA (NA, NA)	NA (NA, NA)	35	63	55.6 (42.5, 68.1)	35	63	55.6 (42.5, 68.1)	42	73	57.5 (45.4, 69.0)
	BSC	3	5	60.0 (14.7, 94.7)	1.10 (0.53, 2.32)	0	2	0.0 -	NA (NA, NA)	44	81	54.3 (42.9, 65.4)	44	79	55.7 (44.1, 66.9)	47	86	54.7 (43.5, 65.4)
	BSSL	7	11	63.6 (30.8, 89.1)	1.26 (0.79, 2.03)	1	2	50.0 (1.3, 98.7)	0.99 (0.25, 4.01)	81	161	50.3 (42.3, 58.3)	80	159	50.3 (42.3, 58.3)	88	172	51.2 (43.4, 58.8)
	BSOS	0	2	0.0 -	NA (NA, NA)	0	1	0.0 -	NA (NA, NA)	37	72	51.4 (39.3, 63.3)	37	71	52.1 (39.9, 64.1)	37	74	50.0 (38.1, 61.9)
	Total	60	86	69.8 (58.9, 79.2)	1.25 (1.07, 1.45)	9	21	42.9 (21.8, 66.0)	0.76 (0.46, 1.25)	384	686	56.0 (52.2, 59.7)	375	665	56.4 (52.5, 60.2)	444	772	57.5 (53.9, 61.0)
45 to 69	BSWN	20	29	69.0 (49.2, 84.7)	1.18 (0.89, 1.56)	5	9	55.6 (21.2, 86.3)	0.94 (0.53, 1.73)	75	128	58.6 (49.6, 67.2)	70	119	58.8 (49.4, 67.8)	95	157	60.5 (52.4, 68.2)
	BSCM	5	10	50.0 (18.7, 81.3)	0.96 (0.5, 1.85)	6	14	42.9 (17.7, 71.1)	0.79 (0.43, 1.51)	37	71	52.1 (39.9, 64.1)	31	57	54.4 (40.7, 67.6)	42	81	51.9 (40.5, 63.1)
	BSAL	3	4	75.0 (19.4, 99.4)	1.56 (0.85, 2.89)	2	5	40.0 (5.3, 85.3)	0.82 (0.28, 2.48)	35	73	47.9 (36.1, 60.0)	33	68	48.5 (36.2, 61.0)	38	77	49.4 (37.8, 61.0)
	BSM	28	35	80.0 (63.1, 91.6)	1.07 (0.89, 1.3)	3	3	100.0 -	1.35 (1.35, 1.5)	99	133	74.4 (66.2, 81.6)	96	130	73.8 (65.4, 81.2)	127	168	75.6 (68.4, 81.9)
	BSCC	9	14	64.3 (35.1, 87.2)	1.16 (0.75, 1.8)	0	1	0.0 -	NA (NA, NA)	47	85	55.3 (44.1, 66.1)	47	84	56.0 (44.7, 66.8)	56	99	56.6 (46.2, 66.5)
	BSC	3	5	60.0 (14.7, 94.7)	1.01 (0.48, 2.1)	0	2	0.0 -	NA (NA, NA)	59	99	59.6 (49.3, 69.3)	59	97	60.8 (50.4, 70.6)	62	104	59.6 (49.5, 69.1)
	BSSL	10	14	71.4 (41.9, 91.6)	1.29 (0.91, 1.84)	1	3	33.3 (0.8, 90.6)	0.60 (0.12, 2.99)	111	201	55.2 (48.1, 62.2)	110	198	55.6 (48.3, 62.6)	121	215	56.3 (49.4, 63.0)
	BSOS	0	3	0.0 -	0.00 (NA, NA)	0	1	0.0 -	NA (NA, NA)	41	86	47.7 (36.8, 58.7)	41	85	48.2 (37.3, 59.3)	41	89	46.1 (35.4, 57.0)
	Total	78	114	68.4 (59.1, 76.8)	1.19 (1.04, 1.36)	12	29	41.4 (23.5, 61.1)	0.71 (0.46, 1.1)	499	867	57.6 (54.2, 60.9)	487	838	58.1 (54.7, 61.5)	577	981	58.8 (55.7, 61.9)

4.i.t, Invasive cancer having chemotherapy, women screened during the 4 years to December 2019

Description: The percentage of women diagnosed with invasive cancer who have chemotherapy, reported by disease character groups. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Among women aged 45–69 years who were diagnosed with invasive cancer, 94% of those whose cancer was node positive, and ER and PR negative had chemotherapy, as did 72% of those with node negative, high risk, and ER and PR negative cancer, 54% of those who were node positive, either ER or PR positive, and 16% of those who were node negative, high risk, and ER or PR positive.

Table 35: 4.i.t.1, Invasive cancer having chemotherapy, women screened during the 4 years to December 2019

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	
45 to 49	Group 1: Node positive, and ER and PR negative	BSWN	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	3	3	100.0 -	3	3	100.0 -	3	3	100.0 -
		BSCM	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)
		BSAL	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)
		BSM	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)	0	0	NA (NA, NA)
		BSCC	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	2	2	100.0 -	2	2	100.0 -	2	2	100.0 -
		BSC	1	1	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	1	1	100.0 -	2	2	100.0 -
		BSSL	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	1.00 (1, 1)	3	3	100.0 -	2	2	100.0 -	3	3	100.0 -
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	2	2	100.0 -	2	2	100.0 -	2	2	100.0 -
	Total	1	1	100.0 -	1.00 (1, 1)	1	1	100.0 -	1.00 (1, 1)	11	11	100.0 -	10	10	100.0 -	12	12	100.0 -	
	Group 2: Node negative, high risk, and ER and PR negative	BSWN	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	6	8	75.0 (34.9, 96.8)	6	8	75.0 (34.9, 96.8)	6	8	75.0 (34.9, 96.8)
		BSCM	1	1	100.0 -	1.00 (1, 1)	1	1	100.0 -	1.00 (1, 1)	3	3	100.0 -	2	2	100.0 -	4	4	100.0 -
		BSAL	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	1.00 (1, 1)	4	4	100.0 -	3	3	100.0 -	4	4	100.0 -
		BSM	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	3	4	75.0 (19.4, 99.4)	3	4	75.0 (19.4, 99.4)	3	4	75.0 (19.4, 99.4)
		BSCC	1	1	100.0 -	1.00 (1, 1)	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	1	1	100.0 -	2	2	100.0 -
		BSC	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	1	2	50.0 (1.3, 98.7)	1	2	50.0 (1.3, 98.7)	1	2	50.0 (1.3, 98.7)
		BSSL	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	7	9	77.8 (40.0, 97.2)	7	9	77.8 (40.0, 97.2)	7	9	77.8 (40.0, 97.2)
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	3	3	100.0 -	3	3	100.0 -	3	3	100.0 -
	Total	2	2	100.0 -	1.21 (1.04, 1.42)	2	2	100.0 -	1.23 (1.23, 1.45)	28	34	82.4 (65.5, 93.2)	26	32	81.3 (63.6, 92.8)	30	36	83.3 (67.2, 93.6)	
	Group 3: Node positive, either ER or PR positive	BSWN	4	4	100.0 -	1.31 (1.09, 1.58)	1	1	100.0 -	1.32 (1.32, 1.6)	26	34	76.5 (58.8, 89.3)	25	33	75.8 (57.7, 88.9)	30	38	78.9 (62.7, 90.4)
		BSCM	7	10	70.0 (34.8, 93.3)	1.08 (0.64, 1.81)	7	11	63.6 (30.8, 89.1)	0.95 (0.61, 1.82)	13	20	65.0 (40.8, 84.6)	6	9	66.7 (29.9, 92.5)	20	30	66.7 (47.2, 82.7)
		BSAL	2	3	66.7 (9.4, 99.2)	0.78 (0.34, 1.76)	3	4	75.0 (19.4, 99.4)	0.85 (0.48, 1.54)	18	21	85.7 (63.7, 97.0)	15	17	88.2 (63.6, 98.5)	20	24	83.3 (62.6, 95.3)
		BSM	8	10	80.0 (44.4, 97.5)	1.51 (0.88, 2.61)	0	0	NA (NA, NA)	NA (NA, NA)	9	17	52.9 (27.8, 77.0)	9	17	52.9 (27.8, 77.0)	17	27	63.0 (42.4, 80.6)
		BSCC	8	10	80.0 (44.4, 97.5)	1.13 (0.73, 1.75)	0	0	NA (NA, NA)	NA (NA, NA)	12	17	70.6 (44.0, 89.7)	12	17	70.6 (44.0, 89.7)	20	27	74.1 (53.7, 88.9)
		BSC	4	8	50.0 (15.7, 84.3)	0.65 (0.31, 1.38)	0	0	NA (NA, NA)	NA (NA, NA)	10	13	76.9 (46.2, 95.0)	10	13	76.9 (46.2, 95.0)	14	21	66.7 (43.0, 85.4)
		BSSL	4	4	100.0 -	1.65 (1.28, 2.14)	2	2	100.0 -	1.71 (1.71, 2.26)	23	38	60.5 (43.4, 76.0)	21	36	58.3 (40.8, 74.5)	27	42	64.3 (48.0, 78.4)
		BSOS	1	1	100.0 -	1.60 (0.94, 2.74)	0	0	NA (NA, NA)	NA (NA, NA)	5	8	62.5 (24.5, 91.5)	5	8	62.5 (24.5, 91.5)	6	9	66.7 (29.9, 92.5)
	Total	38	50	76.0 (61.8, 86.9)	1.10 (0.91, 1.33)	13	18	72.2 (46.5, 90.3)	1.05 (0.79, 1.43)	116	168	69.0 (61.5, 75.9)	103	150	68.7 (60.6, 76.0)	154	218	70.6 (64.1, 76.6)	
	Group 4: Node negative, high risk, either ER or PR positive	BSWN	1	11	9.1 (0.2, 41.3)	0.45 (0.06, 3.26)	0	0	NA (NA, NA)	NA (NA, NA)	8	40	20.0 (9.1, 35.6)	8	40	20.0 (9.1, 35.6)	9	51	17.6 (8.4, 30.9)
BSCM		1	5	20.0 (0.5, 71.6)	0.44 (0.07, 2.6)	1	7	14.3 (0.4, 57.9)	0.27 (0.04, 1.7)	17	37	45.9 (29.5, 63.1)	16	30	53.3 (34.3, 71.7)	18	42	42.9 (27.7, 59.0)	
BSAL		0	0	NA (NA, NA)	NA (NA, NA)	2	7	28.6 (3.7, 71.0)	0.92 (0.29, 3.35)	11	36	30.6 (16.3, 48.1)	9	29	31.0 (15.3, 50.8)	11	36	30.6 (16.3, 48.1)	
BSM		2	14	14.3 (1.8, 42.8)	0.59 (0.14, 2.39)	2	2	100.0 -	5.00 (5, 9.7)	9	37	24.3 (11.8, 41.2)	7	35	20.0 (8.4, 36.9)	11	51	21.6 (11.3, 35.3)	
BSCC		5	11	45.5 (16.7, 76.6)	1.82 (0.73, 4.52)	2	3	66.7 (9.4, 99.2)	3.33 (1.5, 10.22)	7	28	25.0 (10.7, 44.9)	5	25	20.0 (6.8, 40.7)	12	39	30.8 (17.0, 47.6)	
BSC		3	6	NA (NA, NA)	NA (NA, NA)	0	2	0.0 -	NA (NA, NA)	7	22	31.8 (13.9, 54.9)	7	20	35.0 (15.4, 59.2)	10	28	35.7 (18.6, 55.9)	
BSSL		1	4	25.0 (0.6, 80.6)	1.36 (0.23, 8.08)	0	1	0.0 -	NA (NA, NA)	11	60	18.3 (9.5, 30.4)	11	59	18.6 (9.7, 30.9)	12	64	18.8 (10.1, 30.5)	
BSOS		0	2	0.0 -	NA (NA, NA)	0	1	0.0 -	NA (NA, NA)	8	29	27.6 (12.7, 47.2)	8	28	28.6 (13.2, 48.7)	8	31	25.8 (11.9, 44.6)	
Total	13	53	24.5 (13.8, 38.3)	0.91 (0.55, 1.51)	7	23	30.4 (13.2, 52.9)	1.14 (0.61, 2.18)	78	289	27.0 (22.0, 32.5)	71	266	26.7 (21.5, 32.4)	91	342	26.6 (22.0, 31.6)		

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
		Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Pacific / Non-Pacific Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)		
50 to 69	Group 1: Node positive, and ER and PR negative	BSWN	3	3	100.0 -	1.09 (0.92, 1.29)	0	0	NA (NA, NA)	NA (NA, NA)	11	12	91.7 (61.5, 99.8)	11	12	91.7 (61.5, 99.8)	14	15	93.3 (68.1, 99.8)	
		BSCM	1	1	100.0 -	1.14 (0.88, 1.49)	1	1	100.0 -	1.17 (1.17, 1.58)	7	8	87.5 (47.3, 99.7)	6	7	85.7 (42.1, 99.6)	8	9	88.9 (51.8, 99.7)	
		BSAL	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	1.14 (1.14, 1.49)	8	9	88.9 (51.8, 99.7)	7	8	87.5 (47.3, 99.7)	8	9	88.9 (51.8, 99.7)	
		BSM	3	4	75.0 (19.4, 99.4)	0.75 (0.43, 1.32)	0	0	NA (NA, NA)	NA (NA, NA)	6	6	100.0 -	6	6	100.0 -	9	10	90.0 (55.5, 99.7)	
		BSCC	3	4	75.0 (19.4, 99.4)	0.75 (0.43, 1.32)	0	0	NA (NA, NA)	NA (NA, NA)	13	13	100.0 -	13	13	100.0 -	16	17	94.1 (71.3, 99.9)	
		BSC	2	2	100.0 -	1.00 (1, 1)	0	0	NA (NA, NA)	NA (NA, NA)	6	6	100.0 -	6	6	100.0 -	8	8	100.0 -	
		BSSL	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	14	15	93.3 (68.1, 99.8)	14	15	93.3 (68.1, 99.8)	14	15	93.3 (68.1, 99.8)	
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	7	7	100.0 -	7	7	100.0 -	7	7	100.0 -	
		Total	12	14	85.7 (57.2, 98.2)	0.90 (0.73, 1.13)	2	2	100.0 -	1.06 (1.06, 1.12)	72	76	94.7 (87.1, 98.5)	70	74	94.6 (86.7, 98.5)	84	90	93.3 (86.1, 97.5)	
		Group 2: Node negative, high risk, and ER and PR negative	BSWN	1	3	33.3 (0.8, 90.6)	0.40 (0.08, 1.97)	1	1	100.0 -	1.19 (1.19, 1.38)	32	38	84.2 (68.7, 94.0)	31	37	83.8 (68.0, 93.8)	33	41	80.5 (65.1, 91.2)
	BSCM		1	1	100.0 -	1.42 (1.11, 1.82)	4	4	100.0 -	1.53 (1.53, 2.07)	19	27	70.4 (49.8, 86.2)	15	23	65.2 (42.7, 83.6)	20	28	71.4 (51.3, 86.8)	
	BSAL		2	2	100.0 -	1.36 (1.04, 1.78)	2	2	100.0 -	1.42 (1.42, 1.93)	14	19	73.7 (48.8, 90.9)	12	17	70.6 (44.0, 89.7)	16	21	76.2 (52.8, 91.8)	
	BSM		4	6	66.7 (22.3, 95.7)	0.88 (0.48, 1.61)	0	0	NA (NA, NA)	NA (NA, NA)	19	25	76.0 (54.9, 90.6)	19	25	76.0 (54.9, 90.6)	23	31	74.2 (55.4, 88.1)	
	BSCC		0	4	0.0 -	NA (NA, NA)	1	1	100.0 -	1.43 (1.43, 1.9)	15	21	71.4 (47.8, 88.7)	14	20	70.0 (45.7, 88.1)	15	25	60.0 (38.7, 78.9)	
	BSC		2	6	33.3 (4.3, 77.7)	0.49 (0.15, 1.54)	1	1	100.0 -	1.48 (1.48, 1.87)	24	35	68.6 (50.7, 83.1)	23	34	67.6 (49.5, 82.6)	26	41	63.4 (46.9, 77.9)	
	BSSL		3	4	75.0 (19.4, 99.4)	1.11 (0.61, 2.03)	1	1	100.0 -	1.50 (1.5, 1.83)	33	49	67.3 (52.5, 80.1)	32	48	66.7 (51.6, 79.6)	36	53	67.9 (53.7, 80.1)	
	BSOS		0	1	0.0 -	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	17	21	81.0 (58.1, 94.6)	17	21	81.0 (58.1, 94.6)	17	22	77.3 (54.6, 92.2)	
		Total	13	27	48.1 (28.7, 68.1)	0.65 (0.44, 0.97)	10	10	100.0 -	1.38 (1.38, 1.5)	173	235	73.6 (67.5, 79.1)	163	225	72.4 (66.1, 78.2)	186	262	71.0 (65.1, 76.4)	
		Group 3: Node positive, either ER or PR positive	BSWN	13	23	56.5 (34.5, 76.8)	1.12 (0.74, 1.68)	6	9	66.7 (29.9, 92.5)	1.36 (0.86, 2.27)	49	97	50.5 (40.2, 60.8)	43	88	48.9 (38.1, 59.8)	62	120	51.7 (42.4, 60.9)
	BSCM		7	16	43.8 (19.8, 70.1)	0.77 (0.43, 1.4)	8	15	53.3 (26.6, 78.7)	0.93 (0.58, 1.57)	39	69	56.5 (44.0, 68.4)	31	54	57.4 (43.2, 70.8)	46	85	54.1 (43.0, 65.0)	
	BSAL		5	10	50.0 (18.7, 81.3)	0.94 (0.48, 1.82)	4	7	57.1 (18.4, 90.1)	1.08 (0.57, 2.16)	31	58	53.4 (39.9, 66.7)	27	51	52.9 (38.5, 67.1)	36	68	52.9 (40.4, 65.2)	
	BSM		24	55	43.6 (30.3, 57.7)	0.85 (0.6, 1.22)	3	3	100.0 -	2.02 (2.02, 2.48)	49	96	51.0 (40.6, 61.4)	46	93	49.5 (38.9, 60.0)	73	151	48.3 (40.1, 56.6)	
	BSCC		12	35	34.3 (19.1, 52.2)	0.73 (0.44, 1.21)	3	5	60.0 (14.7, 94.7)	1.29 (0.63, 2.73)	43	91	47.3 (36.7, 58.0)	40	86	46.5 (35.7, 57.6)	55	126	43.7 (34.8, 52.8)	
	BSC		2	8	NA (NA, NA)	NA (NA, NA)	2	4	50.0 (6.8, 93.2)	1.14 (0.43, 3.13)	35	79	44.3 (33.1, 55.9)	33	75	44.0 (32.5, 55.9)	37	87	42.5 (32.0, 53.6)	
	BSSL		7	10	70.0 (34.8, 93.3)	1.46 (0.93, 2.3)	0	0	NA (NA, NA)	NA (NA, NA)	47	98	48.0 (37.8, 58.3)	47	98	48.0 (37.8, 58.3)	54	108	50.0 (40.2, 59.8)	
	BSOS		1	2	50.0 (1.3, 98.7)	0.82 (0.2, 3.35)	1	1	100.0 -	1.67 (1.67, 2.07)	34	56	60.7 (46.8, 73.5)	33	55	60.0 (45.9, 73.0)	35	58	60.3 (46.6, 73.0)	
		Total	71	159	44.7 (36.8, 52.7)	0.88 (0.73, 1.06)	27	44	61.4 (45.5, 75.6)	1.23 (0.97, 1.57)	327	644	50.8 (46.8, 54.7)	300	600	50.0 (45.9, 54.1)	398	803	49.6 (46.1, 53.1)	
		Group 4: Node negative, high risk, either ER or PR positive	BSWN	9	69	13.0 (6.1, 23.3)	0.81 (0.41, 1.59)	4	15	26.7 (7.8, 55.1)	1.74 (0.75, 4.24)	39	243	16.0 (11.7, 21.3)	35	228	15.4 (10.9, 20.7)	48	312	15.4 (11.6, 19.9)
	BSCM		4	29	13.8 (3.9, 31.7)	0.75 (0.29, 1.97)	11	49	22.4 (11.8, 36.6)	1.35 (0.8, 2.61)	30	163	18.4 (12.8, 25.2)	19	114	16.7 (10.3, 24.8)	34	192	17.7 (12.6, 23.9)	
	BSAL		3	13	23.1 (5.0, 53.8)	1.34 (0.47, 3.84)	2	23	8.7 (1.1, 28.0)	0.46 (0.12, 1.82)	25	145	17.2 (11.5, 24.4)	23	122	18.9 (12.3, 26.9)	28	158	17.7 (12.1, 24.6)	
	BSM		11	92	12.0 (6.1, 20.4)	1.26 (0.66, 2.44)	2	7	28.6 (3.7, 71.0)	3.18 (0.98, 10.84)	28	296	9.5 (6.4, 13.4)	26	289	9.0 (6.0, 12.9)	39	388	10.1 (7.2, 13.5)	
	BSCC		6	45	13.3 (5.1, 26.8)	0.80 (0.36, 1.81)	1	3	33.3 (0.8, 90.6)	2.04 (0.41, 10.45)	32	193	16.6 (11.6, 22.6)	31	190	16.3 (11.4, 22.4)	38	238	16.0 (11.6, 21.3)	
	BSC		4	33	12.1 (3.4, 28.2)	0.76 (0.29, 2.03)	4	13	30.8 (9.1, 61.4)	2.09 (0.93, 5.11)	29	183	15.8 (10.9, 22.0)	25	170	14.7 (9.7, 20.9)	33	216	15.3 (10.8, 20.8)	
	BSSL		6	31	19.4 (7.5, 37.5)	1.76 (0.8, 3.84)	1	4	25.0 (0.6, 80.6)	2.31 (0.42, 12.96)	36	327	11.0 (7.8, 14.9)	35	323	10.8 (7.7, 14.7)	42	358	11.7 (8.6, 15.5)	
	BSOS		2	6	33.3 (4.3, 77.7)	1.43 (0.44, 4.61)	0	3	0.0 -	NA (NA, NA)	32	137	23.4 (16.6, 31.3)	32	134	23.9 (16.9, 32.0)	34	143	23.8 (17.1, 31.6)	
		Total	45	318	14.2 (10.5, 18.5)	0.95 (0.71, 1.28)	25	117	21.4 (14.3, 29.9)	1.48 (1.05, 2.14)	251	1,687	14.9 (13.2, 16.7)	226	1,570	14.4 (12.7, 16.2)	296	2,005	14.8 (13.2, 16.4)	

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Pacific / Non-Pacific Ratio	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	Invasive Cancers having Chemotherapy	Invasive Cancers	% of Invasive Cancers Having Chemotherapy (95% CI)	
45 to 69	Group 1: Node positive, and ER and PR negative	BSWN	3	3	100.0 -	1.07 (0.94, 1.23)	0	0	NA (NA, NA)	NA (NA, NA)	14	15	93.3 (68.1, 99.8)	14	15	93.3 (68.1, 99.8)	17	18	94.4 (72.7, 99.9)
		BSCM	1	1	100.0 -	1.14 (0.88, 1.49)	1	1	100.0 -	1.17 (1.17, 1.58)	7	8	87.5 (47.3, 99.7)	6	7	85.7 (42.1, 99.6)	8	9	88.9 (51.8, 99.7)
		BSAL	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	1.14 (1.14, 1.49)	8	9	88.9 (51.8, 99.7)	7	8	87.5 (47.3, 99.7)	8	9	88.9 (51.8, 99.7)
		BSM	3	4	75.0 (19.4, 99.4)	0.75 (0.43, 1.32)	0	0	NA (NA, NA)	NA (NA, NA)	6	6	100.0 -	6	6	100.0 -	9	10	90.0 (55.5, 99.7)
		BSCC	3	4	75.0 (19.4, 99.4)	0.75 (0.43, 1.32)	0	0	NA (NA, NA)	NA (NA, NA)	15	15	100.0 -	15	15	100.0 -	18	19	94.7 (74.0, 99.9)
		BSC	3	3	100.0 -	1.00 (1, 1)	0	0	NA (NA, NA)	NA (NA, NA)	7	7	100.0 -	7	7	100.0 -	10	10	100.0 -
		BSSL	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	1.06 (1.06, 1.2)	17	18	94.4 (72.7, 99.9)	16	17	94.1 (71.3, 99.9)	17	18	94.4 (72.7, 99.9)
		BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	9	9	100.0 -	9	9	100.0 -	9	9	100.0 -
		Total	13	15	86.7 (59.5, 98.3)	0.91 (0.74, 1.11)	3	3	100.0 -	1.05 (1.05, 1.1)	83	87	95.4 (88.6, 98.7)	80	84	88.3 (88.3, 98.7)	96	102	94.1 (87.6, 97.8)
	Group 2: Node negative, high risk, and ER and PR negative	BSWN	1	3	33.3 (0.8, 90.6)	0.40 (0.08, 2.01)	1	1	100.0 -	1.22 (1.22, 1.39)	38	46	82.6 (68.6, 92.2)	37	45	82.2 (67.9, 92.0)	39	49	79.6 (65.7, 89.8)
		BSCM	2	2	100.0 -	1.36 (1.1, 1.69)	5	5	100.0 -	1.47 (1.47, 1.92)	22	30	73.3 (54.1, 87.7)	17	25	68.0 (46.5, 85.1)	24	32	75.0 (56.6, 88.5)
		BSAL	2	2	100.0 -	1.28 (1.03, 1.58)	3	3	100.0 -	1.33 (1.33, 1.72)	18	23	78.3 (56.3, 92.5)	15	20	75.0 (50.9, 91.3)	20	25	80.0 (59.3, 93.2)
		BSM	4	6	66.7 (22.3, 95.7)	0.88 (0.48, 1.6)	0	0	NA (NA, NA)	NA (NA, NA)	22	29	75.9 (56.5, 89.7)	22	29	75.9 (56.5, 89.7)	26	35	74.3 (56.7, 87.5)
		BSCC	1	5	20.0 (0.5, 71.6)	0.28 (0.05, 1.62)	1	1	100.0 -	1.40 (1.4, 1.83)	16	22	72.7 (49.8, 89.3)	15	21	71.4 (47.8, 88.7)	17	27	63.0 (42.4, 80.6)
		BSC	2	6	NA (NA, NA)	NA (NA, NA)	1	1	NA (NA, NA)	NA (NA, NA)	25	37	67.6 (50.2, 82.0)	24	36	66.7 (49.0, 81.4)	27	43	62.8 (46.7, 77.0)
		BSSL	3	4	75.0 (19.4, 99.4)	1.09 (0.6, 1.96)	1	1	100.0 -	1.46 (1.46, 1.74)	40	58	69.0 (55.5, 80.5)	39	57	68.4 (54.8, 80.1)	43	62	69.4 (56.3, 80.4)
		BSOS	0	1	0.0 -	0.00 #NUM!	0	0	NA (NA, NA)	NA (NA, NA)	20	24	83.3 (62.6, 95.3)	20	24	83.3 (62.6, 95.3)	20	25	80.0 (59.3, 93.2)
		Total	15	29	51.7 (32.5, 70.6)	0.69 (0.48, 0.99)	12	12	100.0 -	1.36 (1.36, 1.46)	201	269	74.7 (69.1, 79.8)	189	257	73.5 (67.7, 78.8)	216	298	72.5 (67.0, 77.5)
	Group 3: Node positive, either ER or PR positive	BSWN	17	27	63.0 (42.4, 80.6)	1.10 (0.79, 1.52)	7	10	70.0 (34.8, 93.3)	1.25 (0.83, 1.92)	75	131	57.3 (48.3, 65.9)	68	121	56.2 (46.9, 65.2)	92	158	58.2 (50.1, 66.0)
		BSCM	14	26	53.8 (33.4, 73.4)	0.92 (0.62, 1.37)	15	26	57.7 (36.9, 76.6)	0.98 (0.71, 1.45)	52	89	58.4 (47.5, 68.8)	37	63	58.7 (45.6, 71.0)	66	115	57.4 (47.8, 66.6)
		BSAL	7	13	53.8 (25.1, 80.8)	0.87 (0.51, 1.48)	7	11	63.6 (30.8, 89.1)	1.03 (0.66, 1.67)	49	79	62.0 (50.4, 72.7)	42	68	61.8 (49.2, 73.3)	56	92	60.9 (50.1, 70.9)
		BSM	32	65	49.2 (36.6, 61.9)	0.96 (0.71, 1.3)	3	3	100.0 -	2.00 (2, 2.41)	58	113	51.3 (41.7, 60.8)	55	110	50.0 (40.3, 59.7)	90	178	50.6 (43.0, 58.1)
		BSCC	20	45	44.4 (29.6, 60.0)	0.87 (0.6, 1.27)	3	5	60.0 (14.7, 94.7)	1.19 (0.58, 2.49)	55	108	50.9 (41.1, 60.7)	52	103	50.5 (40.5, 60.5)	75	153	49.0 (40.9, 57.2)
		BSC	6	16	37.5 (15.2, 64.6)	0.77 (0.39, 1.49)	2	4	50.0 (6.8, 93.2)	1.02 (0.38, 2.79)	45	92	48.9 (38.3, 59.6)	43	88	48.9 (38.1, 59.8)	51	108	47.2 (37.5, 57.1)
		BSSL	11	14	78.6 (49.2, 95.3)	1.53 (1.11, 2.1)	2	2	100.0 -	1.97 (1.97, 2.33)	70	136	51.5 (42.8, 60.1)	68	134	50.7 (42.0, 59.5)	81	150	54.0 (45.7, 62.2)
		BSOS	2	3	66.7 (9.4, 99.2)	1.09 (0.48, 2.49)	1	1	100.0 -	1.66 (1.66, 2.03)	39	64	60.9 (47.9, 72.9)	38	63	60.3 (47.2, 72.4)	41	67	61.2 (48.5, 72.9)
		Total	109	209	52.2 (45.2, 59.1)	0.96 (0.83, 1.1)	40	62	64.5 (51.3, 76.3)	1.20 (1, 1.46)	443	812	54.6 (51.1, 58.0)	403	750	53.7 (50.1, 57.3)	552	1,021	54.1 (51.0, 57.2)
	Group 4: Node negative, high risk, either ER or PR positive	BSWN	10	80	12.5 (6.2, 21.8)	0.75 (0.4, 1.42)	4	15	26.7 (7.8, 55.1)	1.66 (0.72, 4.02)	47	283	16.6 (12.5, 21.5)	43	268	16.0 (11.9, 21.0)	57	363	15.7 (12.1, 19.9)
		BSCM	5	34	14.7 (5.0, 31.1)	0.63 (0.27, 1.46)	12	56	21.4 (11.6, 34.4)	0.88 (0.53, 1.57)	47	200	23.5 (17.8, 30.0)	35	144	24.3 (17.6, 32.1)	52	234	22.2 (17.1, 28.1)
		BSAL	3	13	23.1 (5.0, 53.8)	1.16 (0.41, 3.27)	4	30	13.3 (3.8, 30.7)	0.63 (0.25, 1.65)	36	181	19.9 (14.3, 26.5)	32	151	21.2 (15.0, 28.6)	39	194	20.1 (14.7, 26.4)
		BSM	13	106	12.3 (6.7, 20.1)	1.10 (0.61, 2)	4	9	44.4 (13.7, 78.8)	4.36 (2.1, 9.7)	37	333	11.1 (7.9, 15.0)	33	324	10.2 (7.1, 14.0)	50	439	11.4 (8.6, 14.7)
		BSCC	11	56	19.6 (10.2, 32.4)	1.11 (0.61, 2.03)	3	6	50.0 (11.8, 88.2)	2.99 (1.34, 7.01)	39	221	17.6 (12.9, 23.3)	36	215	16.7 (12.0, 22.4)	50	277	18.1 (13.7, 23.1)
		BSC	7	39	17.9 (7.5, 33.5)	1.02 (0.49, 2.13)	4	15	26.7 (7.8, 55.1)	1.58 (0.68, 3.88)	36	205	17.6 (12.6, 23.5)	32	190	16.8 (11.8, 22.9)	43	244	17.6 (13.1, 23.0)
		BSSL	7	35	20.0 (8.4, 36.9)	1.65 (0.81, 3.37)	1	5	20.0 (0.5, 71.6)	1.66 (0.29, 9.79)	47	387	12.1 (9.1, 15.8)	46	382	12.0 (9.0, 15.7)	54	422	12.8 (9.8, 16.4)
		BSOS	2	8	25.0 (3.2, 65.1)	1.04 (0.3, 3.55)	0	4	0.0 -	NA (NA, NA)	40	166	24.1 (17.8, 31.3)	40	162	24.7 (18.3, 32.1)	42	174	24.1 (18.0, 31.2)
		Total	58	371	15.6 (12.1, 19.7)	0.94 (0.73, 1.21)	32	140	22.9 (16.2, 30.7)	1.41 (1.04, 1.95)	329	1,976	16.6 (15.0, 18.4)	297	1,836	16.2 (14.5, 17.9)	387	2,347	16.5 (15.0, 18.1)

4.j.t, Invasive cancer having endocrine therapy, women screened during the 4 years to December 2019

Description: The percentage of women diagnosed with invasive cancer who have endocrine therapy reported by disease character group. The 't' in the indicator id marks it as a treatment indicator.

Target: No target

Among women aged 45–69 years who were diagnosed with invasive breast cancer during the four years to December 2019, 92% of those who were node positive and either ER or PR positive had endocrine therapy, as did 75% of those who were node negative, high risk, and either ER or PR positive, and 43% who were node negative, low risk, and either ER or PR positive.

Table 36: 4.j.t.1, Invasive cancer having endocrine therapy, women screened during the 4 years to December 2019

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All				
		Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Pacific / Non-Pacific Ratio	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)		
45 to 49	Group 1: Node positive, either ER or PR positive	BSWN	4	4	100.0 -	1.13 (1, 1.28)	1	1	100.0 -	1.14 (1.14, 1.29)	30	34	88.2 (72.5, 96.7)	29	33	87.9 (71.8, 96.6)	34	38	90.5 (71.1, 97.3)	
		BSCM	9	10	90.0 (55.5, 99.7)	0.90 (0.73, 1.11)	10	10	100.0 -	1.00 (1, 1)	19	19	100.0 -	9	9	100.0 -	28	29	100.0 (78.5, 100)	
		BSAL	3	3	100.0 -	1.11 (0.96, 1.27)	4	4	100.0 -	1.13 (1.13, 1.35)	19	21	90.5 (69.6, 98.8)	15	17	88.2 (63.6, 98.5)	22	24	91.7 (64.6, 98.5)	
		BSM	9	10	90.0 (55.5, 99.7)	1.02 (0.78, 1.34)	0	0	NA (NA, NA)	NA (NA, NA)	15	17	88.2 (63.6, 98.5)	15	17	88.2 (63.6, 98.5)	24	27	92.9 (68.5, 98.7)	
		BSCC	10	10	100.0 -	1.00 (1, 1)	0	0	NA (NA, NA)	NA (NA, NA)	17	17	100.0 -	17	17	100.0 -	27	27	100.0 (81.6, 100)	
		BSC	8	8	100.0 -	1.00 (1, 1)	0	0	NA (NA, NA)	NA (NA, NA)	13	13	100.0 -	13	13	100.0 -	21	21	100.0 (70.1, 100)	
		BSSL	2	4	50.0 (6.8, 93.2)	0.53 (0.2, 1.41)	2	2	100.0 -	1.06 (1.06, 1.15)	36	38	94.7 (82.3, 99.4)	34	36	94.4 (81.3, 99.3)	38	42	91.3 (73.2, 97.6)	
		BSOS	1	1	100.0 -	1.00 (1, 1)	0	0	0.0 -	NA (NA, NA)	8	8	100.0 -	8	8	100.0 -	9	9	100.0 (43.9, 100)	
		Total	46	50	80.8 (80.8, 97.8)	0.98 (0.89, 1.07)	17	17	100.0 -	1.07 (1.07, 1.12)	157	167	94.0 (89.3, 97.1)	140	150	93.3 (88.1, 96.8)	203	217	94.7 (88.9, 97.5)	
		Group 2: Node negative, high risk, either ER or PR positive	BSWN	8	11	72.7 (39.0, 94.0)	0.86 (0.58, 1.26)	0	0	NA (NA, NA)	NA (NA, NA)	34	40	85.0 (70.2, 94.3)	34	40	85.0 (70.2, 94.3)	42	51	81.8 (61.5, 92.7)
			BSCM	5	5	100.0 -	1.32 (1.1, 1.59)	5	7	71.4 (29.0, 96.3)	0.93 (0.58, 1.55)	28	37	75.7 (58.8, 88.2)	23	30	76.7 (57.7, 90.1)	33	42	79.2 (59.5, 90.8)
			BSAL	0	0	NA (NA, NA)	NA (NA, NA)	4	7	57.1 (18.4, 90.1)	0.72 (0.38, 1.41)	27	36	75.0 (57.8, 87.9)	23	29	79.3 (60.3, 92.0)	27	36	66.7 (41.7, 84.8)
BSM	14		14	100.0 -	1.03 (0.97, 1.08)	2	2	100.0 -	1.03 (1.03, 1.09)	36	37	97.3 (85.8, 99.9)	34	35	97.1 (85.1, 99.9)	50	51	95.8 (79.8, 99.3)		
BSCC	10		11	90.9 (58.7, 99.8)	1.06 (0.83, 1.35)	1	3	33.3 (0.8, 90.6)	0.36 (0.07, 1.8)	24	28	85.7 (67.3, 96.0)	23	25	92.0 (74.0, 99.0)	34	39	85.7 (65.4, 95)		
BSC	6		6	100.0 -	1.16 (0.98, 1.37)	2	2	100.0 -	1.18 (1.18, 1.41)	19	22	86.4 (65.1, 97.1)	17	20	85.0 (62.1, 96.8)	25	28	88.9 (67.2, 96.9)		
BSSL	3		4	75.0 (19.4, 99.4)	1.05 (0.58, 1.88)	1	1	100.0 -	1.40 (1.4, 1.65)	43	60	71.7 (58.6, 82.5)	42	59	71.2 (57.9, 82.2)	46	64	68.8 (51.4, 82)		
BSOS	1		2	50.0 (1.3, 98.7)	0.66 (0.16, 2.68)	0	1	0.0 -	NA (NA, NA)	22	29	75.9 (56.5, 89.7)	22	28	78.6 (59.0, 91.7)	23	31	80.0 (54.8, 93)		
Total	47		53	88.7 (77.0, 95.7)	1.10 (0.98, 1.23)	15	23	65.2 (42.7, 83.6)	0.80 (0.59, 1.08)	233	289	80.6 (75.6, 85.0)	218	266	82.0 (76.8, 86.4)	280	342	80.7 (74.1, 85.9)		
Group 3: Node negative, low risk, either ER or PR positive	BSWN		0	3	0.0 -	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	12	28	42.9 (24.5, 62.8)	12	28	42.9 (24.5, 62.8)	12	31	46.7 (24.8, 69.9)	
	BSCM		1	4	25.0 (0.6, 80.6)	1.50 (0.18, 12.46)	1	3	33.3 (0.8, 90.6)	3.00 (0.61, 34.58)	2	12	16.7 (2.1, 48.4)	1	9	11.1 (0.3, 48.2)	3	16	20.0 (5.7, 51)	
	BSAL		1	3	33.3 (0.8, 90.6)	1.78 (0.27, 11.86)	2	2	100.0 -	14.00 (14, 92.55)	3	16	18.8 (4.0, 45.6)	1	14	7.1 (0.2, 33.9)	4	19	33.3 (12.1, 64.6)	
	BSM	2	2	100.0 -	1.06 (0.95, 1.17)	0	0	NA (NA, NA)	NA (NA, NA)	18	19	94.7 (74.0, 99.9)	18	19	94.7 (74.0, 99.9)	20	21	92.3 (66.7, 98.6)		
	BSCC	4	5	80.0 (28.4, 99.5)	3.04 (1.27, 7.26)	1	1	100.0 -	4.50 (4.5, 10.68)	5	19	26.3 (9.1, 51.2)	4	18	22.2 (6.4, 47.6)	9	24	21.4 (7.6, 47.6)		
	BSC	1	1	100.0 -	1.14 (0.95, 1.38)	0	0	NA (NA, NA)	NA (NA, NA)	14	16	87.5 (61.7, 98.4)	14	16	87.5 (61.7, 98.4)	15	17	87.5 (52.9, 97.8)		
	BSSL	0	1	0.0 -	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	9	32	28.1 (13.7, 46.7)	9	32	28.1 (13.7, 46.7)	9	33	12.5 (3.5, 36)		
	BSOS	0	0	NA (NA, NA)	NA (NA, NA)	1	1	100.0 -	2.80 (2.8, 5.65)	6	15	40.0 (16.3, 67.7)	5	14	35.7 (12.8, 64.9)	6	15	0.0 (0, 65.8)		
	Total	9	19	47.4 (24.4, 71.1)	1.08 (0.65, 1.79)	5	7	71.4 (29.0, 96.3)	1.67 (1.05, 2.77)	69	157	43.9 (36.0, 52.1)	64	150	42.7 (34.6, 51.0)	78	176	41.4 (31.6, 51.9)		
	50 to 69	Group 1: Node positive, either ER or PR positive	BSWN	22	23	95.7 (78.1, 99.9)	1.07 (0.95, 1.2)	7	9	77.8 (40.0, 97.2)	0.85 (0.6, 1.22)	61	68	89.7 (79.9, 95.8)	54	59	91.5 (81.3, 97.2)	83	91	92.2 (83, 96.6)
			BSCM	14	16	87.5 (61.7, 98.4)	0.90 (0.74, 1.09)	14	15	93.3 (68.1, 99.8)	0.93 (0.82, 1.07)	41	42	97.6 (87.4, 99.9)	27	27	100.0 -	55	58	94.1 (80.9, 98.4)
			BSAL	8	10	80.0 (44.4, 97.5)	0.95 (0.68, 1.33)	7	7	100.0 -	1.23 (1.23, 1.44)	37	44	84.1 (69.9, 93.4)	30	37	81.1 (64.8, 92.0)	45	54	78.4 (62.8, 88.6)
BSM			53	55	96.4 (87.5, 99.6)	0.98 (0.92, 1.04)	3	3	100.0 -	1.02 (1.02, 1.05)	65	66	98.5 (91.8, 100.0)	62	63	98.4 (91.5, 100.0)	118	121	95.2 (88.3, 98.1)	
BSCC			29	35	82.9 (66.4, 93.4)	0.84 (0.72, 0.99)	4	5	80.0 (28.4, 99.5)	0.80 (0.52, 1.24)	51	52	98.1 (89.7, 100.0)	47	47	100.0 -	80	87	96.2 (87, 98.9)	
BSC			8	8	100.0 (NA, NA)	1.03 (0.98, 1.08)	3	4	75.0 (19.4, 99.4)	0.75 (0.43, 1.32)	38	39	97.4 (86.5, 99.9)	35	35	100.0 -	46	47	100.0 (89.6, 100)	
BSSL			9	10	90.0 (55.5, 99.7)	1.01 (0.81, 1.26)	0	0	NA (NA, NA)	NA (NA, NA)	64	72	88.9 (79.3, 95.1)	64	72	88.9 (79.3, 95.1)	73	82	84.5 (73.1, 91.6)	
BSOS			2	2	100.0 -	1.06 (0.98, 1.16)	1	1	100.0 -	1.07 (1.07, 1.17)	31	33	93.9 (79.8, 99.3)	30	32	93.8 (79.2, 99.2)	33	35	93.1 (78, 98.1)	
Total			145	159	91.2 (85.7, 95.1)	0.98 (0.93, 1.03)	39	44	88.6 (75.4, 96.2)	0.94 (0.85, 1.05)	388	416	93.3 (90.4, 95.5)	349	372	93.8 (90.9, 96.0)	533	575	91.8 (88.6, 94.1)	
Group 2: Node negative, high risk, either ER or PR positive			BSWN	42	69	60.9 (48.4, 72.4)	0.83 (0.67, 1.03)	12	15	80.0 (51.9, 95.7)	1.11 (0.86, 1.46)	108	148	73.0 (65.1, 79.9)	96	133	72.2 (63.7, 79.6)	150	217	67.1 (59.6, 73.8)
			BSCM	21	29	72.4 (52.8, 87.3)	1.01 (0.79, 1.3)	35	49	71.4 (56.7, 83.4)	1.00 (0.84, 1.26)	85	119	71.4 (62.4, 79.3)	50	70	71.4 (59.4, 81.6)	106	148	73.7 (64, 81.5)
			BSAL	7	13	53.8 (25.1, 80.8)	0.96 (0.56, 1.63)	13	23	56.5 (34.5, 76.8)	1.00 (0.7, 1.51)	58	103	56.3 (46.2, 66.1)	45	80	56.3 (44.7, 67.3)	65	116	56.7 (46.4, 66.4)
	BSM	87	92	94.6 (87.8, 98.2)	1.05 (0.98, 1.12)	7	7	100.0 -	1.11 (1.11, 1.17)	160	177	90.4 (85.1, 94.3)	153	170	90.0 (84.5, 94.1)	247	269	90.2 (85.4, 93.6)		
	BSCC	42	45	93.3 (81.7, 98.6)	1.14 (1.01, 1.28)	3	3	100.0 -	1.23 (1.23, 1.34)	95	116	81.9 (73.7, 88.4)	92	113	81.4 (73.0, 88.1)	137	161	82.5 (75, 88.2)		
	BSC	28	33	84.8 (68.1, 94.9)	0.95 (0.81, 1.11)	13	13	100.0 -	1.14 (1.14, 1.22)	107	120	89.2 (82.2, 94.1)	94	107	87.9 (80.1, 93.4)	135	153	90.5 (83.8, 94.6)		
	BSSL	25	31	80.6 (62.5, 92.5)	1.39 (1.12, 1.71)	2	4	50.0 (6.8, 93.2)	0.86 (0.32, 2.3)	111	191	58.1 (50.8, 65.2)	109	187	58.3 (50.9, 65.4)	136	222	58.5 (51.1, 65.5)		
	BSOS	3	6	50.0 (11.8, 88.2)	0.75 (0.33, 1.7)	1	3	33.3 (0.8, 90.6)	0.49 (0.1, 2.45)	52	78	66.7 (55.1, 76.9)	51	75	68.0 (56.2, 78.3)	55	84	59.7 (47.7, 70.6)		
	Total	255	318	80.2 (75.4, 84.4)	1.09 (1.02, 1.16)	86	117	73.5 (64.5, 81.2)	1.00 (0.89, 1.12)	776	1,052	73.8 (71.0, 76.4)	690	935	73.8 (70.9, 76.6)	1,031	1,370	73.9 (71.2, 76.5)		
	Group 3: Node negative, low risk, either ER or PR positive	BSWN	3	25	12.0 (2.5, 31.2)	0.44 (0.14, 1.33)	1	8	12.5 (0.3, 52.7)	0.44 (0.07, 2.8)	26	95	27.4 (18.7, 37.5)	25	87	28.7 (19.5, 39.4)	29	120	24.4 (16.2, 34.9)	
		BSCM	1	15	6.7 (0.2, 31.9)	0.59 (0.07, 4.63)	0	12	0.0 -	NA (NA, NA)	5	44	11.4 (3.8, 24.6)	5	32	15.6 (5.3, 32.8)	6	59	14.7 (6.4, 30.1)	
		BSAL	1	5	20.0 (0.5, 71.6)	7.40 (0.54, 100.61)	0	8	0.0 -	NA (NA, NA)	1	37	2.7 (0.1, 14.2)	1	29	3.4 (0.1, 17.8)	2	42	7.1 (2, 22.6)	
BSM		30	35	85.7 (69.7, 95.2)	0.99 (0.84, 1.16)	2	2	100.0 -	1.16 (1.16, 1.27)	60	67	86.6 (76.7, 93.9)	58	67	86.6 (76.0, 93.7)	90	104	83.9 (72.2, 91.3)		
BSCC		19	29	65.5 (45.7, 82.1)	1.44 (0.95, 2.19)	1	1	100.0 -	2.26 (2.26, 3.17)	20	44	45.5 (30.4, 61.2)	19	43	44.2 (29.1, 60.1)	39	73	55.9 (39.5, 71.1)		
BSC		7	7	100.0 -	1.20 (1.07, 1.35)	2	2	100.0 -	1.21 (1.21, 1.37)	45	54	83.3 (70.7, 92.1)	43	52	82.7 (69.7, 91.8)	52	61	82.6 (69.3, 90.9)		
B																				

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All			
		Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Māori / Non-Māori Ratio	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	Invasive Cancers having Endocrine Therapy	Invasive Cancers	% of Invasive Cancers Having Endocrine Therapy (95% CI)	
45 to 69	Group 1: Node positive, either ER or PR positive	BSWN	26	27	96.3 (81.0, 99.9)	1.08 (0.98, 1.19)	8	10	80.0 (44.4, 97.5)	0.89 (0.65, 1.22)	91	102	89.2 (81.5, 94.5)	83	92	90.2 (82.2, 95.4)	117	129	91.8 (84, 96)
		BSCM	23	26	88.5 (69.8, 97.6)	0.90 (0.78, 1.04)	24	25	96.0 (79.6, 99.9)	0.96 (0.89, 1.04)	60	61	98.4 (91.2, 100.0)	36	36	100.0 -	83	87	95.8 (86, 98.8)
		BSAL	11	13	84.6 (54.6, 98.1)	0.98 (0.76, 1.26)	11	11	100.0 -	1.20 (1.2, 1.35)	56	65	86.2 (75.3, 93.5)	45	54	83.3 (70.7, 92.1)	67	78	81.6 (68.6, 90)
		BSM	62	65	95.4 (87.1, 99.0)	0.99 (0.92, 1.06)	3	3	100.0 -	1.04 (1.04, 1.08)	80	83	96.4 (89.8, 99.2)	77	80	96.3 (89.4, 99.2)	142	148	94.8 (88.5, 97.8)
		BSCC	39	45	86.7 (73.2, 94.9)	0.88 (0.78, 0.99)	4	5	80.0 (28.4, 99.5)	0.80 (0.52, 1.24)	68	69	98.6 (92.2, 100.0)	64	64	100.0 -	107	114	97.1 (90, 99.2)
		BSC	16	16	100.0 (NA, NA)	1.02 (0.98, 1.06)	3	4	75.0 (19.4, 99.4)	0.75 (0.43, 1.32)	51	52	98.1 (89.7, 100.0)	48	48	100.0 -	67	68	100.0 (91.6, 100)
		BSSL	11	14	78.6 (49.2, 95.3)	0.86 (0.65, 1.14)	2	2	100.0 -	1.10 (1.1, 1.17)	100	110	90.9 (83.9, 95.6)	98	108	90.7 (83.6, 95.5)	111	124	86.4 (77.3, 92.2)
		BSOS	3	3	100.0 -	1.05 (0.98, 1.13)	1	1	100.0 -	1.05 (1.05, 1.13)	39	41	95.1 (83.5, 99.4)	38	40	95.0 (83.1, 99.4)	42	44	93.8 (79.9, 98.3)
		Total	191	209	91.4 (86.7, 94.8)	0.98 (0.93, 1.02)	56	61	91.8 (81.9, 97.3)	0.98 (0.91, 1.06)	545	583	93.5 (91.2, 95.3)	489	522	93.7 (91.2, 95.6)	736	792	92.4 (89.8, 94.4)
	Group 2: Node negative, high risk, either ER or PR positive	BSWN	50	80	62.5 (51.0, 73.1)	0.83 (0.69, 1)	12	15	80.0 (51.9, 95.7)	1.06 (0.83, 1.39)	142	188	75.5 (68.7, 81.5)	130	173	75.1 (68.0, 81.4)	192	268	68.8 (61.8, 75)
		BSCM	26	34	76.5 (58.8, 89.3)	1.06 (0.86, 1.3)	40	56	71.4 (57.8, 82.7)	0.98 (0.83, 1.2)	113	156	72.4 (64.7, 79.3)	73	100	73.0 (63.2, 81.4)	139	190	74.8 (66.3, 81.7)
		BSAL	7	13	53.8 (25.1, 80.8)	0.88 (0.52, 1.48)	17	30	56.7 (37.4, 74.5)	0.91 (0.66, 1.28)	85	139	61.2 (52.5, 69.3)	68	109	62.4 (52.6, 71.5)	92	152	58.1 (48.5, 67.1)
		BSM	101	106	95.3 (89.3, 98.5)	1.04 (0.98, 1.1)	9	9	100.0 -	1.10 (1.1, 1.14)	196	214	91.6 (87.0, 94.9)	187	205	91.2 (86.5, 94.7)	297	320	90.8 (86.4, 93.9)
		BSCC	52	56	92.9 (82.7, 98.0)	1.12 (1.01, 1.25)	4	6	66.7 (22.3, 95.7)	0.80 (0.45, 1.42)	119	144	82.6 (75.4, 88.4)	115	138	83.3 (76.0, 89.1)	171	200	83.0 (76.1, 88.2)
		BSC	34	39	87.2 (72.6, 95.7)	0.98 (0.86, 1.12)	15	15	100.0 -	1.14 (1.14, 1.22)	126	142	88.7 (82.3, 93.4)	111	127	87.4 (80.3, 92.6)	160	181	90.3 (84.1, 94.2)
		BSSL	28	35	80.0 (63.1, 91.6)	1.30 (1.08, 1.58)	3	5	60.0 (14.7, 94.7)	0.98 (0.48, 2.01)	154	251	61.4 (55.0, 67.4)	151	246	61.4 (55.0, 67.5)	182	286	60.1 (53.3, 66.5)
		BSOS	4	8	50.0 (15.7, 84.3)	0.72 (0.36, 1.46)	1	4	25.0 (0.6, 80.6)	0.35 (0.06, 1.93)	74	107	69.2 (59.5, 77.7)	73	103	70.9 (61.1, 79.4)	78	115	63.4 (52.6, 73)
		Total	302	371	81.4 (77.1, 85.2)	1.08 (1.02, 1.15)	101	140	72.1 (63.9, 79.4)	0.95 (0.86, 1.06)	1,009	1,341	75.2 (72.8, 77.5)	908	1,201	75.6 (73.1, 78.0)	1,311	1,712	74.9 (72.4, 77.2)
	Group 3: Node negative, low risk, either ER or PR positive	BSWN	3	28	10.7 (2.3, 28.2)	0.35 (0.12, 1.04)	1	8	12.5 (0.3, 52.7)	0.39 (0.06, 2.48)	38	123	30.9 (22.9, 39.9)	37	115	32.2 (23.8, 41.5)	41	151	28.0 (19.9, 37.8)
		BSCM	2	19	10.5 (1.3, 33.1)	0.84 (0.19, 3.71)	1	15	6.7 (0.2, 31.9)	0.46 (0.07, 3.48)	7	56	12.5 (5.2, 24.1)	6	41	14.6 (5.6, 29.2)	9	75	15.9 (7.9, 29.4)
		BSAL	2	8	25.0 (3.2, 65.1)	3.31 (0.72, 15.24)	2	10	20.0 (2.5, 55.6)	4.30 (1.24, 26.95)	4	53	7.5 (2.1, 18.2)	2	43	4.7 (0.6, 15.8)	6	61	13.5 (5.9, 28)
		BSM	32	37	86.5 (71.2, 95.5)	0.98 (0.84, 1.13)	2	2	100.0 -	1.13 (1.13, 1.22)	78	88	88.6 (80.1, 94.4)	76	86	88.4 (79.7, 94.3)	110	125	85.5 (75.3, 91.9)
		BSCC	23	34	67.6 (49.5, 82.6)	1.70 (1.16, 2.5)	2	2	100.0 -	2.65 (2.65, 3.66)	25	63	39.7 (27.6, 52.8)	23	61	37.7 (25.6, 51.0)	48	97	45.8 (32.6, 59.7)
		BSC	8	8	100.0 -	1.19 (1.07, 1.31)	2	2	100.0 -	1.19 (1.19, 1.32)	59	70	84.3 (73.6, 91.9)	57	68	83.8 (72.9, 91.6)	67	78	83.3 (71.3, 91)
BSSL		6	14	42.9 (17.7, 71.1)	1.25 (0.65, 2.39)	0	0	NA (NA, NA)	NA (NA, NA)	43	125	34.4 (26.1, 43.4)	43	125	34.4 (26.1, 43.4)	49	139	35.8 (26.9, 45.8)	
BSOS		3	4	75.0 (19.4, 99.4)	2.63 (1.32, 5.22)	1	1	100.0 -	3.65 (3.65, 5.47)	18	63	28.6 (17.9, 41.3)	17	62	27.4 (16.9, 40.2)	21	67	25.0 (14.9, 38.8)	
Total		79	152	52.0 (43.7, 60.1)	1.22 (1.03, 1.46)	11	40	27.5 (14.6, 43.9)	0.63 (0.38, 1.06)	272	641	42.4 (38.6, 46.4)	261	601	43.4 (39.4, 47.5)	351	793	43.0 (38.7, 47.5)	


Timeliness

5.a, Time taken for provision of screening results

Description: The time since screening that it takes for a woman to be sent the results of her mammogram.

Target: ≥ 90% notified within 10 working days.

Figure 97: 5.a.1, Time taken for provision of screening results, 50 to 69 years, total BSA



Overall, BSA met the target of 90% or more of women receiving their screening results within 10 working days at 93%.

BreastScreen Midland showed a 10% drop from 89% to 78%. BreastScreen Central showed a small decrease to just below the 90% target at 88%.

Figure 98:5.a.1 Time taken for provision of screening results, by LP




Table 37: 5.a.1, Time taken for provision of screening results


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)	Māori / Non-Māori Ratio	Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)	Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)	Women Notified Within 10 Working Days	Women Screened	% of Women Notified Within 10 Working Days (95% CI)
45 to 49		BSWN	2,462	2,527	97.4 (96.7, 98)	0.99 (0.98, 1)	839	848	98.9 (98, 99.4)	1.01 (1, 1.01)	14,983	15,218	98.5 (98.2, 98.6)	14,144	14,370	98.4 (98.2, 98.6)	17,445	17,745	98.3 (98.1, 98.5)
		BSCM	1,703	1,742	97.8 (97, 98.4)	1.00 (0.99, 1.01)	2,694	2,754	97.8 (97.2, 98.3)	1.00 (1, 1.01)	11,120	11,403	97.5 (97.2, 97.8)	8,426	8,649	97.4 (97.1, 97.7)	12,823	13,145	97.6 (97.3, 97.8)
		BSAL	813	867	93.8 (92, 95.2)	1.02 (1, 1.03)	1,043	1,116	93.5 (91.9, 94.8)	1.01 (1, 1.03)	9,572	10,366	92.3 (91.8, 92.8)	8,529	9,250	92.2 (91.6, 92.7)	10,385	11,233	92.5 (91.9, 92.9)
		BSM	2,579	3,237	79.7 (78.3, 81)	1.03 (1.01, 1.05)	217	305	71.1 (65.8, 75.9)	0.92 (0.85, 0.98)	10,398	13,414	77.5 (76.8, 78.2)	10,181	13,109	77.7 (76.9, 78.4)	12,977	16,651	77.9 (77.3, 78.6)
		BSCC	2,298	2,508	91.6 (90.5, 92.6)	0.96 (0.95, 0.98)	239	248	96.4 (93.2, 98.1)	1.02 (0.99, 1.04)	10,114	10,650	95.0 (94.5, 95.4)	9,875	10,402	94.9 (94.5, 95.3)	12,412	13,158	94.3 (93.9, 94.7)
		BSC	1,033	1,222	84.5 (82.4, 86.5)	0.97 (0.95, 1)	478	569	84.0 (80.8, 86.8)	0.97 (0.93, 1)	8,509	9,806	86.8 (86.1, 87.4)	8,031	9,237	86.9 (86.2, 87.6)	9,542	11,028	86.5 (85.9, 87.1)
		BSSL	1,435	1,510	95.0 (93.8, 96)	1.00 (0.99, 1.01)	288	309	93.2 (89.8, 95.5)	0.98 (0.95, 1.01)	19,372	20,401	95.0 (94.6, 95.2)	19,084	20,092	95.0 (94.7, 95.3)	20,807	21,911	95.0 (94.7, 95.2)
		BSOS	582	629	92.5 (90.2, 94.3)	0.99 (0.97, 1.02)	94	99	94.9 (88.7, 97.8)	1.02 (0.97, 1.07)	6,315	6,778	93.2 (92.5, 93.7)	6,221	6,679	93.1 (92.5, 93.7)	6,897	7,407	93.1 (92.5, 93.7)
		Total	12,905	14,242	90.6 (90.1, 91.1)	0.98 (0.98, 0.99)	5,892	6,248	94.3 (93.7, 94.9)	1.02 (1.02, 1.03)	90,383	98,036	92.2 (92, 92.4)	84,491	91,788	92.1 (91.9, 92.2)	103,288	112,278	92.0 (91.8, 92.2)
		50 to 69		BSWN	7,505	7,604	98.7 (98.4, 98.9)	1.00 (0.99, 1)	2,824	2,861	98.7 (98.2, 99.1)	1.00 (0.99, 1)	54,206	54,758	99.0 (98.9, 99.1)	51,382	51,897	99.0 (98.9, 99.1)	61,711
BSCM	4,350			4,449	97.8 (97.3, 98.2)	1.00 (0.99, 1)	7,413	7,582	97.8 (97.4, 98.1)	1.00 (0.99, 1)	35,421	36,113	98.1 (97.9, 98.2)	28,008	28,531	98.2 (98, 98.3)	39,771	40,562	98.0 (97.9, 98.2)
BSAL	2,001			2,146	93.2 (92.1, 94.2)	1.00 (0.99, 1.01)	3,260	3,467	94.0 (93.2, 94.8)	1.01 (1, 1.02)	30,585	32,858	93.1 (92.8, 93.4)	27,325	29,391	93.0 (92.7, 93.3)	32,586	35,004	93.1 (92.8, 93.4)
BSM	8,343			10,501	79.4 (78.7, 80.2)	1.01 (1, 1.02)	649	907	71.6 (68.5, 74.4)	0.91 (0.87, 0.95)	41,473	52,903	78.4 (78, 78.7)	40,824	51,996	78.5 (78.2, 78.9)	49,816	63,404	78.6 (78.2, 78.9)
BSCC	7,382			8,078	91.4 (90.8, 92)	0.96 (0.95, 0.97)	685	727	94.2 (92.3, 95.7)	0.99 (0.97, 1.01)	42,171	44,257	95.3 (95.1, 95.5)	41,486	43,530	95.3 (95.1, 95.5)	49,553	52,335	94.7 (94.5, 94.9)
BSC	3,520			4,039	87.2 (86.1, 88.1)	0.99 (0.97, 1)	1,877	2,163	86.8 (85.3, 88.1)	0.98 (0.96, 1)	33,221	37,595	88.4 (88, 88.7)	31,344	35,432	88.5 (88.1, 88.8)	36,741	41,634	88.2 (87.9, 88.6)
BSSL	4,148			4,302	96.4 (95.8, 96.9)	1.00 (1, 1.01)	739	765	96.6 (95.1, 97.7)	1.01 (0.99, 1.02)	67,603	70,386	96.0 (95.9, 96.2)	66,864	69,621	96.0 (95.9, 96.2)	71,751	74,688	96.1 (95.9, 96.2)
BSOS	1,698			1,772	95.8 (94.8, 96.7)	1.00 (0.99, 1.01)	209	230	90.9 (86.4, 94)	0.95 (0.91, 0.99)	25,086	26,197	95.8 (95.5, 96)	24,877	25,967	95.8 (95.6, 96)	26,784	27,969	95.8 (95.5, 96)
Total	38,947			42,891	90.8 (90.5, 91.1)	0.98 (0.97, 0.98)	17,656	18,702	94.4 (94.1, 94.7)	1.02 (1.01, 1.02)	329,766	355,067	92.9 (92.8, 93)	312,110	336,365	92.8 (92.7, 92.9)	368,713	397,958	92.7 (92.6, 92.7)
45 to 69				BSWN	9,967	10,131	98.4 (98.1, 98.6)	1.00 (0.99, 1)	3,663	3,709	98.8 (98.3, 99.1)	1.00 (1, 1)	69,189	69,976	98.9 (98.8, 99)	65,526	66,267	98.9 (98.8, 99)	79,156
		BSCM	6,053	6,191	97.8 (97.4, 98.1)	1.00 (0.99, 1)	10,107	10,336	97.8 (97.5, 98.1)	1.00 (0.99, 1)	46,541	47,516	97.9 (97.8, 98.1)	36,434	37,180	98.0 (97.8, 98.1)	52,594	53,707	97.9 (97.8, 98)
		BSAL	2,814	3,013	93.4 (92.5, 94.2)	1.01 (1, 1.02)	4,303	4,583	93.9 (93.2, 94.5)	1.01 (1, 1.02)	40,157	43,224	92.9 (92.7, 93.1)	35,854	38,641	92.8 (92.5, 93)	42,971	46,237	92.9 (92.7, 93.2)
		BSM	10,922	13,738	79.5 (78.8, 80.2)	1.02 (1.01, 1.03)	866	1,212	71.5 (68.8, 73.9)	0.91 (0.88, 0.95)	51,871	66,317	78.2 (77.9, 78.5)	51,005	65,105	78.3 (78, 78.7)	62,793	80,055	78.4 (78.2, 78.7)
		BSCC	9,680	10,586	91.4 (90.9, 92)	0.96 (0.95, 0.97)	924	975	94.8 (93.2, 96)	1.00 (0.98, 1.01)	52,285	54,907	95.2 (95, 95.4)	51,361	53,932	95.2 (95, 95.4)	61,965	65,493	94.6 (94.4, 94.8)
		BSC	4,553	5,261	86.5 (85.6, 87.4)	0.98 (0.97, 0.99)	2,355	2,732	86.2 (84.9, 87.4)	0.98 (0.96, 0.99)	41,730	47,401	88.0 (87.7, 88.3)	39,375	44,669	88.1 (87.8, 88.4)	46,283	52,662	87.9 (87.6, 88.2)
		BSSL	5,583	5,812	96.1 (95.5, 96.5)	1.00 (1, 1.01)	1,027	1,074	95.6 (94.2, 96.7)	1.00 (0.99, 1.01)	86,975	90,787	95.8 (95.7, 95.9)	85,948	89,713	95.8 (95.7, 95.9)	92,558	96,599	95.8 (95.7, 95.9)
		BSOS	2,280	2,401	95.0 (94, 95.8)	1.00 (0.99, 1.01)	303	329	92.1 (88.7, 94.6)	0.97 (0.94, 1)	31,401	32,975	95.2 (95, 95.5)	31,098	32,646	95.3 (95, 95.5)	33,681	35,376	95.2 (95, 95.4)
		Total	51,852	57,133	90.8 (90.5, 91)	0.98 (0.98, 0.98)	23,548	24,950	94.4 (94.1, 94.7)	1.02 (1.02, 1.02)	420,149	453,103	92.7 (92.7, 92.8)	396,601	428,153	92.6 (92.6, 92.7)	472,001	510,236	92.5 (92.4, 92.6)

5.b, Time taken from screening visit to first offer of an assessment

Description: The time between screening and the earliest appointment date the woman is offered for assessment. In some cases, this date may not coincide with the actual date of assessment due to the fact that many women arrange for a time that suits them better.

Target: 90% offered an assessment appointment within 15 working days.

Figure 99: 5.b.1, 50 to 69, Time taken from screening visit to first offer of an assessment



The overall proportion of women offered an assessment within 15 working days of their screen was 85%.

BSM decreased to 80% for women aged 45–69 years. BSCC continued to decline to 66%. BSOS remained under target at 78%. BSAL increased significantly to 82%. Other LPs achieved the target or were within 2%.

Figure 100: 5.b.3, 50 to 69, Time taken from screening visit to first offer of an assessment, by LP




Table 38: 5.b.1, Time taken from screening visit to first offer of an assessment


		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)	Māori / Non-Māori Ratio	Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)	Pacific / Non-Pacific Ratio	Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)	Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)	Women Offered Assessment Within 15 Working Days	Women Offered Assessment	% of Women Offered Assessment with 15 days (95% CI)
45 to 49	BSWN	169	197	85.8 (80.2, 90)	0.93 (0.88, 0.99)	45	49	91.8 (80.8, 96.8)	1.00 (0.92, 1.09)	936	1,018	91.9 (90.1, 93.5)	891	969	92.0 (90.1, 93.5)	1,105	1,215	90.9 (89.2, 92.4)
	BSCM	78	90	86.7 (78.1, 92.2)	0.96 (0.88, 1.04)	142	159	89.3 (83.5, 93.2)	0.98 (0.93, 1.04)	627	692	90.6 (88.2, 92.6)	485	533	91.0 (88.3, 93.1)	705	782	90.2 (87.9, 92)
	BSAL	57	67	85.1 (74.7, 91.7)	1.14 (1.02, 1.27)	67	73	91.8 (83.2, 96.2)	1.26 (1.18, 1.37)	502	671	74.8 (71.4, 78)	435	598	72.7 (69, 76.2)	559	738	75.7 (72.5, 78.7)
	BSM	203	250	81.2 (75.9, 85.6)	0.98 (0.91, 1.04)	17	24	70.8 (50.8, 85.1)	0.85 (0.66, 1.1)	726	872	83.3 (80.6, 85.6)	709	848	83.6 (81, 85.9)	929	1,122	82.8 (80.5, 84.9)
	BSCC	69	111	62.2 (52.9, 70.6)	0.94 (0.8, 1.11)	6	8	75.0 (40.9, 92.9)	1.14 (0.77, 1.72)	245	372	65.9 (60.9, 70.5)	239	364	65.7 (60.6, 70.4)	314	483	65.0 (60.7, 69.1)
	BSC	67	74	90.5 (81.7, 95.3)	0.98 (0.91, 1.06)	18	26	69.2 (50, 83.5)	0.74 (0.57, 0.96)	540	586	92.2 (89.7, 94.1)	522	560	93.2 (90.8, 95)	607	660	92.0 (89.6, 93.8)
	BSSL	98	106	92.5 (85.8, 96.1)	0.98 (0.92, 1.03)	12	13	92.3 (66.7, 98.6)	0.97 (0.83, 1.14)	1,351	1,427	94.7 (93.4, 95.7)	1,339	1,414	94.7 (93.4, 95.7)	1,449	1,533	94.5 (93.3, 95.6)
	BSOS	51	65	78.5 (67, 86.7)	1.01 (0.89, 1.16)	7	11	63.6 (35.4, 84.8)	0.82 (0.52, 1.28)	565	729	77.5 (74.3, 80.4)	558	718	77.7 (74.5, 80.6)	616	794	77.6 (74.6, 80.3)
	Total	792	960	82.5 (80, 84.8)	0.96 (0.93, 0.99)	314	363	86.5 (82.6, 89.6)	1.00 (0.96, 1.05)	5,492	6,367	86.3 (85.4, 87.1)	5,178	6,004	86.2 (85.3, 87.1)	6,284	7,327	85.8 (84.9, 86.5)
50 to 69	BSWN	304	349	87.1 (83.2, 90.2)	0.96 (0.92, 1)	114	131	87.0 (80.2, 91.7)	0.96 (0.9, 1.02)	1,820	2,006	90.7 (89.4, 91.9)	1,706	1,875	91.0 (89.6, 92.2)	2,124	2,355	90.2 (88.9, 91.3)
	BSCM	147	174	84.5 (78.4, 89.1)	0.97 (0.9, 1.03)	230	274	83.9 (79.1, 87.8)	0.95 (0.9, 1.01)	1,107	1,267	87.4 (85.4, 89.1)	877	993	88.3 (86.2, 90.2)	1,254	1,441	87.0 (85.2, 88.7)
	BSAL	63	75	84.0 (74.1, 90.6)	0.98 (0.88, 1.08)	123	137	89.8 (83.6, 93.8)	1.05 (0.99, 1.12)	932	1,084	86.0 (83.8, 87.9)	809	947	85.4 (83, 87.5)	995	1,159	85.8 (83.7, 87.7)
	BSM	363	483	75.2 (71.1, 78.8)	0.94 (0.89, 1)	26	35	74.3 (57.9, 85.8)	0.93 (0.77, 1.13)	1,494	1,878	79.6 (77.7, 81.3)	1,468	1,843	79.7 (77.8, 81.4)	1,857	2,361	78.7 (77, 80.3)
	BSCC	126	187	67.4 (60.4, 73.7)	1.01 (0.91, 1.13)	12	15	80.0 (54.8, 93)	1.21 (0.94, 1.56)	516	775	66.6 (63.2, 69.8)	504	760	66.3 (62.9, 69.6)	642	962	66.7 (63.7, 69.6)
	BSC	131	153	85.6 (79.2, 90.3)	0.97 (0.9, 1.03)	73	82	89.0 (80.4, 94.1)	1.01 (0.93, 1.09)	1,226	1,385	88.5 (86.7, 90.1)	1,153	1,303	88.5 (86.6, 90.1)	1,357	1,538	88.2 (86.5, 89.7)
	BSSL	161	177	91.0 (85.8, 94.4)	0.99 (0.94, 1.04)	23	26	88.5 (71, 96)	0.96 (0.84, 1.11)	2,218	2,412	92.0 (90.8, 93)	2,195	2,386	92.0 (90.8, 93)	2,379	2,589	91.9 (90.8, 92.9)
	BSOS	68	90	75.6 (65.8, 83.3)	0.97 (0.86, 1.09)	6	16	37.5 (18.5, 61.4)	0.48 (0.25, 0.9)	967	1,240	78.0 (75.6, 80.2)	961	1,224	78.5 (76.1, 80.7)	1,035	1,330	77.8 (75.5, 80)
	Total	1,363	1,688	80.7 (78.8, 82.6)	0.95 (0.92, 0.97)	607	716	84.8 (82, 87.2)	0.99 (0.96, 1.03)	10,280	12,047	85.3 (84.7, 86)	9,673	11,331	85.4 (84.7, 86)	11,643	13,735	84.8 (84.2, 85.4)
45 to 69	BSWN	473	546	86.6 (83.5, 89.2)	0.95 (0.92, 0.98)	159	180	88.3 (82.8, 92.2)	0.97 (0.92, 1.02)	2,756	3,024	91.1 (90.1, 92.1)	2,597	2,844	91.3 (90.2, 92.3)	3,229	3,570	90.4 (89.4, 91.4)
	BSCM	225	264	85.2 (80.4, 89)	0.96 (0.91, 1.01)	372	433	85.9 (82.3, 88.9)	0.96 (0.93, 1)	1,734	1,959	88.5 (87, 89.9)	1,362	1,526	89.3 (87.6, 90.7)	1,959	2,223	88.1 (86.7, 89.4)
	BSAL	120	142	84.5 (77.7, 89.5)	1.03 (0.96, 1.11)	190	210	90.5 (85.7, 93.8)	1.12 (1.08, 1.18)	1,434	1,755	81.7 (79.8, 83.4)	1,244	1,545	80.5 (78.5, 82.4)	1,554	1,897	81.9 (80.1, 83.6)
	BSM	566	733	77.2 (74, 80.1)	0.96 (0.92, 1)	43	59	72.9 (60.4, 82.6)	0.90 (0.77, 1.05)	2,220	2,750	80.7 (79.2, 82.2)	2,177	2,691	80.9 (79.4, 82.3)	2,786	3,483	80.0 (78.6, 81.3)
	BSCC	195	298	65.4 (59.9, 70.6)	0.99 (0.9, 1.08)	18	23	78.3 (58.1, 90.3)	1.18 (0.95, 1.47)	761	1,147	66.3 (63.6, 69)	743	1,124	66.1 (63.3, 68.8)	956	1,445	66.2 (63.7, 68.6)
	BSC	198	227	87.2 (82.3, 91)	0.97 (0.92, 1.03)	91	108	84.3 (76.2, 89.9)	0.94 (0.86, 1.02)	1,766	1,971	89.6 (88.2, 90.9)	1,675	1,863	89.9 (88.5, 91.2)	1,964	2,198	89.4 (88, 90.6)
	BSSL	259	283	91.5 (87.7, 94.2)	0.98 (0.95, 1.02)	35	39	89.7 (76.4, 95.9)	0.96 (0.87, 1.07)	3,569	3,839	93.0 (92.1, 93.7)	3,534	3,800	93.0 (92.1, 93.8)	3,828	4,122	92.9 (92, 93.6)
	BSOS	119	155	76.8 (69.5, 82.7)	0.99 (0.9, 1.08)	13	27	48.1 (30.7, 66)	0.62 (0.42, 0.91)	1,532	1,969	77.8 (75.9, 79.6)	1,519	1,942	78.2 (76.3, 80)	1,651	2,124	77.7 (75.9, 79.4)
	Total	2,155	2,648	81.4 (79.9, 82.8)	0.95 (0.93, 0.97)	921	1,079	85.4 (83.1, 87.3)	1.00 (0.97, 1.02)	15,772	18,414	85.7 (85.1, 86.2)	14,851	17,335	85.7 (85.1, 86.2)	17,927	21,062	85.1 (84.6, 85.6)

5.c.1, Women receiving a needle biopsy within 5 working days of assessment

Description: The number of needle biopsies performed within 5 working days of assessment as a percentage of total number of needle biopsies.

Target: $\geq 90\%$

Figure 101: 5.c.1.1, 50 to 69, Women receiving a needle biopsy within 5 working days of assessment, total BSA



All LPs achieved the target of 90% or more receiving a needle biopsy within 5 working days of assessment.

Figure 102: 5.c.1.3, 50 to 69, Women receiving a needle biopsy within 5 working days of assessment, by LP




Table 39: 5.c.1.1, Women receiving a needle biopsy within 5 working days of assessment


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)	Māori / Non-Māori Ratio	Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)	Pacific / Non-Pacific Ratio	Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)	Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)	Needle Biopsies Within 5 Working Days of Assessment	Total Needle Biopsies	% of Needle Biopsies Within 5 Working Days of Assessment (95% CI)
45 to 49	BSWN	77	77	100.0 (95.2, 100)	1.00 (1, 1)	20	20	100.0 (83.9, 100)	1.00 (1, 1)	297	297	100.0 (98.7, 100)	277	277	100.0 (98.6, 100)	374	374	100.0 (99, 100)	
	BSCM	42	44	95.5 (84.9, 98.7)	0.98 (0.91, 1.05)	84	86	97.7 (91.9, 99.4)	1.00 (0.97, 1.04)	283	290	97.6 (95.1, 98.8)	199	204	97.5 (94.4, 98.9)	325	334	97.3 (95, 98.6)	
	BSAL	25	26	96.2 (81.1, 99.3)	1.06 (0.97, 1.16)	30	31	96.8 (83.8, 99.4)	1.08 (1.01, 1.17)	209	231	90.5 (86, 93.6)	179	200	89.5 (84.5, 93)	234	257	91.1 (86.9, 94)	
	BSM	103	108	95.4 (89.6, 98)	1.00 (0.95, 1.05)	8	8	100.0 (67.6, 100)	1.05 (1.05, 1.08)	220	231	95.2 (91.7, 97.3)	212	223	95.1 (91.4, 97.2)	323	339	95.3 (92.5, 97.1)	
	BSCC	52	52	100.0 (93.1, 100)	1.01 (0.99, 1.03)	3	3	100.0 (43.9, 100)	1.01 (1.01, 1.03)	104	105	99.0 (94.8, 99.8)	101	102	99.0 (94.7, 99.8)	156	157	99.4 (96.5, 99.9)	
	BSC	22	22	100.0 (85.1, 100)	1.00 (1, 1)	11	11	100.0 (74.1, 100)	1.00 (1, 1)	101	101	100.0 (96.3, 100)	90	90	100.0 (95.9, 100)	123	123	100.0 (97, 100)	
	BSSL	32	34	94.1 (80.9, 98.4)	0.98 (0.9, 1.06)	6	6	100.0 (61, 100)	1.04 (1.04, 1.06)	395	410	96.3 (94.1, 97.8)	389	404	96.3 (94, 97.7)	427	444	96.2 (94, 97.6)	
	BSOS	12	13	92.3 (66.7, 98.6)	0.96 (0.82, 1.12)	2	2	100.0 (34.2, 100)	1.04 (1.04, 1.07)	161	167	96.4 (94.2, 98.3)	159	165	96.4 (92.3, 98.3)	173	180	96.1 (92.8, 98.1)	
	Total	365	376	97.1 (94.8, 98.4)	1.00 (0.99, 1.02)	164	167	98.2 (94.9, 99.4)	1.02 (1, 1.04)	1,770	1,832	96.6 (95.7, 97.4)	1,606	1,665	96.5 (95.5, 97.2)	2,135	2,208	96.7 (95.9, 97.4)	
	50 to 69	BSWN	161	163	98.8 (95.6, 99.7)	1.00 (0.98, 1.02)	144	146	98.6 (95.1, 99.6)	1.00 (0.98, 1.02)	793	805	98.5 (97.4, 99.1)	649	659	98.5 (97.2, 99.2)	954	968	98.6 (97.6, 99.1)
BSCM		103	106	97.2 (92, 99)	0.98 (0.94, 1.01)	99	101	98.0 (93.1, 99.5)	0.98 (0.95, 1.01)	514	516	99.6 (98.6, 99.9)	415	415	100.0 (99.1, 100)	617	622	99.2 (98.1, 99.7)	
BSAL		37	38	97.4 (86.5, 99.5)	1.07 (1.01, 1.14)	33	34	97.1 (85.1, 99.5)	1.08 (1.02, 1.15)	344	379	90.8 (87.4, 93.3)	311	345	90.1 (86.5, 92.9)	381	417	91.4 (88.3, 93.7)	
BSM		225	239	94.1 (90.4, 96.5)	1.00 (0.96, 1.03)	201	219	91.8 (87.4, 94.7)	0.96 (0.93, 1)	837	886	94.5 (92.8, 95.8)	636	667	95.4 (93.5, 96.7)	1,062	1,125	94.4 (92.9, 95.6)	
BSCC		107	109	98.2 (93.6, 99.5)	0.99 (0.96, 1.02)	97	100	97.0 (91.5, 99)	0.97 (0.94, 1.01)	446	450	99.1 (97.7, 99.7)	349	350	99.7 (98.4, 99.9)	553	559	98.9 (97.7, 99.5)	
BSC		40	41	97.6 (87.4, 99.6)	0.98 (0.94, 1.03)	35	36	97.2 (85.8, 99.5)	0.98 (0.93, 1.03)	379	382	99.2 (97.7, 99.7)	344	346	99.4 (97.9, 99.8)	419	423	99.1 (97.6, 99.6)	
BSSL		69	72	95.8 (88.5, 98.6)	1.00 (0.95, 1.05)	64	67	95.5 (87.6, 98.5)	1.00 (0.95, 1.05)	818	853	95.9 (94.3, 97)	754	786	95.9 (94.3, 97.1)	887	925	95.9 (94.4, 97)	
BSOS		30	30	100.0 (88.6, 100)	1.01 (1, 1.02)	31	31	100.0 (89, 100)	1.01 (1.01, 1.02)	364	368	98.9 (97.2, 99.6)	333	337	98.8 (97, 99.5)	394	398	99.0 (97.4, 99.6)	
Total		772	798	96.7 (95.3, 97.8)	1.00 (0.98, 1.01)	704	734	95.9 (94.2, 97.1)	0.99 (0.97, 1)	4,495	4,639	96.9 (96.4, 97.4)	3,791	3,905	97.1 (96.5, 97.6)	5,267	5,437	96.9 (96.4, 97.3)	
45 to 69		BSWN	238	240	99.2 (97, 99.8)	1.00 (0.99, 1.02)	164	166	98.8 (95.7, 99.7)	1.00 (0.98, 1.02)	1,090	1,102	98.9 (98.1, 99.4)	926	936	98.9 (98, 99.4)	1,328	1,342	99.0 (98.3, 99.4)
	BSCM	145	150	96.7 (92.4, 98.6)	0.98 (0.95, 1.01)	183	187	97.9 (94.6, 99.2)	0.99 (0.97, 1.01)	797	806	98.9 (97.9, 99.4)	614	619	99.2 (98.1, 99.7)	942	956	98.5 (97.6, 99.1)	
	BSAL	62	64	96.9 (89.3, 99.1)	1.07 (1.02, 1.12)	63	65	96.9 (89.5, 99.2)	1.08 (1.03, 1.14)	553	610	90.7 (88.1, 92.7)	490	545	89.9 (87.1, 92.2)	615	674	91.2 (88.9, 93.2)	
	BSM	328	347	94.5 (91.6, 96.5)	1.00 (0.97, 1.03)	209	227	92.1 (87.8, 94.9)	0.97 (0.93, 1.01)	1,057	1,117	94.6 (93.1, 95.8)	848	890	95.3 (93.7, 96.5)	1,385	1,464	94.6 (93.3, 95.6)	
	BSCC	159	161	98.8 (95.6, 99.7)	1.00 (0.98, 1.02)	100	103	97.1 (91.8, 99)	0.98 (0.94, 1.01)	550	555	99.1 (97.9, 99.6)	450	452	99.6 (98.4, 99.9)	709	716	99.0 (98, 99.5)	
	BSC	62	63	98.4 (91.5, 99.7)	0.99 (0.96, 1.02)	46	47	97.9 (88.9, 99.6)	0.98 (0.94, 1.03)	480	483	99.4 (98.2, 99.8)	434	436	99.5 (98.3, 99.9)	542	546	99.3 (98.1, 99.7)	
	BSSL	101	106	95.3 (89.4, 98)	0.99 (0.95, 1.04)	70	73	95.9 (88.6, 98.6)	1.00 (0.95, 1.05)	1,213	1,263	96.0 (94.8, 97)	1,143	1,190	96.1 (94.8, 97)	1,314	1,369	96.0 (94.8, 96.9)	
	BSOS	42	43	97.7 (87.9, 99.6)	1.00 (0.95, 1.04)	33	33	100.0 (89.6, 100)	1.02 (1.02, 1.03)	525	535	98.1 (96.6, 99)	492	502	98.0 (96.4, 98.9)	567	578	98.1 (96.6, 98.9)	
	Total	1,137	1,174	96.8 (95.7, 97.7)	1.00 (0.99, 1.01)	868	901	96.3 (94.9, 97.4)	0.99 (0.98, 1.01)	6,265	6,471	96.8 (96.4, 97.2)	5,397	5,570	96.9 (96.4, 97.3)	7,402	7,645	96.8 (96.4, 97.2)	

5.c.2, Women having an open biopsy procedure within 20 working days

Description: The number of open biopsies (level 3 assessments) within 20 working days of notification of the need for this operation as a percentage of total number of open biopsies (Date of final diagnostic biopsy minus date of notification to woman of 1st and 2nd level assessment results).

Target: $\geq 90\%$

Figure 103: 5.c.2.1, 50 to 69, Women having an open biopsy procedure within 20 working days



The proportion of women aged 45–69 years who had their open biopsy within 20 working days was 56% overall, lower for Māori women at 46% and similar for Pacific women at 58%.

The LPs with the highest proportions were BSSL and BSAL (87% each) and BSOS (82%). The lowest proportions were in BSCC (19%), and BSCM (25%).

Figure 104: 5.c.2.3, 50 to 69, Women having an open biopsy procedure within 20 working days, by LP




Table 40: 5.c.2.1, Women having an open biopsy procedure within 20 working days


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Open Biopsies Within 20 Working Days of Notification	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)	Māori / Non-Māori Ratio	Open Biopsies Within 20 Working Days of Notification	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	Open Biopsies Within 20 Working Days of Notification	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)	Open Biopsies Within 20 Working Days of Notification	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)	Open Biopsies Within 20 Working Days of Notification	Total Open Biopsies	% of Open Biopsies Within 20 Working Days of Notification (95% CI)
45 to 49	BSWN	4	9	44.4 (18.9, 73.3)	0.92 (0.4, 2.11)	1	3	33.3 (6.1, 79.2)	0.67 (0.13, 3.47)	13	27	48.1 (30.7, 66)	12	24	50.00 (31.4, 68.6)	17	36	47.2 (32, 63)	
	BSCM	1	5	20.0 (3.6, 62.4)	1.40 (0.16, 12.29)	1	3	33.3 (6.1, 79.2)	3.67 (0.74, 42.93)	2	14	14.3 (4, 39.9)	1	11	9.09 (1.6, 37.7)	3	19	15.8 (5.5, 37.6)	
	BSAL	0	0	NA (NA, NA)	NA (NA, NA)	2	2	100.0 (34.2, 100)	1.00 (1, 1)	22	22	100.0 (85.1, 100)	20	20	100.00 (83.9, 100)	22	22	100.0 (85.1, 100)	
	BSM	4	14	28.6 (11.7, 54.6)	0.65 (0.24, 1.77)	0	0	NA (NA, NA)	NA (NA, NA)	7	16	43.75 (23.1, 66.8)	7	16	43.75 (23.1, 66.8)	11	30	36.7 (21.9, 54.5)	
	BSCC	1	4	25.0 (4.6, 69.9)	2.25 (0.18, 27.66)	0	1	0.0 (0, 79.3)	0.00 (NA, NA)	1	9	11.1 (2, 43.5)	1	8	12.50 (2.2, 47.1)	2	13	15.4 (4.3, 42.2)	
	BSC	1	2	50.0 (9.5, 90.5)	0.75 (0.18, 3.11)	2	2	100.0 (34.2, 100)	1.60 (1.6, 2.34)	12	18	66.7 (43.7, 83.7)	10	16	62.50 (38.6, 81.5)	13	20	65.0 (43.3, 81.9)	
	BSSL	5	5	100.0 (56.6, 100)	1.25 (1.05, 1.49)	0	0	NA (NA, NA)	NA (NA, NA)	24	30	80.00 (62.7, 90.5)	24	30	80.00 (62.7, 90.5)	29	35	82.9 (67.3, 91.9)	
	BSOS	0	0	NA (NA, NA)	NA (NA, NA)	0	0	NA (NA, NA)	NA (NA, NA)	3	5	60.00 (23.1, 88.2)	3	5	60.00 (23.1, 88.2)	3	5	60.0 (23.1, 88.2)	
	Total	16	39	41.0 (27.1, 56.6)	0.69 (0.46, 1.03)	6	11	54.5 (28, 78.7)	0.91 (0.53, 1.59)	84	141	59.6 (51.3, 67.3)	78	130	60.00 (51.4, 68)	100	180	55.6 (48.3, 62.6)	
50 to 69	BSWN	6	17	35.3 (17.3, 58.7)	0.61 (0.31, 1.19)	1	2	50.0 (9.5, 90.5)	0.86 (0.21, 3.48)	47	81	58.0 (47.2, 68.2)	46	79	58.2 (47.2, 68.5)	53	98	54.1 (44.2, 63.6)	
	BSCM	2	6	33.3 (9.7, 70)	1.17 (0.34, 3.99)	3	10	30.0 (10.8, 60.3)	1.07 (0.41, 3.19)	12	42	28.6 (17.2, 43.6)	9	32	28.1 (15.6, 45.4)	14	48	29.2 (18.2, 43.2)	
	BSAL	3	3	100.0 (43.9, 100)	1.25 (1.09, 1.44)	8	9	88.9 (56.5, 98)	1.14 (0.9, 1.51)	40	50	80.0 (67, 88.8)	32	41	78.0 (63.3, 88)	43	53	81.1 (68.6, 89.4)	
	BSM	14	24	58.3 (38.8, 75.5)	1.55 (0.95, 2.51)	0	0	NA (NA, NA)	NA (NA, NA)	20	53	37.7 (25.9, 51.2)	20	53	37.7 (25.9, 51.2)	34	77	44.2 (33.6, 55.3)	
	BSCC	0	2	0.0 (0, 65.8)	NA (NA, NA)	0	1	0.0 (0, 79.3)	NA (NA, NA)	3	12	25.0 (8.9, 53.2)	3	11	27.3 (9.7, 56.6)	3	14	21.4 (7.6, 47.6)	
	BSC	1	3	33.3 (6.1, 79.2)	0.87 (0.16, 4.62)	2	2	100.0 (34.2, 100)	3.00 (3, 5.28)	10	26	38.5 (22.4, 57.5)	8	24	33.3 (18, 53.3)	11	29	37.9 (22.7, 56)	
	BSSL	1	1	100.0 (20.7, 100)	1.11 (1.01, 1.22)	1	1	100.0 (20.7, 100)	1.12 (1.12, 1.23)	44	49	89.8 (78.2, 95.6)	43	48	89.6 (77.8, 95.5)	45	50	90.0 (78.6, 95.7)	
	BSOS	1	1	100.0 (20.7, 100)	1.00 (1, 1)	0	0	NA (NA, NA)	NA (NA, NA)	5	5	100.0 (56.6, 100)	5	5	100.0 (56.6, 100)	6	6	100.0 (61, 100)	
	Total	28	57	49.1 (36.6, 61.7)	0.86 (0.65, 1.14)	15	25	60.0 (40.7, 76.6)	1.06 (0.77, 1.48)	181	318	56.9 (51.4, 62.2)	166	293	56.7 (50.9, 62.2)	209	375	55.7 (50.7, 60.7)	
45 to 69	BSWN	10	26	38.5 (22.4, 57.5)	0.69 (0.41, 1.16)	2	5	40.0 (11.8, 76.9)	0.71 (0.24, 2.11)	60	108	55.6 (46.2, 64.6)	58	103	56.3 (46.7, 65.5)	70	134	52.2 (43.8, 60.5)	
	BSCM	3	11	27.3 (9.7, 56.6)	1.09 (0.38, 3.17)	4	13	30.8 (12.7, 57.6)	1.32 (0.59, 3.52)	14	56	25.0 (15.5, 37.7)	10	43	23.3 (13.2, 37.7)	17	67	25.4 (16.5, 36.9)	
	BSAL	3	3	100.0 (43.9, 100)	1.16 (1.06, 1.27)	10	11	90.9 (62.3, 98.4)	1.07 (0.88, 1.32)	62	72	86.1 (76.3, 92.3)	52	61	85.2 (74.3, 92)	65	75	86.7 (77.2, 92.6)	
	BSM	18	38	47.4 (32.5, 62.7)	1.21 (0.77, 1.89)	0	0	NA (NA, NA)	NA (NA, NA)	27	69	39.1 (28.5, 50.9)	27	69	39.1 (28.5, 50.9)	45	107	42.1 (33.1, 51.5)	
	BSCC	1	6	16.7 (3, 56.4)	0.88 (0.12, 6.43)	0	2	0.0 (0, 65.8)	NA (NA, NA)	4	21	19.0 (7.7, 40)	4	19	21.1 (8.5, 43.3)	5	27	18.5 (8.2, 36.7)	
	BSC	2	5	40.0 (11.8, 76.9)	0.80 (0.26, 2.44)	4	4	100.0 (51, 100)	2.22 (2.22, 3.13)	22	44	50.0 (35.8, 64.2)	18	40	45.0 (30.7, 60.2)	24	49	49.0 (35.6, 62.5)	
	BSSL	6	6	100.0 (61, 100)	1.16 (1.06, 1.27)	1	1	100.0 (20.7, 100)	1.16 (1.16, 1.27)	68	79	86.1 (76.8, 92)	67	78	85.9 (76.5, 91.9)	74	85	87.1 (78.3, 92.6)	
	BSOS	1	1	100.0 (20.7, 100)	1.25 (0.92, 1.7)	0	0	NA (NA, NA)	NA (NA, NA)	8	10	80.0 (49, 94.3)	8	10	80.0 (49, 94.3)	9	11	81.8 (52.3, 94.9)	
	Total	44	96	45.8 (36.2, 55.8)	0.79 (0.63, 1)	21	36	58.3 (42.2, 72.9)	1.01 (0.77, 1.35)	265	459	57.7 (53.2, 62.2)	244	423	57.7 (52.9, 62.3)	309	555	55.7 (51.5, 59.8)	

5.d, Time taken from final diagnostic biopsy to reporting assessment results

Description: The time taken from the final biopsy procedure to reporting the diagnosis to the women.

Target: Results reported to at least 90% of women within five working days of final diagnostic biopsy.

Figure 105: 5.d.1, 50 to 69, Time taken from final diagnostic biopsy to reporting assessment results



The proportion of BSA women aged 45–69 years who received the results of their final diagnostic biopsy within five working days was 85%, lower for Māori (80%) and similar for Pacific women (87%).

LPs ranged from 72% (BSOS) to 91% (BSCM) for total women.

Figure 106: 5.d.3, 50 to 69, Time taken from final diagnostic biopsy to reporting assessment results, by LP












Table 41: 5.d.1, Time taken from final diagnostic biopsy to reporting assessment results


			Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
			Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)	Māori / Non-Māori Ratio	Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)	Pacific / Non-Pacific Ratio	Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)	Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)	Results Reported Within 5 Working Days of Final Biopsy	Number with Final Diagnostic Biopsy	% Received Final Biopsy Results Within 5 Working Days (95% CI)
45 to 49	BSWN	65	77	84.4 (74.7, 90.9)	0.94 (0.85, 1.04)	18	20	90.0 (69.9, 97.2)	1.00 (0.87, 1.16)	267	297	89.9 (85.9, 92.8)	249	277	89.9 (85.8, 92.9)	332	374	88.8 (85.2, 91.6)	
	BSCM	37	44	84.1 (70.6, 92.1)	0.92 (0.8, 1.05)	78	86	90.7 (82.7, 95.2)	0.98 (0.92, 1.06)	266	290	91.7 (88, 94.4)	188	204	92.2 (87.6, 95.1)	303	334	90.7 (87.1, 93.4)	
	BSAL	24	26	92.3 (75.9, 97.9)	1.03 (0.91, 1.16)	29	31	93.5 (79.3, 98.2)	1.05 (0.96, 1.17)	206	230	89.6 (84.9, 92.9)	177	199	88.9 (83.8, 92.6)	230	256	89.8 (85.5, 93)	
	BSM	83	106	78.3 (69.5, 85.1)	1.02 (0.9, 1.15)	6	8	75.0 (40.9, 92.9)	0.97 (0.65, 1.46)	177	230	77.0 (71.1, 81.9)	171	222	77.0 (71.1, 82.1)	260	336	77.4 (72.6, 81.5)	
	BSCC	36	52	69.2 (55.7, 80.1)	0.77 (0.64, 0.94)	3	3	100.0 (43.9, 100)	1.12 (1.12, 1.2)	94	105	89.5 (82.2, 94)	91	102	89.2 (81.7, 93.9)	130	157	82.8 (76.1, 87.9)	
	BSC	18	22	81.8 (61.5, 92.7)	0.93 (0.75, 1.15)	7	11	63.6 (35.4, 84.8)	0.70 (0.45, 1.1)	89	101	88.1 (80.4, 93.1)	82	90	91.1 (83.4, 95.4)	107	123	87.0 (79.9, 91.8)	
	BSSL	25	34	73.5 (56.9, 85.4)	0.84 (0.68, 1.03)	6	6	100.0 (61, 100)	1.14 (1.14, 1.19)	359	410	87.6 (84, 90.4)	353	404	87.4 (83.8, 90.3)	384	444	86.5 (83, 89.4)	
	BSOS	9	13	69.2 (42.4, 87.3)	1.01 (0.7, 1.48)	0	2	0.0 (0, 65.8)	0.00 (NA, NA)	114	167	68.3 (60.9, 74.8)	114	165	69.1 (61.7, 75.6)	123	180	68.3 (61.2, 74.7)	
	Total	297	374	79.4 (75, 83.2)	0.92 (0.88, 0.98)	147	167	88.0 (82.2, 92.1)	1.03 (0.97, 1.09)	1,572	1,830	85.9 (84.2, 87.4)	1,425	1,663	85.7 (83.9, 87.3)	1,869	2,204	84.8 (83.2, 86.2)	
	50 to 69	BSWN	128	147	87.1 (80.7, 91.6)	0.98 (0.91, 1.05)	34	38	89.5 (75.9, 95.8)	1.00 (0.9, 1.12)	622	698	89.1 (86.6, 91.2)	588	660	89.1 (86.5, 91.2)	750	845	88.8 (86.4, 90.7)
BSCM		91	101	90.1 (82.7, 94.5)	0.99 (0.92, 1.06)	123	140	87.9 (81.4, 92.3)	0.95 (0.89, 1.02)	507	555	91.4 (88.7, 93.4)	384	415	92.5 (89.6, 94.7)	598	656	91.2 (88.7, 93.1)	
BSAL		32	34	94.1 (80.9, 98.4)	1.08 (0.98, 1.18)	49	54	90.7 (80.1, 96)	1.05 (0.96, 1.15)	346	397	87.2 (83.5, 90.1)	297	343	86.6 (82.6, 89.8)	378	431	87.7 (84.3, 90.5)	
BSM		159	219	72.6 (66.3, 78.1)	0.89 (0.81, 0.97)	12	15	80.0 (54.8, 93)	0.98 (0.76, 1.26)	558	681	81.9 (78.9, 84.6)	546	666	82.0 (78.9, 84.7)	717	900	79.7 (76.9, 82.2)	
BSCC		77	99	77.8 (68.6, 84.8)	0.92 (0.82, 1.04)	3	5	60.0 (23.1, 88.2)	0.71 (0.35, 1.45)	299	355	84.2 (80.1, 87.6)	296	350	84.6 (80.4, 88)	376	454	82.8 (79.1, 86)	
BSC		32	36	88.9 (74.7, 95.6)	1.03 (0.91, 1.16)	26	33	78.8 (62.2, 89.3)	0.91 (0.76, 1.09)	327	379	86.3 (82.5, 89.4)	301	346	87.0 (83, 90.1)	359	415	86.5 (82.9, 89.5)	
BSSL		55	67	82.1 (71.3, 89.4)	0.95 (0.85, 1.07)	10	12	83.3 (55.2, 95.3)	0.96 (0.75, 1.24)	690	799	86.4 (83.8, 88.6)	680	787	86.4 (83.8, 88.6)	745	866	86.0 (83.6, 88.2)	
BSOS		20	31	64.5 (46.9, 78.9)	0.87 (0.67, 1.14)	5	6	83.3 (43.6, 97)	1.13 (0.79, 1.62)	254	343	74.1 (69.2, 78.4)	249	337	73.9 (68.9, 78.3)	274	374	73.3 (68.6, 77.5)	
Total		594	734	80.9 (77.9, 83.6)	0.94 (0.91, 0.98)	262	303	86.5 (82.2, 89.9)	1.01 (0.97, 1.06)	3,603	4,207	85.6 (84.6, 86.7)	3,341	3,904	85.6 (84.4, 86.6)	4,197	4,941	84.9 (83.9, 85.9)	
45 to 69		BSWN	193	224	86.2 (81, 90.1)	0.96 (0.91, 1.02)	52	58	89.7 (79.2, 95.2)	1.00 (0.92, 1.1)	889	995	89.3 (87.3, 91.1)	837	937	89.3 (87.2, 91.1)	1,082	1,219	88.8 (86.9, 90.4)
	BSCM	128	145	88.3 (82, 92.5)	0.96 (0.91, 1.03)	201	226	88.9 (84.2, 92.4)	0.96 (0.92, 1.01)	773	845	91.5 (89.4, 93.2)	572	619	92.4 (90, 94.2)	901	990	91.0 (89.1, 92.6)	
	BSAL	56	60	93.3 (84.1, 97.4)	1.06 (0.98, 1.14)	78	85	91.8 (84, 96)	1.05 (0.98, 1.13)	552	627	88.0 (85.3, 90.3)	474	542	87.5 (84.4, 90)	608	687	88.5 (85.9, 90.7)	
	BSM	242	325	74.5 (69.5, 78.9)	0.92 (0.86, 0.99)	18	23	78.3 (58.1, 90.3)	0.97 (0.78, 1.21)	735	911	80.7 (78, 83.1)	717	888	80.7 (78, 83.2)	977	1,236	79.0 (76.7, 81.2)	
	BSCC	113	151	74.8 (67.4, 81.1)	0.88 (0.79, 0.97)	6	8	75.0 (40.9, 92.9)	0.88 (0.59, 1.31)	393	460	85.4 (81.9, 88.4)	387	452	85.6 (82.1, 88.6)	506	611	82.8 (79.6, 85.6)	
	BSC	50	58	86.2 (75.1, 92.8)	0.99 (0.89, 1.11)	33	44	60.6 (60.6, 85.4)	0.85 (0.72, 1.02)	416	480	86.7 (83.3, 89.4)	383	436	87.8 (84.4, 90.6)	466	538	86.6 (83.5, 89.2)	
	BSSL	80	101	79.2 (70.3, 86)	0.91 (0.82, 1.01)	16	18	88.9 (67.2, 96.9)	1.02 (0.87, 1.21)	1,049	1,209	86.8 (84.7, 88.6)	1,033	1,191	86.7 (84.7, 88.5)	1,129	1,310	86.2 (84.2, 87.9)	
	BSOS	29	44	65.9 (51.1, 78.1)	0.91 (0.73, 1.14)	5	8	62.5 (30.6, 86.3)	0.86 (0.51, 1.48)	368	510	72.2 (68.1, 75.9)	363	502	72.3 (68.2, 76)	397	554	71.7 (67.8, 75.3)	
	Total	891	1,108	80.4 (78, 82.6)	0.94 (0.91, 0.97)	409	470	87.0 (83.7, 89.8)	1.02 (0.98, 1.05)	5,175	6,037	85.7 (84.8, 86.6)	4,766	5,567	85.6 (84.7, 86.5)	6,066	7,145	84.9 (84, 85.7)	

5.e.t, First surgical treatment, women screened during the 4 years to December 2019

Description: The time from when a woman receives her final diagnostic results to the date of her first surgical treatment. The 't' in the indicator id marks it as a treatment indicator.

Target: 90% of women should normally receive their first surgical treatment within 20 working days of receiving their final diagnostic results.

Figure 107: 5.e.t.3, 50 to 69, First surgical treatment, women screened during the 4 years to December 2019



For total BSA women aged 45–69 years, around half (54%) received their first surgical treatment within 20 working days of their final diagnostic results. The proportions were lower for Māori (47%) and Pacific (48%) than for non-Māori non-Pacific women (56%).

For total women, the proportions were similar for most LPs, lower for BSCC at 45%. For Māori women the proportions ranged from 35% (BSCC) to 60% (BSC). For Pacific women, the proportions ranged from 36% (BSAL and BSCC) to 63% (BSM).

Figure 108: 5.e.t.3, 50 to 69, First surgical treatment, women screened during the 4 years to December 2019, by LP



Table 42: 5.e.t.1, First surgical treatment, women screened during the 4 years to December 2019

		Māori				Pacific				Non-Māori			Non-Māori Non-Pacific			All		
		First Surgical Treatment Within 20 Working Days	Number Having Surgery	% Receiving First Surgery Within 20 Working Days (95% CI)	Māori / Non-Māori Ratio	First Surgical Treatment Within 20 Working Days	Number Having Surgery	% Receiving First Surgery Within 20 Working Days (95% CI)	Pacific / Non-Māori Non-Pacific Ratio	First Surgical Treatment Within 20 Working Days	Number Having Surgery	% Receiving First Surgery Within 20 Working Days (95% CI)	First Surgical Treatment Within 20 Working Days	Number Having Surgery	% Receiving First Surgery Within 20 Working Days (95% CI)	First Surgical Treatment Within 20 Working Days	Number Having Surgery	% Receiving First Surgery Within 20 Working Days (95% CI)
45 to 49	BSWN	17	27	63.0 (42.4, 80.6)	1.04 (0.76, 1.42)	2	3	66.7 (9.4, 99.2)	1.10 (0.49, 2.47)	96	158	60.8 (52.7, 68.4)	94	155	60.6 (52.5, 68.4)	113	185	61.1 (53.7, 68.1)
	BSCM	10	23	43.5 (23.2, 65.5)	0.85 (0.52, 1.41)	16	30	53.3 (34.3, 71.7)	1.07 (0.76, 1.6)	54	106	50.9 (41.0, 60.8)	38	76	50.0 (38.3, 61.7)	64	129	49.6 (40.7, 58.5)
	BSAL	2	8	25.0 (3.2, 65.1)	0.49 (0.14, 1.64)	8	17	47.1 (23.0, 72.2)	0.90 (0.55, 1.55)	59	115	51.3 (41.8, 60.7)	51	98	52.0 (41.7, 62.2)	61	123	49.6 (40.5, 58.8)
	BSM	21	40	52.5 (36.1, 68.5)	1.05 (0.74, 1.49)	1	2	50.0 (1.3, 98.7)	1.00 (0.25, 4.05)	56	112	50.0 (40.4, 59.6)	55	110	50.0 (40.3, 59.7)	77	152	50.7 (42.4, 58.9)
	BSCC	7	33	21.2 (9.0, 38.9)	0.39 (0.2, 0.77)	1	4	25.0 (0.6, 80.6)	0.45 (0.08, 2.47)	54	99	54.5 (44.2, 64.6)	53	95	55.8 (45.2, 66.0)	61	132	46.2 (37.5, 55.1)
	BSC	11	19	57.9 (33.5, 79.7)	1.09 (0.71, 1.69)	3	4	75.0 (19.4, 99.4)	1.45 (0.82, 2.64)	44	83	53.0 (41.7, 64.1)	41	79	51.9 (40.4, 63.3)	55	102	53.9 (43.8, 63.8)
	BSSL	7	14	50.0 (23.0, 77.0)	1.10 (0.64, 1.9)	2	5	40.0 (5.3, 85.3)	0.88 (0.3, 2.6)	93	205	45.4 (38.4, 52.4)	91	200	45.5 (38.5, 52.7)	100	219	45.7 (38.9, 52.5)
	BSOS	3	4	75.0 (19.4, 99.4)	1.50 (0.82, 2.75)	1	2	50.0 (1.3, 98.7)	1.00 (0.25, 4.07)	40	80	50.0 (38.6, 61.4)	39	78	50.0 (38.5, 61.5)	43	84	51.2 (40.0, 62.3)
	Total	78	168	46.4 (38.7, 54.3)	0.90 (0.75, 1.07)	34	67	50.7 (38.2, 63.2)	0.98 (0.77, 1.25)	496	958	51.8 (48.6, 55.0)	462	891	51.9 (48.5, 55.2)	574	1,126	51.0 (48.0, 53.9)
50 to 69	BSWN	53	148	35.8 (28.1, 44.1)	0.54 (0.43, 0.68)	24	42	57.1 (41.0, 72.3)	0.86 (0.66, 1.12)	455	688	66.1 (62.5, 69.7)	431	646	66.7 (62.9, 70.3)	508	836	60.8 (57.4, 64.1)
	BSCM	43	73	58.9 (46.8, 70.3)	1.14 (0.92, 1.4)	52	102	51.0 (40.9, 61.0)	0.98 (0.81, 1.21)	226	436	51.8 (47.0, 56.6)	174	334	52.1 (46.6, 57.6)	269	509	52.8 (48.4, 57.3)
	BSAL	14	37	37.8 (22.5, 55.2)	0.74 (0.48, 1.13)	16	50	32.0 (19.5, 46.7)	0.59 (0.4, 0.9)	204	398	51.3 (46.2, 56.3)	188	348	54.0 (48.6, 59.3)	218	435	50.1 (45.3, 54.9)
	BSM	121	226	53.5 (46.8, 60.2)	0.91 (0.79, 1.04)	11	17	64.7 (38.3, 85.8)	1.10 (0.77, 1.57)	418	709	59.0 (55.2, 62.6)	407	692	58.8 (55.0, 62.5)	539	935	57.6 (54.4, 60.8)
	BSCC	56	146	38.4 (30.4, 46.8)	0.81 (0.65, 1.02)	4	10	40.0 (12.2, 73.8)	0.85 (0.4, 1.82)	243	516	47.1 (42.7, 51.5)	239	506	47.2 (42.8, 51.7)	299	662	45.2 (41.3, 49.0)
	BSC	38	63	60.3 (47.2, 72.4)	1.00 (0.81, 1.24)	9	24	37.5 (18.8, 59.4)	0.61 (0.37, 1.03)	311	518	60.0 (55.7, 64.3)	302	494	61.1 (56.7, 65.5)	349	581	60.1 (56.0, 64.1)
	BSSL	37	74	50.0 (38.1, 61.9)	0.88 (0.69, 1.11)	5	8	62.5 (24.5, 91.5)	1.10 (0.64, 1.89)	505	887	56.9 (53.6, 60.2)	500	879	56.9 (53.5, 60.2)	542	961	56.4 (53.2, 59.6)
	BSOS	8	17	47.1 (23.0, 72.2)	0.93 (0.55, 1.55)	2	6	33.3 (4.3, 77.7)	0.65 (0.21, 2.03)	209	411	50.9 (45.9, 55.8)	207	405	51.1 (46.1, 56.1)	217	428	50.7 (45.9, 55.5)
	Total	370	784	47.2 (43.7, 50.8)	0.84 (0.77, 0.91)	123	259	47.5 (41.3, 53.8)	0.83 (0.73, 0.95)	2,571	4,563	56.3 (54.9, 57.8)	2,448	4,304	56.9 (55.4, 58.4)	2,941	5,347	55.0 (53.7, 56.3)
45 to 69	BSWN	70	175	40.0 (32.7, 47.7)	0.61 (0.51, 0.74)	26	45	57.8 (42.2, 72.3)	0.88 (0.69, 1.14)	551	846	65.1 (61.8, 68.3)	525	801	65.5 (62.1, 68.8)	621	1,021	60.8 (57.8, 63.8)
	BSCM	53	96	55.2 (44.7, 65.4)	1.07 (0.88, 1.3)	68	132	51.5 (42.7, 60.3)	1.00 (0.84, 1.2)	280	542	51.7 (47.4, 55.9)	212	410	51.7 (46.8, 56.6)	333	638	52.2 (48.2, 56.1)
	BSAL	16	45	35.6 (21.9, 51.2)	0.69 (0.46, 1.04)	24	67	35.8 (24.5, 48.5)	0.67 (0.49, 0.93)	263	513	51.3 (46.8, 55.7)	239	446	53.6 (48.8, 58.3)	279	558	50.0 (45.8, 54.2)
	BSM	142	266	53.4 (47.2, 59.5)	0.92 (0.81, 1.05)	12	19	63.2 (38.4, 83.7)	1.10 (0.78, 1.55)	474	821	57.7 (54.3, 61.1)	462	802	57.6 (54.1, 61.1)	616	1,087	56.7 (53.7, 59.6)
	BSCC	63	179	35.2 (28.2, 42.7)	0.73 (0.59, 0.9)	5	14	35.7 (12.8, 64.9)	0.74 (0.36, 1.49)	297	615	48.3 (44.3, 52.3)	292	601	48.6 (44.5, 52.7)	360	794	45.3 (41.8, 48.9)
	BSC	49	82	59.8 (48.3, 70.4)	1.01 (0.84, 1.22)	12	28	42.9 (24.5, 62.8)	0.72 (0.47, 1.1)	355	601	59.1 (55.0, 63.0)	343	573	59.9 (55.7, 63.9)	404	683	59.2 (55.4, 62.9)
	BSSL	44	88	50.0 (39.1, 60.9)	0.91 (0.74, 1.13)	7	13	53.8 (25.1, 80.8)	0.98 (0.59, 1.63)	598	1,092	54.8 (51.8, 57.7)	591	1,079	54.8 (51.7, 57.8)	642	1,180	54.4 (51.5, 57.3)
	BSOS	11	21	52.4 (29.8, 74.3)	1.03 (0.68, 1.57)	3	8	37.5 (8.5, 75.5)	0.74 (0.3, 1.81)	249	491	50.7 (46.2, 55.2)	246	483	50.9 (46.4, 55.5)	260	512	50.8 (46.4, 55.2)
	Total	448	952	47.1 (43.8, 50.3)	0.85 (0.79, 0.91)	157	326	48.2 (42.6, 53.7)	0.86 (0.77, 0.96)	3,067	5,521	55.6 (54.2, 56.9)	2,910	5,195	56.0 (54.7, 57.4)	3,515	6,473	54.3 (53.1, 55.5)

Appendices

Technical notes

Indicator targets

Targets have been set for the majority of indicators. This report includes different targets for women aged 45–49 and 50–69 for breast cancer detection (3.a.2, 3.c.r). For biennial coverage and routine rescreens within 27 months the targets now apply to women aged 45–69 years and 45–67 years respectively. Targets for assessment rates after initial screens (<10%) and subsequent screens (<5%) now apply to women aged 45–49 and 50–69 years. Targets for positive predictive values have been set for women aged 45–49 years (>6% for initial screens and >8% for subsequent screens). Further work is required to develop appropriate targets for positive predictive values for women aged 50–69 years following an initial and a subsequent screen (currently >9% for initial and subsequent screens).

Data source and extraction date

The screening and treatment data used in this report were extracted by the National Screening Unit from the national BreastScreen Aotearoa database during January 2021. This report presents timeseries data for the period January 2015 to June 2020 for all BreastScreen Aotearoa screening and assessment indicators, and data for January 2016 to December 2019 for all treatment indicators (treatment indicators are identified by a 't' at the end of the indicator code)

Ethnicity

For both women screened and in the denominator, women have been prioritised to a single ethnicity using the following priority order: Māori, Pacific, Other. This means that if a woman chooses more than one category, and one of these is Māori, she is counted as Māori.

Confidence intervals

A confidence interval is a range of values that describes the uncertainty surrounding an estimate. Confidence intervals are one way to represent how 'good' an estimate is; the larger a confidence interval, the more caution is required when using the estimate. When presenting percentages this report uses 95% confidence intervals calculated using the exact binomial method. When presenting ratios this report uses 95% confidence intervals calculated using the exact binomial, Poisson, and Monte Carlo methods.

Population projections

The denominators used for calculating coverage were derived from projected resident populations provided by Statistics New Zealand. The projections are based on the 2013 New Zealand Census (2019 update) , assuming medium fertility, medium mortality, medium inter-ethnic mobility and medium migration assumptions. The projections used for calculating coverage for the latest reporting period are provided in Table 43.

Table 43: Mid-year population projections for 2019 by ethnicity, Lead Provider, and 5-year age group

		BSWN	BSCM	BSAL	BSM	BSCC	BSC	BSSL	BSOS	Total
Māori	45-49	3,900	2,820	1,250	6,160	4,580	2,260	2,370	1,020	24,360
	50-54	3,600	2,520	1,130	5,660	4,170	1,990	2,130	950	22,150
	55-59	3,550	2,120	1,090	5,560	4,020	1,780	1,920	830	20,870
	60-64	2,750	1,580	790	4,480	3,290	1,350	1,330	600	16,170
	65-69	1,990	1,130	590	3,240	2,470	920	990	390	11,720
Pacific	45-49	1,400	3,600	1,570	570	405	1,155	495	190	9,385
	50-54	1,390	3,490	1,680	500	370	1,045	445	150	9,070
	55-59	1,150	2,800	1,400	380	325	890	380	130	7,455
	60-64	840	1,960	1,120	340	280	720	235	60	5,555
	65-69	690	1,520	830	280	205	615	195	70	4,405
Non-Māori	45-49	24,570	15,980	15,350	20,380	15,570	16,625	26,465	10,060	145,000
	50-54	23,730	15,390	14,000	20,110	15,615	15,545	26,005	10,150	140,545
	55-59	23,400	14,390	13,090	21,510	17,380	15,405	26,985	11,040	143,200
	60-64	20,980	12,150	11,250	20,400	16,145	13,005	24,385	9,930	128,245
	65-69	18,140	10,090	9,060	19,070	15,040	11,210	21,660	8,680	112,950
Non-Māori Non-Pacific	45-49	23,170	12,380	13,780	19,810	15,165	15,470	25,970	9,870	135,615
	50-54	22,340	11,900	12,320	19,610	15,245	14,500	25,560	10,000	131,475
	55-59	22,250	11,590	11,690	21,130	17,055	14,515	26,605	10,910	135,745
	60-64	20,140	10,190	10,130	20,060	15,865	12,285	24,150	9,870	122,690
	65-69	17,450	8,570	8,230	18,790	14,835	10,595	21,465	8,610	108,545
All	45-49	28,470	18,800	16,600	26,540	20,150	18,885	28,835	11,080	169,360
	50-54	27,330	17,910	15,130	25,770	19,785	17,535	28,135	11,100	162,695
	55-59	26,950	16,510	14,180	27,070	21,400	17,185	28,905	11,870	164,070
	60-64	23,730	13,730	12,040	24,880	19,435	14,355	25,715	10,530	144,415
	65-69	20,130	11,220	9,650	22,310	17,510	12,130	22,650	9,070	124,670